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 Resveratrol, a naturally occurring phytoalexin, has wide pharmacological 
activities.  However, its oral bioavailability in human is observed to be very low.  We 
hypothesized that the high lipophlicity of resveratrol, which leads to low aqueous 
solubility, may impair its oral bioavailability.  The objective of this work was to 
determine whether the hydroxypropyl-β-cyclodextrin (HP-β-CD) and randomly 
methylated-β-cyclodextrin (RM-β-CD) can improve the solubility of resveratrol and, 
if so, whether an increase in the solubility of resveratrol leads to an increase in its oral 
bioavailability.  Water soluble intravenous and oral formulations of resveratrol were 
prepared with HP-β-CD and RM-β-CD, respectively.  Sodium salt and suspension of 
resveratrol in carboxymethyl cellulose (CMC) were used as the reference intravenous 
and oral formulations, respectively.  The pharmacokinetics of resveratrol was assessed 
in Sprague-Dawley rats.  Plasma resveratrol concentrations were measured by high 
performance liquid chromatography (HPLC).  Both HP-β-CD and RM-β-CD 
enhanced the aqueous solubility of resveratrol.  After intravenous administration, 
rapid elimination of resveratrol was observed at all tested doses (5, 10, and 25 mg⋅kg-
1) regardless of formulation types.  RM-β-CD significantly increased the maximal 
plasma concentration of orally administered resveratrol, but, it did not increase the 
oral bioavailability in comparison with the CMC suspension.  Furthermore, the oral 
bioavailability remained unchanged among all tested doses (15, 25, and 50 mg⋅kg-1).  
Therefore, it was concluded that the aqueous solubility barrier might affect the speed 
but not the extent of resveratrol absorption.   
 The very short half-life (~8 – 14 min) and extremely low bioavailability of 
resveratrol have raised concerns regarding its systemic action.  At the same time, 
resveratrol has shown promising therapeutic efficacy towards several lower gastro-
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intestinal (GI) tract diseases like, colon cancer and colitis.  Therefore, it was 
hypothesized that a colon-specific delivery system of resveratrol might be a better 
alternative to the existing treatment of the lower GI tract diseases (e.g., colorectal 
cancer, colitis).  To ameliorate this purpose, this study aimed at devising a multi-
particulate colon-specific delivery system of resveratrol as calcium-pectinate (Ca-
pectinate) and zinc pectinate (Zn-pectinate) beads.  The beads were prepared by 
varying different formulation variables.  Their effects were investigated on the 
physico-chemical characteristics and resveratrol retention pattern of the formulated 
beads.  Preparative conditions were optimized from these studies.  Almost all 
prepared beads were spherical with ~1 mm diameter.  Observations from the present 
study revealed that Ca-/Zn-pectinate beads prepared with optimized formulation 
variables can encapsulate a very high amount of resveratrol and can be used as 
delayed release formulation of resveratrol.   
 However, it was found that pectinate bead alone was insufficient in 
protecting resveratrol release at the small intestinal pH, although it prevented 
resveratrol release at the acidic pH of stomach.  Modification of the pectinate beads 
was therefore needed to achieve colon-specific delivery of resveratrol.  Hence, the 
beads were hardened by adding polyethyleneimine (PEI) or glutaraldehyde in the 
cross-linking solution.  The effects of different formulation variables were 
investigated on the physico-chemical properties and resveratrol retention pattern of 
the formulated beads.  Proper conditions were optimized from these studies.  Cross-
linking solution pH appeared to be a critical factor to produce sufficiently strong 
beads.  Furthermore, addition of PEI/glutaraldehyde to the cross-linking solution, and 
a minimum cross-linking time were found to be crucial for colon-specific release of 
resveratrol.  As PEI/glutaraldehyde was added in the cross-linking solution, hardening 
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of the bead surface occurred simultaneously with bead formation, which eliminated 
extra formulation steps, and reduced the production time and cost.   
In-vivo pharmacokinetic studies in rats were carried out to evaluate the in-vivo 
efficacy of the optimized formulations.  The results demonstrated a delayed 
appearance (after 5 h) of resveratrol in the blood after oral administration of 
optimized pectinate beads hardened with PEI/glutaraldehyde.  Results showed that 
resveratrol-loaded Ca-pectinate bead hardened with glutaraldehyde or PEI and 
resveratrol-loaded Zn-pectinate bead hardened with glutaraldehyde at cross-linking 
solution pH of 1.5 have the potential to be used as colon-specific formulation of 
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within the Zn-pectinate bead treated with glutaraldehyde 
(A) and SER of the Zn-pectinate bead treated with 
glutaraldehyde (B).  The beads were incubated in 
simulated GI conditions.   
 
LXIII 
Figure III.V Effect of pectin to resveratrol ratio on retention of 
resveratrol within the Zn-pectinate bead treated with 
glutaraldehyde (A) and SER of the Zn-pectinate bead 
treated with glutaraldehyde (B).  The beads were 
incubated in simulated GI conditions.     
 
LXV 
Figure III.VI Effect of glutaraldehyde treatment of preformed beads 
on retention of resveratrol within the Zn-pectinate bead 
treated with glutaraldehyde (A) and SER of the Zn-
pectinate bead treated with glutaraldehyde (B).  The 





Figure III.VII FT-IR spectra of pure resveratrol (A), resveratrol-loaded 
Zn-pectinate bead treated with glutaraldehyde (B), and 




Figure III.VIII Stability of resveratrol in the optimized resveratrol-
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1.1. Resveratrol   
Resveratrol (Figure 1.1) is a naturally occurring phytoalexin present in a wide 
variety of plants such as grapes, peanuts, and mulberries.  These plants synthesize the 
stilbene type phytoalexin resveratrol in response to stress, injury, ultraviolet (UV) 
irradiation, and fungal infection and when attacked by pathogens [1].  Resveratrol 
plays a significant role in the defense mechanism of these plants against fungal 
infection [2].   
 
Figure 1.1:  Trans-resveratrol (Trans-3, 5, 4'-trihydroxystilbene)   
 
1.1.1. History   
The history of resveratrol can be traced back to the ancient India (more than 
2000 years ago).  At that time, a well-known “Ayurvedic" medicine, "Darakchasava" 
was prescribed as a cardiotonic and for many other diseases.  The active ingredient of 
"Darakchasava" is Vitis vinifera L [3].  The polyphenolic compound, resveratrol was 
detected in "Darakchasava" by high performance liquid chromatography (HPLC) 
analysis [1].   
 In 1940, resveratrol was first isolated from the roots of white hellebore 
(Veratrum grandiflorum O. Loes) [4].  Later, in 1963 resveratrol was extracted from 
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the roots of Polygonum cuspidatum, a well known plant used in Japanese and Chinese 
traditional medicine, for the treatment of hyperlipemia, suppurative dermatitis, 
athlete's foot (tinea pedis), and gonorrhea favus [5-8].   
 
1.1.2. Pharmacological activities   
1.1.2.1. Cardioprotective effect:  Presence of resveratrol in grapevine was first 
detected in 1976 [2].  But it initiated interest among scientists as a pharmaceutically 
active ingredient, when the cardioprotective effect of red wine was reported [9, 10].  
Since then, extensive research has been going on resveratrol.  Resveratrol was thought 
to be the therapeutically active component in red wine as the available 
epidemiological data demonstrated an inverse correlation between red wine 
consumption and incidence of cardiovascular disease - a phenomenon known as the 
“French paradox” [11].  Later, the cardioprotective effect was confirmed by other 
scientists [12].  Bradamante and coworkers [13] also corroborated the findings of the 
former researchers.   
 
1.1.2.2. Antibacterial, antiviral, and anti-inflammatory activity:  Antibacterial 
activities of resveratrol were reported recently especially on different strains of 
Helicobacter pylori [14-17].  Resveratrol also exhibited antiviral effects against HIV-
1 [18] and the herpes simplex virus [19, 20].  Acute and chronic oedema [21-23], 
osteoarthritis [24] and lipopolysaccharide induced airway inflammation [25] were 
significantly reduced by resveratrol.  Administration of resveratrol could therefore 
present an attractive alternative to current treatments for chronic inflammation as 
long-term use of aspirin and selective COX-2 inhibitors develop many complications 
[10].   
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1.1.2.3. Chemopreventive and chemotherapeutic activity:  After extensive research 
on resveratrol during the last few years, resveratrol was identified as a potential 
chemopreventive agent.  The chemopreventive activity of resveratrol is exhibited on 
three major stages of carcinogenesis: tumor initiation, promotion, and progression 
[21].  Resveratrol has been shown to have a chemopreventive role in a wide variety of 
tumors including skin [21, 26-29], liver [30, 31], colon [32], breast [21, 33-35], lung 
[36, 37], and oesophagus [38].  Though several chemopreventive effects of resveratrol 
have been reported, there are many exceptions where chemopreventive effect of 
resveratrol was not found in-vivo [36, 39, 40].  However, numerous reports suggest 
that resveratrol also exerts therapeutic effects against cancer [41-43].   
 
1.1.2.4. Action on brain:  Usefulness of resveratrol in protecting against brain 
damage following cerebral ischemia has also been reported in various studies [44-47].  
Intra-peritoneal administration of resveratrol prevented seizures induced by 
pentylenetetrazole [48], FeCl3 [47], kainic acid [49], and partially restored cognition 
in rats receiving streptozotocin intracerebroventricularly [50].  Resveratrol is capable 
of penetrating the blood–brain barrier and exerts strong neuroprotective effects, even 
at low doses [10].   
 
1.1.2.5. Effect on colon diseases (e.g., colitis and colon cancer):  Oxidative stress, 
neutrophil infiltration, proinflammatory cytokines, and eicosanoid generation have 
been implicated in inflammatory bowel disease (IBD).  Martin et al. [51, 52] 
investigated the effects of resveratrol on the colon injury caused by intracolonic 
instillation of trinitrobenzenesulphonic acid (TNBS) in rats.  Resveratrol was effective 
in both acute experimental colonic inflammation [51] and chronic experimental colitis 
 4 
[52].  Resveratrol (5 – 10 mg.kg-1.day-1) significantly attenuated the damage score, the 
index of neutrophil infiltration and the levels of the cytokine.  In addition, COX-2 
expression was decreased in colon of resveratrol treated rats.  Furthermore, treatment 
of rats with resveratrol caused a significant increase of TNBS-induced apoptosis in 
colonic cells.  These studies indicated that, resveratrol reduced the damage in 
experimentally induced colitis, alleviated the oxidative events and stimulated 
apoptosis.   
 Several in-vitro studies suggest that resveratrol suppresses proliferation of 
colon cancer cells [32, 53-60].  In an experiment, resveratrol inhibited the growth of 
human derived colon cancer cells HCA-7 and HT-29 with IC50 values of 6 – 26 µM 
[61].  Resveratrol was found to inhibit colon cancers in mice and rats.  Resveratrol 
pretreatment (200 µg.kg-1.day-1 in drinking water) and treatment in the initiation phase 
of azoxymethane-induced colon cancer in F344 rats inhibited the number and 
multiplicity of aberrant crypt foci (ACF) and completely abolished the large ACF [32].  
In another study, resveratrol prevented the formation of colon tumors and reduced the 
formation of small intestinal tumors by 70 % in Min mice [62].  Thus the high 
potency and efficacy of resveratrol supported its use as a therapeutic and 
chemopreventive agent in the management of colorectal cancer.   
 
1.1.2.6. Anti-ageing:  Resveratrol has been shown to extend the lifespan of 
evolutionarily distant species including S. cerevisiae, C. elegans, and D. melanogaster 
[63-66].  Valenzano et al. [67] found that resveratrol ameliorated health and extended 
maximum lifespan by 59 % in a vertebrate fish.  In a recent study, Baur et al. proved 
that resveratrol could improve health and survival of mice on a high-calorie diet [68].   
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1.1.2.7. Other effects:  Furthermore, resveratrol was reported to have a therapeutic 
role in many other diseases.  It has been shown to reduce injuries to the liver [69], 
intestine [70, 71], kidneys [72, 73], lungs [74], and spinal cord [75, 76].  Resveratrol 
can also act as analgesic [77-79], protect against hearing loss [80], and enhance 
lipopolysaccharide-induced anorexia in rats [81].   
 
1.1.3. Pharmacokinetics   
The mechanisms for such a wide range of beneficial effects of resveratrol on 
different diseases and species are not clear yet.  In-vitro studies have shown almost 
universal success, which led to identification of multiple direct targets for resveratrol 
[10].  However, pharmacokinetic studies exhibited rapid metabolism of resveratrol 
and put forward many doubts on the physiological relevance of the high 
concentrations typically used for the in-vitro experiments.   
Several in-vitro experiments studied resveratrol metabolism.  These studies 
revealed that resveratrol is mainly metabolized to glucuronide and sulfate conjugates.  
Kuhnle et al. [82] studied the absorption and metabolism of resveratrol in the jejunum 
in an isolated rat small intestine model.  They detected glucuronide conjugate of 
resveratrol at the serosal side (> 90 % of total amount absorbed).  Only small amounts 
of free resveratrol were absorbed across the enterocytes of the jejunum and ileum.  
This indicated the susceptibility of resveratrol to glucuronidation during transfer 
across the rat jejunum.  In another experiment, the absorption and metabolism of 
resveratrol were investigated using an isolated rat small intestine which was luminally 
and vascularly perfused [83].  Vascular uptake of luminally administered resveratrol 
was 20.5 %.  The majority of the absorbed resveratrol was conjugated to yield 
resveratrol glucuronide (16.8 %), which was also the main luminal metabolite 
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(11.2 %).  Lesser amounts of resveratrol sulfate, 3.0 % and 0.3 % were found on the 
luminal and vascular sides respectively, while only minute amounts of resveratrol and 
resveratrol conjugates (1.9 %) were found in the intestinal tissue.  These findings 
demonstrated that resveratrol was converted to glucuronide conjugate during 
absorption through small intestine and then entered into the blood circulation.   
De Santi et al. [84] found that resveratrol underwent glucuronidation in human 
liver microsome and produced sulfate metabolites in the human liver and duodenum 
[85].  In another study, Yu et al. [86] examined in-vitro metabolism of trans-
resveratrol after incubation of trans-resveratrol with human liver microsomes, human 
hepatocytes, and rat hepatocytes.  In the microsomal incubations, no resveratrol 
metabolites were observed and no phase I metabolites were detected in any samples.  
However, a great extent of trans-resveratrol-3-O-glucuronide and trans-resveratrol-3-
sulfate were identified in rat and human hepatocytes samples.  In addition, Kaldas et 
al. [87] studied transport and metabolism of resveratrol (5 – 40 µM) in Caco-2 cell 
line (human intestinal epithelial cell line).  They found an increase in absorption at the 
highest resveratrol concentration, possibly because of saturation of metabolism.  They 
observed that the principal metabolite was sulfate conjugate of resveratrol.  In another 
study, Potter et al. [88] showed that enzyme CYP1B1 is over-expressed in different 
type of human tumors and resveratrol undergoes metabolism by CYP1B1 and produce 
antileukemic agent piceatannol.  This can be a novel explanation of the 
chemopreventive activity of resveratrol [1].   
Some researchers undertook in-vivo animal studies to confirm in-vitro 
metabolism.  These animal studies exhibited low bioavailability of resveratrol due to 
rapid and extensive metabolism.  Bertilli et al. [89] studied the plasma kinetics and 
tissue bioavailability of resveratrol after oral administration in rats.  Significant 
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cardiac bioavailability and a strong affinity for the liver and kidneys were observed 
from tissue concentrations of resveratrol.  Together with in-vitro experiments, Yu et 
al. [86] examined in-vivo metabolism upon oral or intra-peritoneal administration of 
resveratrol to rats and mice.  They found high concentration of trans-resveratrol-3-O-
glucuronide and trans-resveratrol-3-sulfate in mouse serum and rat urine.  To study 
the structures of these conjugates, incubation samples were treated with β-
glucuronidase and sulfatase to release free resveratrol.  Almost no unconjugated 
resveratrol was detected in the urine or serum samples.  The above studies revealed 
extensive metabolism of resveratrol in rats and mice. 
Similar to in-vivo animal experiments, several in-vivo studies were also 
performed in humans.  The in-vivo human experiments confirmed the finding (i.e. low 
bioavailability due to rapid and extensive metabolism) from animal experiments.  
Goldberg et al [90] . reported that, after an oral dose of resveratrol (25 mg/70 kg body 
weight) to healthy human subjects, the compound appeared in serum and urine 
predominantly as glucuronide and sulfate conjugates and reached peak concentrations 
(10 - 40 nM) in serum around 30 min after consumption and the un-conjugated 
resveratrol accounted for 1.7 - 1.9 % of the peak serum concentrations.  In another 
study, an intravenous dose of resveratrol was converted to sulphate conjugates within 
~ 30 min in humans [91].  On the other hand, both sulfate and glucuronide conjugates 
were detected after oral administration of resveratrol.  They detected five distinct 
metabolites (resveratrol monosulfate, dihydroresveratrol monosulfate, 
dihydroresveratrol monoglucuronide, and two isomeric forms of resveratrol 
monoglucuronide) in urine samples.  However, only trace amount of unchanged 
resveratrol was detected.  Furthermore, they found that the serum half-life of total 
resveratrol metabolites was ~ 9.2 h, which is higher than that for parent resveratrol.   
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The concentration of trans-resveratrol in red wine is ~ 5 mg.l-1, though it 
varies a lot among various wines [92, 93].  Daily intake of two glasses of red wine (~ 
375 ml) by a healthy person (70 kg) would receive a dose of ~ 27µg.kg-1 each day 
[10].  Several liters of red wine need to drink to achieve the required effective dose, 
which is impossible.  Quercetin, which is an inhibitor of resveratrol sulphation in both 
liver and duodenum, is also present in red wine [85].  This clearly indicates that 
pharmacokinetic profiles of pure resveratrol from various red wine could be different 
[10].   
In many instances, literatures on resveratrol are confounding and contradictory.  
The wide range of concentrations (~ 32 nM – 100 μM in-vitro) and doses (~ 100 ng – 
1,500 mg.kg-1 in animals) used to achieve the various effects reported for resveratrol, 
raises many questions about the concentrations that are practically achieved or 
achievable in-vivo [10].  Furthermore, resveratrol has a short initial half-life, about 8 – 
14 min [94, 95].  So, it is very difficult to determine the effective plasma 
concentration and optimal dose of resveratrol from the current literatures.   
 
1.1.4. Maximum tolerable dose   
Although, at a dose of 300 mg.kg-1 showed no detrimental effects in rats, the 
maximum tolerated dose of resveratrol is not known till date [96].  Doses up to 100 
mg.kg-1 have been used routinely in studies on rodents [10].  In a study to evaluate 
whether high doses of trans-resveratrol have harmful effects on Sprague-Dawley rats, 
Juan et al.[97] observed that repeated consumption of resveratrol at 20 mg.kg-1.day-1 




1.1.5. Physico-chemical properties   
Resveratrol (C14H12O3) is an off-white powder with a melting point: 253 – 255 
ºC, molecular weight: 228.25, and log P: 3.08.  It is a poorly water soluble compound, 
but it dissolves in methanol, ethanol, and dimethylsulphoxide.  Resveratrol consists of 
two phenolic rings linked by a styrene double bond to generate 3,4',5-
trihydroxystilbene.  Presence of the double bond leads to two isomeric forms of 
resveratrol, trans- and cis-isomeric forms.  The trans-isomer is sterically more stable 
and pharmacologically active [1].   
 
1.2. Colon-specific delivery systems   
To date, oral route is the most preferred route for drug administration, 
especially for chronic therapies where repeated administration is required.  In addition, 
greater convenience, less pain, higher compliance, reduced risk of cross-infection and 
needle stick injuries are the added advantages for oral delivery when compared to 
other routes of administration [98].  Hence, oral drug delivery systems continue to 
dominate more than half of the drug delivery market share [99].  Despite these 
advantages, the oral route is not amenable to the administration of drug for lower 
gastro-intestinal (GI) diseases due to their release at upper GI tract, which leads to 
their limited/insufficient availability at the lower GI tract.  To overcome this obstacle, 
new strategies of drug delivery have been developed.  Among them, colon-specific 
drug delivery systems have been extensively explored during last two decades.  
Different delivery vehicles from synthetic as well as natural polymers have been 
exploited for colon-specific drug delivery.  However, the design of oral drug delivery 
vehicles that effectively carry drugs to the colon site is challenging as it requires 
fulfilling the following criteria: i) they need to remain intact (by constructing a 
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physical environment using the formulation itself to isolate the incorporated drug 
from outside conditions) when traveling through the upper GI tract in order to prevent 
the release as well as chemical and enzymatic degradation of the incorporated drug,  ii) 
they should be able to release the incorporated drugs immediately upon arriving in the 
colonic region.  The efficiency of these formulations is estimated by the difference 
between the drug released at the colon site and the initial dosage of the drug.  The 
smaller in this difference, the better will be the delivery system.   
 
1.2.1. Rationale for colon targeting   
The challenge of targeting drugs to the colon segment of the GI tract has been 
embraced by scientists over the past two decades [100, 101].  The research on colon 
targeting has been driven primarily by the need to improve the treatment of the 
colonic pathologies.  These disease states range in severity from constipation and 
diarrhoea, to irritable bowel syndrome and inflammatory bowel disease (ulcerative 
colitis and Crohn’s disease), through to infection and colon carcinoma.  While some 
of these disorders are fairly innocuous, the majority are debilitating and life 
threatening (e.g., colorectal cancer is the third most common cause of cancer-related 
death in both men and women [102]).  Generally, surgical intervention is required in 
some patients as the current pharmacotherapy for colonic disorders is generally 
inefficient.  Hence, the introduction of new therapeutic agents would no doubt 
improve the current treatment.  Furthermore, the new and improved delivery 
strategies for targeting the drugs specifically to the colon would provide significant 
clinical benefits.  This would ensure direct treatment at the disease site.  In addition, 
there will be a great possibility of reduction in the administered dose and associated 
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systemic adverse effects.  These are the benefits that can be obtained from the 
perspective of colonic drug delivery.   
 Additional interest in colon-targeted drug delivery system has generated from 
the potential of the colonic site for the entry of some drugs into the systemic 
circulation.  The colonic region is believed to contain lower levels of luminal and 
mucosal digestive enzymes in comparison with stomach and small intestine [103].  
Colonic region therefore can be a preferred site for the systemic absorption of many 
drugs, especially peptides and proteins that are degraded and/or poorly absorbed in 
the upper gut [104].  Furthermore, colon-specific drug delivery could be beneficial 
when an intentional time delay in absorption is required for the treatment of diseases 
that are sensitive to circadian rhythms (chronotherapy), such as angina pectoris, 
arthritis, and asthma [105].   
 
1.2.2. Strategies for colon targeting   
Initially, delivery of drugs to the colon was tried through the rectal route using 
suppository and enema formulations.  Nevertheless, such formulations rarely succeed 
in spreading beyond the descending colon, with little or no drug reaching the proximal 
colon [106, 107].  Moreover, the rectal route is inconvenient or unacceptable for most 
patients.  The oral route is therefore the preferred mode of administration for this 
purpose.   
To achieve colon-specific delivery through oral route, the formulation must 
prevent drug release in the stomach and small intestine but allow release after their 
arrival in the colon.  Although the concept looks quite simple, this is difficult to 
achieve in practice as the colon is the most distal segment of the GI tract.  The 
formulation will be exposed to a range of conditions and environments during its 
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passage through the GI tract, including pH, enzymes, electrolytes, transit time, and 
pressure.  Furthermore, these parameters are subject to considerable inter- and intra-
individual variation and are also affected by disease.  Thus, these factors make the 
delivery of drugs to the colon via the oral route a challenging proposition [108-111].   
The basis of targeting any organ is the identification and exploitation of a 
characteristic that is unique in that target organ.  In the context of colon targeting, the 
exploitable GI features are transit time, pH, pressure, and microflora.  Although a 
range of approaches have been proposed and systems have been developed based on 
these features, most of them have never progressed beyond the bench, with very few 
reaching the stage of clinical evaluation.  Some of them have been investigated in 
humans and have the greatest potential for future clinical use.  Nevertheless, few 
colon-specific drug delivery systems have been commercialised.  To achieve colon-
specific drug delivery, current approaches use systems that (i) release the drug at a 
predetermined time after administration, ii) utilize pH changes within the GI tract, iii) 
make use of GI pressure differences, and iv) exploit microbial enzymes 
predominantly present in the colonic region of the GI tract [102, 112].   
 
1.2.2.1. Time:  The total GI transit time (mouth to rectum) is about 24 hours [113], 
although it shows considerable intra- and inter-individual variability [114].  The 
transit time and rate of solid oral dosage forms through the GI tract is largely 
unpredictable.  The reason is mostly due to the variability in gastric emptying time 
(residence time in the stomach), which can range from a few seconds to few hours 
depending on the size, shape, and density of the dosage form and the feed status of the 
individual [115-117].  Nevertheless, transit time through small intestine is reported to 
be more consistent (3 - 4 h) irrespective of formulation and dietary factors [118], 
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which has been exploited for colon targeting purposes.  Rapid water absorption in the 
ascending colon leads to more viscous environment in the distal colonic region, which 
increases residence time of the contents (12 – 24 h) [119, 120].  Time-based 
formulations are designed to release their drug load after a predetermined lag time of 
5 - 6 h, which is considered as the time required for the dosage form to reach the 
colon [102].  Based on this concept, a number of drug delivery systems have been 
developed.  PulsincapTM was the first one in this category [121].  However, when 
tested in human using gamma scintigraphy, the position of the system at the time of 
release varied considerably; in some individuals the device remained in the stomach, 
while in others the capsule had advanced to the descending colon [122].  Additionally, 
poor emptying properties of the capsule in the distal bowel was revealed in the 
subsequent study, probably because of the lack of fluid in this region [123].   
An enteric coating on the time-based systems has been proposed to minimise 
the impact of gastric emptying on these systems [124, 125].  The outer enteric coat 
protects the system in stomach, dissolves upon arrival in the small intestine and 
exposes the core, which subsequently swells, erodes or dissolves over a period of time 
sufficient to delay drug release from the formulation.  When a formulation that 
combines both pH and time-based mechanisms was tested in volunteer, the site of 
disintegration of the coated capsule was more consistent in the fasted state (ranging 
between the ileocaecal junction and the descending colon) [126].  In contrast, gastric 
emptying and colonic arrival of the capsule was significantly retarded in the fed state.  
Premature disintegration was observed in the small intestine in some volunteers, while 
no capsule disintegration was noted in others.  Likewise, multi-layer coatings on 
tablets have been applied for colon targeting purpose [127].   
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The fundamental premise for the functionality of time-dependant system is 
that GI transit is a consistent parameter.  However, GI transit is prone to considerable 
intra- and inter-individual variability in healthy individuals, greatly influenced by 
disease states [128], and subject to diurnal variations (transit is appreciably slower in 
the evening compared with the morning) [129, 130].  As these systems are unable to 
sense and adapt to an individual’s transit time and merely release their drug load after 
a pre-set lag time, irrespective of whether the formulation is in the colon or not, 
clearly limits their practical utility.   
 
1.2.2.2. pH:  Hydrochloric acid secretion from the parietal cells leads to acidic 
environment in the stomach.  Gastric pH increases to more than 4 when food is 
present but, again falls down to 1.5 – 3.5 once the food mixes with the gastric juice 
[131].  The pH in the small intestine ranges from 5.5 to 6.8, whereas the pH in the 
ascending colon is 6.4, which rises in the transverse colon and approaches neutrality 
in the descending colon (Figure 1.2).  The increment of GI pH from the stomach to 
the small intestine has traditionally been employed to deliver drugs to the small 
intestine using pH sensitive enteric coatings.  These enteric polymer coatings are 
resistant to the acidic conditions of the stomach but ionise and dissolve at the more 
neutral pH of 5 - 6 found in the upper small intestine.  Similar concept has also been 
utilized for colon targeting, using polymers that have a threshold pH for dissolution 
higher than those used in conventional enteric coating [132, 133].  Acrylic polymers 
(Eudragits®) that dissolve above pH 6 have been attempted for this purpose.  The first 
dosage form that utilise GI pH to trigger drug release in the distal gut was Eudragit® S 
(copolymer of methacrylic acid and methyl methacrylate that dissolves above pH 7) 
coated capsule [134].  X-ray imaging study in the volunteers revealed drug release in 
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the distal gut.  The results from a subsequent study of Eudragit® S-coated tablets in 
patients with ulcerative colitis [135] provided the basis for the development and 
subsequent commercialisation of the Asacol® MR preparation (a Eudragit® S-coated 
tablet containing mesalazine).  A number of other modified-release products 
containing mesalazine, such as, Mesren® MR, Ipocol®, and Salofalk® have since 
appeared in the market [136].  However, these products exhibited different in-vitro 
release characteristics and cannot be considered interchangeable [136, 137].  Another 
modified-release budesonide product Budenofalk®, where pellets were coated with a 
Eudragit® L/S, is also commercially available [132].  The more recent preparations 
utilise the multiple-unit design (e.g. Entocort®).   
 
Figure 1.2:  The pH profile of the GI tract of healthy human [138].  RTC = 
radiotelemetry capsule.   
 
This concept is based on the assumption that GI pH continues to increase from 
the small intestine to the colon.  In contrary, the pH in the colon is lower than that in 
the distal small intestine [138].  Moreover, the colonic pH becomes considerably 
lower in ulcerative colitis and Crohn’s disease patients [110].  Thus variable findings 
for the in-vivo efficacy of pH-dependent formulations were observed.  In a gamma 
scintigraphy study involving seven healthy volunteers, the position of the Eudragit® 
S-coated formulation in the GI tract at the time of fragmentation was highly variable, 
 16 
extending from the ileum in the small intestine to the splenic flexure in the distal 
colon [139].  The time of tablet disintegration was also equally variable (5 to > 15 h).  
Similarly, the commercial Asacol® MR and Ipocol® preparations also revealed 
variable product performance with the site of disintegration ranging from the small 
intestine to the descending colon, while in some cases did not disintegrate during their 
passage through the gut [140, 141].  This explains the occasional appearance of intact 
Asacol® MR tablets in the stools of ulcerative colitis patients [111].  The threshold pH 
for polymer dissolution is probably never reached in the GI tract of these patients with 
ulcerative colitis, where the colonic pH is significantly lower, thereby retarding drug 
release.   
 The huge variability in the performance of enteric coated dosage forms has led 
to the conclusion that GI pH is not a reliable mechanism for colonic specific drug 
release [139].  These systems behave in an erratic manner in-vivo, ranging from 
premature release in the small intestine to little or no release throughout the gut.   
 
1.2.2.3. Pressure:  The GI pressure, which is generated via muscular contractions 
of the intestinal wall for grinding and propulsion of luminal contents, was exploited 
for colon-targeted drug delivery purpose [142].  This pressure varies in intensity and 
duration throughout the GI tract and the colon is believed to exert a higher effective 
luminal pressure via the action of haustral contractions coupled with a viscous 
environment.  Unlike the motility of the stomach and small intestine which is 
characterized by the cyclical appearance of the migrating motor complex, under fasted 
and normal physiological conditions, colonic contractile activity can be described by 
irregular alternation of quiescence, prevalence of non-propagating and segmental 
contractions, and infrequent occurrence of propagated contractions [143].  The 
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movement of luminal contents in the stomach and small intestine which is almost 
always in the distal direction, whereas the mixing in proximal colon occurs with 
reduced motility both laterally and longitudinally [144].  Furthermore, colonic 
environment is generally viscous in nature as a consequence of the colonic functions.   
A pressure-controlled colon delivery capsule (PCDC) composed of drug 
dispersion in a suppository base which was coated with the water-insoluble polymer 
ethylcellulose was developed  [142].  The different PCDC manufactured by coating 
the inner surface of a gelatine capsule with an organic ethylcellulose solution [142], 
by a dipping method [145] or by coating capsule shaped pieces of suppository base at 
low temperature [146] have been assessed for their ability to deliver model drugs in-
vivo in beagle dogs [145] and humans [146].  These investigations were based on the 
conventional pharmacokinetic study, where the time for first appearance of drug in 
the plasma were evaluated and compared with the literature values for colon arrival 
times in dogs and in humans.  However, these studies did not conclusively show that 
the capsules had disintegrated in the colon as gastric and small intestinal transit times 
are known to be variable.   
However, although the pressure difference throughout the GI tract provides an 
innovative approach for targeting drugs to the distal gut, limited data on the luminal 
pressures of different regions of the GI tract together with their inter- and intra-
individual variation like pH and transit time preclude extensive study on the pressure-
based systems.   
 
1.2.2.4.  Enzyme:  Most of the recent research on the colon-specific delivery has 
focused on the use of colonic microflora to trigger the drug release from the 
formulations [102, 131, 147].  Although bacteria are distributed throughout the GI 
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tract, the vast majority are present in the distal gut (Figure 1.3).   The microflora of 
the stomach is normally sparse (< 103 CFU ml-1) and only aciduric microorganisms 
can grow and inhabit in the stomach [131].  Similarly, the duodenum is sparsely 
populated (103 – 104 CFU ml-1) with aerobic and gram-positive acid resistant bacteria, 
such as Streptococci, Staphylococci, Lactobacilli etc.  On the other hand, the human 
colon is a dynamic and ecologically diverse environment, containing over 400 distinct 
species of microflora with a population of 1011 to 1012 CFU.ml-1 [148] and 
approximately one third of the fecal dry weight consists of bacteria [149].  Various 
types of oxygen-intolerant anaerobic bacteria, such as, Bacteroides, Bifidobacteria, 
Eubacteria, Enterobacteria, Lactobacillus etc. are predominant in the colon [150].  
The anaerobic bacteria outnumber the aerobes by a factor of 102 –104.  These bacteria 
produce a wide spectrum of enzymes, which are actively involved in many processes 
in the colon (e.g., carbohydrate fermentation) [143].  These anaerobic colonic 
microflora fulfil their energy needs by fermenting carbohydrates such as non-starch 
polysaccharides (i.e., dietary fibers) and di- trioligosaccharides from the chyme, 
which are left undigested at the upper GI tract.  Different enzymes, such as α-L-
arabinofuranosidase, β-D-fucosidase, β-D-galactosidase, β-D-glucosidase, β-
xylosidase etc. are actively engaged in the process of polysaccharides degradation in 
the colon [151].     
 Therefore, the materials that are susceptible to the bacterial degradation in the 
colon, while remaining recalcitrant to the conditions in the stomach and small 
intestine, could be utilised as carriers for drug delivery to the colon.  Among them 
sulfasalazine, a prodrug consisting of mesalazine (active ingredient) linked by an azo 
bond to sulfapyridine (a carrier molecule), was first developed [152, 153].  Although 
colon-specific absorption of mesalazine was observed from this formulation [154], the 
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total incidence of adverse effects or allergic reactions was high [155], which was 
believed to be because of the sulfapyridine component [156].  To overcome this, 
olsalazine (two mesalazine molecules azo bonded to each other) [157] and non-azo-
bonded prodrugs have also been investigated [158].  Nevertheless, reduced azo-
reductase enzyme activity in active Crohn’s disease [159] and potential carcinogenic 
effect of azo-aromatic compounds cast a shadow over the safety and toxicity of 
synthetic azopolymers [160].  These reasons have discouraged the investigation of 
azo-polymer-based systems in humans and clearly limited the usefulness of this 
approach.   
 
Figure 1.3:  Distribution of selected bacteria in the GI tract [161].   
 A universal system would be more useful in terms of transporting any drug 
molecule to the colon.  In this ambit, natural polysaccharides that are degraded 
specifically by bacterial enzymes predominantly present in the colon appeared to be a 
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better alternative.  As most of these polymers constituents of the human diet and are 
already used as pharmaceutical excipients, issues with regard to safety, toxicity, and 
availability are therefore much simplified.  In spite of their specific degradation in the 
colon, hydrophilicity and swelling in the upper GI fluids would result in premature 
drug release from these carriers.  However, these problems with the natural 
polysaccharides can be overcome either by chemical modification or by mixing with 
hydrophobic polymers, which limit dissolution and swelling of the carrier in the upper 
GI tract while release drug in the colon after enzymatic degradation of the matrix or 
coating.  The research on polysaccharides gains popularity as they are non-toxic, easy 
to work with, and mostly FDA approved.  Various well known carbohydrate polymers 
meet these requirements to some extent and demonstrate their potential as starting 
materials for the construction of oral colon-specific drug delivery vehicles [112].  
Different carbohydrate polymers (e.g., pectin [162-175], chitosan [176-179], guar 
gum [180-186], amylase [187-191], chondroitin sulphate [192], alginates [193], inulin 
[194], dextran [195-197]) have been tried as colon-specific carrier.  Among such 
polymers, pectin appeared to be of great practical interest due to their low cost, 
biodegradability, wide variety of types, and flexibility in use.   
 
1.2.3. Pectin   
Pectin (Figure 1.4) is a non-starch heterogeneous (with respect to chemical 
structure and molecular weight) linear polysaccharide  present in the cell wall of most 
plants which is consumed as part of the human diet and used as a food additive [99].  
The influence of pectin intake on the human body has been well studied and regarded 
as safe.  It is composed of partially methoxylated poly α (1 - 4)-D-galacturonic acids 
with some 1-2 linked L-rhamnose groups (either inserted in or attached to the main 
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chains).  It also contains D-galactose and D-arabinose side chains.  Feruloylester 
substituents attach on the side chains in the case of pectin from sugar beet.  The 
average molecular weights of pectin are found to be between 50,000 to 180,000.  The 
pK-value of pectin is about 3.5.  There are different types of pectin available.  In all 
pectin types, carboxyl groups partially methoxylated.  The degree of methoxylation 
(DM) or degree of esterification (DE) refers to the average number of methoxy groups 
per 100 galacturonic acid units.  It is responsible for many of the physicochemical 
properties of the pectin.  DM/DE depends on different parameters, such as source of 
the pectin, enzymatic activity in the process of ripening and maturation, and the 
conditions under which the isolation is conducted [99].  In addition, when ammonia is 
used in the process of de-esterification, some of the carboxyl groups may be 
converted to carboxamide groups, producing amidated pectin.  Like DE, degree of 
amidation (DA) has major influence on physicochemical properties of the pectin.  
Pectin is resistant to enzymes present in stomach and intestine but is almost 
completely degraded by the colonic bacterial enzymes [112].   
 
Figure 1.4:  Chemical structure of pectin.   
The gel forming capability of pectin led to its application in the food industry 
as gelling or thickening agent in the beginning.  During last two decades, pectin is 
used as pharmaceutical excipient, especially in colon-specific formulation [198, 199].  
Several factors may influence the gelling activity, such as the types and 
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concentrations of pectin, DE, DA, temperature, solution pH, the modifications of 
hydroxyl group, the oxidization of the feruloylester substituents (sugar beet pectin), 
and the presence of cations.  Unfortunately, their solubility and swellability in 
aqueous fluid prevent them from efficiently avoiding premature drug release before 
reaching the colon.  However, this can be manipulated through choice of pectin type 
or the presence of additives.   
The DM has an essential influence on the properties of pectin, especially on its 
solubility and its requirements for gelation, which are directly derived from the 
solubility.  The DM of 50 % divides commercial pectins into high methoxy pectins 
(HM) and low methoxy (LM) pectins (DM > 50 % is regarded as HM pectin, while 
DM < 50 % is LM pectin).  The HM and LM pectins are gelled by different 
mechanisms.  Poorly soluble HM pectins have been developed into hydrogels for drug 
delivery [200].  Pectins with high DE also gel in the presence of large concentrations 
of sugar.  HM pectins require a minimum amount of soluble solids and a pH around 3 
to form gels.  LM pectins require the presence of a controlled amount of divalent 
cations for gelation and need neither sugar nor acid.  Gelation of LM pectin resembles 
gelation of alginate.  Additionally, the presence of amide groups in amidated pectins 
reduces hydrophilicity and increases tendency to form gels.  Pectins with high DA and 
low DE have been studied extensively for colon targeted formulations [166, 167].  
Pectins from sugar beet can be cross-linked via the oxidization of feruloylester 
substituents by using peroxide or peroxidase or with persulfate.  Moreover, divalent 
cations (e.g. Ca2+, Zn2+) are able to react with carboxylic groups of the pectin chains 
and produce pectinate gels (macromolecular aggregates) that have less aqueous 
solubility and swellability [199, 201].   
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1.2.4. Use of pectin for colon targeting   
Many approaches have been explored to develop pectin-based colon-specific 
drug delivery system.  These include reduction of swelling of the pectin matrix by 
calcium cross-linking, retardation of water penetration by using a water insoluble 
coating layer etc.  Another way to alleviate premature drug release before colon is by 
the use of hydrophobic polymers (e.g., ethylcellulose, methyl cellulose) which 
restricts the entry of water and consequently swelling of polymer.   
 
Figure 1.5:  The “Egg-box model”.   
Pectins with low degrees of methoxylation (LM pectins) are more soluble but 
they can be cross-linked with divalent cations (e.g. calcium, zinc) to produce a more 
water insoluble pectinate gel which has the potential to be an effective vehicle for 
drug delivery.  Pectins (DE < 50 %) form rigid gels by cross-linking with calcium 
salts or multivalent cations, which cross-link the galacturonic acids of the main 
polymer chains.  An ionic bond formation between the calcium ions and the 
carboxylic acid groups of the pectin molecules produce calcium pectinate network, 
which is known as ‘eggbox’ structure (Figure 1.5) [202].  The calcium-pectinate (Ca-
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pectinate) gel is stable in low solution pH and able to resist extensive hydration in 
vivo in the GI tract but swell in slightly basic solutions.  Since many pectinases have 
been shown to be stimulated by or have an absolute requirement for calcium ions for 
their activity, presence of calcium in the Ca-pectinate network should enhance the 
susceptibility of the polysaccharides to enzymes of the bacterial flora existing in the 
human colon [203].  Although the presence of calcium ions also enhance the activity 
of Gram-positive facultative bacteria, those bacteria do not digest pectins [99].  The 
potential of calcium pectinate for colon-specific drug delivery has been explored in-
vitro and in-vivo as films, gels, droplets, microspheres, and most often, in the form of 
compressed tablets using both water soluble and water insoluble, either small organic 
compounds or active protein drugs [162, 200, 204].  These studies demonstrated the 
tolerance of calcium pectinate in the upper GI tract and its enzymatic degradation in 
the lower GI tract.   
 
1.2.4.1. Multi-particulate systems:  Multiple unit dosage forms have been 
developed because of their several advantages over single unit dosage forms (this will 
be discussed later).  Among the multiple unit systems, pectin beads have been 
extensively studied in recent years.  Various reports suggest that pectin, when cross-
linked with calcium or zinc to form Ca/Zn-pectinate bead, may be a viable carrier for 
site specific drug delivery to the colon [199, 205-207].   
 
1.2.4.1.1. Calcium-pectinate beads   
Ca-pectinate bead formulation has shown great promise as a colon-specific 
drug carrier.  Researchers have prepared Ca-pectinate gel (CPG) beads of 
indomethacin (a poorly soluble drug) by dispersing indomethacin in a solution of 
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pectin and then dropping the dispersion into slightly agitated calcium chloride 
solution [201, 204].  The droplets instantaneously converted into gelled spheres by 
ionotropic gelation.  The effects of several formulation and processing variables (such 
as calcium concentration, drying condition, pectin type, presence of glutaraldehyde 
(hardening agent), hardening time, and drug loading) on the bead properties, size 
distribution, percentage of drug entrapped, and the release characteristics of 
indomethacin were investigated.  The resulting beads were spherical with narrow size 
distribution.  Indomethacin entrapment efficiencies were found to be high in all 
prepared beads.  Drug release, bead size, entrapment efficiency were found to be 
significantly affected by the formulation and processing variables.  The slower drug 
release was achieved from the formulations with higher calcium concentration in the 
cross-linking solution, higher concentration of hardening agent, and longer hardening 
time.  The DM of pectins influence the solubilization of bead matrix and the release 
kinetics of the drug [204].  The drying condition, however, did not influence the drug 
release.  The mechanism of indomethacin release from CPG beads followed the 
diffusion controlled model for an inert porous matrix.  All drug release data fitted well 
to the Higuchi square root time expression.   
Similarly, CPG beads containing bovine serum albumin (BSA, a highly water 
soluble protein) were prepared [205, 208, 209].  Objective of these studies was to 
prepare a colon-specific drug delivery system for therapeutic peptides that are 
degraded in the upper part of the GI tract due to degradation activity of the enzymes.  
The effects of several formulation and processing variables (such as calcium 
concentration, drying condition, pectin type, cross-linking time, BSA loading, pectin 
concentration, and glutaraldehyde concentration) on the encapsulation and release 
characteristics of BSA from the CPG beads were studied.  The drug release studies in 
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simulated GI conditions have shown that CPG beads protects BSA from being 
released completely in the upper GI tract conditions, and is susceptible to the 
enzymatic degradation with consequent drug release.  In addition, the release of BSA 
from CPG beads was strongly affected by calcium concentration, drying condition, 
type of pectin, and cross-linking time but not particularly affected by the amount of 
BSA added [205, 208].  Particle size and drug release rate from the beads were found 
to decrease with increasing calcium concentration in the cross-linking solution [205].  
However, the release was not particularly affected in the presence of low 
concentration of glutaraldehyde (≤ 1 %).  The investigated factors also influenced 
bead sizes and entrapment efficiency.  Size reduction was observed without any 
impact in the swelling behaviour of the beads as the cross-linking time was increased 
[208].  The authors suggested that the CPG beads could be a useful carrier for oral 
controlled delivery of both poorly soluble drugs as well as protein drugs.  In another 
study, Atyabi et al. [209] observed the effect of BSA loading and pectin concentration 
on drug release rate.   
In a study, chloroquine loaded Ca-pectinate beads with varying pectin 
(amidated pectin) to chloroquine ratios were prepared [210].  In-vitro release studies 
in simulated gastric and intestinal fluids demonstrated total release of the entrapped 
chloroquine from the hydrogel beads between 4 and 7 h in simulated intestinal fluid, 
but total release was not achieved in simulated gastric fluid.  The beads prepared with 
highest pectin to chloroquine ratio showed slowest drug release.  Oral administration 
of the beads to rats showed highest plasma concentrations by 7 h, but maximum 
plasma concentrations following chloroquine solution administration were observed 
by 2 h.  The dissolution data and pharmacokinetic profiles of the formulated beads 
suggested chloroquine release in duodenum, jejunum, or ileum. 
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In another study, Ca-pectinate beads were tested as carriers for the controlled 
delivery of theophylline but these dosage forms released about 80 % of the drug after 
4 h [211] whereas the transit time from the mouth to the rectum is much longer.   
 The enzyme activity of β-lactamases upon entrapment in Ca-pectinate beads 
was evaluated [212].  The beads were prepared with either non-amidated (NAP) or 
amidated pectin (AP).  NAP permitted a better encapsulation of β-lactamases than AP.  
A significant loss of β-lactamase activity was observed with increasing both CaCl2 
concentration and bead residence time in the cross-linking solution as well as during 
drying (37 °C for 2 h) of the beads.  Furthermore, calcium content of the beads 
increased with increasing CaCl2 concentration.  Being very hygroscopic, the excess of 
CaCl2 correlates with an increase of moisture content in beads which ultimately 
affects enzyme activity.  After elimination of free calcium from beads, it was shown 
that a small amount is needed to form the Ca-pectinate network and that the activity 
of β-lactamases is preserved in these conditions.  The authors suggested that the 
bioactivity of encapsulated β-lactamases in pectin beads might be preserved by 
selecting appropriate formulation parameters such as pectin type, CaCl2 concentration, 
washing and drying processes. 
 Ca-pectinate beads were also prepared using atenolol (cationic) and piroxicam 
(anionic) as model drugs [213].  Encapsulation of both anionic and cationic drugs was 
high.  The bead properties were regulated by the appropriate choice of drug 
concentrations, drying methods, and calcium chloride concentrations during bead 
preparation.  The study demonstrated the usefulness of this formulation for both 
anionic and cationic drugs. 
 In a separate study, pectin–insulin beads were prepared by the gelation of 
humilin–pectin solutions in the presence of calcium [214].  Pharmacokinetic 
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parameters in streptozocin induced diabetic rats revealed that the orally administered 
pectin–insulin beads were more effective in sustaining plasma insulin concentrations 
than was sub-cutaneous insulin at the same insulin dose.  The results from this study 
suggest that this insulin-loaded amidated pectin hydrogel bead formulation not only 
produces sustained release of insulin, but may also reduce plasma glucose 
concentration in diabetes mellitus. 
 In another study, Ca-pectinate gel bead of pectin hydrolysate was prepared 
[215].  In physiological saline, the beads swelled but erosion of the beads was not 
observed.  By contrast, the beads disintegrated in phosphate buffer (pH 6.8) and the 
rate of disintegration depended on the calcium chloride concentration used to prepare 
the beads.  Drug release rate from the beads in physiological saline decreased when 
prepared with increasing concentrations of calcium chloride.  Whereas, the drug 
release rate of the beads in buffer solution decreased as the rate of gel erosion 
declined.  Consequently, it appears that the Ca-pectinate gel matrix could be effective 
to control the release of drug within the GI tract. 
The drug is generally dissolved or dispersed in pectin solution.  Drugs with 
poor aqueous solubility or large drug molecules diffuse very slowly through the 
hydrogel and exhibit very high entrapment efficiency.  However, for small 
hydrophilic molecules, optimization of the cross-linking time and concentration of the 
cross-linker is necessary as quick diffusion of drug molecules through the hydrogel 
will lead to low entrapment efficiency. 
 
1.2.4.1.2. Zinc-pectinate beads   
Similar to Ca-pectinate beads, zinc-pectinate (Zn-pectinate) beads also 
exhibited their potential as colon-specific drug carrier.  Oral delayed-release system of 
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ketoprofen-loaded Zn-pectinate gel (ZPG) microparticles was prepared using similar 
ionotropic gelation procedure except zinc acetate was used instead of calcium 
chloride [216].  The microparticles were prepared by utilizing 23 factorial design and 
the effect of various formulation variables on the release behaviour of the 
microparticles was studied.  The ZPG microparticles were found to be superior over 
Ca-pectinate microparticles as the release of ketoprofen from ZPG microparticles in 
simulated intestinal fluid (SIF, pH 7.4) was 5.28 – 37.82 times (depending on 
formulation parameters) lower than the conventional Ca-pectinate beads.  
Additionally, the results showed that the release of ketoprofen in SIF was strongly 
affected by cross-linking agent concentration and initial drug amount, but not affected 
by the amount of pectin added.  The tablet was formed from the beads together with 
pectin/dextran mixture.  In-vitro drug release study of the tablet was performed using 
conditions mimicking mouth to colon transit.  The optimum ZPG/tablet system 
provided the expected delayed-release sigmoidal patterns (with a lag-time > 4 h and 
T50 (the time for 50 % of the drug to be released) > 7 h) depending on pectin/dextran 
ratio employed.  Therefore, it was proposed that ZPG microparticles and their 
modified release formulations are promising controlled-release carriers for colon-
targeted delivery of drugs.   
 Furthermore, Ca- and Zn-pectinate beads containing ketoprofen as a model 
drug were produced by ionotropic gelation method and influence of some formulation 
parameters (e.g., type of cross-linking agents, pH of cross-linking solution, 
concentration of cross-linking agents, and the type of capsule shell used (classical or 
enteric capsules)) was investigated upon bead properties and upon their performance 
to target the colon [198, 217].  When beads were introduced in classical hard capsules, 
ketoprofen release in simulated GI conditions was not significantly different between 
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Ca- and Zn-pectinate beads, as it was too premature and too quick due to chemical 
erosion of the pectinate matrix [217].  However, Zn-pectinate beads were found to be 
better than Ca-pectinate beads, when enteric hard capsules were used.  This might be 
due to a stronger network formation during cross-linking between the zinc cations and 
the LM-pectin chains, which induced a reduction of swelling and hydration when in 
contact with release medium, subsequently decreased drug release.  Reduction of 
cross-linking solution pH improved the stability of Zn-pectinate beads in conditions 
mimicking the upper GI tract [198].  Zn-pectinate beads obtained with 10 % zinc 
acetate solution at pH 1.6 exhibited the strongest gel network due to “egg-box” dimer 
formation by hydrogen bonding and a compact three-fold conformation of the gel 
network at low pH.  This matrix structure in enteric capsules induced the lowest drug 
release in the upper gastro-intestinal tract (pH 1.2 followed by pH 7.4) but release 
occurred in the colon in the presence of pectinolytic enzymes.  The carrier was 
suggested as a very promising and efficient for oral colon-specific drug delivery.   
 
1.2.4.1.3. Modified beads   
The main challenge in colon-specific drug delivery is the protection of the 
beads in upper GI tract so that most of the drug will remain inside the beads before 
reaching the colon.  As in some cases, Ca-/Zn-pectinate alone was not capable of 
enduring the 4 – 6 h passage through upper GI tract, modifications of the pectinate 
bead were attempted to ameliorate this purpose.  Researchers used chitosan [167, 218], 
glutaraldehyde [204, 205], PEI [219, 220], dextran [221], and many other chemicals 
for cross-linking of the pectin chains, which will be discussed in the following section.   
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1.2.4.1.3.1. Pectin-Chitosan:  Hydrogel beads were prepared by allowing the 
droplets of solution containing amidated pectin and indomethacin (poorly soluble) or 
sulphamethoxazole (relatively soluble) to fall into agitated calcium chloride solution 
containing chitosan [167, 222].  Calcium ions can cross-link with the pectin chains to 
produce hydrogel beads.  At the same time, chitosan (polycationic polymer) can 
couple to the pectin chains through electrostatic interaction to form a polyelectrolyte 
complex film on the wall of pores inside the gel beads and around the beads.  The 
beads are more stable at lower pH environment in the upper GI tract as the interaction 
between the amidated pectin and chitosan is favoured at low pH.  Both drugs were 
incorporated successfully into the beads.  Sulphamethoxazole release rate was higher 
than that of indomethacin in simulated gastric and small intestinal conditions in 
absence of chitosan but release of both drugs was reduced to satisfactory levels by the 
formation of a chitosan polyelectrolyte complex around the beads [167].  The results 
demonstrate that the pectinolytic enzymes still degraded the beads despite coupling 
with chitosan and complete drug release occurred within 135 min in the simulated 
colonic conditions.  Sriamornsak et al. found that indomethacin release was slow with 
higher molecular weight of chitosan and with increasing cross-linking time [222].  
They also found slightly different drug release profiles with different types of pectin 
used.  The results suggested that the pectin-chitosan composite gel beads could be 
used as a controlled drug delivery carrier.   
In other studies, the in-vitro swelling and release behaviour of BSA from 
chitosan-pectin composite particles [218] and chitosan coated pectin beads were 
investigated [223].  Swelling of the particles was significantly influenced by chitosan, 
pectin, and Ca2+ concentrations [218].  The results suggested that complex formation 
between chitosan and Ca2+, or between chitosan and pectin might have occurred.  
 32 
Negligible and sustained release of BSA from chitosan-pectin composite particles was 
observed in pH 1.4 and pH 7.4 buffers, respectively.  However, pectin degrading 
enzyme increased the protein release from the particles.  Kim et al. showed that the 
release of albumin from pectin beads could be retarded by coating with chitosan [223].  
The increase of CaCl2 concentration induced not much difference in albumin release 
from coated-pectin beads, although it decreased the release from uncoated pectin 
beads.  The higher molecular weight chitosan exhibited less albumin release than the 
lower one.  The pH of coating solution and release medium showed great influence on 
the release of albumin from the chitosan-coated pectin beads as these might affect the 
degree of swelling of pectin beads.   These characteristics of the chitosan-pectin 
composite particles would be useful for colon-specific delivery of macromolecules.   
Some researchers have investigated the influence of microwave irradiation on 
the sodium diclofenac (used as a model water-soluble drug) release property of the 
pectinate beads, chitosonium beads, pectinate beads loaded internally with chitosan 
(chitosan–pectinate beads), and beads coacervated with chitosan externally 
(pectinate–chitosonium beads) [224, 225].  The chemical stability of drug in beads 
was found to be unaffected by the microwave irradiation.  Treatment of pectinate 
beads by microwave did not lead to a decrease, but an increase in the extent and rate 
of drug released owing to reduced pectin–pectin interaction via carbonyl groups of the 
polymer.  Microwave treatment of the pectinate–chitosonium beads increased drug–
polymer and polymer–polymer interaction in beads, which reduced the rate and extent 
of drug released from the matrix.  On the contrary, the microwave treatment of 
chitosan–pectinate matrix increased the extent of drug released.  At the same time, the 
degree of reduction in the extent of drug released from the chitosonium beads was 
lower than that of the pectinate–chitosonium matrix.  The authors concluded that both 
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pectin and chitosan were needed in the formulation of a controlled-release matrix 
using the microwave technology.   
In a separate study, the optimization of a bead formulation based on a mixed 
network of Ca-pectinate and chitosan was performed by varying the relative 
percentages of pectin, chitosan, and calcium chloride [226].  Prednisone and 
theophylline were selected as model insoluble and relatively soluble drugs, 
respectively, in order to evaluate the influence of this parameter as well.  The most 
effective compositions in order to maximize drug encapsulation efficiency were 
evaluated for both drugs.  The different results obtained for the two drugs indicated 
the importance of the drug’s hydrophilicity/lipophilicity in determining the optimal 
bead composition with the highest encapsulation efficiency.   
Further, Ca-pectinate beads containing pectin hydrolysate and/or chitosan 
were prepared [227].  The beads gradually disintegrated in gastrointestinal fluids, and 
the rate of erosion of the beads was changed by modification of the gel matrix.  The 
amount of calcium ion used to make the beads had little effect on drug release; 
however, adding chitosan to the beads markedly suppressed drug release in intestinal 
fluid.   
 
1.2.4.1.3.2. Pectin-Glutaraldehyde:  To improve the colon-specific drug release, Ca-
pectinate beads were hardened with glutaraldehyde to improve the colon-specific drug 
delivery through the bead formulations [204, 205].  Preformed beads were treated 
with glutaraldehyde solution for few minutes.  The effect of glutaraldehyde on the 
drug release pattern from the Ca-pectinate beads has been described elsewhere.  
However, limited research on the effect of glutaraldehyde on the pectinate beads as 
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well as lack of proper in-vitro release study in simulated GI conditions and absence of 
in-vivo study left a vast scope for further exploitation of this approach.  
 
1.2.4.1.3.3. Pectin-Polyethyleneimine:  Hardening of the Ca-pectinate beads’ surface 
was attempted with polyethyleneimine (PEI).  Ca-pectinate beads containing β-
lactamases were prepared according to ionotropic gelation method [219, 220].  Beads 
were washed and introduced into PEI solution for few minutes.  Dried beads had a 
diameter around 1 mm.  PEI coating slightly affected the encapsulation efficiency of 
active β-lactamases.  Coating of the beads with PEI considerably improved their 
stability in simulated intestinal medium, whereas β-lactamases were released from the 
beads in colonic medium due to the matrix degradation by pectinolytic enzymes.  
After oral administration of loaded-beads to CD1 mice, high concentrations of β-
lactamases were recovered from faeces [219].  The beads extracted from the mice 
intestinal tracts revealed core degradation of beads without any degradation of the 
upper layer.  In addition, the pharmacokinetics of amoxicillin in rat after oral 
administration was not modified by the co-administration of beads containing β-
lactamases [220].  These observations indicated that PEI coated Ca-pectinate beads 
could be a useful carrier to target β-lactamases to the colon for the hydrolysis of 
colonic residual antibiotics responsible for the emergence of resistance without 
modification of the absorption of a β-lactam antibiotic when co-administered with 
loaded beads.  However, limited study on this allowed for further study.   
 
1.2.4.1.3.4. Pectin-Eudragit®:  In a study, Ca-pectinate beads containing 5-
fluorouracil (5-FU) were prepared by ionotropic gelation method followed by enteric 
coating with Eudragit® S-100 (enteric coating polymer) [228].  Release of 5-FU in 
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PBS (pH 7.4) and simulated gastric fluid showed almost similar pattern and rate, 
whereas a significant augmentation in drug release was observed in medium 
containing rat caecal content.  In-vivo results showed that Eudragit® S-100 coated 
calcium pectinate beads delivered most of their drug load (> 93 %) to the colon after 9 
h, which reflects its targeting potential to the colon.  The authors concluded that 
Eudragit® S-100 coated Ca-pectinate beads could be used for effective colon-specific 
delivery of 5-FU.   
 In another study, Eudragit® S100 coated calcium pectinate microspheres were 
developed for colon drug delivery using theophylline as a model drug [207].  Enteric 
coating with Eudragit® S100 improved the stability of the microspheres during 
storage, prevented morphologic changes observed for uncoated microspheres stored 
under ambient conditions, and enabled maintenance of microsphere integrity until 
their expected arrival in the colon.  Entrapment efficiency increased with decreasing 
cross-linking time, and with increasing CaCl2 concentration (only in the case of non-
amidated pectin).  Drug release study in conditions mimicking mouth to colon transit 
exhibited an inverse relationship between CaCl2 concentration and drug release rate.  
However, pectin type and cross-linking time showed no influence on drug release rate.  
Unexpectedly, enzymatic degradation of the microspheres was not evident after 
addition of pectinolytic enzymes to the release media.  Notwithstanding this 
unforeseen result, microspheres prepared with low calcium chloride concentration 
(2.5 % w/v) and coated with an appropriate thickness of Eudragit® S100 were able to 
adequately modulate drug release through a mixed approach of pH and transit time 
control, avoiding drug release (< 10 %) in the gastric ambient, and reaching the 
colonic target where complete drug release was achieved within less than 24 h.   
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1.2.4.1.3.5. Pectin-Chitosan-Eudragit®:  In a study, multi-particulate colon-specific 
drug delivery systems (microspheres) based on Ca-pectinate and chitosan were 
developed, using ketoprofen as model drug [206].  The microspheres were coated 
with Eudragit® S100.  Solubility of ketoprofen was improved by forming complex 
with cyclodextrin (HP-β-CD).  Release studies in simulated GI conditions revealed 
that ketoprofen release from the microspheres (without chitosan) containing 
ketoprofen as complex form with HP-β-CD was slower than formulation containing 
ketoprofen alone.  In contrast, the opposite release pattern was found for microsphere 
containing chitosan, due to a competition effect between polymer and drug for the 
cyclodextrin.  Cytotoxicity studies showed the safety of these formulations.  
Permeation studies demonstrated an enhanced permeation of the drug formulated as 
microsphere, particularly marked when the drug was used as complex.  The results 
indicated an enhancing power of both cyclodextrin and chitosan with a synergistic 
effect in improving drug permeation.  In fact, Eudragit-coated Ca-pectinate-chitosan 
microspheres assured a good protection from premature drug release in the upper GI 
conditions, starting drug release only in the simulated colonic environment.   
 In a separate study, pectinate beads containing trimethyl chitosan chloride 
(TMC) as an absorption enhancer were prepared by factorial design using Coomassie 
Brilliant Blue G 250 (high molecular weight water-soluble compound) as a model 
drug [229].  The optimization of the formulations was based on the effects of different 
formulation variables (such as, cross-linker type (calcium chloride and zinc acetate), 
cross-linking time, cross-linker concentration, TMC: pectin ratio, pectin concentration 
and voltage of the bead generator) on in-vitro bead characteristics (release and 
swelling-erosion).  The researchers found that zinc was better cross-linker as it 
reduced drug release in upper GI conditions, although there was no significant effect 
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of cross-linking time.  For further improvement of the bead characteristics and 
prolongation of bead integrity during the GI transit, bio-mineralization of the beads or 
coating them with high-methoxy pectin or Eudragit L30-D 55 was performed.  
Eudragit coating on the optimized core formulation was found to be very promising 
for colon-specific drug delivery.  As Coomassie Brilliant Blue G 250 is an anionic 
drug, TMC was found to form a complex with it and modify the release 
characteristics of the beads.   
 
1.2.4.1.3.6. Pectin-Alginate:  Pellets of sodium alginate, LM pectin and their novel 
binary mixture were produced via cross-linking with calcium ions through ionotropic 
gelation using diclofenac sodium as model drug for site-specific drug delivery in the 
GI tract [230, 231].  The average size of the different pellets was around 1.3 mm and 
drug entrapment capacity was optimized by reducing the calcium chloride solution pH 
to 1.6.  The incorporation of LM pectin (DM ~ 35 %) together with alginate appeared 
to influence the degree of cross-linking and subsequently the physical, mechanical, 
and resilience properties.  Three types of pellet formulations were subjected to 
dissolution studies over a pH range simulating the human GI tract.  Although 
negligible drug release occurred in pH 1 - 4, rate of drug release in pH 6.6 ranged 
from rapid to slow but always in a controlled manner.   
 
1.2.4.1.3.7. Pectin-Dextran/Amylose:  Hydrogel beads of amidated pectins 
containing either indomethacin or sulphamethoxazole have been prepared by 
ionotropic gelation with calcium chloride solution [221].  Either dextran or amylose 
was incorporated into the beads to modify drug release.  Due to the higher aqueous 
solubility, sulphamethoxazole release was more rapid than indomethacin at all pH 
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values.  The incorporation of amylose in the beads restricted the release of 
indomethacin at pH 7.4 in comparison with the beads composed of calcium pectinate 
alone.  Conversely, the inclusion of dextran led to more rapid release of the drugs 
over the first 3 h than when the amylose was incorporated into the calcium pectinate.  
After 5 h, the incorporation of dextran and amylose led to similar levels of tracer 
release.  Beads were still accessible and degraded by the enzymes as the drug release 
was rapid after addition of the pectinolytic enzymes to the release media.   
 
1.2.4.1.3.8. Pectin-Zein:  Novel complex hydrogel beads were prepared from two 
edible polymers: pectin (a carbohydrate from citrus fruits) and zein (a protein from 
corn) [232].  The pectin-zein complex hydrogel did not swell in physiological 
environments, but hydrolyzed in the presence of pectinases.  The formation of strong 
hydrogel beads was due to molecular entanglement of the two polymers.  
 
1.2.4.1.3.9. Others:  Other approaches including spray drying [233], 
microencapsulation [234], nanoparticle formation [235], etc. were studied for pectin 
based multiple unit systems.  However, these approaches were not extensively studied 
due to several shortcomings.   
 
1.2.4.2. Pectin as tablet matrix:  Pectin alone poses a very weak compactibility 
[168, 236] and incorporation of plasticizer in the pectin powder is therefore essential 
for tablet formation [237].  In a previous study [162], pectin or calcium pectinate 
powders and indomethacin were well-mixed and compressed into tablets.  The release 
of indomethacin (hydrophobic) from the tablets was very low in the absence of 
enzymes in the release media, whereas faster drug release was observed in the 
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presence of enzyme.  This study showed calcium salt of pectin as a promising colon 
drug targeting matrix.  However, carefully controlled amount of calcium in calcium 
pectinate gels is necessary for maximum gel strength and to provide optimal 
protection for incorporated drugs in calcium pectinate matrices [166, 238].   
Due to the fast dissolution of water soluble drugs from the surfaces of the 
tablets, dissolved drugs diffused through the matrix, create pores and channels.  This 
fluid migration into matrix promotes the extent and the rate of matrix swelling and 
creates a large surface area, which further accelerates the release of incorporated 
drugs.  In a previous study, calcium pectinate tablet of insulin (water soluble protein) 
was unable to prevent the premature release of insulin before reaching the colon and 
started to release insulin right after the administration [164].  Hence, it seems that the 
use of calcium pectinate matrices for colon-specific drug delivery is highly restricted 
to low water soluble drugs. It was suggested that an additional protective coating is 
required for tablets incorporated with water soluble drugs to isolate the drug from the 
surrounding medium.   
As described earlier, DE and DA of pectins have significant impact on the 
formation of Ca-pectinate gels.  Researchers have demonstrated that the extent of 
calcium ions binding decreased drastically with increasing content of esterified 
residues of pectin chains [239].  In the absence of enzymes, augmentation of calcium 
amount up to the optimal concentration decreased the release of drug from Ca-
pectinate matrices prepared with low DE pectin, but increased the release of drug 
from Ca-pectinate matrices prepared with high DE pectin [166].  The sites for egg-
box formation may be relatively unaffected by the smaller amide groups in 
comparison with methoxyl groups, but it can be further limited as the amide groups 
tend to be distributed in blocks with a random distribution of carboxyl and methylated 
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groups [240].  Another study reported that tablet prepared with either HM pectin or 
LM pectin with a carefully controlled amount of calcium provided optimal colon 
specificity by providing optimal protection of drug in the upper GI conditions and a 
high susceptibility to enzymatic degradation [165].   
In a study, GI transit and disintegration of enteric coated calcium pectinate 
matrix tablets were evaluated in 10 healthy human volunteers by γ-scintigraphic 
evaluation [163].  Enteric coating was performed using pectin (CaP/P) and guar gum 
(CaP/GG) as binder.  CaP/GG tablet showed slower disintegration as compared to 
CaP/P tablet but the time and location of complete tablet disintegration was more 
reproducible with CaP/P tablet as compared to CaP/GG tablet.  However, intact 
tablets reached the colon where they completely degraded.   
In another study, Ahrabi et al. (2000a) developed pectin-based matrix tablets 
containing ropivacaine as model drug.  They found that amidated pectin resulted in 
harder tablets with more enzyme susceptibility than the calcium salt of pectin.  
Furthermore, incorporation of ethylcellulose increased the tablet strength and 
decreased the dissolution rate.   
Other approaches for pectin based matrix tablets include the use of 
epichlorohydrin cross-linked pectin [241, 242] and addition of HPMC or 
microcrystalline cellulose to the pectin powder [168, 236, 243, 244].   
 
1.2.4.3. Pectin as coating:  Another approach for colon-specific delivery is the 
coating of the tablet with Ca-pectinate powder or with pectin in combination with 




1.2.4.3.1. Ca-pectinate powder  
 Compression coating of Ca-pectinate powder surrounding the core tablet 
containing drug is a widely studied technique.  The thick Ca-pectinate coating layer 
prevents physical contact between drug (present in the core tablet) and fluid till the 
outer layer is degraded by colonic enzymes.  One in-vivo study demonstrated a sharp 
increase in blood insulin concentration after 5 – 8 h of oral administration to dogs, 
when the weight ratio of calcium pectinate between the core and the coating layer was 
adjusted to 1 : 1 (w/w) [164].  This time is assumed to be ample for tablets to reach 
the colon of dogs.  An in-vivo gamma-scintigraphic study revealed that the coat 
integrity decreased with decreasing thickness of coating-layer and the coating-layer 
was susceptible to enzyme attack in the colon [200].  Optimum coat thickness is 
required to protect the premature release of the incorporated drug.  Required coat 
thickness increase for pectins with lower DE.  Other studies also reported that Ca-
pectinate coating can prevent premature drug release [211, 245].   
 However, the main difficulty is to coat the core tablets with even coat 
thickness and density in every direction with solid Ca-pectinate powder.  Regions 
with a thin or slack coat swell more easily and collapse faster.  Another limitation of 
compression-coated tablets for clinical applications may be the alteration of the GI 
transit time.  Furthermore, this approach may not be suitable for all dosage forms as 
these coats are bulky.   
 
1.2.4.3.2. Combination of pectin with other polymers   
In many instances, pectin (either plain or chemically modified) was combined 
with other synthetic or natural polymers to make use of the advantages of their parent 
polymers and/or create useful new properties.  For example, the composite of pectin 
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and ethylcellulose combines the enzymatic susceptibility of pectin and the protective 
properties of ethylcellulose.  Composites of pectin and chitosan or pectin and the 
polymethylmethacrylate derivatives carrying various amounts of amonium groups are 
enzymatically degradable but more water resistant, although the polymers themselves 
are water soluble.  However, the ratios of the polymers in the coating mixture need to 
be optimized.  These composites are often used as tablet coating in the form of 
aqueous film-coating dispersion or blended powder, or as excipients in tablet 
formation.  Some of the combinations that have been studied are as follows: 
i) Pectin-Ethylcellulose [99, 169-171, 246-248] 
ii) Pectin-HPMC [249-252] 
iii) Pectin-Eudragit® [170-172, 253] 
iv) Pectin-Chitosan [175, 254] 
v) Pectin-HPMC-Chitosan [173, 174, 252] 
 
1.2.5. Single-unit versus multiple-unit delivery systems   
 Single-unit colon targeted drug delivery systems may suffer from the several 
disadvantages.  Whereas, multiple-unit colon targeted dosage forms pose many 
advantages over single-unit dosage forms.  Unintentional disintegration of the single-
unit dosage forms due to manufacturing inadequacy may lead to unintentional drug 
release in upper GI tract.  The similar phenomenon may happen in case of unusual 
gastric physiology.  This may cause insufficient local therapeutic action in the colon 
or inadequate systemic drug bioavailability.  By contrast, multiple-unit dosage forms 
have potential benefits like predictable gastric emptying, reduced risk of systemic 
toxicity, reproducible and predictable GI transit time, increased bioavailability, more 
reliable drug release profile, and reduced risk of local irritation [255].   
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The importance of multiple-unit dosage forms over single-unit dosage forms 
for colon-specific drug delivery was realized two decades ago, when Hardy et al. [256] 
showed that multiple-unit drug delivery systems enabled the drug to reach the colon 
quickly and were retained in the ascending colon for a relatively long period of time.  
Currently, development of multiple-unit colon targeted drug delivery systems 
attracting more attention in comparison to single-unit systems.  Most commonly 
studied colon specific multi-particulate systems are pellets, beads, granular matrices, 
microspheres, and nano-particles [187, 257-260].  Unlike single-unit formulations, 
multiple-unit formulations are devoid of the danger of alteration in drug release 
profile and formulation behaviour due to unit to unit variation, although they retain 
most of the advantages of single-unit formulations [261].  Multiple-unit dosage forms 
can easily pass through the GI tract due to smaller particle size, leading to less inter- 
and intra-individual variability than single-unit dosage forms [261].  Furthermore, 
multi-particulate dosage forms tend to be more uniformly dispersed in the GI tract and 
also ensure more uniform drug absorption [262].  Multiple-unit systems spread out 
throughout the length of the intestine causing less irritation, enjoy a slower transit 
through the colon, and give a more reproducible drug release [255].  Moreover, 
multiple-unit dosage forms of enzyme specificity quickly spread out upon their arrival 
in the colon and due to an enhanced surface area being exposed to the enzymes, rapid 
drug release occurs in the colon [262].   
In the case of some diseases, such as inflammatory bowel disease (IBD), a 
multiple-unit dosage form in the micron size range could be useful as the drug 
delivery system with a size larger than 200 μm would be subjected to rapid bowel 
evacuation due to diarrhea, resulting in a reduced time available for drug release and 
decreased efficiency [263].  Moreover, some researchers showed that microspheres, 
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nanoparticles or nanoparticles entrapped in microspheres tend to accumulate at the 
site of inflammation in IBD, resulting in prolonged residence time in the desired area 
[264-266].  Inefficient therapy may be expected for tablets and capsules (single-unit 
dosage form) due to faster movement through large intestine, while colonic transit 
speed slow down in case of pellets with diameter of about 1 mm (multiple-unit dosage 
form) [256].  The rapid transit rates of larger size dosage forms due to “streaming” (as 
distinct liquid and solid phases are present in the colon, the two phases can move at 
different rates so that there is streaming of contents in the colon) can be subdued by 
size reduction of drug carrier systems, which prolong the colonic transit time, while 
maintaining the conventional drug release strategies [267].   
In a gamma scintigraphy study of two formulations (pellets (multiple-unit 
dosage form) and a single-unit non-disintegrating tablet) in 8 healthy human subjects 
revealed a statistically significant difference in the mean gastric emptying time 
between pellets (3.6 h) and tablet (9.6 h), although the mean transit through the small 
intestine did not vary significantly for the two formulations (pellets (3.1 h) and tablet 
(2.0 h)) [268].  Furthermore, a longer residence time in the colon in all subjects was 
found for pellets (28 h) as compared with the tablet (15 h).  These studies highlight 
the differences in the in-vivo behaviour of multiple- and single-unit dosage forms.   
 
1.2.6. In-vitro release study   
In-vitro release study can be used as a tool to assess drug release kinetics, 
impact of pH and hydrodynamic conditions on drug release characteristics, 
implications of formulation and manufacturing process changes, drug-release 
controlling mechanism, batch to batch consistency in manufacturing, and possibly to 
act as an in-vivo surrogate [143].  Dissolution testing has been an integral component 
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in pharmaceutical research and development of solid dosage forms.  It is the most 
widely accepted technique to evaluate the drug release pattern from oral dosage forms 
including colon-specific drug delivery systems.  It provides information on 
formulation type, critical processing variables, in-vitro–in-vivo correlation and quality 
assurance during manufacturing.  Development of dissolution method is an essential 
part of drug product applications to regulatory agencies as it is employed as quality 
control tool.  Dissolution testing method should be scientifically justifiable, 
reproducible and most importantly bio-relevant i.e. should be conducted in 
physiochemically and hydrodynamically defined conditions to simulate the 
environment that the dosage form encounters in the GI tract.   
Presently, dissolution study of modified release oral drug delivery systems is 
carried out using four types of dissolution apparatus: USP dissolution apparatus I 
(basket method), II (paddle method), III (reciprocating cylinder) and flow through cell.  
But, some modification of conventional dissolution methodology was deemed 
necessary for complex drug delivery systems like colon-targeted dosage forms, as 
certain restraints associated with routine dissolution methods were discerned [269].  
The dissolution testing method should closely mimic the in-vivo colonic environment 
with regard to pH, the volume and distribution of fluids, bacteria, the composition and 
activity of enzymes, and the mixing intensity, while being able to discriminate the 
impact of upper GI tract transit on the delivery system.  However, limited quantity of 
fluids particularly in the distal colon, the diversity and anaerobic nature of colonic 
microflora, the heterogeneity of fermentation activity in different regions, as well as 
the transient occurrence of motility patterns make the development, standardization 
and validation of such dissolution method highly challenging, if possible at all.  
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Nevertheless, several approaches were attempted in the literature for the testing of 
microbially triggered colon-specific delivery systems.   
 
1.2.6.1. USP dissolution methods:  It is widely accepted that during dissolution 
method development, the compendial apparatus and methods be first used for 
dissolution/release study of any novel/special kind of dosage forms [270].  Some 
scientists used USP dissolution apparatus II and III with slight modification to 
evaluate microbially triggered colon specific delivery system.  However, apparatus III 
(reciprocating cylinder) is more popular due to its’ unique setup (the dissolution tubes 
can be programmed to move along successive rows of vessels).  In addition, the drug 
release can be evaluated using a gradient of media to simulate the passage through 
different sections of the GI tract, varying hydrodynamic conditions and residence time 
in different media to simulate motility patterns and passage time under fasting and fed 
states (programming of sampling time, agitation rates, and medium changes can be 
done) [143, 186, 271, 272].  To mimic the GI tract physiological condition, three 
media are generally used for in-vitro release of colon specific delivery systems: 
simulated gastric fluid (SGF), simulated intestinal fluid (SIF) and simulated colonic 
fluid (SCF).  The SGF and SIF are mainly phosphate buffer of pH 1.2 and 6.8 - 7.5, 
respectively.  The SCF is also a phosphate buffer of pH 5 – 6; but, it normally 
includes enzyme which degrades specifically polysaccharides used in the delivery 
system; for example, pectinase for pectin [206, 207], galactomannanase for guar gum 
[186].  For better representation of the transit time in the GI tract, the duration of 
testing in each medium is usually set as mentioned in the introduction: 1 - 2 h in 
simulated gastric fluid (SGF), 3 - 4 h in simulated intestinal fluid (SIF) and 7 – 8 h in 
simulated colonic fluid (SCF, contain enzyme which specifically degrade the 
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biopolymer used in the formulation), successively.  Many researchers reported the use 
of USP dissolution apparatus for drug release study of colon-specific formulations 
[186, 187, 190, 272-274]  
Although USP dissolution testing is simple and convenient, it neither provides 
information on the validity of the system design nor predicts actual in-vivo 
performance as the volume and composition of dissolution media, and the mixing 
intensity are not representative of the conditions present in the colon due to scarcity of 
fluid and reduced motility in the colon.  It is mainly used to evaluate the integrity of a 
delivery system and provides essential information on the consistency of its 
manufacturing process [187, 190, 273, 275, 276].  Therefore, the drug release 
determined from the current USP dissolution setting is primarily qualitative in nature 
and may not be correlated with the in-vivo situation.   
 
1.2.6.2. Dissolution using rat caecal contents:  The utilization of rat caecal 
contents to subdue the limitations of the conventional dissolution study is a widely 
accepted approach due to the similarity between human and rodent colonic microflora 
[277] as well as easy availability of rats.  Several drug release studies have been 
carried out using rat caecal contents [162, 182, 192, 228, 278-282].  However, 
standardisation of the experimental procedure, such as, pH and viscosity of the media, 
the agitation intensity, the concentration and source of rat caecal contents, and volume 
of testing medium is required to allow meaningful comparison of different delivery 
systems and to establish in-vitro-in-vivo relationship.   
 
1.2.6.3. Dissolution using human fecal slurries:  Usage of human fecal slurries in 
the drug release study from polysaccharides based formulation is also an alternative 
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approach.  The detail procedure can be found elsewhere [187, 190, 273, 274, 283, 
284].   
 
1.2.6.4. Multi-stage compound culture system:  The colon, especially the caecum 
and the ascending colon resembles a continuous culture system as the indigestible 
residues from small intestine are fermented and condensed during transit through the 
colon [143].  Considering this situation, a three stage continuous culture system was 
designed to simulate the colonic microfloral characteristics at various colonic regions 
[285, 286].  This multi-stage system comprises three glass fermentation vessels 
arranged in series as follows: 1st stage - working volume of 200 ml at pH 5.5, 
(simulates proximal colon); 2nd stage - working volume of 200 ml at pH 6.2, 
(simulates transverse colon); and lastly, 3rd stage - working volume of 280 ml at pH 
6.8 (simulates distal colon).  Each fermentation vessel was inoculated with 100 ml of 
freshly prepared 20 % (w/v) fecal slurries from healthy non-methanogenic donors 
with continuous stirring at 37 °C under CO2 atmosphere.  The whole procedure is 
described elsewhere [285, 286].   
Based on the above concept, Molly et al. fabricated a five step multi-chamber 
reactor (simulated human intestinal microbial ecosystem (SHIME)) to simulate both 
small and large intestinal microbial ecosystem [287].  Each reactor in the SHIME 
represented each segment of human GI tract (duodenum and jejunum, ileum, caecum 
and ascending colon, transverse colon, and descending colon).  Despite the possibility 
of standardizing drug dissolution studies using multi-stage culture systems, the 
complexity in setup and operation (e.g., strength and sources of the fecal inoculate, 
buffering of the medium, continuous addition of nutrients for bacterial growth and the 
requirement of special containment facilities [283]) prevent them from routine use.   
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 Though dissolution study in medium containing caecal contents or human 
fecal slurries or in a multi-stage culture system indicates whether or not drug release 
will be initiated by degradation of polysaccharides when exposed to the colonic 
environment, this provide very little information about the delivery system, 
formulation and process development.  Hence, it is advisable to employ USP 
dissolution testing together with the dissolution in bio-relevant media containing rat 
caecal contents or human fecal slurries or the multi-stage culture system to fully 
characterize a colon-specific formulation activated by microflora.   
 
1.2.7. In-vivo study   
Comparison of colon-specific drug delivery systems based on their in-vitro 
drug dissolution profiles can be problematic.  The viscosity, pH, bacterial composition, 
and enzyme activities in the dissolution medium together with agitation intensity are 
only qualitatively comparable to the colonic conditions.  These factors suggest that 
the rate of polysaccharide fermentation and dissolution kinetics would be different in-
vitro than in-vivo.  As the dissolution testing conditions differ significantly from each 
other and from the actual in-vivo condition, actual in-vivo experiments are essential to 
prove the efficacy of the formulations.   
Gamma-scintigraphy based imaging technology has immensely helped in 
generating good evidence of the actual in-vivo behaviour of colon targeted dosage 
forms [184, 288].  Gamma-scintigraphy is a nuclear medicine technique that is used to 
visualise the in vivo behaviour of pharmaceutical dosage forms in a non-invasive 
manner [289, 290].  For example, the performance of Eudragit® S-coated tablets in 
seven healthy volunteers was assessed using gamma-scintigraphy [139].   
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 In another study, Jain et al. [228] evaluated the efficacy of their colon specific 
Ca-pectinate beads in rats.  One rat from each group was sacrificed at predetermined 
time interval after the administration of the formulation.  The GI tract was removed 
and segmented into the stomach, small intestine, caecum, and colon.  The amount of 
drug recovered in different segments of GI tract at different time intervals were 
determined by HPLC analysis.   
Pharmacokinetic study has also been used to check the formulation efficiency.  
Munjeri et al. [210] studied pharmacokinetics of chloroquine-loaded pectin beads in 
rats.  Blood samples were collected at predetermined time interval following oral 
administration of the formulations and amounts of chloroquine were measured.  
Musabayane et al. [214] evaluated the formulation efficacy after oral administration 
of insulin-loaded pectin beads in streptozotocin-diabetic rats.  Blood samples were 
collected for insulin and glucose measurements at different time intervals.  In another 
study, Bourgeois et al. [220] also performed pharmacokinetic study of the pectin 
beads containing β-lactamases to evaluate the efficacy of their formulation.   
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1.3. Hypotheses and objectives of the thesis  
 Resveratrol has shown wide pharmacological activities.  However, its 
therapeutic uses are hampered by its low oral bioavailability.  It was hypothesized that 
the low aqueous solubility of resveratrol may impair its oral bioavailability.  In 
addition, due to its low aqueous solubility, resveratrol is unsuitable for both oral and 
parenteral administration.  Thus, this study first aimed to determine whether 
hydroxypropyl-β-cyclodextrin (HP-β-CD) and randomly methylated-β-cyclodextrin 
(RM-β-CD) can improve the dissolution of resveratrol by forming inclusion 
complexes.  Inclusion complexes were characterized and stability was determined.  
Then, a plasma sample preparation method was developed together with a sensitive, 
accurate, and quick high performance liquid chromatography (HPLC) assay method 
for the pharmacokinetic study.  The pharmacokinetic study in rats was performed with 
resveratrol-cyclodextrin inclusion complexes and resveratrol suspension formulation 
to check whether an increase in the dissolution of resveratrol leads to an increase in its 
oral bioavailability.  In addition, different doses of resveratrol were administered in 
the rats to observe any increase in oral bioavailability due to saturation of metabolism 
or elimination at higher dose.  However, the results indicated that despite a huge 
increase in solubility, the extent of resveratrol absorption was unaffected though the 
rate of absorption was increased.  Dose manipulation also did not enhance its oral 
bioavailability.  Thus, the short half-life and extremely low bioavailability of 
resveratrol have raised concerns regarding its systemic action.  Despite these, 
resveratrol could have therapeutic potentials to the more accessible anatomical site, 
e.g., colon. Resveratrol has shown promising therapeutic efficacy towards several 
colonic diseases (e.g., colon cancer and colitis).  Currently, colonic diseases are 
prevalent throughout the world.  Surgical intervention is often needed to treat these 
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diseases and search for effective therapy is still continuing.  Therefore, it was 
hypothesized that a colon-specific delivery system of resveratrol may appear as an 
alternative to the existing treatments of theses diseases.  To accomplish this purpose, 
this study aimed at devising a multi-particulate colon-specific delivery system of 
resveratrol as calcium-pectinate (Ca-pectinate) and zinc pectinate beads (Zn-
pectinate).  However, unmodified Ca-/Zn-pectinate beads did not show colon-specific 
drug release despite negligible drug release from the beads in the gastric condition.  
Hence, additional modification of the beads was necessary to achieve colon-specific 
drug release.  Polyethyleneimine (PEI) and glutaraldehyde were used to modify the 
beads.  The formulation conditions were optimized from the in-vitro drug release 
study.  The modified beads prepared at the optimized formulation conditions showed 
in-vitro colon-specific drug release.  Finally, the pharmacokinetic profiles of the 
developed colon-specific delivery systems of resveratrol were tested in rats.  
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CHAPTER 2 
SOLUBILITY ENHANCEMENT OF RESVERATROL USING CYCLODEXTRINS  
2.1. Introduction   
Resveratrol has wide pharmacological activities.  It is well known for its anti-
oxidant, anti-inflammatory, analgesic, cardio-protective, neuro-protective, chemo-
preventive, and anti-aging activities [10, 21, 68].  Resveratrol has shown great 
promise in the treatment of cancers and two Phase I/II clinical trials are currently 
underway to determine if resveratrol is useful for the treatment of colorectal cancer 
[291].  More recently, resveratrol has shown to improve general health and survival of 
mice on a high-caloric diet, pointing to new approaches for treating obesity-related 
disorders and diseases of aging [68].  However, due to its low water solubility, 
resveratrol is unsuitable for both oral and parenteral administration.  Thus, we 
hypothesized that the formation of inclusion complexes with cyclodextrins could be 
helpful to overcome this limitation.   
Cyclodextrins (CDs), a family of cyclic oligosaccharides derived from starch, 
have been extensively used as pharmaceutical excipients to increase the solubility of 
poorly water-soluble compounds.  The formation of an inclusion complex between the 
host cyclodextrin molecule and the small guest drug molecules or portions of large 
compounds have been attributed to this solubility enhancement [292].  Generally, 
formation of this inclusion complex does not involve any covalent bonding.  The 
molecular encapsulation of the guest molecule by cyclodextrin results in modification 
of the physico-chemical properties such as, solubility and stability of the guest 
molecule [293, 294].  β-Cyclodextrin (Figure 2.1) possesses seven α-1,4-linked 
glucose residues.  It gives a molecular structure with an appropriate cavity diameter 
that allows the formation of stable complexes with a wide variety of pharmaceutical 
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compounds.  However, its parenteral administration causes severe nephrotoxicity and 
it has limited water solubility (18.6 mg.ml-1) [295].  Subsequently, numerous 
chemically modified β-CDs have been developed due to the solubility limits and the 
safety concerns with β-CD [293].  Among them, hydroxypropyl-β-cyclodextrin (HP-
β-CD) has been extensively used as pharmaceutical excipient due to its advantage of 
greater aqueous solubility and parenteral safety in comparison with β-cyclodextrin.  
The amorphous (non-crystalline) structure of HP-β-CD is responsible for its greater 
solubility and safety [296].  Although some researchers [297] have studied inclusion 
complex of resveratrol with CDs, randomly methylated-β-cyclodextrin (RM-β-CD), 
which usually is better at improving aqueous solubility and oral bioavailability of the 
complexed drug, has never been studied.  Therefore, it is hypothesized that both HP-
β-CD and RM-β-CD could be appropriate excipients to increase solubility of 
resveratrol.  To confirm this hypothesis, phase-solubility of the inclusion complexes 
prepared with HP-β-CD and RM-β-CD was investigated in this study.  The stability of 
resveratrol, pure and complexed, under different storage conditions was evaluated.  
Furthermore, the physicochemical properties of the inclusion complexes (resveratrol-
HP-β-CD and resveratrol-RM-β-CD) were investigated by Fourier transform infrared 
spectrophotometry (FTIR), differential scanning calorimetry (DSC), and X-ray 
diffractometry (X-RD) to confirm the complex formation.  The stability constants of 
the inclusion complexes formed were calculated from the phase-solubility studies.  
Molecular modelling served as a supplementary tool to understand the inclusion 
behaviour of the CDs by predicting the inclusion modes and the stoichiometry of the 
complexes.  The combined uses of different characterization techniques provide the 
best results in terms of reliability of the models.   
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A B  
Figure 2.1:  Chemical structure of β-cyclodextrin (A) and HP-β-CD (B).  In case of 
RM-β-CD, hydroxypropyl groups (-CH2-CH(OH)-CH3) are replaced by methyl group 
(-CH3) in figure B. 
 
2.2. Materials and methods 
2.2.1. Chemicals  
Resveratrol (99.9 % purity, fine crystalline powder) and sodium phosphate 
monobasic were purchased from Sigma (St Louis, MO).  RM-β-CD (degree of 
substitution: ~ 1.8) and HP-β-CD (degree of substitution: ~ 0.6) were kindly donated 
by Wacker Chemie AG (Burghausen, Germany) and Roquette Freres S.A. (Lestrem, 
France), respectively.  HPLC grade methanol and acetonitrile were obtained from 
Tedia Company (Fairfield, OH).  Purified water (18.2 MΩcm at 25ºC) was obtained 
from a Millipore Direct-Q® ultra-pure water system (Billerica, MA) and used 
throughout the study.  Di-sodium hydrogen phosphate anhydrous was purchased from 





2.2.2. High performance liquid chromatography assay 
High performance liquid chromatography (HPLC) assays were performed for 
the phase-solubility study.  A Shimadzu (Kyoto, Japan) 2010A HPLC system was 
used to quantify resveratrol in the formulations.  The chromatography was run with a 
reversed phase HPLC column (ODS Hypersil, 5 µm, 250 mm × 4 mm, Agilent, Palo 
Alto, CA), which was protected with a guard column (Agilent).  The assay was 
performed at 35 ºC through isocratic delivery of the mobile phase, consisting of 
acetonitrile and 30 mM phosphate buffer solution (PBS), pH 7.0 (30:70 v/v) at a flow 
rate of 1 ml⋅min-1.  A 5 µl sample was injected into the HPLC system for each run.  
Resveratrol was quantified by measuring ultraviolet (UV) absorbance at 320 nm.  
Different concentrations of resveratrol were freshly prepared in acetonitrile prior to 
the HPLC analysis.  The calibration curve was linear (R2 > 0.099) within the range of 
1 – 100 µg.ml-1. The intra-day and inter-day variations were less than 5 %.  For the 
concentrated samples from the formulation preparation, they were diluted with 
methanol-PBS, pH 7.4 (1 : 1) and only diluted samples (5 µl) were injected into the 
HPLC. 
 
2.2.3. Solubility study in simulated gastro-intestinal fluids 
Resveratrol solubility was determined in simulated GI fluids.  Excess amount 
of resveratrol was added to simulated gastric fluid (SGF, pH 1.2) and simulated 
intestinal fluids (SIF, pH 6.8 and SIF, pH 7.5); vortexed and kept on a horizontal 
rotary shaker (200 rpm) for 3 days at room temperature.  The suspension was filtered 
through a 0.22 µm membrane filter (Whatman Ltd., Kent, UK) to obtain a clear 
solution.  All samples were prepared in triplicate.  The concentration of resveratrol in 
SGF and SIF was measured by HPLC assay (calibration range 0.1 - 10 µg⋅ml-1). 
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2.2.4. Phase-solubility study 
Resveratrol-cyclodextrin inclusion complexes were prepared with a method 
modified from a previous report [298].  Briefly, an excess amount of resveratrol (40 
mg⋅ml-1) was added to HP-β-CD or RM-β-CD solutions prepared at different 
concentrations (0, 0.01, 0.025, 0.05, 0.10, 0.15, 0.20, 0.30 M) with 10 mM phosphate 
buffer solution (PBS) at pH 7.4.  The suspensions were vortexed and sonicated for 1 h 
and kept on a horizontal rotary shaker (200 rpm) for 3 days at room temperature.  The 
suspension was filtered through a 0.22 µm membrane filter (Whatman Ltd., Kent, UK) 
to obtain a clear solution.  All samples were prepared in triplicate.  Final clear 
solutions were diluted properly with methanol-PBS (1:1, pH 7.4) to the calibration 
range (1 – 100 µg⋅ml-1) and the concentrations of resveratrol in inclusion complex 
solutions were measured by HPLC.  The apparent inclusion rate constant (K1:1) was 






=  ; where Slope1 is slope of the phase-solubility curve and S0 is 
the intrinsic solubility of resveratrol. 
 
2.2.5. Preparation of solid resveratrol–CD complexes 
The solid inclusion complexes were prepared according to a previously 
reported method [300].  The excess amount of resveratrol was added to the aqueous 
solution of HP-β-CD or RM-β-CD.  The mixtures were shaken on a horizontal 
mechanical shaker at room temperature (25 °C) for 3 days and then filtered to remove 
the excess drug.  The resulting solution was frozen at -80 °C for few hours and then 
subjected to lyophilization in a freeze-dryer to obtain the dry powders.  To prepare 
physical mixtures of resveratrol–CD, resveratrol and CDs were separately pulverized 
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in ceramic mortars, and calculated amounts of both compounds (calculated from the 
phase solubility study) were weighed, mixed together, vortexed for 30 s, and then 
mixed again with a spatula.  Pure resveratrol and CDs together with the prepared 
inclusion complexes and the physical mixtures were then subjected to a series of 
physico-chemical analyses. 
 
2.2.6. Characterization of the inclusion complexes  
2.2.6.1. UV scan:  Resveratrol and corresponding inclusion complexes were 
dissolved in methanol (resveratrol is soluble in methanol) and scanned from 200 nm 
to 400 nm in a UV-Vis spectrophotometer (UV – 1601, Shimadzu, Japan). 
 
2.2.6.2. FTIR:  FT-IR study of resveratrol, HP-β-CD, RM-β-CD, corresponding 
physical mixtures, and corresponding inclusion complexes (after freeze drying) were 
performed using a FT-IR Spectrometer (PerkinElmer Spectrum 100 Series, Norwalk, 
CT, USA).  Samples were mixed with anhydrous potassium bromide (1 : 100) and 
ground in a mortar and then pressed in a hydraulic press (14 tons) to small discs.  The 
discs were placed under the infrared beam and the FT-IR spectra were collected in a 
spectral region between 4000 and 450 cm-1. 
 
2.2.6.3. DSC:  The DSC curves of resveratrol, HP-β-CD, RM-β-CD, corresponding 
physical mixtures, and corresponding inclusion complexes (after freeze drying) were 
recorded on a differential scanning calorimeter (Perkin Elmer DSC, Norwalk, CT, 
USA) at heating rate of 10 °C.min-1.  The thermal behavior was studied by heating 5 
mg samples in aluminum crimped pans under nitrogen gas flow within the 
temperature range 10 - 300 °C. 
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2.2.6.4. X-RD:  The powder X-ray diffraction patterns of resveratrol, HP-β-CD, 
RM-β-CD, corresponding physical mixtures, and corresponding inclusion complexes 
(after freeze drying) were recorded with a powder X-ray diffractometer (Bruker-AXS 
D8) with a CuKa radiation detector (k = 1.5405 Å) operating at a voltage of 30 kV 
and a current of 35 mA.  The samples were analysed in the 2θ range from 3 to 60° 
with a scan angular speed of 2°.min-1 and a scan step time of 2 sec. 
 
2.2.7. Molecular Modelling 
Molecular modelling was carried out for further elaboration of the 
complexation modes.  AUTO DOCK software was used for this purpose.  Since RM-
β-CD is a mixture of different structures, dimethyl-β-cyclodextrin (DM-β-CD) was 
adopted as a substitution for RM-β-CD (degree of substitution = 1.8) to facilitate the 
determination of the stable structure of the resveratrol-RM-β-CD complex.  Four 2-
hydroxypropyl groups were added on the primary hydroxyl groups of β-cyclodextrin, 
as the degree of substitution of HP-β-CD used was 0.6 [301].  The structures of 
resveratrol, DM-β-CD, and HP-β-CD were individually minimized.  After thorough 
minimization, docking experiments were carried out on all molecules using the 
‘‘AUTO DOCK’’ software.  This procedure allowed the resveratrol molecule to move 
within the energy field of DM-β-CD or HP-β-CD and vice versa to find the preferred 
binding geometries.  The favorable conformation of the resveratrol molecule was 
introduced into the DM-β-CD or HP-β-CD cavity, and the steric interaction energy 
was computed.  The inclusion complex with the lowest interaction energy was the 




2.2.8. Dilution and re-dissolution study of resveratrol-CD complexes  
In order to examine the suitability of HP-β-CD and RM-β-CD as excipient for 
oral/parenteral delivery of resveratrol, the dilution and re-dissolution study of 
resveratrol-CD complexes were performed.  Resveratrol-HP-β-CD/RM-β-CD 
solutions (10 mg resveratrol was fully dissolved in 1 ml 0.3 M HP-β-CD/RM-β-CD) 
were diluted with PBS (pH 7.4) to produce 2, 5, 10, 25, 50, 100, 500, and 1000 
dilutions.  The diluted solutions were then centrifuged at 10,000 g for 10 min and 
carefully observed for sediments.  In another experiment, 10 ml of resveratrol–HP-β-
CD/RM-β-CD solutions (10 mg.ml-1) were lyophilized for 24 h.  The dried products 
were then re-dissolved in 10 ml PBS (pH 7.4) and diluted to produce 2, 5, 10, 25, 50, 
100, 500, and 1000 dilutions.  The diluted solutions were then centrifuged at 10,000 g 
for 10 min and checked for the presence of sediments.  Both experiments were carried 
out in triplicate. 
 
2.2.9. Stability of inclusion complex  
The stability studies of the following samples were performed under dark 
condition at room temperature (RT) and 4 ºC. 
i) Methanolic solution of pure resveratrol  
ii) Aqueous solution of corresponding inclusion complexes  
iii) Corresponding lyophilized inclusion complexes (samples were re-dissolved in 
PBS just before analysis) 
The solutions were prepared by dissolving 10 mg resveratrol in 1 ml of 
methanol or 0.3 M cyclodextrins.  The clear solutions obtained were stored in the 
same conditions described above.  Samples were withdrawn at specified time intervals, 
and the concentration of resveratrol was determined by HPLC.  The results were 
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expressed as percentage of the remaining resveratrol.  Each test was carried out in 
triplicate.   
 
2.2.10. Statistics 
Statistical analyses were performed using the software Graph-Pad Prism 
Version 2.00 (San Diego, CA).  All experimental data were expressed as mean ± 
standard deviation (SD).  Statistical analysis of phase solubility study between HP-β-
CD and RM-β-CD was performed by two tailed unpaired t test, whereas statistical 
analysis of stability study was performed by using one-way ANOVA with the post 
hoc Tukey test.   
 
2.3. Results and Discussion 
2.3.1. Solubility study in simulated gastro-intestinal fluids 
Resveratrol solubility in simulated gastro-intestinal fluids is pH dependant.  
Solubility of resveratrol in SIF, pH 6.8 and SIF, pH 7.5 is 0.11 ± 0.01 µg.ml-1 and 
0.42 ± 0.03 µg.ml-1, respectively, whereas resveratrol is almost insoluble in SGF, pH 
1.2.  Such low solubility of resveratrol in buffers at different pH was also reported in a 
recently published study by Hung et al. [302].   
 
2.3.2. Phase solubility study 
Figure 2.2 shows the phase solubility profiles of resveratrol in HP-β-CD and 
RM-β-CD solutions.  Both CDs produced a concentration-dependent increase in the 
solubility of resveratrol, with RM-β-CD producing a more enhanced effect than HP-β-
CD on a per molar concentration basis (28.13 mg.ml-1 for RM-β-CD vs. 22.61 mg.ml-
1 for HP-β-CD at 0.3 M CD concentration).  This difference in enhanced solubility is 
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probably due to the extended hydrophobic surface of the inner cavity of RM-β-CD 
molecules [303].  Phase solubility plots were A-L type and linear (R2  > 0.99) from 
0.01 to 0.3 M CD concentration for both CDs.  These results suggest that within the 
concentration range studied, the inclusion stoichiometry of resveratrol with CD was 
mostly 1 : 1, and is consistent with previous observation obtained at lower CD 
concentrations [297].  Inclusion rate constants (K1:1) for HP-β-CD and RM-β-CD 
solutions were calculated from the slope of Figure 2.2 and using S0 (0.0017 mM) 
obtained from phase solubility study.  The calculated values of K1:1 (3.17 x 105 M-1 for 
HP-β-CD and 4.41 x 105 M-1 for RM-β-CD) indicate that the complexes formed 
between resveratrol and HP and RM CDs are moderately stable.   
 
Figure 2.2:  Phase solubility diagrams for resveratrol with HP-β-CD and RM-β-CD at 
25 ºC.  Data represent the mean values (n = 3) of the groups ± S.D.  * p < 0.05.   
 
2.3.3. Characterization of the inclusion complexes 
2.3.3.1. UV scan:  UV scan of pure resveratrol and inclusion complexes were 
performed to investigate any chemical changes in resveratrol after inclusion complex 
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formation.  Figure 2.3 shows similar UV absorption pattern and almost same λmax 
value of pure resveratrol and the inclusion complexes, which indicates no chemical 
change in resveratrol after complex formation. 
 
Figure 2.3:  UV scan result of pure resveratrol (A), resveratrol-HP-β-CD inclusion 
complex (B), and resveratrol-RM-β-CD inclusion complex (C). 
 
2.3.3.2. FT-IR:  Figure 2.4 shows infrared (IR) spectra of pure resveratrol, HP-β-
CD, their physical mixture, and inclusion complex.  Similarly, Figure 2.5 shows IR 
spectra of pure resveratrol, RM-β-CD, their physical mixture, and inclusion complex.  
FT-IR absorption spectrum of resveratrol showed a typical trans olefinic band at 966 
cm-1 and three characteristic intense bands at 1383, 1585, and 1607 cm-1, 
corresponding to C–O stretching, C–C olefinic stretching, and C–C aromatic double-
bond stretching.  The IR spectra of the physical mixtures are approximately the 
superposition of the raw materials.  The IR spectra of the inclusion compounds show 
the changes in the spectral features of the guest molecule (resveratrol).  As a matter of 
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fact, the intensities of the characteristic bands of resveratrol were either decreased or 
disappeared.  These evidences probably suggest the formation of inclusion complexes 
between resveratrol and HP-β-CD/RM-β-CD [304]. 
 
Figure 2.4:  FTIR spectra of pure resveratrol (A), HP-β-CD (B), HP-β-CD-resveratrol 
physical mixture (C), and HP-β-CD-resveratrol inclusion complex (D). 
 
 
Figure 2.5:  FTIR spectra of pure resveratrol (A), RM-β-CD (B), RM-β-CD-
resveratrol physical mixture (C), and RM-β-CD-resveratrol inclusion complex (D). 
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2.3.3.3. DSC:  Researchers have reported thermal analysis as a method to 
characterize cyclodextrin inclusion complexes [305, 306].  In Figure 2.6, DSC 
profiles of pure resveratrol, HP-β-CD, their physical mixture, and inclusion complex 
are shown.  Similarly, DSC profiles of pure resveratrol, RM-β-CD, their physical 
mixture, and inclusion complex are shown in Figure 2.7.  The melting endothermic 
peak of resveratrol at 270 °C was absent in the DSC thermograms of the inclusion 
complexes, whereas the endothermic peak of resveratrol was present in the case of all 
physical mixtures.  The results indicate the formation of the inclusion complexes 
between resveratrol and HP-β-CD/RM-β-CD. 
 
 
Figure 2.6:  DSC thermograms of pure resveratrol (A), HP-β-CD-resveratrol physical 




Figure 2.7:  DSC thermograms of pure resveratrol (A), RM-β-CD-resveratrol 
physical mixture (B), RM-β-CD-resveratrol inclusion complex (C), and RM-β-CD 
(D). 
 
2.3.3.4. X-RD:  X-RD profiles of pure resveratrol, HP-β-CD, their physical mixture, 
and inclusion complex are shown in Figure 2.8.  Similarly, X-RD profiles of pure 
resveratrol, RM-β-CD, their physical mixture, and inclusion complex are shown in 
Figure 2.9.  The X-RD study confirmed the results of DSC analyses.  The diffraction 
peaks of resveratrol indicate the crystalline structure of resveratrol.  The diffraction 
peaks were present in the X-RD pattern of physical mixtures and the patterns are 
approximately the superposition of the raw materials.  The diffraction peaks of 
resveratrol were no longer detectable in the X-RD pattern of the inclusion complexes, 
which may be considered as an indirect proof of complexation between resveratrol 
and HP-β-CD/RM-β-CD [307].  A reduced number as well as remarkably lowered 
intensity of the peaks in the complexes suggests a greater amorphousness of the 
inclusion complexes compared to pure resveratrol. 
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Figure 2.8:  X-Ray diffraction patterns of pure resveratrol (A), HP-β-CD-resveratrol 
physical mixture (B), HP-β-CD-resveratrol inclusion complex (C), and HP-β-CD (D). 
 
 
Figure 2.9:  X-Ray diffraction patterns of pure resveratrol (A), RM-β-CD-resveratrol 
physical mixture (B), RM-β-CD-resveratrol inclusion complex (C), and RM-β-CD 
(D). 
 
2.3.4. Molecular modelling 
Three dimensional (3-D) structure of resveratrol is presented in Figure 2.10A.  
The preferred structure of the HP-β-CD-resveratrol inclusion complex is shown in 
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Figure 2.10B.  A similar study with the resveratrol–DM-β-CD complex was also 
carried out (Figure 2.10C).  Since RM-β-CD is a mixture of different structures, DM-
β-CD was used in this study instead of RM-β-CD.  The orientation of resveratrol in 
the DM-β-CD cavity was found to be similar to the orientation of resveratrol in the 
HP-β-CD cavity.  The figures indicate that the benzene ring containing one hydroxyl 
group was housed in the CD cavity. The difference in energy values (-25.28 and -
20.03 Kcal/mol for DM-β-CD and HP-β-CD, respectively) indicates that the 
interaction between resveratrol and DM-β-CD might be stronger than that between 
resveratrol and HP-β-CD.  This result is consistent with the result of the phase-






Figure 2.10:  3-D structure of resveratrol (A), hypothetical structure of the 
resveratrol–HP-β-CD complex (without surface) (B), and resveratrol–DM-β-CD 
complex (with surface) (C). 
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2.3.5. Dilution and re-dissolution study of resveratrol-CD complexes  
After 2 - 1000 times dilutions with PBS (pH 7.4), no sedimentation was 
observed in any of the samples.  Furthermore, upon reconstitution and subsequent 
dilution of the lyophilized products prepared from the aqueous solution of resveratrol 
in 0.3 M HP-β-CD/RM-β-CD, clear solutions of resveratrol were formed and no re-
precipitations were observed.  As the clinical safety for intravenous administration of 
HP-β-CD has been documented, a parenteral formulation of resveratrol formulated 
with HP-β-CD is feasible, which would provide an alternative dosing route for 
resveratrol.  This parenteral formulation might improve its therapeutic usage and 
could overcome first pass metabolism.  Oral solution formulation of resveratrol 
prepared with HP-β-CD or RM-β-CD may also be helpful to increase GI absorption of 
poorly soluble resveratrol. 
 
2.3.6. Stability studies 
The stability of resveratrol in methanol and the corresponding inclusion 
complexes in aqueous solution was investigated under dark condition at RT and 4 ºC.  
Different concentrations of resveratrol solution were freshly prepared in acetonitrile 
before HPLC analysis for the construction of calibration curve.  Hence, the resveratrol 
peak in the HPLC chromatogram can be considered as pure resveratrol peak and the 
calibration curve was due to pure resveratrol.  Thus, the analytical method used to 
determine the resveratrol concentration in the stability samples was stable and valid.  
As shown in Figure 2.11, all samples were > 97 % stable in all conditions after 1 
month except, MeOH RT, RM RT, and HP RT.  Lyophilized samples were found to 
be significantly more stable than aqueous solution due to negligible moisture content 
in the lyophilized samples.  Stability of all samples was significantly higher at 4 ºC.  
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Stability of the samples after 1 month was found to decrease in the following order: 
RM-lyo 4 ºC > MeOH 4 ºC > HP-lyo 4 ºC > RM-lyo RT > RM 4 ºC > HP 4 ºC > HP-
lyo RT > MeOH RT > RM RT > HP RT.  Methanolic solution of resveratrol was used 
as control.   
 
Figure 2.11:  Stability profile of methanolic solution and inclusion complexes of 
resveratrol in different storage conditions.  Data presented as mean ± SD.  Here, 
MeOH = methanolic solution of resveratrol, HP = resveratrol-HP-β-CD inclusion 
complex, RM = resveratrol-RM-β-CD inclusion complex, lyo = lyophilized. RT = 
room temperature.  # p < 0.05 between HP RT and MeOH 4 °C, ## p < 0.05 between 
HP RT and RM-lyo 4 °C, * p < 0.05 between 15 days with 0, 1, 3, and 30 days, ** p < 
0.05 between 30 days with 0, 1, 3, and 7 days, *** p < 0.05 between 30 days with 0 
and 1 day, @ p < 0.05 between 0 day and 7 days, ### p < 0.05 between 0 day and 30 
days, $ p < 0.05 between 15 days and 0 day, $$ p < 0.05 between 30 days with 0, 1, 
and 3 days, & p < 0.05 between 15 days with 0 and 1 day.   
 
2.4. Summary and conclusions 
Although poorly soluble drug resveratrol showed pH dependant solubility, its 
solubility in the simulated GI fluids are very low.  CD derivatives, HP-β-CD and RM-
β-CD can improve the apparent aqueous solubility of resveratrol to a great extent in a 
concentration dependent manner.  However, RM-β-CD showed greater efficiency for 
this purpose.  This improvement of solubility was probably due to inclusion complex 
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formation between resveratrol and CDs.  This complex formation was further 
supported by UV scan, FTIR, DSC, XRD, and molecular modelling experiments.  
Molecular modelling study indicates 1 : 1 stoichiometry of both the resveratrol–CD 
complexes, which is consistent with the results of phase solubility studies.  Moreover, 
dilution and re-dissolution studies of resveratrol-CD complexes indicate the suitability 
of the inclusion complexes for parenteral administration, where the complexes will be 
diluted in biological fluids.  The stability study confirms that both HP-β-CD and RM-
β-CD form stable complexes with resveratrol.  Future studies could focus on HP-β-
CD for parenteral delivery of resveratrol (HP-β-CD is safe for parenteral 
administration but RM-β-CD is not safe) or on RM-β-CD for oral delivery of 
resveratrol (solubility enhanced by RM-β-CD was more than HP-β-CD and RM-β-CD 
is regarded as oral absorption enhancer).   
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CHAPTER 3 
PLASMA SAMPLE PREPARATION AND HPLC ASSAY METHOD DEVELOPMENT 
3.1. Introduction 
 Resveratrol is widely used as a nutritional supplement and its pharmacological 
properties have been extensively studied.  However, its pharmacokinetics needs 
further exploration in terms of oral absorption and bioavailability.  Moreover, there is 
an urgent need of the oral modified release or controlled release or site-specific 
formulations of resveratrol.  Pharmacokinetic study of these formulations is required 
to evaluate their in-vivo performance.  The first step of in-vivo pharmacokinetic study 
is to develop an assay for determining the drug concentration in plasma.  Although 
many publications [308-311] have reported various assays for determination of 
resveratrol concentrations in wine in the last decade, few publications are available on 
the quantification of resveratrol and its metabolites [86, 312-316].  Bertelli et al. [317, 
318] analyzed resveratrol concentrations in rat plasma and in different organs after 
administration of red wine.  Blache et al. [319] developed a gas chromatographic 
method for the determination of resveratrol concentrations in human plasma.  
However, the limit of quantitation for resveratrol in this study was high (50 ng.ml-1).  
In a recent publication, He et al. [313] described a rapid chromatographic method for 
analysis of resveratrol in rat plasma for pharmacokinetic analysis.  However, the 
method was unable to resolve any metabolites of resveratrol and had a relatively high 
limit of detection for resveratrol.   
As part of ongoing investigations into the pharmacokinetics and 
bioavailability of resveratrol, the goal was to develop an efficient method for 
extracting resveratrol from plasma and a sensitive analytical method that can 
effectively resolve the major metabolites from resveratrol and allow proper 
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quantification of the parent compound in a reasonably short run time.  In this study, 
development of a liquid -liquid extraction method and a sensitive and accurate HPLC 
assay for measuring resveratrol in rat plasma were performed. With the developed 
HPLC assay, pharmacokinetics of resveratrol was studied.  The HPLC assay method 
with UV detection allowed resolution of several phase II metabolites of resveratrol 
from the parent compound.  Part of the development and refinement of the analytical 
assay included the validation of a HPLC assay for plasma.  To assess the in-vivo 
performance of this method, resveratrol was administered orally to the rats and it was 
detected in plasma. 
 
3.2. Materials and methods 
3.2.1. Chemicals 
Sodium salt of carboxymethyl cellulose (CMC) and carbamazepine were 
purchased from Sigma (St Louis, MO).  Other materials used are same as described 
earlier (Chapter 2).   
 
3.2.2. Instrumentation 
A Shimadzu 2010A HPLC system (Kyoto, Japan) equipped with an automatic 
injector was used to quantify resveratrol in the formulation and plasma samples.  The 
instrument was connected to a personal computer with Shimadzu Class VP software.   
 
3.2.3. Chromatographic conditions  
The chromatography was run with a reversed phase HPLC column (ODS 
Hypersil, 5 µm, 250 mm × 4 mm, Agilent, Palo Alto, CA), which was protected with 
a guard column (Agilent).  The assay was performed at 35 ºC through isocratic 
delivery of the mobile phase, consisting of acetonitrile and 30 mM PBS, pH 7.0 
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(30:70 v/v) at a flow rate of 1 ml⋅min-1 and detection was made at 320 nm.  The 
mobile phase was filtered through 0.2 µm nylon membrane, degassed by sonication 
for 20 min at RT prior to use, and an online degassing was used during analysis.  The 
injection volume of the samples was 30 µl. 
 
3.2.4. Stock and standard solutions  
Stock solution of resveratrol (1 mg⋅ml-1) and the internal standard, 
carbamazepine (1 mg⋅ml-1) were prepared in methanol, stored at 4 ºC, and protected 
from light.  Standard working solutions of resveratrol (50 µg⋅ml-1) and carbamazepine 
(50 µg⋅ml-1) in water-methanol mixture (1:1) were freshly prepared before 
experiments.   
 
3.2.5. Plasma samples 
Blood was collected into the separate heparinised tubes from each healthy rat 
for method development and standard curve preparation.  The tubes were stored in an 
ice box immediately after blood collection and then plasma was separated after 
centrifugation at 5,500 g for 10 min.  Supernatant from each tube was collected in a 
big tube (pulled blank plasma).  The plasma was then divided into small cryotubes 
and stored at -80 °C until use.  The blank plasma was taken out from -80 °C and 
thawed at RT in the dark, and thoroughly mixed before extraction.  Standard working 
solution of resveratrol (50 µg⋅ml-1) was serially diluted with water-methanol (1:1) 
mixture and known amounts (10 µl) of the solutions were spiked into the blank 
plasma (100 µl), and extracted by liquid-liquid extraction according to the protocol 
described below.  Nine standard calibration solutions of resveratrol were prepared to 
obtain final concentrations ranging from 0 ng.ml-1 to 1000 ng.ml-1. 
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3.2.6. Sample preparation 
The procedure for plasma clean up was modified from a previously reported 
method [320].  Briefly, 5 µl of internal standard working solution (50 µg⋅ml-1) was 
first spiked into 100 µl plasma in a clean 2-ml centrifuge tube.  The samples were 
mixed well and 40 µl of PBS (30 mM, pH 6) was added to the tube and the content 
was mixed for another 15 sec.  Finally, ethyl acetate (300 µl) was added and the 
content was mixed for 30 sec.  After ethyl acetate extraction, the content was 
centrifuged at 5,500 g for 10 min and the upper organic layer was carefully 
transferred to a clean tube.  The extraction procedure was repeated for another two 
times and the combined organic layers were evaporated to dryness under nitrogen gas 
at 35 °C.  The residue was reconstituted with 75 µl mobile phase and centrifuged for 1 
min at 5,500 g and 30 µl of the supernatant was injected to the HPLC system.  All 
procedures were carried out away from direct light.  
 
3.2.7. Calculations  
The peak area ratio method (peak area of resveratrol/peak area of internal 
standard) was used for quantitation.  The resveratrol concentrations in the rat plasma 
samples were determined by interpolation from the calibration curve. 
 
3.2.8. Validation 
For quality control, the method was validated according to The United States 
Pharmacopoeia (USP XXIII; 1995; Vol. 1225, pp 1982-1984.).  The analytical 
performance parameters including selectivity/specificity, extraction efficiency or 
recovery, linearity, sensitivity, and precision and accuracy were evaluated. 
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3.2.9. Stability of resveratrol in plasma 
Resveratrol was spiked into blank plasma and the spiked plasma was stored at 
RT, 4 ºC, and -80 ºC.  The initial concentration of resveratrol in the plasma was 100 
ng.ml-1.  Resveratrol concentrations were measured by HPLC (according to the above 
procedure) in samples after storage for 3 days, 1 week (7 days), 15 days, 1 month (30 
days), and 3 months (90 days).  The experiments were performed in triplicate. 
 
3.2.10. Application  
To check the in-vivo efficacy of the method, resveratrol (resveratrol 
suspension in 0.5 % CMC, pH 7.4) was administered orally to four male Sprague-
Dawley rats (250 - 300 g) at 25 mg.kg-1 dose after overnight fasting.  After 30 min of 
oral resveratrol administration, venous blood samples (200 µl) from the right jugular 
vein of the rats were withdrawn into the heparinised tubes, then centrifuged at 5,500 g 
for 10 min, supernatant (plasma) was stored at -80 °C until analysis.  Plasma samples 
were extracted and analyzed by HPLC using the protocol described above.  Details of 
the pharmacokinetic study procedure in rats are described in Chapter 4. 
 
3.2.11. Statistics   
Statistical analyses were performed using the software Graph-Pad Prism 
Version 2.00 (San Diego, CA).  All experimental data were expressed as mean ± 
standard deviation (SD).  Statistical comparisons were performed by using one-way 





3.3. Results and Discussion 
3.3.1. Chromatography spectrum  
Blank plasma samples were analyzed to check the selectivity of the method.  
The chromatogram of blank plasma extract (Figure 3.1A) did not show any interfering 
components.  As can be seen, the extraction was very selective, and the resveratrol 
(25 ng.ml-1) and carbamazepine (250 ng.ml-1) peaks were well separated from 
endogenous interference (Figure 3.1B).  The retention times of resveratrol and 
internal standard were 5.5 and 10.4 min, respectively.  The HPLC run took less than 
12 min, and due to the automatic sample injector more than 100 samples could be 
analyzed per day by this HPLC method, including time for the re-equilibration of the 
column.   
 
3.3.2. Validation of the HPLC assay method  
3.3.2.1. Selectivity:  Resveratrol was quantified at its maximum absorbance (320 
nm) to improve its selectivity.  The chromatogram at this wavelength shown in Figure 
3.1B indicates that resveratrol was well resolved and free from interfering peaks. 
 
3.3.2.2. Extraction efficiency/Recovery:  The absolute recovery of resveratrol from 
plasma was calculated by comparing the peak area obtained from extracts of spiked 
plasma samples to that obtained from the direct injection of same concentrations of 
standard solutions of resveratrol.  The analysis was performed in five replicates at 
different concentration levels: low (25 ng.ml-1), medium (100 ng.ml-1), and high (500 
ng.ml-1).  The extraction recovery rate of resveratrol in plasma was 95 ± 3.8 %, 95 ± 
4.2 %, and 97 ± 4.4 % for 500, 100, and 25 ng⋅ml-1, respectively (Table 3.1).  The 
very high extraction efficiency proved the suitability of the extraction method for use 
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with plasma samples.  The recovery of the internal standard was also found to be very 





Figure 3.1:  Chromatogram of blank rat plasma (A), blank rat plasma spiked with 
resveratrol (1) and carbamazepine (2) (B).  
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Table 3.1:  Recovery study of resveratrol from plasma (N=5) 
Concentration (ng.ml-1) Recovery (mean ± SD, %) R.S.D. (%) 
25 96.9 ± 4.4 4.5 
100 95.4 ± 4.2 4.4 
500 95.0 ± 3.8 4.0 
 
3.3.2.3. Linearity:  The standard calibration curve of resveratrol was constructed 
and its linearity was determined.  It was prepared by plotting the peak area ratio of 
resveratrol to the internal standard against the concentration of resveratrol.  It was 
calculated by least-squares linear regression method according to the following 
formula: y = mx + c, where y is the peak area ratio of resveratrol to internal standard, 
m (the slope) and c (the y-intercept) are constants, and x is the resveratrol 
concentration (ng⋅ml-1).  The calibration curve, obtained by spiking resveratrol into 
pooled rat plasma, was linear (R2 = 0.9999) within the range of 5 - 1,000 ng⋅ml-1 
(Figure 3.2).  The values of the regression parameters, m and c, were calculated as 
0.0062 and -0.0072, respectively.  The intercept coefficients were not significantly 
different from 0, indicating the potential for accurate recovery at concentrations 5 
ng⋅ml-1.  
 
3.3.2.4. Sensitivity:  The limit of detection (LOD) and the limit of quantification 
(LOQ) were calculated by measuring the drug peak in comparison to the magnitude of 
the analytical background response.  LOD (minimum detectable concentration) is 
defined as signal to-noise ratio of 3 and LOQ is defined as signal-to-noise ratio of 7 
[321].  LOQ is the lowest point on the calibration curve which could be detected with 
a variation of less than 15 %.  At 320 nm, the LOQ of resveratrol in this assay was 5 
ng⋅ml-1, whereas the LOD of resveratrol in this assay was determined to be 2.5 ng⋅ml-1.  
 80 
The LOQ was subsequently validated by the analysis of 5 standards at the LOQ 
concentration. 
 


















Figure 3.2:  Standard curve of resveratrol in plasma.  Each point represents mean ± 
SD, N = 3.  
 
3.3.2.5. Precision and Accuracy:  The intra-day precisions were determined by 
analyzing five 30 µl aliquots of spiked plasma samples containing 5, 10, 25, 50, 100, 
250, 500, and 1000 ng⋅ml-1 of resveratrol.  The inter-day precisions were determined 
by analyzing 30 µl aliquots of spiked plasma samples (5, 10, 25, 50, 100, 250, 500, 
and 1000 ng⋅ml-1 of resveratrol) in triplicates on five different days.  The precision is 
expressed as the coefficient of variation (CV) or relative standard deviation (RSD).  
Mean measured resveratrol concentrations in the samples were compared with the 
respective true values and expressed as accuracy.  The intra-day and inter-day 
variation were less than 5 % and accuracy was more than 95 % (Table 3.2).  These 
values were within the acceptable limit according to the CV established for intra-
laboratory analysis.  The data proved good precision and accuracy of the method. 
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Precision (%) Accuracy (%) Precision (%) Accuracy (%) 
5 4.5 104.1 3.7 100.4 
10 3.7 97.6 3.0 95.9 
25 4.1 98.0 2.5 95.9 
50 3.4 96.6 3.3 96.4 
100 1.6 100.4 3.9 96.2 
250 2.5 97.2 2.9 96.4 
500 1.2 98.8 2.9 96.8 
1000 1.5 99.9 2.0 98.7 
 
3.3.3. Application  
The chromatogram of a plasma sample from a rat that received 25 mg.kg-1 
resveratrol orally is shown in Figure 3.3.  Unidentified metabolites were found in 
plasma collected after oral administration of resveratrol.  The plasma concentration of 
resveratrol at 30 min after oral administration was quantified as 151.66 ± 120.53 
ng⋅ml-1 (N = 4).   
 
3.3.4. Stability 
Figure 3.4 reveales that plasma samples were stable when stored at – 80 °C.  
Stability of resveratrol at – 80 °C was > 99 % even after 3 months (90 days).  Stability 
of resveratrol at 4 °C was ~ 95 % after 3 months (90 days).  However, RT was not 
suitable for storage of plasma samples.  Resveratrol degraded quickly when plasma 




Figure 3.3:  Chromatogram of rat plasma collected 30 min after oral administration 




Figure 3.4:  Stability of resveratrol in plasma sample at different storage conditions.  
Data presented as mean± SD.  * p < 0.05 for difference between RT with 4 °C and -
80 °C.  # p < 0.05 for difference between 30 days with 0, 3, 7, and 15 days.  ## p < 
0.05 for difference between 90 days with 0, 3, 7, 15, and 30 days.  ### p < 0.05 for 




3.4. Summary and conclusions 
 In the present study, a reliable, reproducible extraction procedure was 
developed together with a simple, rapid, reliable, and sensitive HPLC assay method.  
The HPLC method was validated for the determination of resveratrol in rat plasma.  
The method allowed quantification of resveratrol and separation of conjugate 
metabolites from the parent compound in rat plasma.  The method gives good 
linearity and reproducibility with a LOQ of 5 ng.ml-1.  Reproducible high recovery of 
resveratrol was achieved.  The fast and non-intensive sample preparation method 
simplifies large sample processing for clinical trials.  Because of its highly 
satisfactory sensitivity, accuracy, linearity, stability, and specificity, this extraction 
and HPLC methodology could thus be an appropriate tool for further determination of 




PHARMACOKINETIC STUDY OF RESVERATROL 
4.1. Introduction 
As the pharmacology of resveratrol was subjected to extensive studies during 
the past decade, its pharmacokinetics has also been investigated in pre-clinical models 
as well as in humans [10, 322].  Unfortunately, the pharmacokinetic properties of 
resveratrol are not as favorable when compared with its beneficial pharmacological 
activities in various disease models [322].  Resveratrol has a very short initial half-life 
(~ 8 – 14 min) [10].  Upon administration, it is metabolized quickly and extensively in 
the body [322].  Further, its oral bioavailability in human is observed to be very low 
[90, 91, 323].   
Oral bioavailability is generally believed to be dependent on the aqueous 
solubility, membrane permeability, and metabolic stability of the given drugs [324, 
325].  As a polyphenolic compound (log P > 3.1), gastrointestinal permeability of 
resveratrol across the epithelial cells is not considered to be a concern.  Indeed, two 
recent published studies indicated that transport of resveratrol across biological barrier 
was not a problem [87, 326].  However, the high lipophlicity of resveratrol also leads 
to low aqueous solubility [297], which may impair its oral bioavailability.  Despite 
such proposition, it is interesting to note that no study to date has examined the direct 
role of aqueous solubility on oral bioavailability of resveratrol.  Poor metabolic 
stability of resveratrol has been well documented for restricting the oral 
bioavailability of resveratrol [10, 91, 95].  Resveratrol undergoes extensive phase II 
metabolism to form glucuronide and sulfate conjugates [10, 86, 87, 92, 95, 326].  
However, two recent studies have reported metabolic saturation of resveratrol in 
Caco-2 cells which leads to increased transport of resveratrol across the Caco-2 
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monolayer [87, 326].  These results suggest that metabolism of resveratrol in gastro-
intestinal tract could be saturated at higher resveratrol concentration and dose 
escalation of resveratrol might be employed as a tool to enhance its oral 
bioavailability. 
Cyclodextrins (CDs) are well known for their abilities to form inclusion 
complexes with a variety of guest molecules.  They have traditionally been used to 
increase oral bioavailability by increasing the dissolution of a given drug.  The result 
in Chapter 2 has already shown that inclusion of resveratrol into CDs led to an 
enhancement in its aqueous solubility.  The objective of this work was to determine if 
oral bioavailability of resveratrol can be enhanced by manipulating the aqueous 
solubility and doses of resveratrol.  To achieve this objective, the pharmacokinetics of 
resveratrol formulated as sodium salt or as HP-β-CD, RM-β-CD inclusion complexes 
and resveratrol suspended in CMC were compared after the respective intravenous 
and oral administration.   
 
4.2. Materials and methods 
4.2.1. Chemicals 
The same chemicals were used as described in Chapter 2 and 3. 
 
4.2.2. Preparation of dosing formulations  
The parenteral safety of HP-β-CD has been well documented [292].  Therefore, 
HP-β-CD (0.3 M) was used in the current study to prepare the intravenous injection 
formulation.  The resveratrol concentration in HP-β-CD solution was measured with 
HPLC and subsequently diluted to 20 mg⋅ml-1.  In order to determine whether the 
formation of inclusion complex with HP-β-CD affects the kinetic profile of 
 86 
resveratrol after intravenous administration, sodium salt solution of resveratrol was 
used as a control.  It was freshly prepared by dissolving 20 mg of resveratrol in 1 ml 
of 0.9 % NaCl-0.3 % NaOH (w/v) solution.  The final clear solution indicated 
complete dissolution of resveratrol.  Such simple preparation method has been used to 
form intravenous formulations of retinoic acids in pre-clinical studies [327, 328].  
Since RM-β-CD usually has superior solubility and bioavailability enhancing ability, 
it was used to form a water soluble oral formulation of resveratrol.  The preparation 
procedure has been described in the phase-solubility study.  The resveratrol 
concentration was measured by HPLC and subsequently diluted to 25 mg⋅ml-1.  The 
resveratrol suspension for oral dosing was prepared by suspending 25 mg resveratrol 
in 1 ml 0.5 % CMC (pH 7.4).  The suspension was freshly prepared and shaken 
vigorously before oral gavage. 
 
4.2.3. Animals 
The study design and the animal handling protocol of this pharmacokinetic 
study were modified from several previous studies [327-329] and approved by the 
Institutional Animal Care and Use Committee of the National University of Singapore.  
Adult male Sprague–Dawley rats (250 – 300 g) were supplied by the Laboratory 
Animal Center of the National University of Singapore.  The rats were housed in 
Animal Holding Unit of the university under temperature- (22 ± 1 ºC) and humidity- 
(60 – 70 %) controlled environment.  A 12-h light/dark cycle was maintained and the 
rats were given free access to food and water before surgery.  A polyethylene tube (i.d. 
0.58 mm, o.d. 0.965 mm, Becton Dickinson, Sparks, MD) was placed into the right 
jugular vein through surgical implant under anesthesia on the day before the 
pharmacokinetic study.  This cannula was used for intravenous drug administration as 
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well as blood sample collection.  The rats were randomly divided into 10 groups (n = 
4 per group); four groups received intravenous administration of resveratrol while six 
groups received oral dosing through gavage.  As oral absorption may be influenced by 
different dietary regimens and the inherent bile salt solubilization capacity in the 
intestine, the rats were kept in fasting condition overnight prior to the oral gavage and 
during blood collection, but they were allowed to have free access to water.  Such 
restriction was not applied to the rats that received intravenous administration.  
Resveratrol-HP-β-CD inclusion complex solution was intravenously administered to 
the rats in groups 1, 2, and 3 at the dose of 25, 10, and 5 mg⋅kg-1, respectively.  Rats 
in group 4 received a single bolus dose intravenous injection of resveratrol sodium 
salt solution at a dose of 10 mg⋅kg-1.  Ethical considerations (primarily a limitation of 
the high pH imposed by the sodium salt of resveratrol) prevented the use of higher 
dose of sodium resveratrol in this parallel study.  Rats in groups 5, 6, and 7 were 
administered single dose of resveratrol-RM-β-CD inclusion complex solution by oral 
gavage at the dose of 50, 25, and 15 mg⋅kg-1, respectively.  Similarly, groups 8, 9, and 
10 were given single oral doses of resveratrol suspension in 0.5 % CMC (pH 7.4) at 
the dose of 50, 25, and 15 mg⋅kg-1, respectively.  Serial blood samples (200 µl) were 
collected from each animal through the catheter at 5 min, 15 min, 30 min, 45 min, 1 h, 
1.5 h, 2 h, 3 h, 4 h, and 5 h after intravenous administration and at 5 min, 15 min, 30 
min, 1 h, 1.5 h, 2 h, 3 h, 4 h, 6 h, and 8 h after oral gavage.  The cannula was flushed 
and blood was replaced by an equivalent volume of heparin-saline (5 U⋅ml-1 heparin 
in normal saline) after each draw of blood sample.  After centrifugation at 5,500 g for 




4.2.4. Sample preparation   
The plasma sample preparation procedure has been described in Chapter 3 (page no. 
75).   
 
4.2.5. Sample analysis   
The plasma sample was analyzed using the HPLC assay method described in Chapter 
3 (page no. 73).   
 
4.2.6. Pharmacokinetic analysis 
Most of the pharmacokinetic parameters were calculated by non-
compartmental model using the software WinNonlin standard Version 1.0 (Scientific 
Consulting Inc., Apex, NC).  The area under the plasma concentration versus time 
curve (AUC0→t) in rats that received oral administration (Groups 5 to 10) was 
calculated by the linear trapezoidal rule with the time point from 0 to the last 
detectable time point, whereas the AUC0→t in rats that received intravenous dosing 
(Groups 1-4) was calculated through the same rule except the logarithmic scale was 
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The apparent volume of distribution (V) after intravenous administration was 
calculated by assuming first order kinetics with the first 3 data points (up to 0.5 h) in 
group 3; with the first 4 data points (up to 0.75 h) in group 2 and 4, and with the first 
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5 data points (up to 1 h) in group 1.  Such plasma resveratrol concentration-time data 
was fitted into one compartment open model ( tkeCC ⋅−⋅= 0 ) (fit with nonlinear least 
squares regression with a weighting factor of 1/Y2), where V was calculated as: 
0C
DoseV = . 
 
4.2.7. Statistics 
Statistical analyses were performed using the software Graph-Pad Prism 
Version 2.00 (San Diego, CA).  All experimental data were expressed as mean ± 
standard deviation (SD) except for the point pertaining to time to maximal 
concentration (Tmax) after oral administration, as it was a non-continuous data due to 
the pre-decided sampling schedule.  Statistical comparisons of the pharmacokinetic 
parameters among the different doses with the same formulations (resveratrol-HP-β-
CD inclusion complex or resveratrol-RM-β-CD inclusion complex or resveratrol in 
0.5 % CMC) were performed by using one-way ANOVA with the post hoc Tukey test.  
Two-tail independent sample t-test was used to compare the pharmacokinetic 
parameters between the two different formulations at the same dose (resveratrol 
sodium salt versus resveratrol-HP-β-CD, resveratrol suspended in 0.5 % CMC versus 
resveratrol-RM-β-CD).  Statistical comparisons of the Tmax values among Groups 5, 6, 
and 7 were performed by using Kruskal–Wallis test with the post hoc Dunn test.  
Similar test was performed to compare Tmax values among Groups 8, 9, and 10.  Again 
two-tail Mann–Whitney test were used to compare the Tmax of different formulations 
with same dose (Group 5 vs 8, Group 6 vs 9, and Group 7 vs 10).  Statistical 




4.3.1. Pharmacokinetics after intravenous administration 
Figure 4.1 shows the pharmacokinetic profiles of resveratrol following single 
intravenous bolus dose of either sodium salt of resveratrol (10 mg⋅kg-1) or resveratrol-
HP-β-CD complexes (5, 10, and 15 mg⋅kg-1).  In all cases, plasma resveratrol 
concentration declined rapidly over the first hour that was followed by the appearance 
of a second peak at 2 h.  The reappearance of a second peak after the initial decline of 
resveratrol is most likely due to enterohepatic recirculation, which is a well-
documented phenomenon [95].   





10000 HP-β-CD: 5 mg.kg-1
HP-β-CD: 10 mg.kg-1
HP-β-CD: 25 mg.kg-1























Figure 4.1:  Pharmacokinetic profiles of resveratrol after a single intravenous 
administration.  Data represent the mean values (n = 4) of the groups ± SD.  
Concentration of resveratrol was below the LOQ of HPLC assay after 45 min and 2 h 
at 5 and 10 mg.kg-1 doses, respectively. 
 
The pharmacokinetic parameters describing resveratrol in the plasma are 
shown in Table 4.1.  At 10 mg⋅kg-1 of resveratrol, there are no significant differences 
(p > 0.05) in the V and Cl values between sodium salt of resveratrol (Group 4) and 
resveratrol-HP-β-CD inclusion complex solution (Group 2).  These results suggest 
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that HP-β-CD did not exert a significant impact on the intravenous pharmacokinetic 
profile of resveratrol even though HP-β-CD formed inclusion complex with 
resveratrol.  After intravenous administration of resveratrol-HP-β-CD inclusion 
complex solution, there was no significant difference in the V value between Groups 1 
through 3 (p > 0.05) and the Cl values remained unchanged for Groups 2 and 3 (p > 
0.05).  In contrast, Cl value was significantly lower (11.6 ± 1.6 L⋅h⋅kg -1) in Group 1 
than in Groups 2 and 3 (p < 0.05).  Based on these observations, it can be 
hypothesized that at higher dose (Group 1: 25 mg⋅kg-1), it is probable that elimination 
kinetics may become saturated and non-linear, which can invariably lead to higher 
resveratrol concentration in plasma.  For this reason, AUC (Group 2) was chosen to 
determine the bioavailability of orally administered resveratrol.  
 
Table 4.1.  Pharmacokinetic parameters of resveratrol after intravenous administration* 
  Group 1 Group 2 Group 3 Group 4 
Formulation HP-β-CD HP-β-CD HP-β-CD Sodium salt 
Dose (mg.kg -1) 25 10 5 10 
V (L.kg -1) 2.24 ± 0.15 2.60 ± 0.37 2.49 ± 0.72 2.69 ± 0.12 
Cl (L.h.kg -1) 11.6 ± 1.6 a, b 20.0 ± 2.6 21.6 ± 3.6 18.9 ± 1.8 
AUC (ng.h.ml-1) 2196.2 ± 343.3 505.9 ± 68.1 236.1 ± 35.2 532.9 ± 55.0 
* Data presented as Mean ± SD, n = 4;  a p < 0.05 between Group 1 and 2; b p < 0.05 between 
Group 1 and 3 
 
4.3.2. Pharmacokinetics after oral administration 
The plasma pharmacokinetic profiles and the pharmacokinetic parameters 
following single oral dosing of resveratrol-RM-β-CD complexes (15, 25, and 50 
mg⋅kg-1) and resveratrol suspensions (15, 25, and 50 mg⋅kg-1) are shown in Figure 4.2 
and Table 4.2, respectively.   
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Figure 4.2:  Pharmacokinetics of resveratrol after a single oral dose.  A. 15 mg.kg-1; 
B. 25 mg.kg-1; C. 50 mg.kg-1.  The line represents the predicted values.  Symbols 
represent the mean observed values (n = 4) ± SD. 
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Table 4.2.  Pharmacokinetic parameters of resveratrol after oral administration* 
  Group 5 Group 6 Group 7 Group 8 Group 9 Group 10 





Dose (mg.kg -1) 50 25 15 50 25 15 
Tmax (min) 5-15 min 5 - 15 min 5 - 15 min 60 - 90 min a 5 - 15 min 5 - 15 min 
Cmax (mg.L -1) 1.75 ± 0.72 b, c, d 0.86 ± 0.19 e 0.71 ± 0.05 f 0.43 ± 0.09 g 0.27 ± 0.06 0.36 ± 0.08 
AUC (ng.h.ml-1) 1009.0 ±  186.6 480.1 ± 24.2 351.4 ± 75.2 981.0 ± 49.5 485.3 ± 114.1 352.0 ± 59.1 
F (%) 39.9 ± 7.38 38.0± 1.91 46.3 ± 9.92 38.8 ± 1.96 38.4 ± 9.02 46.4 ± 7.78 
* Data is presented as Mean ± SD, N = 4; a p < 0.05 between Group 5 and 8; b p < 0.05 between Group 5 and 6; c p < 0.05 between 
Group 5 and 7; d p < 0.05 between Group 5 and 8; e p < 0.05 between Group 6 and 9; f p < 0.05 between Group 7 and 10; g p<0.05 
between Group 8 and 9. 
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In all cases, formulating resveratrol in RM-β-CD resulted in a significantly (p 
< 0.05) higher maximal concentration (Cmax) than the suspension formulations.  
However, there were no significant differences (p > 0.05) in bioavailability (F value) 
between the suspension and solution formulations at all doses (Table 4.2).  Within 
each formulation, a significantly different Cmax was observed between those of 50 and 
25 mg.kg-1 doses, 50 and 15 mg.kg-1 doses (p < 0.05), but not between 25 and 15 
mg.kg-1 doses ( p > 0.05) (Table 4.2).  Tmax was not significantly different between 
solution and suspension formulations (p > 0.05) at 15 and 25 mg.kg-1 doses, but at 50 
mg.kg-1 dose, Tmax was significantly different (p < 0.05) between solution and 
suspension formulations (Table 4.2).  The higher Tmax seen in Group 8 (between 60 
and 90 min) implies a delayed absorption of resveratrol.  These findings indicated that 




This study describes the preparation of CD complexes with resveratrol and 
evaluated the pharmacokinetics and bioavailability of resveratrol in Sprague-Dawley 
rats following intravenous and oral administration of resveratrol.  The objective was 
to determine whether increased solubility of resveratrol due to complexation with 
CDs, and dose escalation, which may theoretically reduce metabolism of resveratrol, 
could lead to increased bioavailability of resveratrol.   
Formulation with HP-β-CD significantly increased the aqueous solubility of 
resveratrol (~ 59,500 fold increase).  Despite inclusion complex formation between 
resveratrol and HP-β-CD, no statistical differences in pharmacokinetic parameters 
between sodium resveratrol (Group 4) and HP-β-CD-resveratrol (Group 2) after 
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intravenous administration were found (Table 4.1).  These observations are consistent 
with previous findings with retinoic acids [327, 330] and miconazole [331] that HP-β-
CD did not exert significant impact on intravenous pharmacokinetic of poorly soluble 
drugs.  After intravenous administration, the major driving force for dissociation of 
weakly to moderately bound drugs from the cyclodextrin inclusion complex is simple 
dilution and the drug release is rapid (in fraction of seconds) and quantitative in most 
cases [332].  From the phase solubility study, a moderate inclusion stability constant 
(3.17 x 105 M-1) was found between resveratrol and HP-β-CD.  This value is close to 
the reported binding constant between resveratrol and human serum albumin (1.76 x 
105 L.M-1) [333].  Hence, upon administration it is expected that resveratrol would 
rapidly dissociate from HP-β-CD and bind to the plasma proteins, and explain why 
HP-β-CD would increase the aqueous solubility of resveratrol but not its intravenous 
pharmacokinetic profiles (V, Cl, and AUC, Group 2 vs. Group 4, Table 4.1).   
Although many studies have looked at various aspects of resveratrol 
pharmacokinetics, this study is the first to demonstrate dose-dependent clearance of 
resveratrol in-vivo.  At higher intravenous resveratrol dose (Group 1, 25 mg.kg-1), a 
significant lower Cl and higher AUC were observed in animals compared to those 
given lower dose of resveratrol (Groups 2 and 3) (Table 4.1).  It is plausible at high 
intravenous dose, clearance process for resveratrol may be saturated, which implies 
that dose escalation beyond its metabolic threshold may increase the plasma levels of 
resveratrol.  It is noteworthy to mention irrespective of intravenous doses and dosage 
forms, a second peak appeared at 2 - 4 h after the rapid initial decline of the plasma 
concentration of resveratrol.  The appearance of a secondary peak is consistent with 
the findings of an earlier study [95] and is probably due to enterohepatic recirculation 
of resveratrol.  As expected, the extra dissolution step causes the suspension 
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formulations to display a more sustained plasma resveratrol concentration profile than 
solution formulations, which decreased rapidly upon administration.  Hence, 
suspension formulation can be a useful means to maintain resveratrol plasma 
concentration above minimum effective concentration (MEC) for longer time than 
solution formulation.   
Oral bioavailability of small molecular drugs is generally believed to be 
determined by the aqueous solubility, membrane permeability, and metabolic stability 
of the given drugs [334].  Previous works imply that poor oral bioavailability of 
resveratrol may not be a membrane permeability issue [87, 91, 326].  The results in 
this study did not suggest poor aqueous solubility was responsible for poor oral 
bioavailability of resveratrol as any significant differences in bioavailability of all 
dosages between resveratrol-RM-β-CD solutions and resveratrol suspension in 0.5 % 
CMC were found (Table 4.2).  However, initial plasma resveratrol concentration and 
Cmax values of RM-β-CD formulations were much higher than the corresponding 
doses of suspension formulations (4.1, 3.2, and 2 times higher in RM-β-CD 
formulations than suspension formulations at 50, 25 and 15 mgkg-1 dosages, 
respectively). These results indicated that increasing aqueous solubilization of 
resveratrol might enhance its oral absorption rate but it does not affect its extent of 
absorption.   The present findings raise a concern that resveratrol might be extracted 
out of the complexes following immediate dilution in the GI tract, thus explaining 
why the enhanced solubility via cyclodextrin complexation did not result in increased 
oral bioavailability of resveratrol.  While seem logical, the poor solubility of 
resveratrol in aqueous environment coupled with its rapid occurrence in the plasma 
will refute such a possibility (Figure 4.2).  Alternatively, it is possible that solubility 
of resveratrol is pH-dependent; hence its absorption from the GI tract will no longer 
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be just an issue of solubility but a pH concern as well.  To address this concern, 
solubility experiments utilizing simulated gastric and intestinal fluids (SGF and SIF) 
were conducted.  Although data clearly indicated a pH-dependent effect (soluble in 
neutral SIF but almost insoluble in acidic SGF), the results are not enough to explain 
why bioavailability of resveratrol did not increase with enhanced solubility.  This is 
because regardless of doses, all dosage forms face the same GI environment, and 
therefore, same release and solubility conditions.  While the mechanism responsible 
for this peculiar observation remains to be elucidated, it is speculated that a rapid and 
extensive metabolism of resveratrol (both at the intestinal and hepatic levels) [82, 83, 
85-87, 90, 91, 95, 323, 326] at the studied doses may underscore the present results.  
Alexandra et al. recently demonstrated a concentration-dependent 
biotransformation of resveratrol to its metabolites (mono-glucuronides and mono-
sulfate) in Caco-2 cells [326].  At high dose (200 µM), biotransformation was either 
inhibited or saturated, which resulted in an increase in the total amount of resveratrol 
transported across the Caco-2 monolayers [326].  In the present study, no evidence 
was found to suggest that inhibition or saturation of biotransformation of resveratrol 
had occurred as there was no significant difference seen in bioavailability among all 
oral Groups even when the doses of resveratrol were increased (15 - 50 mg.kg-1).  One 
interpretation of the data presented here is that the concentration (200 µM: 45.6 × 103 
ngml-1) that led to metabolic saturation in Caco-2 cells is unlikely to be achievable at 
in vivo level.  Assuming one-compartmental elimination kinetics, the concentration at 
time zero (C0) or the maximal concentration after receiving intravenous resveratrol 








In the present study, saturation in clearance did not appear until the intravenous dose 
was increased from 10 mgkg-1 to 25 mgkg-1.  The results suggest that the dose that 
led to metabolic saturation must be greater than 10 mgkg-1 and imply that the least 
concentration that causes saturation of systemic elimination in rats have to be higher 
than 3.8 × 103 ngml-1.  Unfortunately, such level was not achievable even after oral 
administration of 50 mgkg-1 resveratrol.  It is interesting to comment although the 
local concentration of resveratrol in the intestinal tissue may be higher than that in the 
peripheral vein, it is still difficult to achieve a local concentration as high as 45.6 × 
103 ngml-1; a concentration which is 25 fold higher than the Cmax after oral dosing of 
50 mgkg-1 resveratrol in RM-β-CD formulation.  Taken together, the results suggest 
that dose manipulation may not be a viable and feasible approach to enhance the oral 
bioavailability of resveratrol.  
 
4.5. Summary and Conclusions 
In this study, we have shown that (1) HP-β-CD and RM-β-CD could increase 
resveratrol solubility to a great extent and HP-β-CD did not change the 
pharmacokinetic profile of resveratrol after intravenous administration, (2) oral 
bioavailability of resveratrol was not influenced by the formulation types (solution 
and suspension), although the suspended dosage form (CMC suspension) showed a 
lower Cmax and a plasma concentration that was more sustained than the solution 
dosage form (RM-β-CD), (3)  dose escalation (15 - 50 mg.kg-1) did not influence the 
oral bioavailability of resveratrol, although non-linear elimination was observed at 25 
mg.kg-1 intravenous dose.   
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CHAPTER 5 
DELAYED RELEASE DELIVERY SYSTEMS OF RESVERATROL 
5.1. Introduction 
Resveratrol has shown promising activities towards several lower gastro-
intestinal tract diseases like, colon cancer, colitis, etc [32, 51, 52, 62].  However, the 
pharmacokinetic properties of resveratrol are not as favorable when compared to its 
beneficial pharmacological activities [322].  As described earlier, upon oral 
administration, resveratrol is rapidly absorbed and undergoes extensive phase II 
metabolism in the upper GI tract and liver [10, 87, 92, 95, 326].  The very short half-
life (~ 8 – 14 min) [10, 335] and extremely low bioavailability (see Chapter 4) of 
resveratrol have raised concerns regarding its systemic action [10, 68].  Consequently, 
it was hypothesized that development of a site-specific drug delivery system that 
protects resveratrol during its transit through the upper GI tract and allows its release 
at the colonic region could provide a potential approach to treat lower GI diseases 
such as colorectal cancer and colitis.  This delivery system should be able to bypass 
the rapid absorption and metabolism issues of resveratrol. 
To achieve colon-specific drug delivery, current approaches use systems that 
(i) release the drug at a predetermined time after administration, ii) utilize pH changes 
within the GI tract, iii) make use of GI pressure differences, and iv) exploit microbial 
enzymes predominantly present in the colonic region of the GI tract [102, 112].  A 
system relying on the transit time, pH and/or pressure of the GI tract is expected to be 
poor as all these parameters are extremely variable in individuals.  In contrast, 
bacterial degradation of bio-polymers in the colon to achieve colon-specific drug 
delivery is a well established phenomenon and thus could be a more realistic approach 
than the other approaches mentioned above [99, 102].  In this ambit, various well 
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known natural polysaccharides are currently exploited, in virtue of their specific 
degradation by colonic micro-flora which made them suitable carriers for colon 
targeted delivery system [112].  Among such polymers, pectins appeared to be of 
great practical interest due to their low cost, biodegradability, wide variety of types, 
and flexibility in use. 
As described in the Chapter 1, pectin is a heterogeneous polysaccharide 
present in the cell wall of most plants which is consumed as part of the human diet 
and used as a food additive.  The influence of pectin intake on the human body has 
been well studied and regarded as safe.  It is resistant to enzymes present in stomach 
and intestine but can be almost completely degraded by the colonic bacterial enzymes 
[112].  Unfortunately, their solubility and swellability in aqueous fluid prevent them 
from efficiently avoiding premature drug release before reaching the colon.  However, 
this can be manipulated through the choice of pectin type or the presence of additives.  
Pectins with low degree of methoxylation (LM pectins) are more soluble, but they can 
be cross-linked with divalent cations (e.g., calcium, zinc) to produce a more water 
insoluble pectinate gel which has the potential to be an effective vehicle for drug 
delivery.  Various reports suggest that pectin, when cross-linked with calcium or zinc 
to form a multi-particulate Ca or Zn-pectinate bead system, may be a viable carrier for 
site specific drug delivery to the colon [198, 205-207, 216, 217].  However, there is 
no prior study that looks at delivery of resveratrol specifically to the colonic region.  
Hence, present study attempted to prepare different resveratrol loaded Ca-/Zn-
pectinate beads by varying different formulation variables (cross-linking solution pH, 
concentration of cross-linking agent, cross-linking time, drying condition, 
concentration of pectin, and pectin to resveratrol ratio) and thoroughly studied their 
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effect on different physicochemical properties and resveratrol retention pattern of the 
formulated beads in the release media.   
 
5.1.1. Reasons for selection of pectin type  
In general, pectin (i.e., LM pectin) that has more free carboxylic group (DE < 
50 %) forms a more rigid gel structure than when most of the carboxyl groups are in 
esterified form (i.e., HM pectin) [99].  Furthermore, amidated pectins forms stronger 
network than non-amidated pectin as hydrophilicity of pectin is reduced in the 
presence of amide group which increases its gel-forming ability [166].  In addition, 
hydrogen bonding between amide groups also leads to increased gel strength [336].  
These interactions in amidated LM pectin allow consolidating cross-linking between 
pectin chains leading to the formation of a more compact Ca or Zn-pectinate network 
than non-amidated and/or HM pectin.  Generally, LM pectins are soluble at high pH; 
but, calcium or zinc binding to pectin reduces the solubility and induces non-covalent 
associations of the carbohydrate chains.  These were the reasons behind selecting 
amidated LM pectin for the formulation development. 
 
5.1.2. Reasons for selection of formulation type 
 Several kinds of delivery systems have been studied for colon specific 
delivery, such as beads, matrices, tablets, capsules, and micro-/nano-particles.  Multi-
particulate systems proved to be better than single-unit dosage forms due to their 
reproducibility and predictable GI transit time, more reliable drug release profile, and 
less local irritation [207].  The advantages of multi-particulate dosage forms have 
been described in detail in Chapter 1.  Further, multiple-unit dosage forms of enzyme 
specificity quickly spread out upon their arrival in the colon and due to an enhanced 
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surface area being exposed to the enzymes, rapid drug release occurs at the colon 
[262].  Indeed, some researchers have previously exploited Ca/Zn-pectinate beads 
(multi-particulate system) as colon specific drug carriers [198, 199, 205, 207, 212, 
215-217, 229]. 
 
5. 2. Materials and methods 
5. 2.1. Materials 
Amidated low methoxy (LM) pectin (GENU® pectin type LM-104 AS-FS; 
degree of esterification (DE) = 28 % and degree of amidation (DA) = 20 %) was a 
generous gift from CPKelco (Denmark).  Resveratrol (99.12 % purity, fine crystalline 
powder) and calcium chloride dihydrate were purchased from Shaanxi Sciphar 
Biotecnology Co., Ltd. (Xi’an, China) and Merck (Darmstadt, Germany), respectively.  
Sodium hydroxide, Tween® 80, zinc acetate dehydrate, and Pectinex® Ultra SP-L 
(pectinase/pectinolytic enzyme from Aspergillus aculeatus) were obtained from 
Sigma (St Louis, MO, USA).  Monobasic potassium phosphate was purchased from 
Fluka (Steinheim, Germany).  Other materials used are same as described in the 
earlier chapters.  All materials were used as received. 
 
5. 2.2. Formulation of pectinate gel beads containing resveratrol  
Ca-/Zn-pectinate beads were prepared using previously reported iontophoretic 
gelation method with slight modification (Figure 5.1) [207, 220, 224].  Briefly, pectin 
was dissolved in deionized water.  Resveratrol was then added to the pectin solution 
and homogeneously dispersed by a homogenizer.  Air bubbles were removed from the 
dispersion by sonication on a bath sonicator.  The pectin-resveratrol mixture was then 
dropped slowly (1 ml.min-1) into gently agitated cross-linking solution (calcium 
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chloride/zinc acetate aqueous solution) through the blunt end of a 25G needle from 5 
cm distance at room temperature (RT).  The beads formed were allowed to stand in 
the solution for specified time interval with gentle agitation, separated, washed with 
distilled water and dried at various conditions mentioned for individual formulations. 
 
Figure 5.1:  Schematic presentation of the formulation procedure of Ca-/Zn-pectinate 
beads.   
The effects of different formulation variables on bead size and shape, moisture 
content (MC), water loss during drying (WL), calcium content, resveratrol loading (L) 
and entrapment/encapsulation efficiency (EE), swelling and erosion behavior, and 
resveratrol retention patterns were evaluated by varying the formulation variables (see 
formulation design sections).  Formulation variables were optimized based on their 
effects on bead characteristics, EE, and retention of resveratrol within the beads (or 
drug (resveratrol) release profile).  All batches were prepared in triplicate. 
 
5. 2.3. Characterization of resveratrol-loaded pectin beads 




5. 2.3.1. Morphological study:  Morphological examination (bead surface and cross 
section) of the resveratrol-free and resveratrol-loaded beads were conducted using a 
JEOL scanning electron microscope (JSM-5200) at an excitation voltage of 20 kV.  
Pectinate beads were fixed on an aluminum stub and coated with platinum (30 
seconds) to a thickness of 2 nm (under vacuum by auto fine coater) and examined at 
different magnifications. 
 
5. 2.3.2. Particle size and shape:  The average diameter of 50 beads randomly 
selected from each batch was determined before and after drying by microscopic 
method, using an optical microscope (LEICA DM IL, Switzerland).  The length and 
breadth of each bead was measured by pre-calibrated image analysis program (LAS 
EZ, version 1.4.0) after images were taken through a digital camera (LEICA EC3, 
Switzerland) connected with the microscope.  The size of each bead was calculated 
from the average of these two dimensions [224] and expressed as the mean diameter 
(µm) ± standard deviation (SD).  The mean diameters of beads before and after drying 
were compared.  
The elongation ratio (ER) of the above mentioned beads was calculated to 
represent bead shape.  ER is the quotient of length to breadth of the bead [224].  An 
elongation ratio value of unity represents a perfect sphere while higher values 
represent greater elongation or more deviation from spherical shape (ER = 1, 1 < ER< 
1.25, and ER > 1.25 represent a perfect spherical, spherical, and non-spherical shape, 
respectively). 
 
5. 2.3.3. FT-IR:  Possible chemical interactions between resveratrol and bead 
components were studied using infrared spectroscopy.  Infrared (IR) spectra of pure 
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resveratrol, resveratrol-free pectin bead and resveratrol-loaded pectin bead were 
compared using FT-IR spectrometer (PerkinElmer Spectrum 100 Series, Norwalk, CT, 
USA).  Pectin beads were squashed and dried in a vacuum desiccator for 3 days to 
remove the moisture completely.  Sample (~ 2 mg) was mixed with ~ 198 mg dry KBr 
(FT-IR grade, Aldrich, Germany).  The mixture was ground into a fine powder using 
mortar and pestle before compressing into a disc.  Each disc was scanned at a 
resolution of 4 cm-1 over a wave number region of 400 – 4000 cm-1 using the FT-IR 
spectrometer.  The characteristic peaks of IR transmission spectra were recorded. 
 
5. 2.3.4. Determination of calcium/zinc content in beads:  In order to evaluate the 
amount of calcium/zinc retained in the beads, ~ 20 mg of weighed beads were 
dissolved in 19 ml of 50 mM sodium phosphate buffer (pH 7.4) containing 1 % 
ethylenediaminetetraacetic acid (EDTA).  The solution was acidified by adding 1 ml 
of concentrated hydrochloric acid.  The solution obtained was then centrifuged at 
10,000 x g for 10 minutes.  Supernatants were diluted to the calibration range and the 
amount of calcium/zinc present was determined by atomic absorption spectroscopy 
(AAS, PerkinElmer AAnalyst 100 model, Norwalk, CT, USA).  The beads were 
analyzed for its calcium content as a function of the formulation variables. 
 
5. 2.3.5. Determination of weight and weight-loss of the beads after drying:  The 
WL of the beads was determined by gravimetric analysis.  Fifty randomly selected 
beads from each batch were weighed with an analytical balance with readability of 
0.00001 g (Metler Toledo, Switzerland) before and after drying at RT for 24 h (except 
in case of the beads dried at different conditions mentioned in Table 5.1).  The mean 









WL         (1) 
where, WW is the initial weight of the beads measured just after washing and WD is the 
weight of the beads after drying.  Experiment was performed in triplicate for each 
batch.  
 
5. 2.3.6. Moisture content:  The MC of the beads was also determined using 
gravimetric method.  Fifty randomly selected beads from each batch were dried 
completely at elevated temperature (60 °C) until no further weight change was 





WWMC         (2) 
where, WD is the weight of the beads after drying and W is the weight of fully dried 
beads.  Experiment was performed in triplicate for each batch and average was 
calculated. 
 
5. 2.4. Resveratrol loading and entrapment/encapsulation efficiency 
Resveratrol content in the beads was determined by direct and indirect 
methods using a spectrophotometer (UV-Visible Spectrophotometer UV – 1601, 
Shimadzu, Japan) at a wavelength of 320 nm.   
5. 2.4.1. Direct method:  Beads (~ 25 mg) were dispersed in 5 ml of phosphate 
buffer (50 mM, pH 7.4) by continuous stirring on a magnetic stirrer.  To ensure 
solubilization of poorly soluble resveratrol, 10 ml of methanol was added to the 
system and mixed well on a magnetic stirrer.  The mixture was centrifuged at 10,000 
x g (10 min) to remove the pectin.  The supernatant containing the resveratrol was 
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diluted to the calibration range (0.1 – 10 µg⋅ml-1) with methanol-water mixture (1 : 1).  
Beads prepared without resveratrol were used as blank. 




AQEE          (3) 
where, AQ is the actual quantity of drug present in the beads (drug content) and TQ is 
the theoretical quantity of drug (initial resveratrol loading dose during the preparation 
of the beads). 
%100(%) ×=
PW
AQL          (4) 
where, WP was the weight of pectin used to prepare the beads. 
5. 2.4.2. Indirect method:  For further confirmation, L and EE of the beads for 
resveratrol were also determined by the indirect method.  In this method, an exact 
volume (6 ml) of pectin gel mixture containing resveratrol was employed to prepare 
beads in 100 ml of cross-linking solution.  The amount of resveratrol lost in the cross-
linking solution as well as washing solution was assayed spectrophotometrically.  EE 






QQEE         (5) 
where, QT is the amount of drug added initially during the batch preparation and QI is 





QQL         (6) 
All experiments were performed in triplicate. 
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5. 2.5. Solubility of resveratrol in different fluids 
Resveratrol solubility was determined in simulated gastric fluid (SGF, pH 1.2 
(USP30–NF25)), simulated intestinal fluid (SIF, pH 6.8 (USP30–NF25)), and in the 
presence of 0.2 % (v/v) Tween 80.  Excess resveratrol was added to the corresponding 
fluids; vortexed and kept on a water bath shaker (100 rpm) for 1 day at 37 ºC.  The 
suspension was filtered through a 0.22 µm membrane filter (Whatman Ltd., Kent, UK) 
to obtain a clear solution.  All samples were prepared in triplicate.  The concentration 
of resveratrol in the fluids was determined by HPLC assay as described earlier [335].  
Solubility of resveratrol in SGF was undetectable (detection limit was 0.01 μg.ml−1), 
whereas solubility in SIF was found to be 0.11 ± 0.01 μg.ml−1 and 0.72 ± 0.13 μg.ml−1 
when in the presence of 0.2 % (v/v) Tween 80. 
 
5. 2.6. Resveratrol release studies from beads 
 As formulations in large quantity are difficult to prepare using laboratory-scale 
equipment and procedures, it is inconceivable to conduct dissolution experiments 
using the standard dissolution apparatus mentioned in United States Pharmacopeia 
(USP), which requires relatively large amounts of materials.  In addition, there are 
other reasons that prohibit the use of a standard dissolution apparatus for measuring 
drug release including (i) shortage of ingredients, particularly pectin and resveratrol, 
(ii) the presence of a high volume of the buffer which will adversely affect the beads’ 
characteristics when small amount of beads are used (limited by factor (i)) in standard 
dissolution apparatus, and most importantly (iii) the marginal solubility of resveratrol 
in SIF/SGF, release of resveratrol (in SIF/SGF) in standard dissolution apparatus may 
not be observed even in the presence of a high amount of surfactant (0.2 % (v/v) 
Tween 80) (addition of very high amount of surfactant was not at all feasible as a high 
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amount of surfactant may have a deleterious effect on the release characteristic of the 
beads).  Therefore, an alternative method was devised in which only small amounts of 
beads are needed to measure drug release and this method preclude measurement of 
drug released (either in dissolved or particulate form) in the release media (SIF/SGF).  
In this method, the amount of resveratrol remaining in the intact beads after each time 
point was estimated instead of measuring the drug released into the media.  This is 
because much of the drug is in particulate form (rather than in dissolved form) due to 
the poor aqueous solubility of resveratrol and hence will impede the proper 
quantification. 
Briefly, resveratrol-loaded beads were weighed (~ 25 mg) into screw capped 
glass test tubes and suspended in 37 ± 0.2 °C releasing medium (10 ml).  Separate 
tubes were used for each time point.  The tubes were kept at 37 ± 0.2 °C with 
continuous stirring (reciprocal) in shaking water bath (100 rpm).  At selected time 
intervals, intact beads were separated from the specified tubes.  The beads were 
dissolved/dispersed in 5 ml PBS (pH 7.4, 50 mM) and fully dissolved by the addition 
of methanol (10 ml).  The mixture was mixed and centrifuged (10,000 x g) for 10 min.  
The supernatant was collected, diluted with methanol-water (1 : 1) to the calibration 
range.  The drug content in the supernatant (or remaining in the beads) was 
determined spectrophotometrically (UV-Visible Spectrophotometer UV – 1601, 
Shimadzu) at 320 nm.  Beads devoid of resveratrol were used as a control. 
SIF (pH 6.8) was used as release media throughout the bead optimization 
process.  Optimized beads were also tested in SIF (pH 6.8) containing 300 PG (i.e., 
0.032 µl.ml-1) Pectinex® Ultra SP-L (simulating the colonic environment), and in SGF 
(pH 1.2) to investigate resveratrol release from the bead formulation in colonic and 
gastric conditions, respectively. 
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Percentage of resveratrol remaining in the intact beads (in comparison to the 
initial resveratrol amount in the beads) was plotted against time.  Times 
corresponding to 25, 50, and 75 % resveratrol retention in the beads (T25, T50, and T75) 
during release study were then determined.  All experiments were performed in 
triplicate. 
 
5. 2.7. Kinetics of drug release 
The drug release kinetics from the beads were investigated by fitting the drug 
release data into zero order and Higuchi’s dissolution models.  The zero order 
equation is expressed as 
tkQQ 00 −=           (7) 
where, Q is the percentage of drug remaining at time t (h), Q0 is the percentage of 
drug at t = 0 h, and k0 is the zero order release rate constant.  
A simplified Higuchi’s equation (square root of time equation (SQRT)) can be 
obtained by plotting the percent drug released versus square-root of time as follows: 
tkQt =            (8) 
in which, Qt is the percentage of drug released at time t (h) and k is the Higuchi’s 
release rate constant.  The original equation described by Higuchi for drug release 




=         (9) 
Where, Qt is the amount of drug released per unit area of exposed surface of the 
matrix, D is the diffusion coefficient of the drug in the matrix, ε is the total porosity of 
the matrix after the drug has been extracted, A is the amount of drug in the matrix, CS 
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is the solubility of the drug in the polymeric matrix, t is the time and τ  is the 
tortuosity. 
Experimental drug release data was fitted into the dissolution models and the 
appropriate model was selected after linear regression analysis.  R2 > 0.95 was set for 
linearity.  The release rate constants were calculated from the slope of each straight 
line of best fit model.  
 
5. 2.8. Swelling–erosion behavior of the beads 
Pre-weighed (~ 25 mg) dry beads were placed in the glass test tube containing 
enzyme-free SIF (pH 6.8) at 37 ± 0.2 °C.  The test tubes were placed in the shaking 
water bath (37 ± 0.2 °C) at 100 rpm (exactly the same condition as in release study).  
One test tube was assigned to each time point.  The beads were removed at every time 
point up to 6 h, blotted with filter paper to remove the excess water and weighed.  
Optimized beads were also tested in SIF (pH 6.8) containing 300 PG Pectinex® Ultra 








WWSER T         (10) 
where, WT is the  weight of the beads at the given time point, W0 is the initial weight 
of the dry beads.  Positive SER and upward trend denote overall swelling and weight 
gain of beads with water absorption, while negative SER and downward trend 
demonstrate the erosion and/or drug release of beads.  Each determination was 
performed in triplicate and the results were averaged.  Percentage SER was plotted 
against time to depict SER profile of the beads in SIF. 
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5. 2.9. Enzymatic degradation 
 The beads prepared with optimized formulation parameters were incubated in 
SIF (pH 6.8) with or without 300 PG pectinase enzyme for 3 h.  Subsequently, the 
beads were separated from the media and lyophilized.  JEOL scanning electron 
microscopy (JSM-5200) was used to examine the appearance of the enzyme-treated 
beads and compared with the non-enzyme-treated beads.  Similar scanning electron 
microscopy parameters to those of the morphological study were used in this study.  
 
5. 2.10. Stability 
 The optimized beads (~ 100 mg) were stored at 3 different conditions: cold (4 
ºC), RT, and accelerated temperature (40 ºC) for 6 months.  Three samples were 
stored for each time point.  The samples were analyzed for resveratrol contents at 
predetermined time intervals (0 day, 3 days, 7 days, 15 days, 30 days, 90 days, and 
180 days) by UV spectrometer using the same procedure described in release study. 
 
5. 2.11. Statistical analysis   
Statistical analysis of drug release parameters were performed using the 
software Graph-Pad Prism Version 2.00 (San Diego, CA).  All experimental data 
were expressed as mean ± standard deviation (SD).  One-way ANOVA with the post 
hoc Tukey test and two-tail unpaired t test were performed for statistical analysis, 
where applicable.  Statistical significance was set at p < 0.05. 
 
5.3. Optimization of calcium-pectinate bead 
5.3.1. Formulation design 
The different formulation variables used to prepare the beads are listed in Table 5.1
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Table 5.1:  Formulation design of Ca-pectinate beads   
Variables Values Constants 
Calcium chloride 









Calcium chloride conc. 
(% w/v) 
2.5 - 1.5 0.5 RT 5 3 : 1 
5 - 1.5 0.5 RT 5 3 : 1 
10 - 1.5 0.5 RT 5 3 : 1 
20 - 1.5 0.5 RT 5 3 : 1 
Cross-linking solution 
pH 
1.5 10 - 0.5 RT 5 3 : 1 
3.5 10 - 0.5 RT 5 3 : 1 
5.5 10 - 0.5 RT 5 3 : 1 
Cross-linking time (h) 0.25 10 1.5 - RT 5 3 : 1 
0.5 10 1.5 - RT 5 3 : 1 
2 10 1.5 - RT 5 3 : 1 
24 10 1.5 - RT 5 3 : 1 
Drying RT (25 ºC) 10 1.5 0.5 - 5 3 : 1 
37 ºC 10 1.5 0.5 - 5 3 : 1 
50 ºC 10 1.5 0.5 - 5 3 : 1 
FD 10 1.5 0.5 - 5 3 : 1 
Pectin conc. (% w/v) 3  10 1.5 0.5 RT - 3 : 1 
4  10 1.5 0.5 RT - 3 : 1 
5 10 1.5 0.5 RT - 3 : 1 
6 10 1.5 0.5 RT - 3 : 1 
Pectin : Resveratrol 1 : 1 10 1.5 0.5 RT 5 - 
2 : 1 10 1.5 0.5 RT 5 - 
3 : 1 10 1.5 0.5 RT 5 - 
4 : 1 10 1.5 0.5 RT 5 - 
Blank - 10 1.5 0.5 RT 5 - 
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5.3.2. Results and Discussion 
5.3.2.1. Preparation of Ca-pectinate bead:  In the present study, when the highly 
water insoluble resveratrol was homogeneously dispersed into the aqueous solution of 
pectin and subsequently added dropwise to a counter ion solution of calcium, gelled 
sphere instantaneously formed by ionotropic gelation method.  Ionic interaction 
between the negatively charged carboxylic groups on pectin molecules and the 
positively charged divalent calcium ions led to intermolecular cross-linking (known as 
‘egg-box’ conformation [202]) and formation of gelled spheres.  The beads were 
easily prepared without any sophisticated instruments. 
 
5.3.2.2. Morphology:  SEM images of both blank and resveratrol-loaded Ca-
pectinate beads are shown in Figure 5.2.  At X 75 magnification, a smooth surface 
topography was observed for the blank bead (Figure 5.2A).  The topology of the 
resveratrol-loaded bead changed to a rough and rugged surface, which was noticed 
even at lower magnification (X 35) (Figure 5.2B).  Analyses of SEM pictures of both 
surface and cross-section of the drug-loaded beads taken at higher magnifications (X 
500 and X 1,000) revealed that the drug crystals are embedded in the bead matrix 
(Figure 5.2C, 5.2D, and 5.2E).  Similar findings were reported for pectin bead loaded 




















Figure 5.2:  Scanning electron micrographs of blank Ca-pectinate bead surface (X 75) 
(A), surface of resveratrol-loaded Ca-pectinate bead (X 35) (B), surface of 
resveratrol-loaded Ca-pectinate bead (X 500) (C), surface of resveratrol-loaded Ca-
pectinate bead (X 1000) (D) , and cross-section of resveratrol loaded Ca-pectinate 
bead (X 1000) (E).  Magnifications corresponding to each figure are presented in 
brackets. 
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5.3.2.3. Particle size and shape, and weight:  The mean diameter and ER of the 
dried and un-dried beads are listed in Table 5.2.  The mean diameter ranged from 0.97 
to 1.22 mm for the dry beads (except lyophilized bead), and > 2 mm for the wet beads.  
The size of the beads formed generally depends on the diameter (25G) of the needle 
used to prepare the beads.  Because a 25G needle was used throughout the experiment, 
it is obvious that other formulation variables were affecting the particle size of the 
dried beads.  Augmentation of particle size was observed with increased calcium 
chloride concentration in the cross-linking medium.  This can be explained by 
increased retention of un-cross-linked calcium chloride which leads to higher water 
retention in beads (Table 5.3) due to the hygroscopic character of calcium chloride 
[212].  However, other researchers demonstrated an inverse relationship between the 
particle size and calcium chloride concentration due to pronounced gel bead shrinkage 
caused by syneresis [205].  Nevertheless, the cross-linking time resulted in an 
insignificant change in the diameter of beads.  An inverse relationship between the 
particle size and drying temperature however was noted.  This can be explained by 
lower MC due to higher drying temperature (Table 5.3).  On the other hand, the size 
of the lyophilized beads was bigger than all other beads.  It is possible that during 
freeze drying, moisture evaporates from the beads without affecting the bead structure.  
Slight enhancement of particle size was also observed with increased resveratrol 
concentration.  This is anticipated because of lower polymer to drug ratio. During 
drying size of the bead was decreased due to contraction of pectin as particle size of 
the drug cannot be reduced.  In case of low pectin to resveratrol ratio, less amount of 
pectin is present in the beads, which means less contraction of the beads after drying.  
Diminution of pH of the cross-linking solution created particles with smaller size.  A 
probable reason is that at reduced pH, non-ionic interaction occurred along with ionic 
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interaction between pectin chains, which led to small and compact beads.  This 
phenomenon will be discussed later in detail.  Higher MC at high pH is also a 
probable reason behind enhanced particle size.  Bead size was found to be 
independent of the pectin concentration.  Further, beads without drug were much 
smaller than drug-loaded beads.   
From ER, it can be seen that almost all beads (except dried beads prepared 
with 3 % pectin) were spherical in shape (ER < 1.25) (Table 5.2).  Weight of wet as 
well as dry beads slightly increased with increasing cross-linking solution pH, 
calcium chloride concentration, cross-linking time, resveratrol concentration, and with 
decreasing pectin concentration and drying temperature (Table 5.2). This can be 
explained by MC. 
 
5.3.2.4. FT-IR:  The FT-IR spectra of pure resveratrol, resveratrol-free and 
resveratrol-load Ca-pectinate bead are depicted in Figure 5.3.  FT-IR absorption 
spectrum of resveratrol showed a typical trans olefinic band at 966 cm-1 and three 
characteristic intense bands at 1383, 1585, and 1607 cm-1, corresponding to C–O 
stretching, C–C olefinic stretching, and C–C aromatic double-bond stretching .  All 
these major peaks are present in the resveratrol-loaded Ca-pectinate bead, indicating 
that resveratrol was not chemically modified when formulated into Ca-pectinate beads. 
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Table 5.2:  Particle size and shape, and weight of the Ca-pectinate beads (Data presented as mean ± SD, N = 50 beads) 
Variables Values Size (µm ± SD) Shape (ER ± SD) Weight of 50 beads (mg ± SD) 





2.5 2192.82 ± 90.79 976.41 ± 74.46 1.19 ± 0.05 1.13 ± 0.08 304.50 ± 9.01 25.42 ± 1.05 
5 2202.51 ± 83.72 997.42 ± 38.45 1.02 ± 0.02 1.12 ± 0.09 306.63 ± 9.17 28.79 ± 0.26 
10 2211.28 ± 66.23 1077.77 ± 72.97 1.07 ± 0.05 1.06 ± 0.06 309.87 ± 3.93 32.62 ± 0.77 
20 2218.93 ± 42.58 1217.23 ± 44.03 1.03 ± 0.02 1.16 ± 0.08 315.38 ± 8.75 47.59 ± 0.67 
Cross-linking 
pH 
1.5 2211.28 ± 66.23 1077.77 ± 72.97 1.07 ± 0.05 1.06 ± 0.06 309.87 ± 3.93 32.62 ± 0.77 
3.5 2240.21 ± 53.13 1100.12 ± 78.14 1.05 ± 0.03 1.09 ± 0.05 314.43 ± 5.10 33.75 ± 0.41 
5.5 2264.43 ± 74.28 1148.68 ± 83.85 1.03 ± 0.01 1.14 ± 0.13 326.00 ± 9.41 35.95 ± 0.23 
Cross-linking 
time (h) 
0.25 2198.07 ± 184.64 1036.84 ± 28.06 1.10 ± 0.08 1.12 ± 0.06 306.30 ± 8.01 27.13 ± 0.28 
0.5 2211.28 ± 66.23 1077.77 ± 72.97 1.07 ± 0.05 1.06 ± 0.06 309.87 ± 3.93 32.62 ± 0.77 
2 2245.01 ± 106.75 1078.13 ± 63.21 1.03 ± 0.02 1.12 ± 0.07 314.57 ± 2.40 35.79 ± 1.42 
24 2288.43 ± 94.18 1081.94 ± 67.88 1.17 ± 0.08 1.08 ± 0.05 328.30 ± 5.98 39.19 ± 0.92 
Drying RT 2211.28 ± 66.23 1077.77 ± 72.97 1.07 ± 0.05 1.06 ± 0.06 309.87 ± 3.93 32.62 ± 0.77 
37 ºC 2211.28 ± 66.23 1052.19 ± 49.14 1.07 ± 0.05 1.16 ± 0.05 309.87 ± 3.93 31.99 ± 0.32 
50 ºC 2211.28 ± 66.23 1005.51 ± 30.26 1.07 ± 0.05 1.19 ± 0.11 309.87 ± 3.93 26.26 ± 0.44 




3 2194.99 ± 142.03 1057.04 ± 75.52 1.13 ± 0.09 1.41 ± 0.15 315.03 ± 5.12 33.42 ± 0.87 
4 2161.47 ± 144.16 1029.66 ± 84.62 1.11 ± 0.05 1.11 ± 0.10 312.47 ± 5.85 33.06 ± 0.20 
5 2211.28 ± 66.23 1077.77 ± 72.97 1.07 ± 0.05 1.06 ± 0.06 309.87 ± 3.93 32.62 ± 0.77 
6 2181.83 ± 118,47 1075.93 ± 105.13 1.04 ± 0.03 1.10 ± 0.08 307.57 ± 9.53 31.97 ± 0.44 
Pectin : 
Resveratrol 
1 : 1 2231.10 ± 50.66 1123.50 ± 33.85 1.06 ± 0.04 1.17 ± 0.10 374.37 ± 9.25 42.54 ± 2.17 
2 : 1 2225.82 ± 54.17 1099.74 ± 98.19 1.04 ± 0.03 1.10 ± 0.07 316.67 ± 1.42 35.85 ± 0.39 
3 : 1 2211.28 ± 66.23 1077.77 ± 72.97 1.07 ± 0.05 1.06 ± 0.06 309.87 ± 3.93 32.62 ± 0.77 
4 : 1 2210.37 ± 49.92 1020.58 ± 45.42 1.05 ± 0.03 1.06 ± 0.04 299.3 ± 5.20 31.49 ± 0.71 





Figure 5.3:  FTIR spectra of blank Ca-pectinate bead (A), resveratrol loaded Ca-
pectinate bead (B), and pure resveratrol (C). 
 
5.3.2.5. Determination of calcium content in beads:  Various formulation 
parameters have potential impact on the amount of calcium retained in the beads 
(Table 5.3).  The findings from this study indicated that calcium content per mg of 
beads increased with calcium chloride concentration in cross-linking solution, cross-
linking solution pH, and cross-linking time; on the other hand, calcium content 
decreased with pectin concentration and resveratrol concentration.  Increase in 
calcium chloride concentration in cross-linking solution supplied more calcium for 
gelation of beads that led to enhanced calcium retention in beads.  This observation is 
in line with a previous work [212].  Similarly, increasing cross-linking time allows 
calcium more time to react with the beads, which ultimately increases its entrapment 
in the beads.  It should be noted that a rapid increase in calcium entrapment was only 
observed in the beginning phase (i.e. from 0.25 to 0.5 h) of the process.  This can be 
explained by the mechanism of Ca-pectinate network formation, which normally 
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occurs very quickly in a two-step fashion: formation of dimers followed by their 
aggregation.  Formation of dimers, which precedes aggregation of dimers, requires a 
huge amount of calcium ions [336].  By contrast, aggregation of  dimers occurs if 
more calcium is available but it requires less calcium ions than the initial dimer 
formation [212]. 
Ionization of carboxylic group on the pectin moiety is expected to be subdued 
after suppressing the pH of the cross-linking medium.  Thus, less calcium is bound 
with the pectin chain at low cross-linking solution pH, which repressed the calcium 
entrapment.  As the concentration of resveratrol increased, pectin to resveratrol ratio 
decreased.  So, at higher resveratrol concentration, less pectin is available for cross-
linking which could probably explain lower calcium retention.  More interestingly, 
augmentation of calcium entrapment was observed at lower pectin concentration, 
which was probably due to easy penetration of calcium-chloride into the dilute pectin 
drops during gelation.  As a result, it can be anticipated that more calcium would be 
present as free calcium chloride in the beads with low pectin concentration.  Moreover 
calcium retention was found in the order of RT < 37 ºC < 50 ºC < FD.  Weight of the 
beads decreased with drying temperature and was lowest in the case of freeze dried 
beads.  So, higher amount of calcium retained per mg of beads was rational for lower 
weighing beads.  Calcium is an essential micronutrient for human and considered as 
safe for oral intake.  
 
5.3.2.6. Weight loss after drying:  After drying, beads lost 88 - 92 % of their initial 
weight depending on the formulation conditions (Table 5.3).  WL slightly increased 
with decreasing calcium chloride concentration, cross-linking solution pH, and cross-
linking time; as well as, with increasing pectin concentration, resveratrol 
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concentration and drying temperature (FD > 50 ºC).  In most cases, this increase was 
not significant.  
 
5.3.2.7. Moisture content:  The MCs corresponding to each type of formulations 
are given in Table 5.3.  The moisture content of the beads was clearly correlated with 
the type of drying method undertaken.  Only small amount of moisture (< 2 %) was 
detected in freeze dried beads and those dried at elevated temperature (50 ºC); with 
the lowest moisture entrapment in the case of lyophilized beads.  Very high moisture 
content was observed in beads prepared with 20 % calcium chloride as cross-linking 
solution.  One earlier report already demonstrated that only small amount of calcium 
is needed for Ca-pectinate network formation with the majority of calcium remaining 
as free calcium chloride in Ca-pectinate beads.  This phenomenon imparts 
hygroscopicity to the beads that induces retention of water [212].  The MC of dried 
beads was also found to increase linearly with increasing pH of cross-linking solution, 
cross-linking time, and resveratrol concentration.  The hydration of pectin was 
reduced in acid-induced pectin gels, which led to less MC.  By contrast, decreased 
pectin concentration caused an increase in beads MC.  In all cases except resveratrol 
concentration and drying condition, calcium retention was related to MC.   
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Table 5.3:  L, EE, WL, MC, and calcium content of the Ca-pectinate beads (Data presented as mean ± SD, N = 3) 
Variables Values WL # (%) MC (%) Ca content  
(µg.mg-1 bead) 
Direct method Indirect method 





2.5  91.65 ± 0.21 15.42 ± 1.26 12.94 ± 1.34 f 98.18 ± 0.21 32.73 ± 0.07 98.43 ± 0.17 32.81 ± 0.06 
5  90.61 ± 0.19 16.16 ± 1.00 36.65 ± 1.28 98.34 ± 0.18 32.78 ± 0.06 98.65 ± 0.21 32.88 ± 0.07 
10  89.47 ± 0.17 16.63 ± 0.25 44.53 ± 1.87 98.68 ± 0.18 32.89 ± 0.06 98.97 ± 0.09 32.99 ± 0.03 
20  84.90 ± 0.38 33.79 ± 1.76 a 52.99 ± 1.15 99.05 ± 0.25 o 33.02 ± 0.08 99.42 ± 0.06 33.14 ± 0.02 
Cross-linking 
pH 
1.5 89.47 ± 0.17 16.63 ± 0.25 44.53 ± 1.87 g 98.68 ± 0.18 g 32.89 ± 0.06 98.97 ± 0.09 32.99 ± 0.03 
3.5 89.26 ± 0.15 16.90 ± 1.08 48.01 ± 1.43 98.43 ± 0.20 32.81 ± 0.07 98.75 ± 0.44 32.92 ± 0.15 
5.5 88.97 ± 0.25 18.90 ± 1.22 51.19 ± 0.95 98.18 ± 0.07 32.73 ± 0.02 98.72 ± 0.25 32.91 ± 0.08 
Cross-linking 
time (h) 
0.25 91.14 ± 0.32 14.99 ± 0.80 b 40.68 ± 0.95 b 98.84 ± 0.13 b 32.95 ± 0.04 99.08 ± 0.18 33.03 ± 0.06 
0.5 89.47 ± 0.17 16.63 ± 0.25 c 44.53 ± 1.87 98.68 ± 0.18 p 32.89 ± 0.06 98.97 ± 0.09 32.99 ± 0.03 
2 88.62 ± 0.50 17.76 ± 0.75 46.31 ± 2.26 97.99 ± 0.05 32.66 ± 0.02 98.27 ± 0.47 32.76 ± 0.16 
24 88.06 ± 0.50 19.58 ± 1.61 48.86 ± 2.08 97.79 ± 0.25 32.60 ± 0.08 97.91 ± 0.36 32.64 ± 0.12 
Drying RT 89.47 ± 0.17 16.63 ± 0.25 d 44.53 ± 1.87 h 98.68 ± 0.18 32.89 ± 0.06 98.97 ± 0.09 32.99 ± 0.03 
37 ºC 89.67 ± 0.23 14.88 ± 0.69 44.75 ± 0.82 i 98.61 ± 0.12 32.87 ± 0.04 98.97 ± 0.09 32.99 ± 0.03 
50 ºC 91.52 ± 0.25 01.54 ± 0.15 52.69 ± 2.11 98.48 ± 0.08 32.82 ± 0.03 98.97 ± 0.09 32.99 ± 0.03 




3  89.39 ± 0.11 17.32 ± 0.81 54.59 ± 1.14 j 98.28 ± 0.07 j 32.76 ± 0.02 98.58 ± 0.31 32.86 ± 0.10 
4  89.42 ± 0.25 17.11 ± 1.21 54.04 ± 1.35 k 98.37 ± 0.07 q 32.79 ± 0.02 98.66 ± 0.32 32.89 ± 0.11 
5  89.47 ± 0.17 16.63 ± 0.25 44.53 ± 1.87 98.68 ± 0.18 32.89 ± 0.06 98.97 ± 0.09 32.99 ± 0.03 
6  89.60 ± 0.43 16.38 ± 1.82 43.89 ± 1.41 98.70 ± 0.14 32.90 ± 0.05 98.97 ± 0.07 32.99 ± 0.02 
Pectin : 
Resveratrol 
1 : 1 88.64 ± 0.31 18.79 ± 0.65 e 37.06 ± 1.66 l 99.56 ± 0.04 r 99.56 ± 0.04 99.61 ± 0.04 99.61 ± 0.04 
2 : 1 88.68 ± 0.16 17.24 ± 1.22 41.10 ± 1.47 m 99.15 ± 0.16 49.58 ± 0.08 99.26 ± 0.01 49.63 ± 0.01 
3 : 1 89.47 ± 0.17 16.63 ± 0.25 44.53 ± 1.87 n 98.68 ± 0.18 32.89 ± 0.06 98.97 ± 0.09 32.99 ± 0.03 
4 : 1 89.48 ± 0.16 15.65 ± 0.07 49.04 ± 0.84 98.36 ± 0.06 24.59 ± 0.01 98.84 ± 0.07 24.71 ± 0.02 
Blank - 89.62 ± 0.43 15.21 ± 1.12 50.62 ± 1.11 - - - - 
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a p < 0.05 between 2.5 and 20 %, between 5 and 20 %, and between 10 and 20 %  calcium chloride concentration; b p < 0.05 between 
0.25 and 2 h, and between 0.25 and 24 h; c p < 0.05 between 0.5 and 24 h; d p < 0.05 among RT, 37 ºC, 50 ºC, and FD, except between 50 
ºC, and FD;  e p < 0.05 between 1 : 1 and 3 : 1, between 1 : 1 and 4 : 1, and between blank and 1 : 1 pectin to resveratrol ratio; f p < 0.05 
among all calcium chloride concentration; g p < 0.05 between pH 1.5 and 5.5; h p < 0.05 between RT and 50 ºC, and between RT and FD; 
i p < 0.05 between 37 ºC and 50 ºC, and between 37 ºC and FD; j p < 0.05 between 3 and 5 %, and between 3 and 6 % pectin; k p < 0.05 
between 4 and 5 %, and between 4 and 6 % pectin; l p < 0.05 between 1 : 1 and 3 : 1, between 1 : 1 and 4 : 1, and between blank and 1 : 1 
pectin to resveratrol ratio; m p < 0.05 between 2 : 1 and 4 : 1, and between blank and 2 : 1 pectin to resveratrol ratio; n p < 0.05 between 3 : 
1 and 4 : 1, and between blank and 3 : 1 pectin to resveratrol ratio, o p < 0.05 between 20 and 2.5 %, and between 20 and 5 % calcium 
chloride concentration; p p < 0.05 between 0.5 and 2 h, and between 0.5 and 24 h; q p < 0.05 between 4 and 6 % pectin; r p < 0.05 among 
1 : 1, 2 : 1, 3 : 1, and 4 : 1 pectin to resveratrol ratio.  





5.3.2.8. Encapsulation efficiency and loading:  EE and L of each formulation type are 
depicted in Table 5.3.  Instantaneous gelation of pectin allowed easy entrapment of 
resveratrol in Ca-pectinate beads.  Indeed, very high resveratrol entrapment was found in 
all cases (> 97.7 %).  Poor aqueous solubility of resveratrol led to such high percentage of 
drug entrapment in the beads.  Nevertheless, a small increase in entrapment and loading 
was observed in the present study with increasing calcium chloride concentration, pectin 
concentration, resveratrol concentration, and with decreasing cross-linking solution pH, 
cross-linking time.  As a matter of fact, drug concentration increment generally leads to 
lower EE due to reduced polymer to drug ratio [201].  On the other hand, EE and L 
slightly increased with increasing resveratrol concentration.  This is probably due to the 
lower resveratrol solubility in the cross-linking solution.  At constant temperature, 
resveratrol reaches saturation in the solution.  Hence, when more resveratrol was added 
into the pectin solution, only limited resveratrol came out from the beads to the cross-
linking solution, which consequently led to higher entrapment and loading of resveratrol. 
 
5.3.2.9. Effect of formulation variables on resveratrol retention and SER:  The 
following sections discuss the effects of different formulation variables on the resveratrol 
retention profiles, release parameters, and SER of all beads in SIF.  Drug retention 
profiles are represented by plotting resveratrol retention in bead against time (Figure 
5.4A – 5.9A); whereas SERs (%) are plotted against time to indicate the swelling of 
beads in SIF pH 6.8 at each time point (Figure 5.4B – 5.9B).  Further, release parameters 
(T75, T50, T25) are cited in Table 5.4. 
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Table 5.4:  Resveratrol retention within the Ca-pectinate beads (Data presented as mean 
± SD, N = 3)  
 










2.5 0.9554 0.8849 1.76 ± 0.07 a 3.53 ± 0.05 a 5.90 ± 0.05 a 
5  0.9720 0.9233 2.18 ± 0.17 4.27 ± 0.15 7.04 ± 0.08 
10  0.9582 0.9276 2.72 ± 0.11 5.01 ± 0.09 8.00 ± 0.24 
20  0.8887 0.9346 - - - 
Cross-linking 
pH 
1.5 0.9582 0.9276 2.72 ± 0.11 b 5.01 ± 0.09 b 8.00 ± 0.24 b 
3.5 0.9709 0.9312 2.28 ± 0.11 3.99 ± 0.17 6.17 ± 0.32 
5.5 0.9761 0.9208 1.59 ± 0.16 3.09 ± 0.11 5.07 ± 0.07 
Cross-linking 
time (h) 
0.25 0.9700 0.9322 2.04 ± 0.06 c 3.73 ± 0.09 c 5.91 ± 0.14 c 
0.5 0.9582 0.9276 2.72 ± 0.11 5.01 ± 0.09 8.00 ± 0.24 
2 0.9564 0.9190 2.73 ± 0.26 5.07 ± 0.13 8.13 ± 0.31 
24 0.9265 0.9458 - - - 
Drying 
RT 0.9582 0.9276 2.72 ± 0.11 5.01 ± 0.09 8.00 ± 0.24 d 
37 ºC 0.9557 0.9257 2.79 ± 0.16 5.13 ± 0.19 8.18 ± 0.26 
50 ºC 0.9701 0.9555 3.06 ± 0.19 5.60 ± 0.29 8.89 ± 0.42 




3  0.9682 0.9028 1.89 ± 0.03 f 3.69 ± 0.03 f, g 6.10 ± 0.05 f 
4  0.9861 0.9431 2.14 ± 0.23 h 4.05 ± 0.20 h 6.56 ± 0.13 h 
5  0.9582 0.9276 2.72 ± 0.11 5.01 ± 0.09 8.00 ± 0.24 
6  0.9516 0.9105 2.60 ± 0.10 4.90 ± 0.13 7.93 ± 0.28 
Pectin : 
Resveratrol 
1 : 1 0.9506 0.8808 1.65 ± 0.14 i 3.04 ± 0.11 i 4.85 ± 0.04 i 
2 : 1 0.9623 0.9014 2.04 ± 0.08 4.00 ± 0.09 6.63 ± 0.13 
3 : 1 0.9582 0.9276 2.72 ± 0.11 5.01 ± 0.09 8.00 ± 0.24 
4 : 1 0.9573 0.9349 2.86 ± 0.09 5.24 ± 0.14 8.34 ± 0.44 
Enzyme - 0.9945 0.9898 1.75 ± 0.02 j 3.17 ± 0.05 j 5.01 ± 0.14 j 
SQRT = square root equation 
a p < 0.05 among 2.5, 5, and 10 % calcium chloride concentration; b p < 0.05 among pH 
1.5, 3.5, and 5.5; c p < 0.05 between 0.25 h and 0.5 h, and between 0.25 h and 1 h; d p < 
0.05 between RT and 50 ºC; e p < 0.05 between RT and FD, between 37 ºC and FD, and 
between 50 ºC and FD; f p < 0.05 between 3 and 5 % pectin, and between 3 and 6 % 
pectin; g p < 0.05 between 3 and 4 % pectin; h p < 0.05 between 4 and 5 % pectin, and 
between 4 and 6 % pectin; i p < 0.05 among 1 :1, 2 :1, and 3 : 1 pectin to resveratrol ratio; 





5.3.2.9.1. Effect of calcium chloride concentration   
Because calcium chloride concentration at < 2.5 % or > 20 % produced either 
irregular-shaped beads or beads that adsorbed considerable amount of moisture, calcium 
concentration was kept between 2.5 to 20 % in the present study.  As shown in Figure 
5.4A and Table 5.4, the retention of resveratrol in beads within this range was clearly 
dependent upon the calcium chloride concentration.  Bead retention of resveratrol 
increased with elevated concentration of calcium; although, in case of 20 % calcium, 
resveratrol leaked out very quickly after 4 h.  In particular, the release of resveratrol was 
significantly faster at 2.5 and 5 % calcium chloride when compared to 10 %.  In addition, 
the kinetic profile of beads prepared in different counterion concentration had similar 
features but shifted to lower drug retention with low calcium chloride concentrations.  
This is in line with previous works that showed drug release subdued at higher cross-
linking agent concentration [198, 205, 209].  The effect of counterion concentration on 
the release parameters (T75, T50, and T25) is shown in Table 5.4.  Retention of resveratrol 
was more pronounced when a higher concentration of calcium chloride was used for 
cross-linking.  An exception to this was observed for beads prepared with 20 % calcium 
chloride which showed an opposite trend at T25.  Huge difference in SER was detected 
when different calcium concentration was used (Figure 5.4B).  In general, SER decreased 
with increasing concentration of calcium.  At low concentration, the calcium cation leads 
to dimer formation with pectin chain, whereas at high concentration, the number and/or 
strength of cross-links between pectin and counter ions increase as well.  Furthermore, 
under such condition, aggregation of initial dimers also occurs , which gives rise to a 
greater degree of cross-linking [212].  In summary, higher drug retention and lower SER 
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were observed due to higher gel strength at high calcium concentrations.  Based on this 
finding, the optimal concentration for subsequent study was chosen to be 10 % calcium 
chloride. 
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Figure 5.4:  Effects of calcium chloride (CaCl2) concentration on retention of resveratrol 
within the Ca-pectinate beads (A) and on SER of the Ca-pectinate beads (B).  The beads 
were incubated in SIF (release medium).  Data presented as mean ± SD.  * p < 0.05. 
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5.3.2.9.2. Effect of cross-linking solution pH   
As shown in Figure 5.5A, drug retention decreased with increasing pH.  Beads 
formulated at pH 1.5 showed more pronounced resveratrol retention while T75, T50, and 
T25 are lower in the case of the higher pH (Table 5.4).  Chambin et al. demonstrated 
similar effects of cross-linking solution pH on pectinate beads prepared with either 
calcium or zinc ion.  They noticed repression of drug release at lower pH, though the 
effect was more pronounced in Zn-pectinate beads [198].  The data (Figure 5.5B) also 
showed SER increased with increasing pH.  This is because acidic counter ion solution 
can lead to formation of a stronger matrix by forming a strong pectinate counter ion 
network [230].  Several authors reported that in addition to ionic interaction with calcium 
cation, polymeric chains of pectin in “egg-box” model of Ca-pectinate gel are also 
involved with different non-ionic interactions such as hydrophobic interaction and 
hydrogen bonding [337-339].  Though non-ionic interactions are more obvious with high-
methoxy pectin gels, Lootens et al. reported that stronger gels for amidated pectin were 
formed at pH below 3 (lower than pectin intrinsic pKa value) [339].  According to them, 
low pH decreases solubility of the pectin chain and suppresses intermolecular 
electrostatic repulsion by protonation of carboxyl groups that allows the carbonyl groups 
to act as hydrogen bond donors.  In addition, lowering the charges of the polymer chains 
promotes conformational ordering and intermolecular association by nonionic 
interactions [339].  It has been previously demonstrated that the chain would be extended 
by intermolecular charge-charge repulsion at high pH values where most of the carbonyl 
groups are ionized, allowing conformations close to the extended two-fold structure (two 
residues per turn of the helix) [338].  By contrast, reduction in pH at fixed temperature 
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reduced charge density and promoted conformational transition from the two-fold to the 
more compact three-fold helical conformation of the polygalacturonate chains of pectin 
in the Ca-pectinate network [338]. 
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Figure 5.5:  Effects of cross-linking solution pH on retention of resveratrol within the 
Ca-pectinate beads (A) and on SER of the Ca-pectinate beads (B).  The beads were 
incubated in SIF.  Data presented as mean ± SD.  * p < 0.05. 
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5.3.2.9.3. Effect of cross-linking time 
The release profiles of resveratrol from beads prepared with various cross-linking 
times are shown in Figure 5.6A).  It can be seen from these graphs that the retention of 
resveratrol within the calcium pectinate beads after incubation in SIF depends on the 
cross-linking time used to prepare the beads.  Drug retention within the beads and the 
resveratrol release parameters (T75, T50, and T25) were lowest when the cross-linking time 
was the shortest (0.25 h) (Figure 5.6A and Table 5.4, respectively), whereas insignificant 
differences in drug retention were observed between the beads prepared at cross-linking 
times of 0.5 h and 2 h, but higher drug retention was noticed in these beads than the beads 
prepared at 0.25 h cross-linking time.  In contrast, when longer cross-linking time (24 h) 
was employed to prepare the beads, drug retention was much higher in the first 3 h 
whence drug retention dropped rapidly afterwards (T75 was highest; T50 and T25 were 
higher than the beads prepared at 0.25 h cross-linking time but lower than the beads 
prepared at 0.5 h and 2 h cross-linking time).  Other researchers have also reported an 
inverse relationship between drug release and cross-linking time (i.e., direct relationship 
between drug retention and cross-linking time) [199, 209, 340].  The observed 
phenomena indicate that SER is clearly dependent on the cross-linking time (Figure 
5.6B).  As expected, 24 h cross-linking time gave the lowest and 0.25 h gave the highest 
(only for the first 4 h whence SER slowly dropped afterwards) SER.  As a comparison, 
SER was the same for the first 4 h for beads prepared with 0.5 and 2 h cross-linking time.  
After 4 h, the SER for the beads decreased as follows: 0.5 > 2 > 0.25 > 24 h.  The 
observed SER and delayed release pattern can be explained by the promotion of cross-
links between pectin chains and calcium ions with respect to time.  Corresponding to the 
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higher calcium concentration; higher cross-linking time also probably helped in the 
aggregation of primary dimmers, which, thereby, causes greater gel strength.  In this 
study, the optimized cross-linking time was found to be 0.5 h.  
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Figure 5.6:  Effects of cross-linking time on retention of resveratrol within the Ca-
pectinate beads (A) and on SER of the Ca-pectinate beads (B).  The beads were incubated 
in SIF.  Data presented as mean ± SD.  * p < 0.05. 
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5.3.2.9.4. Effect of drying condition 
The effect of drying condition on resveratrol release is illustrated in Figure 5.7A.  
Drug retention pattern was clearly influenced by the drying method used to prepare the 
beads.  Resveratrol release was markedly more rapid from the lyophilized beads than 
beads dried by other procedures.  Freeze-drying produced spherical porous beads which 
were fragile and easily breakable upon handling.  This explains why drug retention (T75, 
T50, and T25) profile of freeze-dried bead was very poor (Table 5.4).  The rapid 
degradation and higher SER (Figure 5.7B) of freeze dried product was probably 
explained by the higher porosity of the lyophilized beads.  Lyophilized beads tend to float 
on the release medium while other beads stayed at the bottom of the tubes and degraded 
slowly.  Therefore freeze-dried beads were unsuitable as delivery system.  A significant 
slow release and low SER were observed in the case of beads dried at 50 ºC.  Drying at 
high temperature produced dense beads with very low moisture content.  This may be the 
cause of slower release and lower SER for beads dried at higher temperature.  By contrast, 
beads dried at room temperature and at 37 ºC appears to have no significant difference in 
their release properties.  Sriamornsak et al. also noticed similar effect of drying condition 
on the beads [205].  In short, the rank order of SER as a function of drying conditions 


























































Figure 5.7:  Effects of drying condition on retention of resveratrol within the Ca-
pectinate beads (A) and on SER of the Ca-pectinate beads (B).  The beads were incubated 
in SIF.  Data presented as mean ± SD.  * p < 0.05. 
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5.3.2.9.5. Effect of pectin concentration 
Because of its capability of bead formation, amidated LM pectin was chosen to 
prepare resveratrol-loaded beads.  Introduction of amide group to the pectin molecule 
causes its hydrophilicity to decrease, which increases its tendency to form gels (compared 
to conventional low-methoxy pectin) [166].  Irregular shaped beads were produced when 
< 3 % pectin concentration was used.  By contrast, drop like structure were formed 
when > 6 % pectin concentration was used (data not shown).  Based on these 
observations, a pectin concentration between 3 to 6 % was chosen for subsequent studies.  
As shown in Figure 5.8A, 5.8B, and Table 5.4, both drug retention capability and SER 
increased with increasing pectin concentration (3 to 5 %).  By contrast, almost similar 
retention and SER was observed between 5 and 6 %.  These observations showed 5 % 
pectin as the optimum concentration for resveratrol loading. 
 
5.3.2.9.6. Effect of pectin to resveratrol ratio  
Figure 5.9A and 5.9B demonstrate the effect of pectin to resveratrol ratio on drug 
retention and SER, respectively.  The retention of resveratrol (T75, T50, and T25) for beads 
prepared with different pectin to resveratrol ratio was in the general order of 1 : 1 < 2 : 1 
< 3 : 1, 4 : 1 (Table 5.4 and Figure 5.9A).  This observation was in accordance with the 
previous studies, where the authors reported enhanced drug release for beads with high 
drug encapsulation (high drug-carrier ratio) [201, 209].  SER decreased with increasing 
resveratrol concentration.  The decrease in resveratrol retention and SER prepared with 
high percentage of resveratrol can probably be explained by the decrease in the polymer 
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to drug ratio.  Since at high resveratrol concentration, only little pectin would be available 
for drug retention and swelling. 
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Figure 5.8:  Effects of pectin concentration on retention of resveratrol within the Ca-
pectinate beads (A) and on SER of the Ca-pectinate beads (B).  The beads were incubated 






















































Figure 5.9:  Effects of pectin to resveratrol ratio (P : R) on retention of resveratrol within 
the Ca-pectinate beads (A) and on SER of the Ca-pectinate beads (B).  The beads were 
incubated in SIF.  Data presented as mean ± SD.  * p < 0.05. 
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5.3.2.10. Effect of release media on resveratrol retention and SER:  From the above 
discussed observations, resveratrol-loaded pectin beads were prepared according to the 
following conditions: pectin concentration at 5 %, calcium chloride concentration at 10 %, 
cross-linking time of 0.5 h, cross-linking solution pH at 1.5, pectin to resveratrol ratio of 
3 : 1, and drying at 50 ºC.  Figure 5.10A and 5.10B demonstrate the effect of release 
media on drug retention and SER, respectively.  The beads incubated in SGF showed 
very high resveratrol retention (> 97 % even after 6 h) within the beads and very low 
SER.  This might be because of the stability of the Ca-pectinate network at low pH.  
Enzyme-specific degradation of optimized pectin bead was then investigated by addition 
of 0.032 µl.ml-1 (300 PG) pectinase to the release medium and drug retention in bead was 
compared between two different release media (SIF, pH 6.8 with and without pectinase).  
The addition of pectinase allowed to mimic the colonic environment and to check the 
suitability of pectin beads for colon specific drug delivery.  Relatively faster release of 
resveratrol from pectin beads was evident in SIF with pectinase than SIF alone, although 
the difference was not huge (Figure 5.10A).  T75, T50, and T25 were lower in the case of 
enzymatic degradation than non-enzymatic degradation (Table 5.4).  Several authors 
investigated Ca-pectinate beads for specific targeting of drug to the colon [198, 205].  
SER study revealed that erosion exceeded swelling of the beads in the presence of 
















































Figure 5.10:  Effects of release medium on retention of resveratrol within the Ca-
pectinate beads (A) and on SER of the Ca-pectinate beads (B).  Data presented as mean ± 
SD.  * p < 0.05. 
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5.3.2.11. Enzymatic degradation:  After 3 h incubation in the release media (SIF, pH 
6.8 with or without enzyme), very small pores were found scattered all over the beads 
(like honey comb) (Figure 5.11A and 5.11B).  This is due to the release of drug particles 
from the bead matrix [205].  The release rate of drug particles from the beads in SIF 
containing enzyme was higher than in SIF without enzyme due to the degradation of 
matrix by enzyme.  This conclusion is supported by SEM data which indicated a more 
porous bead structure after 3 hr incubation in SIF with enzyme than without enzyme 
(Figure 5.11A and 5.11B, respectively).  It is plausible that enzymatic degradation and 
subsequent erosion of the matrix led to formation of pores.  These pores allowed 
resveratrol particles to come out through the partially degraded matrix.  These 






Figure 5.11:  Scanning electron micrographs of surface of resveratrol-loaded Ca-
pectinate bead after 3 h incubation in SIF containing 300 PG pectinase (X 350) (A), and 
surface of resveratrol loaded Ca-pectinate bead after 3 h incubation in SIF (X 350) (B).  




5.3.2.12. Release kinetics:  In the present study, it was noticed that the drug release 
kinetics of most beads (except those prepared in 20 % calcium chloride and cross-linked 
for 24 hours) fit more appropriately with the Higuchi’s model (Table 5.4) with an initial 
lag period of < 1 h (the point where the extrapolation of the linier plot intersects the x-
axis is the lag time).  It is possible that a certain degree of water penetration is needed to 
loosen up the gel matrix before drug release can occur.  In most cases, zero order kinetics 
was not obeyed.  Other authors have established Higuchi’s diffusion model for Ca-
pectinate beads [201].  Figure 5.12 shows the linearity of plots for the cumulative percent 
resveratrol released versus square root of time.   However, although resveratrol release 
data more appropriately fit with Higuchi’s square root of time equation, release kinetics 
in this case might not follow the rules of Higuchi’s model.  As resveratrol has very low 
solubility (0.11 ± 0.01 μg.ml−1) in the release media (SIF), most of the resveratrol 
particles should not be dissolved in the release media that penetrated into the bead matrix.  
Thus, there might not be diffusion of the dissolved resveratrol molecules which is the 
basis of Higuchi’s diffusion model.  Furthermore, Higuchi’s model is applicable to the 
formulations that are non-swelling and non-eroding.  But, prepared Ca-pectinate beads 
showed both swelling and erosion behavior.  Thus, Higuchi’s diffusion model is not 
applicable for resveratrol-loaded Ca-pectinate beads.  The appropriate release model for 
these beads remains to be elucidated.  The release of drug was due to three phenomena: (i) 
hydration of the matrix followed by (ii) swelling and erosion of the matrix followed by 
(iii) the release of resveratrol from the matrix as undissolved particles rather than 
diffusion of the soluble resveratrol.  As the resveratrol particles fall off from the beads, 
pores are created in the matrix that allow more fluid penetration in to the matrix and most 
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likely more resveratrol particles fall off and the bead matrix erodes.  When the gel layer 
is thick, the length of the pathway required to pass through for resveratrol particles is 
crucial and it slows down the drug release.  In addition, the calcium pectinate is even 
more sensitive to the erosion phenomenon if the ionic strength of the gel is low.   
 
Figure 5.12:  The release of resveratrol from Ca-pectinate beads after incubation in SIF 
with and without pectinolytic enzyme, plotted as the cumulative percent resveratrol 
released versus square root of time. Data presented as mean ± SD.  The beads were 
prepared at the following conditions: Cross-linking solution pH = 1.5, calcium chloride 
concentration = 10 %, cross-linking time = 0.5 h, pectin concentration = 5 %, pectin to 
resveratrol ratio = 3:1, and drying condition = 50 ºC. 
 
5.3.2.13. Stability:  The stability profile of resveratrol in the optimized beads is 
presented in Figure 5.13.  It can be seen that even after 6 months, stability was > 99.5% 
in the case of storage at 4 ºC and room temperature (RT), whereas ~ 97.5 % when stored 
at accelerated condition (40 ºC).  These results indicate desired stability of resveratrol 




Figure 5.13:  Stability of resveratrol in the optimized resveratrol-loaded Ca-pectinate 
beads.  Data presented as mean ± SD.  * p < 0.05 for the difference between 180 days 
with 0,3,7,15, and 30 days, ** p < 0.05 for the difference between 30 days with 0,3,7, and 
15 days, *** p < 0.05 for the difference between 90 days with 0,3,7,15, and 30 days, 
**** p < 0.05 for the difference between 180 days with 0,3,7,15, 30, and 90 days, # p < 
0.05 for the difference between 40 °C with 4 °C, and RT. 
 
5.3.3. Summary 
As resveratrol is rapidly absorbed and quickly metabolized at the upper GI tract, it 
becomes indispensable that a special dosage form be developed to deliver the drug to the 
lower GI tract, for treatment of colonic diseases such as colorectal cancer, colonic 
inflammation etc. (where it is potentially active).  The present study on resveratrol loaded 
Ca-pectinate beads for site specific and sustained release drug delivery, has underlined 
the importance of formulation parameters and process variables to ameliorate this 
purpose.  Calcium entrapment in the beads was dependent on different formulation 
variables and the moisture content was clearly influenced by the calcium retention in the 
prepared beads.  The study also unveils that some formulation parameters had a vital 
influence upon SER and ability of the beads to resist degradation in the upper GI tract, 
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while others had minor effect.  Although drug release mechanism from the beads did not 
satisfy the Higuchi’s model, resveratrol release data more appropriately fit with the 
cumulative percent resveratrol released versus square root of time plots.  Resveratrol was 
stable and highly entrapped inside the beads.   
 
5.4. Optimization of Zinc-pectinate bead  
Similar procedures were adopted to optimize the formulation variables of 
resveratrol-loaded Zn-pectinate beads.  The detail of the formulation design and results of 
this section is provided in Appendix I.  Formulation variables were optimized as follows: 
i) Zinc acetate concentration: 5 % (w/v) 
ii) Cross-linking solution pH: 1.5 
iii) Cross-linking time: 0.5 h 
iv) Drying condition: RT 
v) Pectin concentration: 5 % (w/v) 
vi) Pectin to resveratrol ratio: 3:1 
The study revealed that Zn-pectinate beads are better than Ca-pectinate beads as 
delayed release formulation of resveratrol.   
 
5.5. Conclusions 
Although optimized beads showed prolonged release pattern, it is anticipated that 
additional modifications of the beads such as enteric coating, use of hardening agent, and 
complexation with other polymers are necessary to achieve site specificity to lower GI 




COLON-SPECIFIC DELIVERY SYSTEMS OF RESVERATROL 
6.1. Introduction 
 The multi-particulate Ca- and Zn-pectinate bead formulations of resveratrol was 
developed in the previous study [341], which is the only study that looks at the delivery 
of resveratrol specifically to the colonic region.  However, similar to findings by others 
[205], it was found that pectinate bead alone was insufficient in protecting resveratrol 
release at the small intestinal pH, although it prevented resveratrol release at the acidic 
pH of stomach [341].  Modification of pectinate beads is therefore needed to achieve 
better colon-specific delivery of resveratrol.  Recently, PEI [220, 342] and glutaraldehyde 
[204, 205] have been evaluated as the hardening agent for the pectin formulations.  Hence, 
in this study, resveratrol-loaded Ca/Zn-pectinate beads hardened with PEI/glutaraldehyde 
were formulated and subsequently the effects of different formulation variables on the 
beads’ characteristics and resveratrol release profiles were evaluated.  The formulation 
variables were optimized mainly based on resveratrol retention patterns in simulated GI 
conditions and resveratrol encapsulation efficiency of the beads.   
 
6.2. Materials and methods  
6.2.1. Materials 
Polyethyleneimine (PEI) and glutaraldehyde (50 % (w/w) aqueous solution) were 
purchased from Sigma (St Louis, MO, USA).  Other materials used are same as described 




6.2.2. Formulation  
 Pectinate beads were prepared (Figure 6.1) using a method (iontophoretic gelation) 
modified (hardening agent was added to the cross-linking solution) from the previous 
study [341].  Briefly, pectin (5 % w/v) was dissolved in deionized water and resveratrol 
(amounts as specified in that formulation type) was homogeneously dispersed in it by a 
homogenizer.  Air bubbles were removed from the dispersion by sonication in a bath 
sonicator.  The pectin-resveratrol mixture was then added dropwise (1 ml.min-1 at 5 cm 
distance) to a gently agitated cross-linking solution (calcium chloride (10 % w/v) or zinc 
acetate aqueous solution (5 % w/v) containing different concentration of PEI (0 – 0.3 % 
w/v) or glutaraldehyde (0 – 5 % w/v)) through a blunt end needle (25G) at room 
temperature (RT).  The beads formed were allowed to stand in the solution for specified 
time interval with gentle agitation.  The beads were then separated, washed with distilled 
water, and subsequently dried at RT.   
 
Figure 6.1:  Schematic presentation of the formulation procedure of Ca-/Zn-pectinate 
beads treated with PEI/glutaraldehyde.   
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The beads were prepared by varying the formulation variables (please see 
‘formulation design’ of each section).  The effects of different formulation variables on 
beads’ size, shape, weight, MC, WL, L, EE, swelling and erosion behavior, and 
resveratrol retention patterns in simulated GI conditions were thoroughly evaluated.  The 
formulation variables were optimized after observing their effects on beads’ 
characteristics, EE, and resveratrol retention profile in simulated GI conditions.  All 
batches were prepared in triplicate. 
 
6.2.3. Morphology 
The micrographs of surface and cross section of the resveratrol-loaded beads 
hardened with PEI were recorded using the procedure described in Chapter 5 (page no. 
104).   
 
6.2.4. Size and shape 
The detail of the procedure has been described in Chapter 5 (page no. 104).   
 
6.2.5. Weight and weight-loss during drying 
The detail of the procedure has been described in Chapter 5 (page no. 105).   
 
6.2.6. Moisture content  





6.2.7. Encapsulation and loading efficiency 
Resveratrol EE and L were determined by the methods as described in Chapter 5 
(page no. 106) with minor modification (pectinase enzyme was added in phosphate buffer 
to disintegrate the beads in direct method) [341].   
 
6.2.8. Drug release study 
 The drug release study method was modified from the procedure described in 
Chapter 5 (page no. 108).  To simulate the GI conditions, the following release media 
were used in subsequent manner (i.e., first medium was removed after a predetermined 
time point; beads were gently washed (to remove the release medium from bead surface) 
and incubated into the next medium, and so on):  
2 h: Simulated gastric fluid, pH 1.2 (SGF), 
2 – 5 h: Simulated intestinal fluid, pH 6.8 (SIF), 
5 – 8 h: Phosphate buffer (50 mM, pH 6) with 300 PG Pectinex® Ultra SP-L (simulated 
colonic fluid (SCF)). 
 Upon oral administration, dosage forms pass through stomach (pH = ~ 1.5 – 3.5, 
transit time = ~ 1 – 2 h) and small intestine (pH = ~ 5.5 – 6.8, transit time = ~ 3 – 6 h ) 
before arrival to large intestine  (pH = ~ 6.4 – 7, transit time = ~ 12 – 24 h) [99].  
Therefore, the above gastric and intestinal conditions were chosen for the release study.  
Simultaneously, as optimum pH for the activity of pectinolytic enzyme was 3 – 5, a 





6.2.9. Swelling–erosion behavior  
For swelling-erosion study, similar conditions were followed to the release study.  
The beads were separated at every time point (up to 5 h), blotted with filter paper to 
remove the excess water and weighed.  The swelling–erosion ratio (SER) was calculated 
by the equation described in Chapter 5 (page no. 111).  Experiments were performed in 
triplicate.   
 
6.2.10. FT-IR 
Possible chemical interactions between resveratrol and bead components were 
studied by observing the IR spectra of pure resveratrol, resveratrol-free and resveratrol-
loaded pectin bead following the same procedure described in Chapter 5 (page no. 104).   
 
6.2.11. Stability 
The detail of the procedure has been described in Chapter 5 (page no. 112).   
 
6.2.12. Statistics   
The detail of the statistical calculation has been mentioned in Chapter 5 (page no. 
112).   
 
6.3. Modification of the Ca-pectinate beads using PEI  
6.3.1. Formulation design   
Based on results from our preliminary experiments (Appendix II), beads were 
prepared by varying: 
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a) cross-linking solution pH (1.5, 6, and 10.5 (normal pH of the solution)); while 
keeping PEI concentration (0.2 % (w/v)), cross-linking time (2 h), and pectin to 
resveratrol ratio (3 : 1) constant. 
b) PEI concentration (0, 0.05, 0.1, 0.2, and 0.3 % (w/v)); while keeping cross-linking 
solution pH (1.5), cross-linking time (2 h), and pectin to resveratrol ratio (3 : 1) 
constant. 
c) cross-linking time (0.08, 0.5, 2, and 24 h); while keeping cross-linking solution 
pH (1.5), PEI concentration (0.2 % (w/v)), and pectin to resveratrol ratio (3 : 1) 
constant. 
d) pectin to resveratrol ratio (1 : 1 and 3 : 1); while keeping cross-linking solution 
pH (1.5), PEI concentration (0.2 % (w/v)), and cross-linking time (2 h) constant. 
e) pectin to resveratrol ratio (1 : 1 and 3 : 1); while keeping cross-linking solution 
pH (1.5), PEI concentration (0.1 % (w/v)), and cross-linking time (2 h) constant. 
f) Ca-pectinate beads were prepared at cross-linking solution = 10 % (w/v) calcium 
chloride without PEI (pH 1.5), cross-linking time = 2 h, and pectin to resveratrol 
ratio = 3 : 1.  Then these preformed beads were suspended in 1 % (w/v) PEI 
solution (pH 1.5) for 2 h with gentle agitation.  
 
6.3.2. Results   
6.3.2.1. Morphology:  SEM images of both blank and resveratrol-loaded Ca-pectinate 
beads are shown in Figure 6.2A – 6.2E.  At X 350 magnification, a smooth surface 
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topography was observed for the blank bead (Figure 6.2A).  The topology of the 
resveratrol-loaded bead changed to a rough and rugged surface, which was noticed even 
at lower magnification (X 75) (Figure 6.2B).  This roughness is probably due to the drug 
crystals that are embedded in the bead matrix.  Analyses of SEM images of both surface 
and cross-section of the drug-loaded beads taken at higher magnifications (X 350 and X 
500, respectively) revealed that a thin layer was formed on the outer surface of the beads 
(Figure 6.2C and 6.2D, respectively).   
SEM image of the surface of the bead prepared at higher hardening solution pH 
(Figure 6.2E) was different from the bead prepared at lower hardening solution pH 
(Figure 6.2C).  Due to some unknown reasons, beads prepared at cross-linking solution 
pH 10.5 were yellowish, while beads prepared at cross-linking solution pH of 6 and 1.5 
were whitish.  
 
6.3.2.2. Size and shape of beads:  As homogeneous dispersion of resveratrol in 
aqueous solution of pectin was added dropwise to the cross-linking solution, beads were 
formed instantly.  All formulated beads were spherical in shape (ER < 1.15) and more 
than 2 mm in diameter, which upon drying became smaller (about 1 mm in diameter) 
while retaining their spherical shape (Table 6.1).  Insignificant changes in bead size were 



















Figure 6.2:  Scanning electron micrographs of the surface of drug-free Ca-pectinate 
beads treated with PEI (X 350) (A), resveratrol-loaded Ca-pectinate beads treated with 
PEI (X 75) (B), resveratrol-loaded Ca-pectinate beads treated with PEI (X 350) (C), 
cross-section of resveratrol-loaded Ca-pectinate beads treated with PEI (X 500) (D), and 
resveratrol-loaded Ca-pectinate beads treated with PEI at pH 10.5 (X 350) (E).  
Magnifications corresponding to each figure are presented in brackets. 
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6.3.2.3. Effect of formulation parameters on bead characteristics:  Weight of the 
formulated beads is presented in Table 6.1.  Effect of different formulation parameters on 
MC, WL, EE, and L of the beads are listed in Table 6.2, while their effect on resveratrol 
retention pattern and SER in the simulated GI environment is depicted in Figure 6.3 – 6.7.  
Drug retention profile is represented by plotting resveratrol retention in bead against time.  
Simultaneously, SERs are plotted versus time to indicate the swelling and erosion 
behaviors of the beads in simulated GI condition.  The following sections discuss the 
effects of different formulation parameters on the beads’ characteristics. 
 
6.3.2.3.1. Effect of cross-linking solution pH  
 Weight of the beads decreased with decreasing cross-linking solution pH (Table 
6.1) which contained less moisture after drying and lost more weight during drying 
(Table 6.2).  Furthermore, rapid augmentation of EE and L was found with decreased 
cross-linking solution pH (Table 6.2).  When tested in GI condition, beads prepared in 
cross-linking solution pH 1.5 was able to retain most of the resveratrol inside the beads 
(> 87 % of initial resveratrol amount) after incubating in SGF for 2 h followed by SIF for 
3 h and degraded very fast in SCF (Figure 6.3A).  Whereas, beads prepared in cross-
linking solution pH 6 and 10.5 (i.e., without modifying the pH) were stable (> 90 % of 
initial resveratrol amount) in upper GI conditions (SGF 2 h followed by SIF 3 h) but 
degraded very slowly in SCF (> 53 % of initial resveratrol remained in beads after 8 h).  
At the same time, an insight into the SER aspect revealed that SER increased with 




Table 6.1:  Size, shape, weight of the Ca-pectinate beads treated with PEI (Data presented as mean ± SD, N = 50 beads) 
Variables Values Size (µm ± SD) Shape (ER ± SD) Weight of 50 beads (mg ± SD) 
Wet beads Dry beads Wet beads Dry beads Wet beads Dry beads 
Cross-linking 
solution pH 
10.5 2183.28 ± 119.27 1042.24 ± 82.91 1.04 ± 0.03 1.08 ± 0.07 312.73 ± 16.55 32.75 ± 3.84 
6 2182.82 ± 104.21 1034.47 ± 77.48 1.07 ± 0.04 1.09 ± 0.06 320.08 ± 20.51 28.79 ± 2.19 




0 2245.01 ± 106.75 1078.13 ± 63.21 1.03 ± 0.02 1.12 ± 0.07 314.57 ± 2.40 35.79 ± 1.42 
0.05 2274.26 ± 99.27 1072.17 ± 99.21 1.05 ± 0.03 1.1 ± 0.06 318.26 ± 8.49 32.53 ± 2.19 
0.1 2203.82 ± 107.28 1037.28 ± 82.81 1.06 ± 0.02 1.02 ± 0.01 314.59 ± 13.47 28.26 ± 3.67 
0.2 2182.38 ± 112.68 1026.23 ± 42.65 1.03 ± 0.01 1.07 ± 0.05 320.21 ± 20.25 27.89 ± 4.50 
0.3 2237.18 ± 102.79 1005.16 ± 92.72 1.01 ± 0.01 1.05 ± 0.04 318.95 ± 20.53 27.61 ± 4.02 
Cross-linking 
time (h) 
0.08 2219.19 ± 84.27 1069.16 ± 53.57 1.07 ± 0.03 1.14 ± 0.12 310.23 ± 17.74 31.90 ± 4.19 
0.5 2192.19 ± 93.28 1048.23 ± 59.45 1.07 ± 0.06 1.08 ± 0.05 303.32 ± 25.07 28.12 ± 2.38 
2 2182.38 ± 112.68 1026.23 ± 42.65 1.03 ± 0.01 1.07 ± 0.05 320.21 ± 20.25 27.89 ± 4.50 
24 2107.00 ± 131.27 1017.67 ± 73.72 1.06 ± 0.02 1.04 ± 0.03 313.04 ± 15.56 26.69 ± 2.86 
P : R (0.2 % 
PEI) 
1 : 1 2297.28 ± 119.23 1100.72 ± 91.26 1.05 ± 0.02 1.10 ± 0.07 335.20 ± 11.06 32.68 ± 4.03 
3 : 1 2182.38 ± 112.68 1026.23 ± 42.65 1.03 ± 0.01 1.07 ± 0.05 320.21 ± 20.25 27.89 ± 4.50 
P : R (0.1 % 
PEI) 
1 : 1 2296.27 ± 126.17 1087.27 ± 87.36 1.06 ± 0.04 1.09 ± 0.06 330.28 ± 24.68 35.74 ± 3.98 
3 : 1 2203.82 ± 107.28 1037.28 ± 82.81 1.06 ± 0.02 1.02 ± 0.01 314.59 ± 13.47 28.26 ± 3.67 
PEI post 0.1 % 2219.27 ± 105.27 1073.25 ± 90.37 1.03 ± 0.02 1.08 ± 0.04 314.31 ± 17.46 33.58 ± 3.48 
PEI post = preformed beads were hardened with PEI, P : R = pectin to resveratrol ratio. 
154 
 
Table 6.2:  WL, MC, EE, and L of the Ca-pectinate beads treated with PEI (Data presented as mean ± SD, N = 3) 
Variables Values WL (% ± SD) MC (% ± SD) Direct method # Indirect method 
EE (% ± SD) L (% ± SD) EE (% ± SD) L (% ± SD) 
Cross-linking 
solution pH 
10.5 89.49 ± 1.57 10.43 ± 1.64 70.04 ± 0.34 23.35 ± 0.11 70.97 ± 0.47 c 23.66 ± 0.16 c 
6 90.95 ± 1.24 10.03 ± 1.29 93.70 ± 0.58 31.23 ± 0.19 95.01 ± 0.67 31.67 ± 0.22 




0 88.62 ± 0.50 17.76 ± 0.75 a 97.99 ± 0.05 32.66 ± 0.02 98.27 ± 0.47 32.76 ± 0.16 
0.05 89.76 ± 0.96 12.31 ± 1.86 97.74 ± 0.39 32.58 ± 0.13 98.00 ± 0.96 32.67 ± 0.32 
0.1 90.97 ± 1.55 10.17 ± 1.74 97.29 ± 0.57 32.43 ± 0.19 97.92 ± 0.32 32.64 ± 0.11 
0.2 91.21 ± 1.97 9.56 ± 1.27 97.00 ± 0.63 32.33 ± 0.21 97.81 ± 0.03 32.60 ± 0.01 
0.3 91.26 ± 1.89 9.44 ± 2.11 96.71 ± 0.79 32.24 ± 0.26 97.43 ± 0.99 32.48 ± 0.33 
Cross-linking 
time (h) 
0.08 89.74 ± 0.87 13.47 ± 1.51 b 99.44 ± 0.41 33.15 ± 0.14 99.61 ± 0.33 b 33.20 ± 0.11 b 
0.5 90.73 ± 0.04 9.87 ± 0.91 98.01 ± 0.71 32.67 ± 0.24 98.33 ± 0.17 d 32.78 ± 0.06 d 
2 91.21 ± 1.97 9.56 ± 1.27 97.00 ± 0.63 32.33 ± 0.21 97.81 ± 0.03 32.60 ± 0.01 
24 91.47 ± 0.76 9.30 ± 1.36 96.48 ± 0.54 32.16 ± 0.18 97.59 ± 0.22 32.53 ± 0.07 
P : R (0.2 % 
PEI) 
1 : 1 90.22 ± 1.51 9.87 ± 0.98 99.19 ± 0.65 99.19 ± 0.65 99.28 ± 0.27 e 99.28 ± 0.27 e 
3 : 1 91.21 ± 1.97 9.56 ± 1.27 97.00 ± 0.63 32.33 ± 0.21 97.81 ± 0.03 32.60 ± 0.01 
P : R (0.1 % 
PEI) 
1 : 1 89.16 ± 1.14 10.60 ± 0.89 99.36 ± 0.55 99.36 ± 0.55 99.43 ± 0.16 f 99.43 ± 0.16 f 
3 : 1 90.97 ± 1.55 10.17 ± 1.74 97.29 ± 0.57 32.43 ± 0.19 97.92 ± 0.32 32.64 ± 0.11 
PEI post 0.1 % 89.33 ± 0.62 13.74 ± 1.38 95.68 ± 0.46 31.89 ± 0.15 96.75 ± 0.20 g 32.25 ± 0.07 g 
a p < 0.05 for the difference between 0 % PEI with  0.05, 0.1, 0.2, and 0.3 % PEI, b p < 0.05 for the difference between 0.08 h 
with  0.5, 2, and 24 h, c p < 0.05 among pH 10.5, 6, and 1.5, d p < 0.05 for the difference between 0.5 and 24 h, e p < 0.05 for 
the difference between pectin to resveratrol ratio 1:1 and 3:1, f p < 0.05 for the difference between pectin to resveratrol ratio 
1:1 and 3:1, g p < 0.05 for the difference between pre and post PEI treatment. 


















































Figure 6.3:  Effects of cross-linking solution pH on retention of resveratrol within the 
Ca-pectinate beads treated with PEI (A) and SER of the Ca-pectinate beads treated with 
PEI (B).  The beads were incubated in simulated GI conditions.  Data presented as mean 
± SD.  * p < 0.05.   
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6.3.2.3.2. Effect of PEI concentration 
 When PEI concentration in the cross-linking solution was increased, weight of the 
beads (dry) decreased (Table 6.1).  WL was increased with increased PEI concentration 
(Table 6.2).  Simultaneously, moisture content inside the dry beads was decreased 
dramatically with higher PEI concentration (Table 6.2).  Furthermore, EE and L were 
decreased with increased PEI concentration (Table 6.2).  Although most of the drug 
retained in the beads for first 2 h (SGF), beads prepared in cross-linking solution with 
0.05 % or without PEI degraded very fast in SIF (Figure 6.4A).  Concurrently, beads 
prepared in cross-linking solution containing 0.1 and 0.2 % PEI showed good stability in 
the upper GI conditions (> 86 % of initial resveratrol remained in the beads at 5 h) and 
degraded rapidly in SCF, although there was almost no difference in drug retention 
pattern between them.  However, beads prepared in cross-linking solution with 0.3 % PEI 
showed very little degradability even in SCF (> 87 % of initial resveratrol remained in 
the beads at 8 h).  SER profile of the beads prepared in cross-linking solution with 0.05 % 
or without PEI revealed that erosion subdued swelling of the beads in SIF (Figure 6.4B).  
At higher PEI concentration, SER increased with decreased PEI concentration (0.1 > 























































Figure 6.4:  Effects of PEI concentration on retention of resveratrol within the Ca-
pectinate beads treated with PEI (A) and SER of the Ca-pectinate beads treated with PEI 
(B).  The beads were incubated in simulated GI conditions.  Data presented as mean ± SD.  
* p < 0.05.   
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6.3.2.3.3. Effect of cross-linking time 
 The beads cross-linked for longer time was lighter (Table 6.1) and MC was 
noticeably lower (Table 6.2).  Increase of WL was found with increased cross-linking 
time (Table 6.2).  EE and L decreased with increased cross-linking time (Table 6.2).  
Cross-linking time of 0.08 h produced beads which were unstable in SIF though they 
remained almost intact in SGF (Figure 6.5A).  Beads cross-linked for 0.5 h were 
sufficiently stable in upper GI fluids (SGF and SIF) and retained almost 85 % of initial 
resveratrol into the beads at 5 h, and degraded very fast in SCF.  On the other hand, 
cross-linking time of 2 and 24 h produced stronger beads than cross-linking time of 0.5 h, 
which retained > 87 (87.77 and > 91.57 % for 2 and 24 h, respectively) of initial 
resveratrol after 5 h in GI condition (2 h in SGF followed by 3 h in SIF) and immediately 
released most of the resveratrol in SCF.  The SER profiles depicted that erosion repress 
swelling of the beads in GI fluids in case of the beads prepared after 0.08 h cross-linking 





















































Figure 6.5:  Effects of cross-linking time on retention of resveratrol within the Ca-
pectinate beads treated with PEI (A) and SER of the Ca-pectinate beads treated with PEI 
(B).  The beads were incubated in simulated GI conditions.  Data presented as mean ± SD.  
* p < 0.05.   
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6.3.2.3.4. Effect of pectin to resveratrol ratio 
Weight of beads (Table 6.1) and MC (Table 6.2) increased with decreased pectin 
to resveratrol ratio.  On the other hand, WL decreased with decreased pectin to 
resveratrol ratio (Table 6.2).  Simultaneously, augmentation of EE and L was observed 
when pectin to resveratrol ratio decreased (Table 6.2).  On the other hand, similar drug 
retention pattern in GI condition was depicted by the beads prepared with both tested 
pectin to resveratrol ratio at 0.2 % (w/v) PEI concentration (Figure 6.6A), while greater 
SER was observed in the case of beads prepared with higher pectin to resveratrol ratio 
(Figure 6.6B).  On the other hand, in the case of beads prepared with 0.1 % (w/v) PEI 
concentration, a huge decrease of drug retention was observed for lower pectin to 
resveratrol ratio (~ 57 % versus ~ 87 %).  Greater SER was observed in the case of beads 
prepared with higher pectin to resveratrol ratio.  An early phase of swelling followed by 
erosion was observed for beads prepared with lower pectin to resveratrol ratio.  
 
6.3.2.3.5. Effect of PEI treatment on preformed beads 
 When preformed beads were treated with PEI solution, weight (Table 6.1) and 
MC (Table 6.2) of the beads increased, while opposite trends were noticed in the case of 
WL, EE, and L (Table 6.2).  Preformed beads hardened with 0.1 % (w/v) PEI degraded 
very fast in SIF though they were stable in SGF (Figure 6.7A).  Resveratrol retention 
after 5 h incubation in simulated upper GI condition was ~ 25 %.  Whereas, > 86 % 
resveratrol retention was observed for beads prepared in cross-linking solution containing 
0.1 % (w/v) PEI.  Preformed beads hardened with 0.1 % (w/v) PEI solution exhibited an 
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Figure 6.6:  Effects of pectin to resveratrol ratio on retention of resveratrol within the 
Ca-pectinate beads treated with PEI (A) and SER of the Ca-pectinate beads treated with 
PEI (B).  The beads were incubated in simulated GI conditions.  Data presented as mean 















































Figure 6.7:  Effects of PEI treatment of preformed beads on retention of resveratrol 
within the Ca-pectinate beads treated with PEI (A) and SER of the Ca-pectinate beads 
treated with PEI (B).  The beads were incubated in simulated GI conditions.  Data 




6.3.2.4. FT-IR:  The FT-IR spectra of pure resveratrol, blank and resveratrol-loaded 
bead are depicted in Figure 6.8.  All of the major peaks of resveratrol are present in the 
resveratrol-loaded Ca-pectinate bead, indicating that resveratrol was not chemically 
modified when formulated into Ca-pectinate beads. 
 
 
Figure 6.8:  FTIR spectra of pure resveratrol (A), resveratrol-loaded Ca-pectinate beads 
treated with PEI (B), and blank Ca-pectinate beads treated with PEI (C). 
 
6.3.2.5. Stability:  The stability profile of the formulated beads at different storage 
conditions is presented in Figure 6.9.  The formulated beads were found to be stable for 6 





Figure 6.9:  Stability of resveratrol in the optimized resveratrol-loaded Ca-pectinate 
beads treated with PEI.  Data presented as mean ± SD.  † p < 0.05 for the difference 
between 180 days with 0 and 3 days, # p < 0.05 for the difference between 30 days with 0 
and 3 days, ## p < 0.05 for the difference between 90 days with 0, 3, 7, and 15 days, ### 
p < 0.05 for the difference between 180 days with 0, 3, 7, and 15 days, †† p < 0.05 for the 
difference between 90 days with 0, 3, 7, 15, and 30 days, ††† p < 0.05 for the difference 
between 180 days with 0, 3, 7, 15, 30, and 90 days, * p < 0.05 for the difference between 
40 °C with 4 °C and RT, ** p < 0.05 for the difference between 40 °C and 4 °C. 
 
6.3.3. Discussion 
 In the present study, the formulated beads were spherical in shape and easily 
prepared without any sophisticated instruments.  In addition, morphological examination 
showed that the drug crystals are embedded in the polymer matrix, which led to rough 
surface.  Cross-section also reveals a thin layer on the bead surface, which is anticipated 
due to surface hardening by PEI.  However, the surface was different when beads were 
prepared at high cross-linking solution pH.   
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 Because a 25G needle was used throughout the experiment and beads were dried 
at RT, it is obvious other formulation variables were affecting the particle size of the dry 
beads.  This might be due to more compact beads were produced (probably because of 
pronounced gel bead shrinkage caused by syneresis) by lowering cross-linking solution 
pH, increasing PEI concentration in cross-linking solution, and increasing cross-linking 
time, which led to smaller and lighter beads with higher WL and lower MC inside the 
beads.  Moreover, beads with lower pectin to resveratrol ratio led to bigger and heavier 
particles with higher MC and lower WL.  This is anticipated as lesser amount of pectin 
was available in these beads because of lower polymer to drug ratio.  When preformed 
beads were treated with PEI, probably less compact beads were formed which led to 
bigger and heavier beads with higher MC and lower WL. 
 Instantaneous gelation of pectin allowed easy encapsulation of resveratrol in Ca-
pectinate beads.  Indeed, very high resveratrol encapsulation was found in all cases (> 
95 %) except beads prepared in cross-linking solution pH 10.5.  We reasoned that poor 
aqueous solubility of resveratrol led to such high percentage of drug encapsulation in the 
beads.  EE and L depend on the dissolution of resveratrol into the cross-linking solution.  
Resveratrol dissolution in the cross-linking solution increased with increasing cross-
linking solution pH, PEI concentration, and residence time, which ultimately led to 
decreased EE and L.  As a matter of fact, drug concentration increment generally leads to 
lower EE due to reduced polymer to drug ratio [201].  On the other hand, EE and L 
increased with increased resveratrol concentration.  This phenomenon has been discussed 
in the previous chapter.  When preformed beads were treated with PEI solution, 
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resveratrol leaked out into both cross-linking solution and PEI solution, which led to 
lower EE and L.  
 As described in Appendix II, pre-exposure to acidic medium drastically affected 
the beads’ behavior and decrease their resistance in SIF (basically a phosphate buffer, pH 
6.8).  Unmodified Ca-pectinate beads cannot tolerate this ‘acid-base attack’.  However, 
Ca-pectinate beads hardened with PEI revealed their tolerance to ‘acid-base attack’.  The 
importance of cross-linking solution pH during formulation of the colon-specific Ca-
pectinate beads hardened with PEI was found in this study.  This study revealed that 
beads prepared in low cross-linking solution pH can resist ‘acid-base attack’ and 
degraded very fast in SCF.  On the other hand, beads prepared in cross-linking solution of 
higher pH can also resist acid-base attack but drug release from the beads in SCF was 
very slow.  This indicates that beads prepared at low pH have sensitivity to pectinase, 
while beads prepared at high pH have not.  The exact reason is unknown.  Probably a 
very hard surface was formed during PEI cross-linking at high pH.  The higher 
resveratrol retention in upper GI condition in the case of beads prepared with higher PEI 
concentration was probably because higher amount of PEI promoted the formation of 
cross-links between pectin chains.  A dense surface was formed in presence of more than 
0.1 % PEI.  Similarly, longer cross-linking time provided more time for cross-linking of 
the Ca-pectinate network and hardening of the bead surface, which led to prepare 
stronger beads.  The PEI cross-linking made the Ca-pectinate network more stable and 
prevented rapid dissolution of Ca-pectinate network in the higher pH ranges of the 
intestine.  The swelling and drug release of these beads were in a controlled manner 
unlike the beads prepared without PEI.  When PEI concentration (0.1 – 0.3 %) in the 
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cross-linking solution decreased, more swelling of the beads was observed.  Lower PEI 
concentration led to the formation of weaker Ca-pectinate network, which absorbed more 
water and swelled.  Erosion of bead surface overshadowed swelling in the case of beads 
prepared with very low PEI concentration (≤ 0.05 %) or cross-linked for very short time 
(0.08 h) due to formation of weakly cross-linked beads.   
 Furthermore, 0.2 % PEI in cross-linking solution at pH 1.5 and cross-linked for 2 
h was sufficient to form strong beads which were able to load high amount of resveratrol 
(pectin to resveratrol ratio = 1 : 1) and revealed similar resveratrol retention pattern (in 
simulated GI condition) to lower resveratrol concentration (pectin to resveratrol ratio = 3 : 
1).  On the other hand, increase of resveratrol amount in the beads prepared with 0.1 % 
PEI led to lower drug retention in simulated upper GI condition due to reduced pectin 
amount which is required to form cross-linked network.  As the availability of polymer 
reduced at low pectin to resveratrol ratio, water absorption capacity of the beads was also 
diminished. This led to lower SER of beads prepared with lower pectin to resveratrol 
ratio.  Erosion was prominent in the case of beads prepared with 0.1 % PEI and pectin to 
resveratrol ratio of 1 to 1 due to weak cross-linking.  The release study revealed that 
pectinolytic enzyme was able to degrade the beads despite the presence of PEI.  
Consequently, stability data indicates that beads were stable when stored at 4 °C or RT. 
 Although penetration of PEI into the inner matrix of the beads looks impossible 
due to its very high molecular weight (~ 25,000), cross-linking of pectin chains with PEI 
might occur at the inner matrix when beads prepared in cross-linking solution containing 
PEI.  Therefore, strong bead formation occurs due to cross-linking of pectin chains with 
PEI at the inner matrix as well as outer surface of the beads, which can resist ‘acid-base 
168 
 
attack’ at the upper GI conditions.  But, if preformed beads were hardened in PEI 
solution even at pH 1.5, only beads surface exposed to PEI solution and most likely 
cross-linking between pectin chains and PEI occur exclusively at beads’ surface.  Thus, 
strong beads might not be produced in this way.  This may be the probable explanation 
for rapid degradation of these beads in SIF.  Erosion of beads after early swelling should 
be because of weakly cross-linked bead formation.  These incidences proved the 
importance of formulation procedure to produce colon-specific pectinate beads. 
 
6.3.4. Summary 
 The present study on resveratrol loaded Ca-pectinate beads for colon-specific 
drug delivery, has underlined the importance of formulation parameters and process 
variables.  The study revealed that pH of the cross-linking solution in the presence of PEI 
is a crucial factor to produce colon targeted Ca-pectinate beads.  Moreover, a minimum 
PEI concentration and hardening time are essential to produce sufficiently strong beads to 
resist degradation in the upper gastro-intestinal tract.  In addition, very high amount of 
resveratrol can be encapsulated within the beads without altering the resveratrol retention 
pattern in simulated GI condition.  Furthermore, this study revealed the importance of 
PEI addition in cross-linking solution.  The study also unveils that some formulation 
parameters have vital influence upon SER, while others have minor effect.  Resveratrol 
was stable inside the beads and very high resveratrol encapsulation was observed.  Hence, 
sufficiently strong resveratrol-loaded beads were produced using a small amount of PEI 
(0.1 – 0.2 %), which could resist acid-base attack of GI tract required for colon-specific 
delivery.  Since low concentration of PEI was used during bead preparation and the 
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excess amount was washed off after cross-linking, very less amount of PEI is likely to 
remain in the beads.  Further, addition of PEI in the cross-linking solution leads to a cost 
effective procedure by eliminating extra formulation steps.   
 
6.4. Modification of the beads using glutaraldehyde  
6.4.1. Calcium-pectinate bead   
6.4.1.1. Formulation design   
Based on results from our previous experiments, beads were prepared by varying: 
a) cross-linking solution pH (1.5 and 3.3 (normal pH of the solution)); while keeping 
glutaraldehyde concentration (2.5 % (v/v)), cross-linking time (2 h), and pectin to 
resveratrol ratio (3 : 1) constant. 
b) glutaraldehyde concentration (0, 0.25, 0.5, 1, 2.5, and 5 % (v/v)); while keeping 
cross-linking solution pH (1.5), cross-linking time (2 h), and pectin to resveratrol 
ratio (3 : 1) constant. 
c) cross-linking time (0.08, 0.5, 2, and 24 h); while keeping cross-linking solution 
pH (1.5), glutaraldehyde concentration (2.5 % (v/v)), and pectin to resveratrol 
ratio (3 : 1) constant. 
d) pectin to resveratrol ratio (1 : 1 and 3 : 1); while keeping cross-linking solution 
pH (1.5), glutaraldehyde concentration (2.5 % (v/v)), and cross-linking time (2 h) 
constant. 
e) pectin to resveratrol ratio (19:1 and 3:1); while keeping cross-linking solution pH 




f) glutaraldehyde concentration (1 and 2.5 % (v/v)); where preformed Ca-pectinate 
beads (prepared at cross-linking solution of 10 % (w/v) calcium chloride without 
glutaraldehyde (pH 1.5), cross-linking time of 2 h, pectin to resveratrol ratio of 
3:1) were suspended in glutaraldehyde solution (pH 1.5) for 2 h with gentle 
agitation.  
g) Glutaraldehyde solution pH (3.7 (normal pH of the solution)); where preformed 
Ca-pectinate beads (prepared at cross-linking solution of10 % (w/v) calcium 
chloride without glutaraldehyde (pH 1.5), cross-linking time of 2 h, pectin to 




6.4.1.2.1. Morphology:  A smooth surface topography was observed for the blank bead 
at X 350 magnification (Figure 6.10A).  The topology of the resveratrol-loaded bead 
changed to a rough and rugged surface, which was noticed even at lower magnification 
(X 75) (Figure 6.10B).  Analyses of SEM pictures of the drug-loaded beads’ surface 
taken at higher magnifications (X 500) revealed that the drug crystals are embedded in 
the bead matrix (Figure 6.10C), which is the probable reason for roughness of beads’ 
surface.  The surface morphology of the beads hardened with glutaraldehyde (Figure 
6.10C) was little different from the non-hardened beads (X 500, Figure 6.10D).  A thin 
layer on the surface was evident from cross-section at X 1000 magnification (Figure 
















Figure 6.10:  Scanning electron micrographs of the surface of blank Ca-pectinate bead 
treated with glutaraldehyde (X 350) (A), resveratrol-loaded Ca-pectinate bead treated 
with glutaraldehyde (X 75) (B), resveratrol-loaded Ca-pectinate bead treated with 
glutaraldehyde (X 500) (C), non-hardened Ca-pectinate beads (X 500) (D), and cross-
section of Ca-pectinate bead treated with glutaraldehyde (X 1000) (E).  Magnifications 
corresponding to each figure are presented in brackets. 
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6.4.1.2.2. Size and shape of the beads:  All formulated beads were spherical in shape 
(ER < 1.15) and more than 2 mm in diameter.  Upon drying the beads became smaller 
(about 1 mm in diameter) while retaining their spherical shape (Table 6.3 and Figure 
6.10B).  Augmentation in size of both wet and dry beads was observed with decreasing 
glutaraldehyde concentration, cross-linking time, and pectin to resveratrol ratio, and with 
increasing cross-linking solution pH.  When preformed beads were placed into 
glutaraldehyde solution (pH 1.5), larger beads (both wet and dry) were produced.  
Furthermore, preformed beads cross-linked with glutaraldehyde solution of unmodified 
pH (pH 3.7) produced even larger beads (both wet and dry).   
 
6.4.1.2.3. Effect of formulation parameters on bead characteristics:  Weights of the 
beads are shown in Table 6.3.  Effect of different formulation parameters on MC, WL, 
EE, and L of beads are listed in Table 6.4, while their effects on resveratrol retention 
pattern and SER in the artificial GI environment are depicted in Figure 6.11 – 6.16.  The 
following sections discuss the effects of different formulation parameters on the beads’ 





Table 6.3:  Size, shape, and weight of Ca-pectinate bead treated with glutaraldehyde (Data presented as mean ± SD, N = 50 
beads)  
Variables Values Size (µm ± SD) Shape (ER ± SD) Weight of beads (mg ± SD) 
Wet beads Dry beads Wet beads Dry beads Wet beads Dry beads 
Cross-linking 
solution pH 
3.3 2372.25 ± 104.28 1075.85 ± 75.68 1.13 ± 0.11 1.06 ± 0.04 301.33 ± 12.47 33.31 ± 3.72 
1.5 2205.39 ± 85.27 1004.27 ± 55.87 1.04 ± 0.02 1.03 ± 0.02 296.87 ± 7.83 30.82 ± 3.14 
Glutaraldehyde 
concentration (%) 
0 2245.01 ± 106.75 1078.13 ± 63.21 1.03 ± 0.02 1.12 ± 0.07 314.57 ± 2.40 35.79 ± 1.42 
0.25 2245.00 ± 99.93 1075.37 ± 73.24 1.09 ± 0.06 1.12 ± 0.09 313.96 ± 13.63 35.38 ± 4.02 
0.5 2240.27 ± 105.32 1064.38 ± 89.35 1.01 ± 0.01 1.04 ± 0.02 311.98 ± 14.49 34.80 ± 4.48 
1 2227.47 ± 113.72 1047.89 ± 63.82 1.05 ± 0.04 1.06 ± 0.04 308.00 ± 17.03 33.51 ± 2.65 
2.5 2205.39 ± 85.27 1004.27 ± 55.87 1.04 ± 0.02 1.03 ± 0.02 296.87 ± 7.83 30.82 ± 3.14 
5 2201.41 ± 123.51 1001.53 ± 53.54 1.06 ± 0.03 1.04 ± 0.01 292.20 ± 8.54 28.68 ± 4.00 
Cross-linking time 
(h) 
0.08 2301.37 ± 98.26 1089.97 ± 73.62 1.15 ± 0.09 1.15 ± 0.08 313.40 ± 10.72 33.78 ± 3.53 
0.5 2258.21 ± 117.24 1047.84 ± 59.92 1.1 ± 0.08 1.11 ± 0.07 303.23 ± 6.23 31.55 ± 4.80 
2 2205.39 ± 85.27 1004.27 ± 55.87 1.04 ± 0.02 1.03 ± 0.02 296.87 ± 7.83 30.82 ± 3.14 
24 2202.36 ± 126.21 1001.01 ± 46.8 1.06 ± 0.03 1.04 ± 0.03 295.20 ± 16.00 30.44 ± 4.36 
P : R (2.5 % 
glutaraldehyde) 
1 : 1 2572.35 ± 137.43 1198.96 ± 95.63 1.11 ± 0.07 1.13 ± 0.11 341.08 ± 14.80 44.59 ± 4.14 
3 : 1 2205.39 ± 85.27 1004.27 ± 55.87 1.04 ± 0.02 1.03 ± 0.02 296.87 ± 7.83 30.82 ± 3.14 
P : R (1 % 
glutaraldehyde) 
19 : 1 2102.00 ± 94.72 1016.67 ± 85.83 1.02 ± 0.01 1.05 ± 0.03 300.61 ± 8.56 26.46 ± 2.74 
3 : 1 2227.47 ± 113.72 1047.89 ± 63.82 1.05 ± 0.04 1.06 ± 0.04 308.00 ± 17.03 33.51 ± 2.65 
Post-glu conc. (%)  1 2301.82 ± 128.23 1056.25 ± 83.45 1.14 ± 0.11 1.07 ± 0.05 295.88 ± 13.72 24.28 ± 4.44 
2.5 2237.27 ± 93.58 1032.35 ± 75.32 1.07 ± 0.05 1.08 ± 0.07 285.14 ± 10.45 23.27 ± 1.85 
Post-glu (2.5 %)  pH 3.7 2279.93 ± 101.42 1093.45 ± 91.28 1.12 ± 0.1 1.1 ± 0.06 299.58 ± 10.27 25.45 ± 3.26 
Post-glu = preformed beads were hardened in glutaraldehyde solution.   
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Table 6.4:  WL, MC, EE, and L of the Ca-pectinate bead treated with glutaraldehyde (Data presented as mean ± SD, N = 3) 
Variables Values WL (% ± SD) MC (% ± SD) Direct method # Indirect method 
EE (% ± SD) L (% ± SD) EE (% ± SD) L (% ± SD) 
Cross-linking 
solution pH 
3.3 88.93 ± 1.30 13.78 ± 2.06 d 96.06 ± 0.24 32.02 ± 0.08 96.51 ± 0.53 32.17 ± 0.18 
1.5 89.63 ± 0.88 9.02 ± 1.52 97.00 ± 0.69 32.33 ± 0.23 97.24 ± 0.17 32.41 ± 0.06 
Glutaraldehyde 
concentration (%) 
0 88.62 ± 0.50 17.76 ± 0.76 e 97.99 ± 0.05 32.66 ± 0.02 98.27 ± 0.47 32.76 ± 0.16 
0.25 88.71 ± 1.47 16.93 ± 1.65 f 97.75 ± 0.68 32.58 ± 0.23 98.05 ± 0.11 32.68 ± 0.04 
0.5 88.80 ± 1.87 12.47 ± 2.01 97.58 ± 0.55 32.53 ± 0.18 97.85 ± 0.15 32.62 ± 0.05 
1 89.10 ± 1.08 9.76 ± 1.33 97.52 ± 0.88 32.51 ± 0.29 97.67 ± 0.18 32.56 ± 0.06 
2.5 89.63 ± 0.88 9.02 ± 1.52 97.00 ± 0.69 32.33 ± 0.23 97.24 ± 0.17 h 32.41 ± 0.06 h 
5 90.15 ± 1.65 8.91 ± 1.37 93.79 ± 0.38 31.26 ± 0.13 94.60 ± 0.28 i 31.53 ± 0.09 i 
Cross-linking time 
(h) 
0.08 89.21 ± 1.17 15.01 ± 1.83 g 98.25 ± 0.84 32.75 ± 0.28 98.90 ± 0.49 32.97 ± 0.16 
0.5 89.57 ± 1.78 10.02 ± 1.41 97.39 ± 0.67 32.46 ± 0.22 97.84 ± 0.27 32.61 ± 0.09 
2 89.63 ± 0.88 9.02 ± 1.52 97.00 ± 0.69 32.33 ± 0.23 97.24 ± 0.17 32.41 ± 0.06 
24 89.65 ± 1.83 8.85 ± 0.90 94.38 ± 0.63 31.46 ± 0.21 95.50 ± 1.32 j 31.83 ± 0.44 j 
P : R (2.5 % 
glutaraldehyde) 
1 : 1 86.88 ± 1.76 7.32 ± 1.46 98.95 ± 0.33 98.95 ± 0.33 98.83 ± 0.14 k 98.83 ± 0.14 
3 : 1 89.63 ± 0.88 9.02 ± 1.52 97.00 ± 0.69 32.33 ± 0.23 97.24 ± 0.17 32.41 ± 0.06 k 
P : R (1 % 
glutaraldehyde) 
19 : 1 91.21 ± 0.74 a 11.47 ± 1.81 85.97 ± 0.86 4.52 ± 0.05 85.34 ± 0.54 a 4.49 ± 0.03 a 
3 : 1 89.10 ± 1.08 9.76 ± 1.33 97.52 ± 0.88 32.51 ± 0.29 97.67 ± 0.18 32.56 ± 0.06 
Post-glu conc. (%)  1 91.82 ± 1.23 b 10.95 ± 2.20 96.00 ± 0.79 32.00 ± 0.26 96.09 ± 0.65 b 32.03 ± 0.22 b 
2.5 91.84 ± 0.56 c 10.23 ± 1.71 95.93 ± 1.04 31.98 ± 0.35 95.73 ± 0.64 c 31.91 ± 0.21 c 
Post-glu (2.5 %)  pH 3.7 91.50 ± 1.07 11.13 ± 2.06 95.38 ± 0.84 31.79 ± 0.28 94.98 ± 1.09 31.66 ± 0.36 
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a p < 0.05 between pectin to resveratrol ratio 19:1 and 1:1, b p < 0.05 between pre and post treatment, c p < 0.05 between pre 
and post treatment, d p < 0.05 between pH 3.3 and 1.5, e p < 0.05 between 0 % glutaraldehyde with 0.5, 1, 2.5, and 5 % 
glutaraldehyde, f p < 0.05 between 0.25 % glutaraldehyde with 0.5, 1, 2.5, and 5 % glutaraldehyde, g p < 0.05 between 0.08 h 
with 0.5, 2, and 24 h, h p < 0.05 between 2.5 % glutaraldehyde with 0 and 0.25 % glutaraldehyde, i p < 0.05 between 5 % 
glutaraldehyde with 0, 0.25, 0.5, 1, and 2.5 % glutaraldehyde, j p < 0.05 between 24 h with 0.08 and 0.5 h, k p < 0.05 between 
pectin to resveratrol concentration 1 : 1 and 3 : 1.  




6.4.1.2.3.1. Effect of cross-linking solution pH 
Reduction of cross-linking solution pH led to the production of lighter beads 
(dry and wet) (Table 6.3) which lost more weight during drying and contained less 
moisture after drying (Table 6.4).  Furthermore, enhancement in EE and L was found 
with decreased cross-linking solution pH (Table 6.4).  When tested in GI condition, 
beads prepared in cross-linking solution pH 1.5 were able to retain most of the 
resveratrol inside the beads (> 93 % of initial resveratrol amount) after incubating in 
SGF for 2 h followed by SIF for 3 h (Figure 6.11A).  But beads prepared in cross-
linking solution pH 3.3 (i.e., without modifying the pH) degraded very fast in SIF 
though the beads were stable for first 2 h in SGF.  At the same time, an insight into 
the SER aspect revealed that SER increased with decreasing cross-linking solution pH 
(Figure 6.11B).  In contact with simulated GI fluids swelling overpowered erosion in 
the case of beads prepared in cross-linking solution pH 1.5, whereas an opposite trend 
















































Figure 6.11:  Effects of cross-linking solution pH on retention of resveratrol within 
the Ca-pectinate bead treated with glutaraldehyde (A) and SER of the Ca-pectinate 
bead treated with glutaraldehyde (B).  The beads were incubated in simulated GI 




6.4.1.2.3.2. Effect of glutaraldehyde concentration 
When glutaraldehyde concentration in the cross-linking solution was increased, 
weight of the beads (dry and wet) decreased (Table 6.3).  WL increased with 
increasing glutaraldehyde concentration (Table 6.4).  Simultaneously, MC decreased 
dramatically with higher glutaraldehyde concentration (Table 6.4).  Furthermore, EE 
and L also decreased with increasing glutaraldehyde concentration (Table 6.4).  Beads 
prepared in 5 % (v/v) glutaraldehyde exhibited much lower EE than others.  Although 
all beads were able to retain most of the drug within the beads for 2 h in SGF, beads 
prepared in cross-linking solution with 0.25 % (v/v) or without glutaraldehyde 
degraded very fast in SIF (Figure 6.12A).  Whereas, beads prepared in cross-linking 
solution with 0.5 % (v/v) glutaraldehyde degraded slower than previous two but not 
sufficiently slow for colon specificity (~ 45 % of initial resveratrol remained in the 
beads after 5 h).  Concurrently, beads prepared in cross-linking solution with 1 % (v/v) 
glutaraldehyde showed good resistance in SIF and more than 75 % of initial 
resveratrol remained in the beads at 5 h.  On the other hand, beads prepared in cross-
linking solution with 2.5 and 5 % (v/v) glutaraldehyde showed very good stability in 
upper GI condition and degraded very fast in SCF, although there was almost no 
difference in drug retention pattern between them.  More than 93 % of initial 
resveratrol remained in the beads after 5 h in both cases.  SER increased with 
increasing glutaraldehyde concentration, though SER of beads prepared with 5 % (v/v) 
glutaraldehyde was lower than beads prepared with 2.5 % (v/v) glutaraldehyde after 3 
h (Figure 6.12B).  Erosion overpowered swelling of beads after 3 h in the case of 
beads prepared in cross-linking solution with 0.25 % (v/v) or without glutaraldehyde.  
An early phase of swelling (up to 4 h) followed by erosion was observed in the case 

























































Figure 6.12:  Effects of glutaraldehyde concentration on retention of resveratrol 
within the Ca-pectinate bead treated with glutaraldehyde (A) and SER of the Ca-
pectinate bead treated with glutaraldehyde (B).  The beads were incubated in 
simulated GI conditions.  Data presented as mean ± SD.  * p < 0.05.   
180 
 
6.4.1.2.3.3. Effect of cross-linking time 
The beads cross-linked for longer time were lighter (both wet and dry) (Table 
6.3) and MC was noticeably lower (Table 6.4).  Insignificant increase of WL was 
found with increased cross-linking time (Table 6.4).  EE and L decreased with 
increasing cross-linking time (Table 6.4).  Beads cross-linked for 24 h possessed 
significantly lower EE.  Cross-linking time of 0.08 h produced beads which were 
unstable in SIF though they remained almost intact in SGF (Figure 6.13A).  Beads 
cross-linked for 0.5 h were sufficiently stable in upper GI fluids (SGF and SIF) and 
retained more than 87 % of initial resveratrol into the beads after 5 h, and degraded 
very fast in SCF.  On the other hand, cross-linking time of 2 and 24 h produced 
stronger beads which retained about 93 % of initial resveratrol after 5 h in GI 
condition (2 h in SGF followed by 3 h in SIF) and immediately released most of the 
resveratrol in SCF.  The SER profiles depicted that with increased cross-linking time, 
swelling became predominant in upper GI fluids (0.08 to 2 h) (Figure 6.13B).  In case 
of beads cross-linked for 0.08 h, swelling was overshadowed by erosion in GI fluids.  




















































Figure 6.13:  Effects of cross-linking time on retention of resveratrol within the Ca-
pectinate bead treated with glutaraldehyde (A) and SER of the Ca-pectinate bead 
treated with glutaraldehyde (B).  The beads were incubated in simulated GI conditions.  
Data presented as mean ± SD.  * p < 0.05.   
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6.4.1.2.3.4. Effect of pectin to resveratrol ratio 
Weight of beads (both wet and dry) increased with reduction of pectin to 
resveratrol ratio (Table 6.3), whereas MC and WL decreased with decreased pectin to 
resveratrol ratio (Table 6.4).  Simultaneously, augmentation of EE and L were 
observed when pectin to resveratrol ratio decreased (Table 6.4).  On the other hand, 
almost similar drug retention pattern in GI condition was depicted by the beads 
prepared with both tested pectin to resveratrol ratio at both tested glutaraldehyde 
concentration (Figure 6.14A).  Consequently, greater SER was observed in case of 
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Figure 6.14:  Effects of pectin to resveratrol ratio on retention of resveratrol within 
the Ca-pectinate bead treated with glutaraldehyde (A) and SER of the Ca-pectinate 
bead treated with glutaraldehyde (B).  The beads were incubated in simulated GI 




6.4.1.2.3.5. Effect of glutaraldehyde treatment on preformed beads 
When preformed beads were treated with glutaraldehyde solution, weight of 
beads (dry and wet) (Table 6.3), EE and L (Table 6.4) were lower, while opposite 
trends were noticed in the case of WL and MC (Table 6.4).  However, weight and MC 
of the beads increased with decreasing glutaraldehyde concentration and with 
increasing pH of glutaraldehyde solution, while opposite trends were noticed in case 
of WL.  EE and L decreased with increasing glutaraldehyde concentration and pH of 
glutaraldehyde solution (Table 6.4).  Preformed beads hardened with 2.5 % (v/v) 
glutaraldehyde solution at pH 3.7 degraded very fast in SIF, although degradation was 
slower in the case of pH 1.5 (Figure 6.15A).  Resveratrol retention after 5 h 
incubation in simulated upper GI conditions was ~ 21 % and ~ 87 % when preformed 
beads were treated with 2.5 % (v/v) glutaraldehyde solution at pH 3.7 and 1.5, 
respectively.  Furthermore, preformed beads hardened with 1 % (v/v) glutaraldehyde 
solution at pH 1.5 also degraded very fast in SIF (~ 27 % resveratrol retention at 5 h) 
(Figure 6.16A).  On the other hand, beads prepared in cross-linking solution 
containing same percentages of glutaraldehyde at pH 1.5 produced very strong beads 
which retained > 93 % and > 75 % resveratrol after 5 h incubation in simulated upper 
GI condition at 2.5 and 1 % glutaraldehyde, respectively.  Preformed beads hardened 
with 2.5 % glutaraldehyde solution at pH 3.7 and 1 % (v/v) glutaraldehyde solution at 
pH 1.5 exhibited an early phase swelling (up to 3 h) followed by rapid erosion (Figure 
6.15B and 6.16B, respectively), while beads hardened with 2.5 % (v/v) glutaraldehyde 


















































Figure 6.15:  Effects of glutaraldehyde (2.5 %) treatment of preformed beads on 
retention of resveratrol within the Ca-pectinate bead treated with glutaraldehyde (A) 
and SER of the Ca-pectinate bead treated with glutaraldehyde (B).  The beads were 
incubated in simulated GI conditions.  Data presented as mean ± SD.  * p < 0.05.  (Pre 
= beads were prepared in cross-linking solution containing glutaraldehyde; Post = 
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Figure 6.16:  Effects of glutaraldehyde (1 %) treatment of preformed beads on 
retention of resveratrol within the Ca-pectinate bead treated with glutaraldehyde (A) 
and on SER of the Ca-pectinate bead treated with glutaraldehyde (B).  The beads were 





6.4.1.2.4. FT-IR:  The FT-IR spectra of pure resveratrol, blank and resveratrol-
loaded bead are depicted in Figure 6.17.  All of the major peaks of resveratrol are 
present in the resveratrol-loaded Ca-pectinate bead, indicating that resveratrol was not 
chemically modified when formulated into Ca-pectinate beads.  Glutaraldehyde is 
highly reactive and it is able to modify many drugs.  However, chemical modification 




Figure 6.17:  FTIR spectra of pure resveratrol (A), resveratrol-loaded Ca-pectinate 
bead treated with glutaraldehyde (B), and blank Ca-pectinate bead treated with 
glutaraldehyde (C).  Beads were prepared in the cross-linking solution containing 
2.5 % glutaraldehyde. 
 
6.4.1.2.5. Stability:  The stability profile of resveratrol in the optimized beads is 
presented in Figure 6.18.  It can be observed that even after 6 months, stability was > 
99 % in the case of storage at 4 ºC and room temperature (RT); whereas, ~ 93 % when 




Figure 6.18:  Stability of resveratrol in the optimized resveratrol-loaded Ca-pectinate 
beads treated with glutaraldehyde.  Data presented as  mean ± SD.  # p < 0.05 for the 
difference between 90 days with 0, 3, 7, 15, and 30 days, ## p < 0.05 for the difference 
between 180 days with 0, 3, 7, 15, 30, and 90 days, * p < 0.05 for the difference 
between 40 °C with 4 °C and RT.  
 
6.4.1.3. Discussion   
In the current study, when the aqueous solution of pectin containing 
resveratrol was added dropwise in a counter ion solution of calcium, gelled sphere 
instantaneously formed by ionic interaction between the negatively charged 
carboxylic groups on pectin molecules and the positively charged divalent calcium 
ions as well as covalent cross-linking between pectin chains and glutaraldehyde.  The 
formulated beads were spherical in shape and easily prepared without any 
sophisticated instruments.  In addition, morphological examination showed that the 
drug crystals were embedded in the polymer matrix, which led to rough surface.  
Surface of the beads prepared with glutaraldehyde revealed different appearance from 
beads prepared without glutaraldehyde, which is anticipated due to surface hardening 
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by glutaraldehyde.  The SEM image of cross-section further supported surface 
hardening.   
 Lowering of cross-linking solution pH and augmentation of glutaraldehyde 
concentration and cross-linking time resulted in lighter beads with smaller size, lower 
MC and higher WL.  This might be due to more compact beads produced probably 
because of pronounced gel bead shrinkage caused by syneresis.  Moreover, beads with 
lower pectin to resveratrol ratio led to bigger particles with lower MC and WL.  This 
is anticipated as lesser amount of pectin was available in these beads because of lower 
polymer to drug ratio.  When preformed beads were treated with glutaraldehyde 
solution, probably less compact pectinate network formed (this will be discussed 
later), which led to bigger size with more MC.   
 Instantaneous gelation of pectin and poor aqueous solubility of resveratrol 
allowed easy encapsulation (> 94 %) of resveratrol in Ca-pectinate beads.  As 
described earlier, EE and L depend on the dissolution of resveratrol into the cross-
linking solution.  Resveratrol dissolution in the cross-linking solution increases with 
increasing cross-linking solution pH, glutaraldehyde concentration, and residence 
time, which ultimately led to decreased EE and L.  By contrast, EE and L increased 
with increasing resveratrol concentration (i.e., decreasing pectin to resveratrol ratio).  
This phenomenon has been discussed earlier.  Nevertheless, when preformed beads 
were treated with glutaraldehyde solution, resveratrol leaked out into cross-linking 
solution during bead formation as well as in glutaraldehyde solution during 
glutaraldehyde treatment of preformed beads, which led to lower EE and L.  Lower 
EE and L observed with higher glutaraldehyde concentration and pH in this case can 
be explained by resveratrol solubility in glutaraldehyde solution.   
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 Drug retention and SER of the formulated beads in the simulated GI condition 
decreased with increased cross-linking solution pH.  The results demonstrated lower 
drug release in SIF from the pectinate beads prepared at lower cross-linking solution 
pH, which have been discussed in Chapter 5 [341].  However, these phenomena were 
not sufficient to resist acid-base attack of actual in-vivo condition.  We noticed that 
beads prepared in cross-linking solution pH 1.5 without glutaraldehyde degraded very 
fast in SIF after 2 h incubation in SGF, while beads prepared in cross-linking solution 
pH 1.5 with glutaraldehyde were stable.  These observations probably can be 
explained by the following fact.  Two terminal aldehyde groups of glutaraldehyde 
form acetal linkage with the existing hydroxyl groups of pectin chains.  The formation 
of this covalently cross-linked network is exclusively facilitated under acidic 
environment (Figure 6.19) [343].  Thus, a more compact and strong three dimensional 
Ca-pectinate network was formed in the presence of glutaraldehyde at cross-linking 
solution pH 1.5 than pH 3.3.  These phenomena were responsible for higher 
resveratrol retention inside the beads formulated at cross-linking solution pH 1.5 
under upper GI condition.  In addition, glutaraldehyde might have promoted cross-
linking between pectin chains as it enhanced the cross-linking with carboxamide 
groups of amidated pectin to form three-dimensional network.  As a result, rapid 
swelling by water absorption but negligible erosion was prominent due to strong bead 
formation at cross-linking solution pH 1.5.  Whereas, an opposite trend was noticed 




Figure 6.19: Mechanism of cross-linking between pectin chains and glutaraldehyde 
under acidic environment [343].   
 
 The higher resveratrol retention in upper GI condition in the case of beads 
prepared with higher glutaraldehyde concentration was probably because higher 
amount of glutaraldehyde promoted the formation of cross-links between pectin 
chains.  As a result, a dense surface was formed in the presence of more than 1 % 
glutaraldehyde in cross-linking solution.  Similarly, enhanced cross-linking time also 
facilitated the formation of highly cross-linked Ca-pectinate network and hardening of 
the bead surface, which led to preparation of stronger beads.  The glutaraldehyde 
cross-linking made the Ca-pectinate network more stable and prevented rapid 
dissolution of Ca-pectinate network in the higher pH ranges of the intestine.  The 
swelling and drug release of these beads demonstrated a controlled pattern unlike the 
beads prepared without glutaraldehyde.  Due to weaker cross-linking, erosion of bead 
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surface overshadowed swelling when the beads were prepared at low glutaraldehyde 
concentration or cross-linked for shorter time.   
 Furthermore, 2.5 % glutaraldehyde in cross-linking solution at pH 1.5 and 2 h 
cross-linking time were sufficient to form strong beads which were able to load high 
amount of resveratrol (pectin to resveratrol ratio = 1 : 1) and revealed similar 
resveratrol retention pattern (in simulated GI condition) to lower resveratrol 
concentration (pectin to resveratrol ratio = 3 : 1).  Additionally, no significant 
difference in drug release pattern was evident when beads were prepared with 19 : 1 
and 3 : 1 pectin to resveratrol ratio at 1 % glutaraldehyde concentration.  These 
indicate formation of very strong beads which can encapsulate very high amount of 
drug without altering their resistance to upper GI conditions.  As the availability of 
polymer reduced at low pectin to resveratrol ratio, water absorption capacity of the 
beads was also diminished, though erosion was found to be negligible.  This led to 
lower SER of beads prepared with lower pectin to resveratrol ratio.   
 When beads were prepared in cross-linking solution containing glutaraldehyde 
at pH 1.5, cross-linking of pectin chains with glutaraldehyde might occur at the inner 
matrix as well as outer surface of the beads.  This produced very strong beads which 
could resist ‘acid-base attack’ at upper GI condition.  But, if preformed beads were 
hardened in glutaraldehyde solution even at pH 1.5, only bead surface was exposed to 
glutaraldehyde solution.  In this case, cross-linking between pectin chains and 
glutaraldehyde most likely occurred exclusively at beads’ surface.  Thus, strong beads 
might not be produced in this way.  This may be the probable explanation for rapid 
degradation of these beads in SIF, though this observation was not very prominent for 
preformed beads treated with 2.5 % (v/v) glutaraldehyde solution.  This was probably 
because 2.5 % (v/v) glutaraldehyde solution might form very strong cross-linking on 
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bead surface.  But, the difference was very obvious at 1 % (v/v) glutaraldehyde.  In 
addition, when preformed beads were hardened in glutaraldehyde solution at pH 3.7, 
rapid degradation occurred in SIF.  This observation further strengthens the 
hypothesis that low pH is required for better cross-linking between pectin chains and 
glutaraldehyde.  Erosion of beads after early swelling should be because of weakly 
cross-linked bead formation when preformed beads were hardened in 1 % 
glutaraldehyde at pH 1.5 or in 2.5 % glutaraldehyde at pH 3.7.  These incidences 
proved the importance of formulation procedure to produce colon-specific pectinate 
beads.  Furthermore, the release study revealed that pectinolytic enzyme was able to 
degrade the beads despite the presence of glutaraldehyde.  Consequently, stability 
data indicate that beads were sufficiently stable when stored at 4 °C or RT. 
 One group had earlier exploited the effect of glutaraldehyde on drug release 
from indomethacin and bovine serum albumin loaded Ca-pectinate bead [204, 205].  
But, their formulation and evaluation procedures were totally different form this study.  
They prepared the drug-loaded Ca-pectinate beads first and then hardened the beads 
in glutaraldehyde solution without modifying the cross-linking or hardening solution 
pH.  Most importantly, they did not perform release study in simulated GI conditions.  
That means they ignored the acid-base attack phenomenon which will be obvious in 
in-vivo condition.  Moreover, they did not perform any in-vivo study to prove the 
efficacy of their formulations.  In the present study, importance of cross-linking 
solution pH for the formulation of colon-specific Ca-pectinate beads hardened with 
glutaraldehyde was demonstrated.  This study revealed that beads prepared in low 
cross-linking solution pH can resist ‘acid-base attack’, while beads prepared in cross-
linking solution of unaltered pH cannot.  In addition, beads prepared in cross-linking 
solution containing glutaraldehyde (pH 1.5) appeared to be much better (resistant to 
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‘acid-base attack’) than glutaraldehyde hardening of preformed beads.  When 
glutaraldehyde was added in the cross-linking solution, cross-linking of pectin chains 
with glutaraldehyde and hardening of the bead surface occurred simultaneously with 
bead formation.  As described earlier, this led to elimination of some extra 
formulation steps and consequently reduction of production cost.  Moreover, 
sufficiently strong resveratrol-loaded beads were produced by this procedure, which 
could resist acid-base attack of GI tract required for colon-specific delivery.  Our data 
also indicate that only a small amount of glutaraldehyde is needed for formulating 
resveratrol-loaded colon-specific Ca-pectinate beads.  Since low concentration of 
glutaraldehyde was used during bead preparation and the excess amount was washed 
off after cross-linking, very less amount of glutaraldehyde was likely to remain in the 
beads.   
 
6.4.1.4. Summary   
The study revealed that pH of the cross-linking solution in the presence of 
glutaraldehyde is a critical factor to produce colon-targeted Ca-pectinate beads.  
Moreover, a minimum glutaraldehyde concentration and hardening time are essential 
to produce sufficiently strong beads to resist degradation in the upper gastro-intestinal 
tract.  In addition, very high amount of resveratrol can be efficiently encapsulated into 
the beads without altering the resveratrol retention pattern in simulated GI conditions.  
Furthermore, this study also revealed the importance of glutaraldehyde addition in 
cross-linking solution rather than glutaraldehyde treatment on the preformed beads.  
The study also unveils that some formulation parameters had a vital influence upon 
SER.  Resveratrol was stable inside the beads upon storage at RT and 4 °C.  Further, 
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addition of glutaraldehyde in the cross-linking solution leads to a cost effective 
procedure by eliminating extra formulation steps.   
 
6.4.2. Zinc-pectinate bead   
Similar procedures were adopted to optimize the formulation variables of 
resveratrol-loaded Zn-pectinate beads.  The details of the formulation design and 
results of this section are provided in Appendix III.  The formulation variables were 
optimized as follows: 
i) Cross-linking solution pH: 1.5 
ii) Glutaraldehyde concentration: 0.5 % (v/v) 
iii) Cross-linking time: 2 h 
iv) Pectin to resveratrol ratio: 3 to1 
The study revealed the importance of direct addition of glutaraldehyde in the 
cross-linking solution.  Data also indicate that very small amount of glutaraldehyde 
(0.5 % (v/v)) is needed for formulating resveratrol-loaded colon-specific Zn-pectinate 
beads.   
 
6.5. Conclusions 
 As PEI/glutaraldehyde was added in the cross-linking solution, cross-linking 
of pectin chains with PEI/glutaraldehyde and hardening of the bead surface occurred 
simultaneously with bead formation.  This leads to elimination of surface hardening 
of the preformed beads (hence, hardening time), which shortens the production time.  
Thus, this formulation procedure is unique in the sense that it reduced production cost 
by cutting down extra steps of washing and hardening, and by decreasing production 
time and manpower requirement.  In addition, this procedure produced stronger beads 
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than the procedure where preformed beads were hardened in PEI/glutaraldehyde 
solution.  Data also indicate that very small amount of PEI/glutaraldehyde is needed 
for formulating resveratrol-loaded colon-specific pectinate beads.  This study 
established the importance of cross-linking solution pH, which has been overlooked in 
the earlier studies.  The formulated beads encapsulated very high amount of 
resveratrol and were stable at the storage conditions.  Though this study showed that 
formulated beads were able to protect resveratrol release in simulated upper GI 
conditions and release at simulated colonic condition, further in-vivo investigation is 





ANIMAL STUDY OF THE RESVERATROL-LOADED COLON-SPECIFIC 
FORMULATIONS 
7.1. Introduction   
As in-vivo conditions are quite different from in-vitro studies, the formulations 
need to be tested in-vivo to evaluate their actual efficacy.  Pharmacokinetic study is 
one of the popular in-vivo methods to check the efficiency of the colon-specific 
formulations [210, 214, 220].  Measuring plasma concentration of drug at different 
time intervals after oral administration of the drug-loaded formulations is an indirect 
proof of drug release in the GI tract.  Generally, upon oral administration, any 
formulation takes about 5 – 6 h to reach the colonic region [99].  Thus, appearance of 
drug in blood after 5 h of oral administration will be considered as drug release from 
the formulation at the colonic region.  The beads prepared using the optimized 
formulation variables (Chapter 5 and 6) were selected for pharmacokinetic study in 
the rats due to their in-vitro colon-specific drug release patterns.  This study aimed to 
measure resveratrol concentration in blood after oral administration of the optimized 
beads in rats.   
 
7.2. Materials and methods   
7.2.1. Materials   
Resveratrol (99.9 % purity) were purchased from Sigma (St Louis, MO).  The 






7.2.2. Preparation of the formulations  
The preparation procedure of the formulations used in this study has been 
described in Chapter 4, 5, and 6.  The bead formulations were prepared using the 
optimized formulation variables for each type.  The type of formulations for each 
group and the optimized values of the formulation variables used to prepare the 
formulations together with dose are listed in Table 7.1.  The amount of resveratrol in 
each formulation was measured with HPLC before their administration to the rats.   
 
Table 7.1:  Type and dosage of the formulations   
Rats Formulation 
type 
Preparation condition Resveratrol 
Dose 
Group 11 Ca-pectinate 
beads 
Pectin = 5 %, P : R = 3:1, CaCl2 = 




Group 12 Zn-pectinate 
beads 
Pectin = 5 %, P : R = 3:1, ZnAc = 5 %, 
CS pH = 1.5, CT = 0.5 h, Dry = RT 
 
25 mg.kg-1 




CS pH = 1.5, Glutaraldehyde = 2.5 %, 
CT = 2 h, P : R = 3:1 
 
25 mg.kg-1 
Group 14 Ca-pectinate-PEI 
beads  
CS pH = 10.5, PEI = 0.2 %, CT = 2 h, 
P : R = 3:1 
 
25 mg.kg-1 
Group 15 Ca-pectinate-PEI 
beads  
CS pH = 1.5, PEI = 0.2 %, CT = 2 h, 







CS pH = 1.5, Glutaraldehyde = 0.5 %, 
CT = 2 h, P : R = 3:1 
 
25 mg.kg-1 
Group 9 CMC suspension 0.5% CMC (pH 7.4) 25 mg.kg-1 
 
CS = cross-linking solution, CT = cross-linking time, P : R = pectin to  resveratrol 







The study design and the animal handling protocol of this pharmacokinetic 
study were modified from our previous study [335], and approved by the Institutional 
Animal Care and Use Committee of the National University of Singapore.  Adult 
male Sprague–Dawley rats (250 – 300 g) were used for this study.  Details of the 
housing and cannulation of the rats are described in Chapter 4.  The cannula was used 
for blood sample collection.  The rats were randomly divided into 6 groups (n = 6) 
and each group received the formulations specified in Table 7.1.  The different bead 
formulations were administered as follows (Group 11 – 16):  The rats were kept 
anaesthetized by isoflurane gas throughout the surgery.  A small ventral incision was 
made on the abdomen after hair removal and held open using a retractor.  Underlying 
tissues were separated to see the stomach clearly.  A small puncture (3 mm) was made 
on the stomach and accurately weighed beads were inserted into the stomach.  
Leakage of the stomach content was prevented by keeping the incision upwards.  
Incisions in the viscera followed by peritoneal cavity, subcutaneous tissue, and skin of 
animals were closed with sutures.  Rats in Group 9 were administered single oral 
doses of resveratrol suspension in 0.5 % carboxymethyl cellulose (CMC, pH 7.4) by 
oral gavage, which has been described in Chapter 4.  The rats in all Groups received 
25 mg.kg-1 resveratrol.  Control rats were sham treated with resveratrol-free beads 
(equivalent weight of resveratrol-loaded beads).  Because oral absorption may be 
influenced by different dietary regimens and the inherent bile salt solubilization 
capacity in the intestine, the rats were kept in fasting condition overnight prior to the 
oral gavage and during blood collection but free access to water were allowed.  Serial 
blood samples (200 µl) were collected in heparinized tubes from each animal through 
the catheter at 1 h, 2 h, 3 h, 4 h, 5 h, 6 h, 7 h, 8 h, 9 h, 10 h, 11 h, and 12 h after 
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administration of beads and at 5 min, 15 min, 30 min, 1 h, 1.5 h, 2 h, 3 h, 4 h, 6 h and 
8 h after oral gavage of resveratrol suspension.  The cannula was flushed and blood 
was replaced by an equivalent volume of heparin-saline after each draw of blood 
sample.  After centrifugation at 5,500 x g for 10 min, plasma samples were collected 
and stored at -80º C until HPLC analysis.   
 
7.2.4. Sample preparation   
The plasma sample preparation procedure has been described in Chapter 3 
(page no. 75).   
 
7.2.5. Sample analysis   
The plasma sample was analyzed using the HPLC assay method described in 
Chapter 3 (page no. 73).   
 
7.2.6. Pharmacokinetic analysis 
The peak plasma resveratrol concentration (Cmax) and the time for peak plasma 
resveratrol concentration (Tmax) were obtained from the graph.  The area under the 
plasma concentration versus time curve (AUC0→t) in rats was calculated by the linear 
trapezoidal rule with the time point from 0 to the last detectable time point.  































Statistical analyses were performed using the software Graph-Pad Prism 
Version 2.00 (San Diego, CA).  All experimental data were expressed as mean ± 
standard deviation (SD) except for the point pertaining to time to maximal 
concentration (Tmax) after oral administration, as it was a non-continuous data due to 
the pre-decided sampling schedule.  Statistical comparisons of the pharmacokinetic 
parameters among the formulations were performed by using one-way ANOVA with 
the post hoc Tukey test.  Statistical comparisons of the Tmax values among the Groups 
were performed by using Kruskal–Wallis test with the post hoc Dunn test.  Statistical 
significance was set at p < 0.05. 
 
7.3. Results 
The plasma concentration versus time profiles upon oral administration of 
resveratrol either as suspension or as beads are presented in Figure 7.1, 7.2, and 7.3, 
whereas the pharmacokinetic parameters are depicted in Table 7.2.  All bead 
formulations exhibited very high Tmax and low Cmax in comparison to suspension 
formulation.  However, the AUC and F value of bead formulations (except Group 14) 
were not significantly different from suspension formulation.  Ca-pectinate beads 
showed lower Tmax when compared to both glutaraldehyde and PEI hardened beads.  
Similarly, Zn-pectinate beads showed lower Tmax when compared to glutaraldehyde 
hardened beads.  Little reduction of Cmax was evident in the case of Ca-pectinate 
beads hardened with glutaraldehyde or PEI at cross-linking solution pH 1.5.  However, 
when beads were hardened with PEI without modifying pH (10.5), a very low Cmax, 
AUC, and F were observed.  Figure 7.1 demonstrates that appearance of resveratrol in 
the blood was slower with the Ca-pectinate bead formulation when compared to the 
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suspension formulation.  The appearance of resveratrol was further slowed down with 
the beads hardened with glutaraldehyde.  Resveratrol was not detected in plasma for 
the first 3 h and detected in low concentration from 3 – 5 h in the case of 
glutaraldehyde treated beads.  Subsequently, rapid absorption was observed after 5 h.  
Similar phenomenon was noticed with the Zn-pectinate beads (Figure 7.2).  In this 
case, after oral administration of glutaraldehyde treated beads, resveratrol was not 
detected in plasma before 4 h and detected in low concentration at 4 and 5 h followed 
by rapid increase in concentration.  Ca-pectinate beads hardened with PEI, also 
indicate delayed appearance of resveratrol in the blood in comparison to non-
hardened Ca-pectinate beads and suspension, though the resveratrol concentration in 
blood was very low when beads were hardened at pH 10.5 (Figure 7.3).   
 






























Figure 7.1:  Plasma concentration of resveratrol after a single oral dose of the 
respective Ca-pectinate bead, Ca-pectinate bead treated with glutaraldehyde, and 
CMC suspension formulation.  The line represents the predicted values.  Symbols 
represent the mean observed values ± S.D (n = 6). 
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Figure 7.2:  Plasma concentrations of resveratrol after a single oral dose of Zn-
pectinate bead, Zn-pectinate bead treated with glutaraldehyde, and CMC suspension 
formulation.  The line represents the predicted values.  Symbols represent the mean 
observed values ± S.D (n = 6). 































Figure 7.3:  Plasma concentrations of resveratrol after a single oral dose of Ca-
pectinate bead, Ca-pectinate bead treated with PEI at pH 1.5, Ca-pectinate bead 
treated with PEI at pH 10.5, and CMC suspension formulation.  The line represents 
the predicted values.  Symbols represent the mean observed values ± S.D (n = 6). 
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Table 7.2:  Pharmacokinetic parameters of resveratrol after oral administration* 
 Group 11 Group 12 Group 13 Group 14 Group 15 Group 16 Group 9 
Formulation Ca Zn Ca-glu-1.5 Ca-PEI-high Ca-PEI-1.5 Zn-glu-1.5 CMC suspension 
Dose (mg.kg−1) 25 25 25 25 25 25 25 
Tmax (h) 3 – 4 i 3 – 4 i 7 – 8 ii 8 – 10 iii, a 6 – 7 iv 7 – 8 v 0.08 - 0.25 vi, b 
Cmax (ng.ml−1) 150.28 ± 25.26 120.47 ± 27.39 115.72 ± 21.24 39.30 ± 9.31 c 112.06 ± 13.63 124.64 ± 18.22 270.00 ± 60.00 d 
AUC (ng.h.ml−1) 472.65 ± 51.24 451.18 ± 56.39 477.30 ± 100.30 193.12 ± 32.91 c 455.92 ± 64.04 443.05 ± 49.78 485.3 ± 114.1 
F (%) 37.37 ± 4.05 35.67 ± 4.46 37.74 ± 7.93 15.27 ± 2.60 c 36.05 ± 5.06 35.03 ± 3.94 38.4 ± 9.02 
* Data is presented as Mean ± SD, N = 6 (except group 7, where N = 4). 
i one rat 3 h and five rats 4 h, ii three rats 7 h and three rats 8 h, iii two rats 8 h, two rats 9 h, and two rats 10 h, iv one rat 6 h and five rats 7 
h, v four rats 7 h and two rats 8 h, vi two rats 0.08 h and two rats 0.25 h.   
a p < 0.05 between Group 14 with Group 11 and 12, b p < 0.05 between Group 9 with Group 13, 14, and 16, c p < 0.05 between Group 14 





The results from the in-vitro resveratrol retention study indicated that 
resveratrol-loaded Ca-pectinate beads with high degree of drug loading (P : R = 3 : 1), 
prepared in the presence of 2.5 % glutaraldehyde in cross-linking solution at pH 1.5, 
and cross-linked for 2 h showed the desired resveratrol retention profile in simulated 
GI conditions.  Thus, these beads were chosen for in-vivo animal study and compared 
with beads prepared without glutaraldehyde treatment and with CMC suspension of 
resveratrol.  The outcomes from the animal study indicated that Tmax shifted to higher 
values from CMC suspension to beads without glutaraldehyde hardening and then to 
beads hardened with glutaraldehyde.  Upon oral administration of glutaraldehyde 
treated beads, resveratrol was either not detected or detected only in low 
concentration before 5 h followed by rapid increase in plasma resveratrol 
concentration.  For colon-specific drug delivery, this property is most desirable as it 
has been reported that any particle takes about 5 – 6 h to reach the colon [99].  
Though beads prepared without glutaraldehyde also showed delayed release pattern, it 
was not sufficient for colon specificity as the results indicated that most of the drug 
release occurred before 5 h.  Similar effect of glutaraldehyde was observed with Zn-
pectinate beads.  In the case of Zn-pectinate beads, much lower amount of 
glutaraldehyde (0.5 %) was sufficient to reveal colon specific release.  Thus, this 
study suggests that cross-linking in the presence of glutaraldehyde is necessary for 
colon-specificity of Ca-pectinate beads.  Therefore, the observed in-vivo results 
confirmed the in-vitro findings.  When Ca-pectinate beads were hardened with PEI 
the delayed appearance of resveratrol in blood indicated delayed drug release from the 
formulations.  Thus pharmacokinetic study of PEI hardened Ca-pectinate beads 
indicated drug release at colonic region.  However, when beads prepared in cross-
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linking solution containing PEI at unmodified pH (i.e., 10.5), the drug release was too 
slow, which led too very low concentration of resveratrol in blood.  This is probably 
due to very strong bead formation at this condition, which was not degraded fully 
even in colon.  Low drug release from the beads prepared at unmodified pH was also 
observed in the in-vitro drug release study.   
 
7.5. Summary and Conclusions 
The present study indicates that despite delayed release profile of Ca-/Zn-
pectinate beads, additional modification of the formulations is necessary for colon-
specific release of resveratrol.  The results demonstrate that glutaraldehyde and PEI 
can be a potential tool for this purpose.  In addition, cross-linking solution pH was 
also appeared to be a critical factor to prepare colon-specific Ca-/Zn-pectinate bead 
formulations hardened with glutaraldehyde/PEI.  Hence, resveratrol-loaded Ca-
pectinate bead hardened with glutaraldehyde or PEI and resveratrol-loaded Zn-
pectinate bead hardened with glutaraldehyde at cross-linking solution pH of 1.5 have 





CONCLUSIONS AND FUTURE DIRECTIONS 
8.1. Conclusions 
The goal of this study was to find out whether the CD derivatives (HP-β-CD 
and RM-β-CD) can improve the solubility of resveratrol and, if so, whether an 
increase in the solubility of resveratrol leads to an increase in its oral bioavailability.  
The results showed that both the CD derivatives can increase the solubility of 
resveratrol to a great extent.  However, the RM-β-CD was found more effective than 
the HP-β-CD in solubilization.  As the solubility of resveratrol was increased by the 
CD derivatives, HP-β-CD was used for intravenous formulation (as RM-β-CD is toxic 
for intravenous administration) and RM-β-CD was used for oral formulation (as RM-
β-CD is safe for oral administration and has enhancive effect on absorption) for 
pharmacokinetic study.  The results indicated that HP-β-CD did not change the 
pharmacokinetic profile of resveratrol after intravenous administration.  The results 
also showed that the oral bioavailability (extent) of resveratrol was not affected by the 
formulation types (solution and suspension), although the suspended dosage form 
(CMC suspension) showed a lower Cmax and a plasma concentration that was more 
sustained than the solution dosage form (RM-β-CD).  Additionally, we found that 
after oral administration, resveratrol rapidly passed through the GI wall and attained 
the highest plasma concentration within 5 – 15 minutes, followed by a rapid decrease 
in plasma resveratrol concentration.  This indicated rapid absorption accompanied 
with rapid elimination of resveratrol from the systemic circulation.  It was also tried to 
explore whether an increase in dose can augment the oral bioavailability of resveratrol.  
The results indicated that dose escalation (15 - 50 mg.kg-1) did not influence the oral 
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bioavailability of resveratrol, although non-linear elimination was observed at 25 
mg.kg-1 intravenous dose.   
As the results showed that resveratrol is rapidly absorbed in the upper GI tract 
and quickly eliminated from the systemic circulation, the aim was to develop a special 
dosage form to deliver the drug to the lower GI tract for treatment of colon specific 
diseases such as colorectal cancer, colonic inflammation etc. (where resveratrol has 
therapeutic efficacy).  In this study pectin was used to deliver resveratrol to the colon 
due to its specific degradation by colonic micro-flora as well as low cost, wide variety 
of types, and flexibility in use.  Also, due to several advantages over single unit 
dosage forms, multiple unit dosage forms of pectin were developed in this study.   
Pectinate beads (multiple-unit dosage forms) produced by cross-linking 
between pectin chains and divalent cations (e.g. Ca2+, Zn2+) have shown great 
potential as delayed release formulation.  The present study on resveratrol loaded Ca- 
or Zn-pectinate beads for site specific and delayed release drug delivery has 
underlined the importance of formulation parameters and process variables.  Calcium 
and zinc entrapments in the beads depended on different formulation variables and the 
moisture content of the beads was clearly influenced by the calcium retention in the 
prepared beads.  This study also unveiled that some formulation parameters had a 
vital influence upon SER and ability of the beads to resist degradation in the upper GI 
tract, while others had only minor effects.  In general, the release data more 
appropriately fit with ‘square root of time’ and the ‘zero order’ equations for Ca-
pectinate and Zn-pectinate beads, respectively.  Resveratrol was stable and highly 
entrapped inside the beads.  Similar to findings by others, this study revealed that 
although Ca-/Zn-pectinate beads prevented the release of resveratrol at the acidic pH 
of the stomach, it alone was insufficient to prevent resveratrol being released at the 
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small intestinal pH [205].  Modification of Ca-/Zn-pectinate beads was therefore 
necessary for colon-targeted delivery.   
Recently, PEI and glutaraldehyde were evaluated as a hardening agent of the 
Ca-pectinate beads’ surface.  Hence, in this study, we formulated resveratrol-loaded 
Ca- and Zn-pectinate beads hardened with either PEI or glutaraldehyde and 
subsequently evaluated the effects of the formulation parameters on the bead 
characteristics.  The formulation parameters were optimized based on resveratrol 
retention profile in simulated GI condition and resveratrol encapsulation.  The 
optimized beads were further subjected to in-vivo pharmacokinetic study in rats and 
compared with beads prepared without glutaraldehyde/PEI and with resveratrol 
suspension formulation. 
The present study on resveratrol loaded Ca- and Zn-pectinate beads for site 
specific drug delivery has revealed the importance of formulation parameters and 
process variables to prepare colon-specific delivery system.  The study revealed that 
the pH of the cross-linking solution in presence of PEI and glutaraldehyde may be a 
critical factor in producing colon-targeted Ca- and Zn-pectinate beads.  Also, a very 
low amount of PEI or glutaraldehyde concentration and hardening time are essential 
to produce sufficiently strong beads to resist degradation in the upper gastro-intestinal 
tract.  A very high amount of resveratrol can be encapsulated in the beads.  This study 
also demonstrated the importance of PEI or glutaraldehyde addition in cross-linking 
solution over post PEI or glutaraldehyde treatment of preformed beads.  Resveratrol 
was stable inside the beads and a very high amount of resveratrol can be encapsulated.  
More importantly, the in-vivo results supported the in-vitro release study and 
exhibited colon specific release of resveratrol.  In-vivo study in rat exhibited desired 
pharmacokinetic profiles after oral administration of Ca- and Zn-pectinate beads 
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hardened with glutaraldehyde (2.5 and 0.5 %, respectively) and Ca-pectinate beads 
hardened with PEI (0.2 %) all at cross-linking solution pH 1.5 and cross-linked for 2 h.  
These pharmacokinetic profiles indicated that most of the drug was released in the 
colonic region and minimum drug release took place in the upper GI tract.   
 
8.2. Future Directions 
In future, plasma concentration of the resveratrol metabolites should be 
determined following oral administration of resveratrol-cyclodextrin inclusion 
complex.  This may clearly demonstrate the reason for unchanged bioavailability 
value (extent of absorption) of resveratrol even after administration of solution 
formulation. 
In-vivo pharmacodynamic studies in the disease models and clinical 
pharmacokinetic studies were beyond the scope of this research because of time 
constraint.  It will be important to test these formulations in colon cancer or colitis 
induced animal models.   
Ulcerative colitis (UC) is a nonspecific inflammatory disorder involving 
primarily the mucosa and sub-mucosa of the colon.  Ulcerative colitis is a major cause 
of concern in developing countries.  Till now, only few drugs are available to cure UC.  
Conventional therapies for UC have focused on small molecule anti-inflammatory and 
immunosuppressive agents [344].  With the recent advent of biotechnology, new 
therapeutic opportunities involving peptides and proteins have been and are being 
explored for treatment of individuals with UC.  Optimal delivery (i.e. to the correct 
location and for the proper duration) will likely be critical for the effective and safe 
administration of some of these new therapeutic agents.  Since inflammation is 
confined to colon, it is possible to deliver drugs specifically to the site of 
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inflammation i.e. colon.  In site-specific (targeted) drug delivery it is possible to 
reduce the total amount of drug administered thus reducing side effects.   
The anti-inflammatory activity of resveratrol has been well documented in 
many studies.  Inflammation can have a role in the development of cancer [10].  
Previous studies have documented the therapeutic efficacy of resveratrol on 
experimental UC [51, 52].  Hence, an improved formulation of resveratrol in order to 
deliver it locally to the colon tissue may be a better alternative to the existing 
treatments.  Thus, the optimized pectinate bead formulations could therefore be a 
promising strategy for the treatment of UC as well as can ameliorate the colon cancer 
therapy.  There is an established animal model available for UC.  Hence, the rat UC 
model to check efficacy of the newly developed formulation may be a better choice.  
The effects of the optimized resveratrol-loaded pectinate beads on the colon injury 
caused by intracolonic administration of trinitrobenzene sulfonic acid (TNBS) in rats 
may be evaluated.  The inflammation response can be assessed by histology and 
myeloperoxidase (MPO) activity, as an index of quantitative inflammation and 
neutrophil infiltration in the mucosa.  Histological and histochemical analysis of the 
lesions may also be carried out.  The expression of COX-1 and -2 can be investigated 
by western blotting and immunohistochemistry in order to gain a better insight into 
the protective effects of resveratrol.   
In addition, efficacy of the formulations can be evaluated in the colorectal 
cancer model.  Furthermore, clinical study of these formulations should help us to 





[1] B.B. Aggarwal, A. Bhardwaj, R.S. Aggarwal, N.P. Seeram, S. Shishodia, Y. 
Takada, Role of resveratrol in prevention and therapy of cancer: preclinical and 
clinical studies. Anticancer Res 24(5A) (2004) 2783-2840. 
[2] P. Langcake, R.J. Pryce, The production of resveratrol by Vitis vinifera and 
other members of the vitaceae as a response to infection and injury. Physiol. Plant 
Pathol. 9 (1976) 77–86. 
[3] B. Paul, I. Masih, J. Deopujari, C. Charpentier, Occurrence of resveratrol and 
pterostilbene in age-old darakchasava, an ayurvedic medicine from India. J 
Ethnopharmacol 68(1-3) (1999) 71-76. 
[4] M.J. Takaoka, Of the phenolic substances of white hellebore (Veratrum 
grandiflorum Loes. fil.). J. Faculty Sci. Hokkaido Imperial University 3 (1940) 1-16. 
[5] S. Nonomura, H. Kanagawa, A. Makimoto, [Chemical Constituents of 
Polygonaceous Plants. I. Studies on the Components of Ko-J O-Kon. (Polygonum 
Cuspidatum Sieb. Et Zucc.)]. Yakugaku Zasshi 83 (1963) 988-990. 
[6] S.K. Lee, Z.H. Mbwambo, H. Chung, L. Luyengi, E.J. Gamez, R.G. Mehta, 
A.D. Kinghorn, J.M. Pezzuto, Evaluation of the antioxidant potential of natural 
products. Comb Chem High Throughput Screen 1(1) (1998) 35-46. 
[7] B.C. Vastano, Y. Chen, N. Zhu, C.T. Ho, Z. Zhou, R.T. Rosen, Isolation and 
identification of stilbenes in two varieties of Polygonum cuspidatum. J Agric Food 
Chem 48(2) (2000) 253-256. 
[8] R.H. Cichewicz, S.A. Kouzi, Resveratrol oligomers: structure, chemistry, and 
biological activity. J Nat Prod Chem 26 (2002) 507-579. 
[9] E.H. Siemann, L.L. Creasy, Concentration of the phytoalexin resveratrol in 
wine. Am. J. Eno. Vitic. 43 (1992) 49–52. 
[10] J.A. Baur, D.A. Sinclair, Therapeutic potential of resveratrol: the in vivo 
evidence. Nat Rev Drug Discov 5(6) (2006) 493-506. 
[11] P. Kopp, Resveratrol, a phytoestrogen found in red wine. A possible 
explanation for the conundrum of the ‘French paradox’? Eur. J. Endocrinol. 138 
(1998) 619–620. 
[12] L.M. Hung, J.K. Chen, S.S. Huang, R.S. Lee, M.J. Su, Cardioprotective effect 
of resveratrol, a natural antioxidant derived from grapes. Cardiovasc Res 47(3) (2000) 
549-555. 
[13] S. Bradamante, L. Barenghi, A. Villa, Cardiovascular protective effects of 
resveratrol. Cardiovasc Drug Rev 22(3) (2004) 169-188. 
[14] G.B. Mahady, S.L. Pendland, Resveratrol inhibits the growth of Helicobacter 
pylori in vitro. Am J Gastroenterol 95(7) (2000) 1849. 
[15] F. Daroch, M. Hoeneisen, C.L. Gonzalez, F. Kawaguchi, F. Salgado, H. Solar, 
A. Garcia, In vitro antibacterial activity of Chilean red wines against Helicobacter 
pylori. Microbios 104(408) (2001) 79-85. 
[16] M.M. Chan, Antimicrobial effect of resveratrol on dermatophytes and 
bacterial pathogens of the skin. Biochemical pharmacology 63(2) (2002) 99-104. 
[17] G.B. Mahady, S.L. Pendland, L.R. Chadwick, Resveratrol and red wine 
extracts inhibit the growth of CagA+ strains of Helicobacter pylori in vitro. Am J 
Gastroenterol 98(6) (2003) 1440-1441. 
[18] A. Heredia, C. Davis, R. Redfield, Synergistic inhibition of HIV-1 in activated 
and resting peripheral blood mononuclear cells, monocyte-derived macrophages, and 
selected drug-resistant isolates with nucleoside analogues combined with a natural 
product, resveratrol. J Acquir Immune Defic Syndr 25(3) (2000) 246-255. 
213 
 
[19] J.J. Docherty, M.M. Fu, B.S. Stiffler, R.J. Limperos, C.M. Pokabla, A.L. 
DeLucia, Resveratrol inhibition of herpes simplex virus replication. Antiviral Res 
43(3) (1999) 145-155. 
[20] J.J. Docherty, J.S. Smith, M.M. Fu, T. Stoner, T. Booth, Effect of topically 
applied resveratrol on cutaneous herpes simplex virus infections in hairless mice. 
Antiviral Res 61(1) (2004) 19-26. 
[21] M. Jang, L. Cai, G.O. Udeani, K.V. Slowing, C.F. Thomas, C.W. Beecher, 
H.H. Fong, N.R. Farnsworth, A.D. Kinghorn, R.G. Mehta, R.C. Moon, J.M. Pezzuto, 
Cancer chemopreventive activity of resveratrol, a natural product derived from grapes. 
Science (New York, N.Y 275(5297) (1997) 218-220. 
[22] M. Bohm, S. Rosenkranz, U. Laufs, Alcohol and red wine: impact on 
cardiovascular risk. Nephrol Dial Transplant 19(1) (2004) 11-16. 
[23] G. Chen, W. Shan, Y. Wu, L. Ren, J. Dong, Z. Ji, Synthesis and anti-
inflammatory activity of resveratrol analogs. Chem Pharm Bull (Tokyo) 53(12) (2005) 
1587-1590. 
[24] N. Elmali, I. Esenkaya, A. Harma, K. Ertem, Y. Turkoz, B. Mizrak, Effect of 
resveratrol in experimental osteoarthritis in rabbits. Inflamm Res 54(4) (2005) 158-
162. 
[25] M.A. Birrell, K. McCluskie, S. Wong, L.E. Donnelly, P.J. Barnes, M.G. 
Belvisi, Resveratrol, an extract of red wine, inhibits lipopolysaccharide induced 
airway neutrophilia and inflammatory mediators through an NF-kappaB-independent 
mechanism. Faseb J 19(7) (2005) 840-841. 
[26] M. Jang, J.M. Pezzuto, Effects of resveratrol on 12-O-tetradecanoylphorbol-
13-acetate-induced oxidative events and gene expression in mouse skin. Cancer Lett 
134(1) (1998) 81-89. 
[27] F. Afaq, V.M. Adhami, N. Ahmad, H. Mukhtar, Botanical antioxidants for 
chemoprevention of photocarcinogenesis. Front Biosci 7 (2002) d784-792. 
[28] G.J. Kapadia, M.A. Azuine, H. Tokuda, M. Takasaki, T. Mukainaka, T. 
Konoshima, H. Nishino, Chemopreventive effect of resveratrol, sesamol, sesame oil 
and sunflower oil in the Epstein-Barr virus early antigen activation assay and the 
mouse skin two-stage carcinogenesis. Pharmacol Res 45(6) (2002) 499-505. 
[29] G.J. Soleas, L. Grass, P.D. Josephy, D.M. Goldberg, E.P. Diamandis, A 
comparison of the anticarcinogenic properties of four red wine polyphenols. Clin 
Biochem 35(2) (2002) 119-124. 
[30] V.M. Breinholt, A.M. Molck, G.W. Svendsen, B. Daneshvar, A.M. Vinggaard, 
M. Poulsen, L.O. Dragsted, Effects of dietary antioxidants and 2-amino-3-
methylimidazo[4,5-f]- quinoline (IQ) on preneoplastic lesions and on oxidative 
damage, hormonal status, and detoxification capacity in the rat. Food Chem Toxicol 
41(10) (2003) 1315-1323. 
[31] L. Yu, Z.J. Sun, S.L. Wu, C.E. Pan, Effect of resveratrol on cell cycle proteins 
in murine transplantable liver cancer. World J Gastroenterol 9(10) (2003) 2341-2343. 
[32] L. Tessitore, A. Davit, I. Sarotto, G. Caderni, Resveratrol depresses the growth 
of colorectal aberrant crypt foci by affecting bax and p21(CIP) expression. 
Carcinogenesis 21(8) (2000) 1619-1622. 
[33] K.P. Bhat, D. Lantvit, K. Christov, R.G. Mehta, R.C. Moon, J.M. Pezzuto, 
Estrogenic and antiestrogenic properties of resveratrol in mammary tumor models. 
Cancer Res 61(20) (2001) 7456-7463. 
[34] S. Banerjee, C. Bueso-Ramos, B.B. Aggarwal, Suppression of 7,12-
dimethylbenz(a)anthracene-induced mammary carcinogenesis in rats by resveratrol: 
214 
 
role of nuclear factor-kappaB, cyclooxygenase 2, and matrix metalloprotease 9. 
Cancer Res 62(17) (2002) 4945-4954. 
[35] M. Sato, R.J. Pei, T. Yuri, N. Danbara, Y. Nakane, A. Tsubura, Prepubertal 
resveratrol exposure accelerates N-methyl-N-nitrosourea-induced mammary 
carcinoma in female Sprague-Dawley rats. Cancer Lett 202(2) (2003) 137-145. 
[36] S.S. Hecht, P.M. Kenney, M. Wang, N. Trushin, S. Agarwal, A.V. Rao, P. 
Upadhyaya, Evaluation of butylated hydroxyanisole, myo-inositol, curcumin, 
esculetin, resveratrol and lycopene as inhibitors of benzo[a]pyrene plus 4-
(methylnitrosamino)-1-(3-pyridyl)-1-butanone-induced lung tumorigenesis in A/J 
mice. Cancer Lett 137(2) (1999) 123-130. 
[37] A. Revel, H. Raanani, E. Younglai, J. Xu, I. Rogers, R. Han, J.F. Savouret, 
R.F. Casper, Resveratrol, a natural aryl hydrocarbon receptor antagonist, protects lung 
from DNA damage and apoptosis caused by benzo[a]pyrene. J Appl Toxicol 23(4) 
(2003) 255-261. 
[38] Z.G. Li, T. Hong, Y. Shimada, I. Komoto, A. Kawabe, Y. Ding, J. Kaganoi, Y. 
Hashimoto, M. Imamura, Suppression of N-nitrosomethylbenzylamine (NMBA)-
induced esophageal tumorigenesis in F344 rats by resveratrol. Carcinogenesis 23(9) 
(2002) 1531-1536. 
[39] K. Bove, D.W. Lincoln, M.F. Tsan, Effect of resveratrol on growth of 4T1 
breast cancer cells in vitro and in vivo. Biochem Biophys Res Commun 291(4) (2002) 
1001-1005. 
[40] C.C. Ziegler, L. Rainwater, J. Whelan, M.F. McEntee, Dietary resveratrol does 
not affect intestinal tumorigenesis in Apc(Min/+) mice. J Nutr 134(1) (2004) 5-10. 
[41] N. Carbo, P. Costelli, F.M. Baccino, F.J. Lopez-Soriano, J.M. Argiles, 
Resveratrol, a natural product present in wine, decreases tumour growth in a rat 
tumour model. Biochem Biophys Res Commun 254(3) (1999) 739-743. 
[42] Y. Kimura, H. Okuda, Resveratrol isolated from Polygonum cuspidatum root 
prevents tumor growth and metastasis to lung and tumor-induced neovascularization 
in Lewis lung carcinoma-bearing mice. J Nutr 131(6) (2001) 1844-1849. 
[43] H.S. Liu, C.E. Pan, W. Yang, X.M. Liu, Antitumor and immunomodulatory 
activity of resveratrol on experimentally implanted tumor of H22 in Balb/c mice. 
World J Gastroenterol 9(7) (2003) 1474-1476. 
[44] K. Sinha, G. Chaudhary, Y.K. Gupta, Protective effect of resveratrol against 
oxidative stress in middle cerebral artery occlusion model of stroke in rats. Life Sci 
71(6) (2002) 655-665. 
[45] H. Inoue, X.F. Jiang, T. Katayama, S. Osada, K. Umesono, S. Namura, Brain 
protection by resveratrol and fenofibrate against stroke requires peroxisome 
proliferator-activated receptor alpha in mice. Neurosci Lett 352(3) (2003) 203-206. 
[46] Q. Wang, J. Xu, G.E. Rottinghaus, A. Simonyi, D. Lubahn, G.Y. Sun, A.Y. 
Sun, Resveratrol protects against global cerebral ischemic injury in gerbils. Brain Res 
958(2) (2002) 439-447. 
[47] Y.K. Gupta, G. Chaudhary, K. Sinha, A.K. Srivastava, Protective effect of 
resveratrol against intracortical FeCl3-induced model of posttraumatic seizures in rats. 
Methods Find Exp Clin Pharmacol 23(5) (2001) 241-244. 
[48] Y.K. Gupta, G. Chaudhary, A.K. Srivastava, Protective effect of resveratrol 
against pentylenetetrazole-induced seizures and its modulation by an adenosinergic 
system. Pharmacology 65(3) (2002) 170-174. 
[49] Y.K. Gupta, S. Briyal, G. Chaudhary, Protective effect of trans-resveratrol 
against kainic acid-induced seizures and oxidative stress in rats. Pharmacol Biochem 
Behav 71(1-2) (2002) 245-249. 
215 
 
[50] M. Sharma, Y.K. Gupta, Chronic treatment with trans resveratrol prevents 
intracerebroventricular streptozotocin induced cognitive impairment and oxidative 
stress in rats. Life Sci 71(21) (2002) 2489-2498. 
[51] A.R. Martin, I. Villegas, C. La Casa, C.A. de la Lastra, Resveratrol, a 
polyphenol found in grapes, suppresses oxidative damage and stimulates apoptosis 
during early colonic inflammation in rats. Biochemical pharmacology 67(7) (2004) 
1399-1410. 
[52] A.R. Martin, I. Villegas, M. Sanchez-Hidalgo, C.A. de la Lastra, The effects 
of resveratrol, a phytoalexin derived from red wines, on chronic inflammation 
induced in an experimentally induced colitis model. British journal of pharmacology 
147(8) (2006) 873-885. 
[53] M. Mahyar-Roemer, A. Katsen, P. Mestres, K. Roemer, Resveratrol induces 
colon tumor cell apoptosis independently of p53 and precede by epithelial 
differentiation, mitochondrial proliferation and membrane potential collapse. Int J 
Cancer 94 (2001) 6156-6122. 
[54] F. Wolter, J. Stein, Resveratrol enhances the differentiation induced by 
butyrate in Caco-2 colon cancer cells. Journal of Nutrition 132(7) (2002) 2082-2086. 
[55] F. Wolter, B. Akoglu, A. Clausnitzer, J. Stein, Downregulation of the cyclin 
D1/Cdk4 complex occurs during resveratrol-induced cell cycle arrest in colon cancer 
cell lines. Journal of Nutrition 131(8) (2001) 2197-2203. 
[56] D. Delmas, C. ReÌbeÌ, S. Lacour, R. Filomenko, A. Athias, P. Gambert, M. 
Cherkaoui-Malki, B. Jannin, L. Dubrez-Daloz, N. Latruffe, E. Solary, Resveratrol-
induced Apoptosis Is Associated with Fas Redistribution in the Rafts and the 
Formation of a Death-inducing Signaling Complex in Colon Cancer Cells. Journal of 
Biological Chemistry 278(42) (2003) 41482-41490. 
[57] Y.C. Liang, S.H. Tsai, L. Chen, S.Y. Lin-Shiau, J.K. Lin, Resveratrol-induced 
G2 arrest through the inhibition of CDK7 and p34CDC2 kinases in colon carcinoma 
HT29 cells. Biochemical pharmacology 65(7) (2003) 1053-1060. 
[58] K.A. Nam, S. Kim, Y.H. Heo, S.K. Lee, Resveratrol Analog, 3,5,2â€²,4â€²-
Tetramethoxy-trans-stilbene, Potentiates the Inhibition of Cell Growth and Induces 
Apoptosis in Human Cancer Cells. Archives of Pharmacal Research 24(5) (2001) 
441-445. 
[59] T. Ito, Y. Akao, T. Tanaka, M. Iinuma, Y. Nozawa, Vaticanol C, a novel 
resveratrol tetramer, inhibits cell growth through induction of apoptosis in colon 
cancer cell lines. Biological & pharmaceutical bulletin 25(1) (2002) 147-148. 
[60] F. Wolter, A. Clausnitzer, B. Akoglu, J. Stein, Piceatannol, a natural analog of 
resveratrol, inhibits progression through the s phase of the cell cycle in colorectal 
cancer cell lines. Journal of Nutrition 132(2) (2002) 298-302. 
[61] S. Sale, R.D. Verschoyle, D. Boocock, D.J. Jones, N. Wilsher, K.C. Ruparelia, 
G.A. Potter, P.B. Farmer, W.P. Steward, A.J. Gescher, Pharmacokinetics in mice and 
growth-inhibitory properties of the putative cancer chemopreventive agent resveratrol 
and the synthetic analogue trans 3,4,5,4'-tetramethoxystilbene. Br J Cancer 90(3) 
(2004) 736-744. 
[62] Y. Schneider, B. Duranton, F. Gosse, R. Schleiffer, N. Seiler, F. Raul, 
Resveratrol inhibits intestinal tumorigenesis and modulates host-defense-related gene 
expression in an animal model of human familial adenomatous polyposis. Nutr 
Cancer 39(1) (2001) 102-107. 
[63] K.T. Howitz, K.J. Bitterman, H.Y. Cohen, D.W. Lamming, S. Lavu, J.G. 
Wood, R.E. Zipkin, P. Chung, A. Kisielewski, L.L. Zhang, B. Scherer, D.A. Sinclair, 
216 
 
Small molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan. 
Nature 425(6954) (2003) 191-196. 
[64] S. Jarolim, J. Millen, G. Heeren, P. Laun, D.S. Goldfarb, M. Breitenbach, A 
novel assay for replicative lifespan in Saccharomyces cerevisiae. FEMS Yeast Res 
5(2) (2004) 169-177. 
[65] J.G. Wood, B. Rogina, S. Lavu, K. Howitz, S.L. Helfand, M. Tatar, D. Sinclair, 
Sirtuin activators mimic caloric restriction and delay ageing in metazoans. Nature 
430(7000) (2004) 686-689. 
[66] M. Viswanathan, S.K. Kim, A. Berdichevsky, L. Guarente, A role for SIR-2.1 
regulation of ER stress response genes in determining C. elegans life span. Dev Cell 
9(5) (2005) 605-615. 
[67] D.R. Valenzano, E. Terzibasi, T. Genade, A. Cattaneo, L. Domenici, A. 
Cellerino, Resveratrol prolongs lifespan and retards the onset of age-related markers 
in a short-lived vertebrate. Curr Biol 16(3) (2006) 296-300. 
[68] J.A. Baur, K.J. Pearson, N.L. Price, H.A. Jamieson, C. Lerin, A. Kalra, V.V. 
Prabhu, J.S. Allard, G. Lopez-Lluch, K. Lewis, P.J. Pistell, S. Poosala, K.G. Becker, 
O. Boss, D. Gwinn, M. Wang, S. Ramaswamy, K.W. Fishbein, R.G. Spencer, E.G. 
Lakatta, D. Le Couteur, R.J. Shaw, P. Navas, P. Puigserver, D.K. Ingram, R. de Cabo, 
D.A. Sinclair, Resveratrol improves health and survival of mice on a high-calorie diet. 
Nature 444(7117) (2006) 337-342. 
[69] A. Fulgenzi, A.A. Bertelli, E. Magni, E. Ferrero, M.E. Ferrero, In vivo 
inhibition of TNFalpha-induced vascular permeability by resveratrol. Transplant Proc 
33(3) (2001) 2341-2343. 
[70] R.P. Korolkiewicz, M. Ujda, J. Dabkowski, J. Ruczynski, P. Rekowski, J. 
Petrusewicz, Differential salutary effects of nonselective and selective COX-2 
inhibitors in postoperative ileus in rats. J Surg Res 109(2) (2003) 161-169. 
[71] R.P. Korolkiewicz, J. Sein-Anand, J. Ruczynski, P. Rekowski, L. 
Bieniaszewski, Z. Chodorowski, J. Petrusewicz, M. Ujda, J. Dabkowski, M. Bitel, S. 
Kato, K. Takeuchi, The role and interactions of nitric oxide (NO), carbon monoxide 
(CO), and prostanoids in the pathogenesis of postoperative ileus in rats. J Gastrointest 
Surg 8(3) (2004) 346-357. 
[72] S. Cadenas, G. Barja, Resveratrol, melatonin, vitamin E, and PBN protect 
against renal oxidative DNA damage induced by the kidney carcinogen KBrO3. Free 
Radic Biol Med 26(11-12) (1999) 1531-1537. 
[73] L. Giovannini, M. Migliori, B.M. Longoni, D.K. Das, A.A. Bertelli, V. 
Panichi, C. Filippi, A. Bertelli, Resveratrol, a polyphenol found in wine, reduces 
ischemia reperfusion injury in rat kidneys. J Cardiovasc Pharmacol 37(3) (2001) 262-
270. 
[74] S.D. McClintock, G.O. Till, M.G. Smith, P.A. Ward, Protection from half-
mustard-gas-induced acute lung injury in the rat. J Appl Toxicol 22(4) (2002) 257-
262. 
[75] Y. Yang, Y. Piao, [Effects of resveratrol on Ca2+, Mg(2+)-ATPase activities 
after spinal cord trauma in rats]. Zhong Yao Cai 25(12) (2002) 882-885. 
[76] Y.B. Yang, Y.J. Piao, Effects of resveratrol on secondary damages after acute 
spinal cord injury in rats. Acta Pharmacol Sin 24(7) (2003) 703-710. 
[77] M. Gentilli, J.X. Mazoit, H. Bouaziz, D. Fletcher, R.F. Casper, D. Benhamou, 
J.F. Savouret, Resveratrol decreases hyperalgesia induced by carrageenan in the rat 
hind paw. Life Sci 68(11) (2001) 1317-1321. 
217 
 
[78] V. Granados-Soto, C.F. Arguelles, M.I. Ortiz, The peripheral antinociceptive 
effect of resveratrol is associated with activation of potassium channels. 
Neuropharmacology 43(5) (2002) 917-923. 
[79] J.E. Torres-Lopez, M.I. Ortiz, G. Castaneda-Hernandez, R. Alonso-Lopez, R. 
Asomoza-Espinosa, V. Granados-Soto, Comparison of the antinociceptive effect of 
celecoxib, diclofenac and resveratrol in the formalin test. Life Sci 70(14) (2002) 
1669-1676. 
[80] M. Seidman, S. Babu, W. Tang, E. Naem, W.S. Quirk, Effects of resveratrol 
on acoustic trauma. Otolaryngol Head Neck Surg 129(5) (2003) 463-470. 
[81] F. Lugarini, B.J. Hrupka, G.J. Schwartz, C.R. Plata-Salaman, W. Langhans, A 
role for cyclooxygenase-2 in lipopolysaccharide-induced anorexia in rats. Am J 
Physiol Regul Integr Comp Physiol 283(4) (2002) R862-868. 
[82] G. Kuhnle, J.P. Spencer, G. Chowrimootoo, H. Schroeter, E.S. Debnam, S.K. 
Srai, C. Rice-Evans, U. Hahn, Resveratrol is absorbed in the small intestine as 
resveratrol glucuronide. Biochem Biophys Res Commun 272(1) (2000) 212-217. 
[83] W. Andlauer, J. Kolb, K. Siebert, P. Furst, Assessment of resveratrol 
bioavailability in the perfused small intestine of the rat. Drugs Exp Clin Res 26(2) 
(2000) 47-55. 
[84] C. de Santi, A. Pietrabissa, F. Mosca, G.M. Pacifici, Glucuronidation of 
resveratrol, a natural product present in grape and wine, in the human liver. 
Xenobiotica 30(11) (2000) 1047-1054. 
[85] C. De Santi, A. Pietrabissa, R. Spisni, F. Mosca, G.M. Pacifici, Sulphation of 
resveratrol, a natural product present in grapes and wine, in the human liver and 
duodenum. Xenobiotica 30(6) (2000) 609-617. 
[86] C. Yu, Y.G. Shin, A. Chow, Y. Li, J.W. Kosmeder, Y.S. Lee, W.H. 
Hirschelman, J.M. Pezzuto, R.G. Mehta, R.B. van Breemen, Human, rat, and mouse 
metabolism of resveratrol. Pharmaceutical research 19(12) (2002) 1907-1914. 
[87] M.I. Kaldas, U.K. Walle, T. Walle, Resveratrol transport and metabolism by 
human intestinal Caco-2 cells. J Pharm Pharmacol 55(3) (2003) 307-312. 
[88] G.A. Potter, L.H. Patterson, E. Wanogho, P.J. Perry, P.C. Butler, T. Ijaz, K.C. 
Ruparelia, J.H. Lamb, P.B. Farmer, L.A. Stanley, M.D. Burke, The cancer 
preventative agent resveratrol is converted to the anticancer agent piceatannol by the 
cytochrome P450 enzyme CYP1B1. Br J Cancer 86(5) (2002) 774-778. 
[89] A.A. Bertelli, L. Giovannini, R. Stradi, S. Urien, J.P. Tillement, A. Bertelli, 
Evaluation of kinetic parameters of natural phytoalexin in resveratrol orally 
administered in wine to rats. Drugs Exp Clin Res 24(1) (1998) 51-55. 
[90] D.M. Goldberg, J. Yan, G.J. Soleas, Absorption of three wine-related 
polyphenols in three different matrices by healthy subjects. Clin Biochem 36(1) (2003) 
79-87. 
[91] T. Walle, F. Hsieh, M.H. DeLegge, J.E. Oatis, Jr., U.K. Walle, High 
absorption but very low bioavailability of oral resveratrol in humans. Drug Metab 
Dispos 32(12) (2004) 1377-1382. 
[92] A.J. Gescher, W.P. Steward, Relationship between mechanisms, bioavailibility, 
and preclinical chemopreventive efficacy of resveratrol: a conundrum. Cancer 
Epidemiol Biomarkers Prev 12(10) (2003) 953-957. 
[93] S. Pervaiz, Resveratrol: from grapevines to mammalian biology. Faseb J 17(14) 
(2003) 1975-1985. 
[94] M. Asensi, I. Medina, A. Ortega, J. Carretero, M.C. Bano, E. Obrador, J.M. 
Estrela, Inhibition of cancer growth by resveratrol is related to its low bioavailability. 
Free Radic Biol Med 33(3) (2002) 387-398. 
218 
 
[95] J.F. Marier, P. Vachon, A. Gritsas, J. Zhang, J.P. Moreau, M.P. Ducharme, 
Metabolism and disposition of resveratrol in rats: extent of absorption, 
glucuronidation, and enterohepatic recirculation evidenced by a linked-rat model. J 
Pharmacol Exp Ther 302(1) (2002) 369-373. 
[96] J.A. Crowell, P.J. Korytko, R.L. Morrissey, T.D. Booth, B.S. Levine, 
Resveratrol-associated renal toxicity. Toxicol Sci 82(2) (2004) 614-619. 
[97] M.E. Juan, M.P. Vinardell, J.M. Planas, The daily oral administration of high 
doses of trans-resveratrol to rats for 28 days is not harmful. J Nutr 132(2) (2002) 257-
260. 
[98] H. Chen, R. Langer, Oral particulate delivery: Status and future trends. 
Advanced Drug Delivery Reviews 34(2-3) (1998) 339-350. 
[99] L. Liu, M.L. Fishman, J. Kost, K.B. Hicks, Pectin-based systems for colon-
specific drug delivery via oral route. Biomaterials 24(19) (2003) 3333-3343. 
[100] D.R. Friend, Colon-specific drug delivery. Advanced Drug Delivery Reviews 
7(1) (1991) 149-199. 
[101] M.K. Chourasia, S.K. Jain, Pharmaceutical approaches to colon targeted drug 
delivery systems. Journal of Pharmacy and Pharmaceutical Sciences 6(1) (2003) 33-
66. 
[102] A.W. Basit, Advances in colonic drug delivery. Drugs 65(14) (2005) 1991-
2007. 
[103] S.A.W. Gibson, C. McFarlan, S. Hay, G.T. Macfarlane, Significance of 
microflora in proteolysis in the colon. Applied and Environmental Microbiology 55(3) 
(1989) 679-683. 
[104] M. Saffran, G.S. Kumar, C. Savariar, A new approach to the oral 
administration of insulin and other peptide drugs. Science 233(4768) (1986) 1081-
1084. 
[105] B.B.C. Youan, Chronopharmaceutics: Gimmick or clinically relevant 
approach to drug delivery? Journal of Controlled Release 98(3) (2004) 337-353. 
[106] M. Jay, R.M. Beihn, G.A. Digenis, F.H. Deland, L. Caldwell, A.R. 
Mlodozeniec, Disposition of radiolabelled suppositories in humans. J Pharm 
Pharmacol 37(4) (1985) 266-268. 
[107] J.G. Hardy, S.W. Lee, A.G. Clark, J.R. Raynolds, Enema volume and 
spreading. International Journal of Pharmaceutics 31(1-2) (1986) 151-155. 
[108] L. Barrow, R.C. Spiller, C.G. Wilson, Pathological influences on colonic 
motility: Implications for drug delivery. Advanced Drug Delivery Reviews 7(1) (1991) 
201-218. 
[109] J.M. Hebden, P.E. Blackshaw, A.C. Perkins, C.G. Wilson, R.C. Spiller, 
Limited exposure of the healthy distal colon to orally-dosed formulation is further 
exaggerated in active left-sided ulcerative colitis. Alimentary Pharmacology and 
Therapeutics 14(2) (2000) 155-161. 
[110] S.G. Nugent, D. Kumar, D.S. Rampton, D.F. Evans, Intestinal luminal pH in 
inflammatory bowel disease: Possible determinants and implications for therapy with 
aminosalicylates and other drugs. Gut 48(4) (2001) 571-577. 
[111] A. Sinha, D.J. Ball, A.L. Connor, J. Nightingale, I.R. Wilding, Intestinal 
Performance of Two Mesalamine Formulations in Patients with Active Ulcerative 
Colitis as Assessed by Gamma Scintigraphy. Practical Gastroenterology 27(10) (2003) 
56-69. 
[112] D.R. Friend, New oral delivery systems for treatment of inflammatory bowel 
disease. Adv Drug Deliv Rev 57(2) (2005) 247-265. 
219 
 
[113] I.R. Wilding, The Enterion Capsule: A novel technology for understanding the 
biopharmaceutical complexity of new molecular entities (NMEs). Drug Deliv Tech 
1(1) (2001) 8-11. 
[114] C. Tuleu, A.W. Basit, W.A. Waddington, P.J. Ell, J.M. Newton, Colonic 
delivery of 4-aminosalicylic acid using amylose-ethylcellulose-coated 
hydroxypropylmethylcellulose capsules. Alimentary Pharmacology and Therapeutics 
16(10) (2002) 1771-1779. 
[115] J.E. Devereux, J.M. Newton, M.B. Short, The influence of density on the 
gastrointestinal transit of pellets. Journal of Pharmacy and Pharmacology 42(7) (1990) 
500-501. 
[116] S.S. Davis, J.G. Hardy, M.J. Taylor, The effect of food on the gastrointestinal 
transit of pellets and an osmotic device (Osmet). International Journal of 
Pharmaceutics 21(3) (1984) 331-340. 
[117] L.C. Kaus, J.T. Fell, H. Sharma, D.C. Taylor, On the intestinal transit of a 
single nondisintegrating object. Int. J. Pharm. 14 (1984) 143-148. 
[118] S.S. Davis, J.G. Hardy, J.W. Fara, Transit of pharmaceutical dosage forms 
through the small intestine. Gut 27(8) (1986) 886-892. 
[119] J.H. Cummings, S.A. Bingham, K.W. Heaton, M.A. Eastwood, Fecal weight, 
colon cancer risk, and dietary intake of nonstarch polysaccharides (dietary fiber). 
Gastroenterology 103(6) (1992) 1783-1789. 
[120] A.M. Metcalf, S.F. Phillips, A.R. Zinsmeister, R.L. MacCarty, R.W. Beart, 
B.G. Wolff, Simplified assessment of segmental colonic transit. Gastroenterology 
92(1) (1987) 40-47. 
[121] I.R. Wilding, S.S. Davis, M. Bakhshaee, H.N.E. Stevens, R.A. Sparrow, J. 
Brennan, Gastrointestinal transit and systemic absorption of captopril from a pulsed-
release formulation. Pharmaceutical Research 9(5) (1992) 654-657. 
[122] J.M. Hebden, C.G. Wilson, R.C. Spiller, P.J. Gilchrist, E. Blackshaw, M.E. 
Frier, A.C. Perkins, Regional differences in quinine absorption from the undisturbed 
human colon assessed using a timed release delivery system. Pharmaceutical 
Research 16(7) (1999) 1087-1092. 
[123] I. Wilding, Site-specific drug delivery in the gastrointestinal tract. Critical 
Reviews in Therapeutic Drug Carrier Systems 17(6) (2000) 557-620. 
[124] I.R. Wilding, S.S. Davis, F. Pozzi, P. Furlani, A. Gazzaniga, Enteric coated 
timed release systems for colonic targeting. International Journal of Pharmaceutics 
111(1) (1994) 99-102. 
[125] M.E. Sangalli, A. Maroni, L. Zema, C. Busetti, F. Giordano, A. Gazzaniga, In 
vitro and in vivo evaluation of an oral system for time and/or site-specific drug 
delivery. Journal of Controlled Release 73(1) (2001) 103-110. 
[126] T. Ishibashi, G.R. Pitcairn, H. Yoshino, M. Mizobe, I.R. Wilding, 
Scintigraphic evaluation of a new capsule-type colon specific drug delivery system in 
healthy volunteers. Journal of Pharmaceutical Sciences 87(5) (1998) 531-535. 
[127] T. Goto, N. Tanida, T. Yoshinaga, S. Sato, D.J. Ball, I.R. Wilding, E. 
Kobayashi, A. Fujimura, Pharmaceutical design of a novel colon-targeted delivery 
system using two-layer-coated tablets of three different pharmaceutical formulations, 
supported by clinical evidence in humans. Journal of Controlled Release 97(1) (2004) 
31-42. 
[128] A.J. Coupe, S.S. Davis, I.R. Wilding, Variation in gastrointestinal transit of 




[129] R.H. Goo, J.G. Moore, E. Greenberg, N.P. Alazraki, Circadian variation in 
gastric emptying of meals in humans. Gastroenterology 93(3) (1987) 515-518. 
[130] J.M. Hebden, P.J. Gilchrist, E. Blackshaw, M.E. Frier, A.C. Perkins, C.G. 
Wilson, R.C. Spiller, Night-time quiescence and morning activation in the human 
colon: Effect on transit of dispersed and large single unit formulations. European 
Journal of Gastroenterology and Hepatology 11(12) (1999) 1379-1385. 
[131] V.R. Sinha, R. Kumria, Microbially triggered drug delivery to the colon. Eur J 
Pharm Sci 18(1) (2003) 3-18. 
[132] S. EdsbÃ¤cker, T. Andersson, Pharmacokinetics of budesonide (Entocortâ„¢ 
EC) capsules for Crohn's disease. Clinical Pharmacokinetics 43(12) (2004) 803-821. 
[133] C.S. Leopold, Coated dosage forms for colon-specific drug delivery. 
Pharmaceutical Science and Technology Today 2(5) (1999) 197-204. 
[134] M.J. Dew, P.J. Hughes, M.G. Lee, An oral preparation to release drugs in the 
human colon. British Journal of Clinical Pharmacology 14(3) (1982) 405-408. 
[135] M.J. Dew, R.E.J. Ryder, N. Evans, Colonic release of 5-amino salicylic acid 
from an oral preparation in active ulcerative colitis. British Journal of Clinical 
Pharmacology 16(2) (1983) 185-187. 
[136] A. Forbes, A. Cartwright, S. Marchant, P. McIntyre, M. Newton, Review 
article: Oral, modified-release mesalazine formulations - Proprietary versus generic. 
Alimentary Pharmacology and Therapeutics 17(10) (2003) 1207-1214. 
[137] H.M. Fadda, A.W. Basit, Dissolution of pH responsive formulations in media 
resembling intestinal fluids: Bicarbonate versus phosphate buffers. Journal of Drug 
Delivery Science and Technology 15(4) (2005) 273-279. 
[138] D.F. Evans, G. Pye, R. Bramley, A.G. Clark, T.J. Dyson, J.D. Hardcastle, 
Measurement of gastrointestinal pH profiles in normal ambulant human subjects. Gut 
29(8) (1988) 1035-1041. 
[139] M. Ashford, J.T. Fell, D. Attwood, H. Sharma, P.J. Woodhead, An in vivo 
investigation into the suitability of pH dependent polymers for colonic targeting. 
International Journal of Pharmaceutics 95(1-3) (1993) 193-199. 
[140] I.R. Wilding, A scintigraphic study to evaluate what happens to Pentasa and 
Asacol in the human gut. Pract Gastroenterol 23(SUPPL.) (1999) 1-8. 
[141] G. Sciaretta, A. Furno, M. Mazzoni, A. Ferrieri, P. Malaguti, Scintigraphic 
study of gastrointestinal transit and disintegration sites of mesalazine tablets labeled 
with technetium-99m. Scandinavian Journal of Gastroenterology 28(9) (1993) 783-
785. 
[142] T. Takaya, C. Ikeda, N. Imagawa, K. Niwa, K. Takada, Development of a 
colon delivery capsule and the pharmacological activity of recombinant human 
granulocyte colony-stimulating factor (rhG-CSF) in beagle dogs. Journal of Pharmacy 
and Pharmacology 47(6) (1995) 474-478. 
[143] L. Yang, Biorelevant dissolution testing of colon-specific delivery systems 
activated by colonic microflora. J Control Release 125(2) (2008) 77-86. 
[144] H.S. Wiggins, J.H. Cummings, Evidence for the mixing of residue in the 
human gut. Gut 17(12) (1976) 1007-1011. 
[145] Y.I. Jeong, T. Ohno, Z. Hu, Y. Yoshikawa, N. Shibata, S. Nagata, K. Takada, 
Evaluation of an intestinal pressure-controlled colon delivery capsules prepared by a 
dipping method. Journal of Controlled Release 71(2) (2001) 175-182. 
[146] Z. Hu, S. Mawatari, T. Shimokawa, G. Kimura, Y. Yoshikawa, N. Shibata, K. 
Takada, Colon delivery efficiencies of intestinal pressure-controlled colon delivery 
capsules prepared by a coating machine in human subjects. Journal of Pharmacy and 
Pharmacology 52(10) (2000) 1187-1193. 
221 
 
[147] T.F. Vandamme, A. Lenourry, C. Charrueau, J.C. Chaumeil, The use of 
polysaccharides to target drugs to the colon. Carbohydrate Polymers 48(3) (2002) 
219-231. 
[148] J.H. Cummings, G.T. Macfarlane, The control and consequences of bacterial 
fermentation in the human colon. Journal of Applied Bacteriology 70(6) (1991) 443-
459. 
[149] G.L. Simon, S.L. Gorbach, Intestinal flora in health and disease. 
Gastroenterology 86(1) (1984) 174-193. 
[150] R.R. Scheline, Metabolism of foreign compounds by gastrointestinal 
microorganisms. Pharmacol Rev 25(4) (1973) 451-523. 
[151] H.N. Englyst, S. Hay, G.T. Macfarlane, Polysaccharide breakdown by mixed 
populations of human faecal bacteria. FEMS Microbiology Letters 45(3) (1987) 163-
171. 
[152] N. Svartz, Sulfasalazine: II. Some notes on the discovery and development of 
salazopyrin. American Journal of Gastroenterology 83(5) (1988) 497-503. 
[153] A.K. Azad Khan, J. Piris, S.C. Truelove, An experiment to determine the 
active therapeutic moiety of sulphasalazine. Lancet 2(8044) (1977) 892-895. 
[154] B. Myers, D.N.W. Evans, J. Rhodes, Metabolism and urinary excretion of 5-
amino salicylic acid in healthy volunteers when given intravenously or released for 
absorption at different sites in the gastrointestinal tract. Gut 28(2) (1987) 196-200. 
[155] S.A. Riley, What dose of 5-aminosalicylic acid (mesalazine) in ulcerative 
colitis? Gut 42(6) (1998) 761-763. 
[156] U. Klotz, Clinical pharmacokinetics of sulphasalazine, its metabolites and 
other prodrugs of 5-aminosalicylic acid. Clinical Pharmacokinetics 10(4) (1985) 285-
302. 
[157] A.N. Wadworth, A. Fitton, Olsalazine. A review of its pharmacodynamic and 
pharmacokinetic properties, and therapeutic potential in inflammatory bowel disease. 
Drugs 41(4) (1991) 647-664. 
[158] V.R. Sinha, R. Kumria, Colonic drug delivery: Prodrug approach. 
Pharmaceutical Research 18(5) (2001) 557-564. 
[159] O. Carrette, C. Favier, C. Mizon, C. Neut, A. Cortot, J.F. Colombel, J. Mizon, 
Bacterial enzymes used for colon-specific drug delivery are decreased in active 
Crohn's disease. Digestive Diseases and Sciences 40(12) (1995) 2641-2646. 
[160] G. Van Den Mooter, B. Maris, C. Samyn, P. Augustus, R. Kinget, Use of azo 
polymers for colon-specific drug delivery. Journal of Pharmaceutical Sciences 86(12) 
(1997) 1321-1327. 
[161] M.A. Shamat, The role of the gastrointestinal microflora in the metabolism of 
drugs. International Journal of Pharmaceutics 97(1-3) (1993) 1-13. 
[162] A. Rubinstein, R. Radai, M. Ezra, S. Pathak, J.S. Rokem, In vitro evaluation of 
calcium pectinate: A potential colon-specific drug delivery carrier. Pharmaceutical 
Research 10(2) (1993) 258-263. 
[163] D.A. Adkin, C.J. Kenyon, E.I. Lerner, I. Landau, E. Strauss, D. Caron, A. 
Penhasi, A. Rubinstein, I.R. Wilding, The use of scintigraphy to provide 'proof of 
concept' for novel polysaccharide preparations designed for colonic drug delivery. 
Pharmaceutical Research 14(1) (1997) 103-107. 
[164] A. Rubinstein, R. Radai, In vitro and in vivo analysis of colon specificity of 
calcium pectinate formulations. European Journal of Pharmaceutics and 
Biopharmaceutics 41(5) (1995) 291-295. 
222 
 
[165] M. Ashford, J. Fell, D. Attwood, H. Sharma, P. Woodhead, STUDIES ON 
PECTIN FORMULATIONS FOR COLONIC DRUG-DELIVERY. Journal of 
Controlled Release 30(3) (1994) 225-232. 
[166] Z. Wakerly, J. Fell, D. Attwood, D. Parkins, Studies on amidated pectins as 
potential carriers in colonic drug delivery. J Pharm Pharmacol 49(6) (1997) 622-625. 
[167] O. Munjeri, J.H. Collett, J.T. Fell, Hydrogel beads based on amidated pectins 
for colon-specific drug delivery: The role of chitosan in modifying drug release. 
Journal of Controlled Release 46(3) (1997) 273-278. 
[168] S.F. Ahrabi, G. Madsen, K. Dyrstad, S.A. Sande, C. Graffner, Development of 
pectin matrix tablets for colonic delivery of model drug ropivacaine. European 
Journal of Pharmaceutical Sciences 10(1) (2000) 43-52. 
[169] Z. Wakerly, J.T. Fell, D. Attwood, D. Parkins, Pectin/ethylcellulose film 
coating formulations for colonic drug delivery. Pharmaceutical Research 13(8) (1996) 
1210-1212. 
[170] R. Semde, K. Amighi, D. Pierre, M.J. Devleeschouwer, A.J. Moe?s, Leaching 
of pectin from mixed pectin/insoluble polymer films intended for colonic drug 
delivery. International Journal of Pharmaceutics 174(1-2) (1998) 233-241. 
[171] R. SemdeÌ, K. Amighi, M.J. Devleeschouwer, A.J. MoeÌˆs, Effect of 
pectinolytic enzymes on the theophylline release from pellets coated with water 
insoluble polymers containing pectin HM or calcium pectinate. International Journal 
of Pharmaceutics 197(1-2) (2000) 169-179. 
[172] R. SemdeÌ, K. Amighi, M.J. Devleeschouwer, A.J. MoeÌˆs, Studies of pectin 
HM/EudragitÂ® RL/EudragitÂ® NE film-coating formulations intended for colonic 
drug delivery. International Journal of Pharmaceutics 197(1-2) (2000) 181-192. 
[173] G.S. Macleod, J.T. Fell, J.H. Collett, H.L. Sharma, A.M. Smith, Selective drug 
delivery to the colon using pectin : chitosan : hydroxypropyl methylcellulose film 
coated tablets. International Journal of Pharmaceutics 187(2) (1999) 251-257. 
[174] G.S. Macleod, J.T. Fell, J.H. Collett, An in vitro investigation into the 
potential for bimodal drug release from pectin/chitosan/HPMC-coated tablets. 
International Journal of Pharmaceutics 188(1) (1999) 11-18. 
[175] M.J. Fernandez-Hervas, J.T. Fell, Pectin/chitosan mixtures as coatings for 
colon-specific drug delivery: an in vitro evaluation. International Journal of 
Pharmaceutics 169(1) (1998) 115-119. 
[176] H. Tozaki, J. Komoike, C. Tada, T. Maruyama, A. Terabe, T. Suzuki, A. 
Yamamoto, S. Muranishi, Chitosan Capsule for colon-specific drug delivery: 
Improvement of insulin absorption from the rat colon. Journal of Pharmaceutical 
Sciences 86(9) (1997) 1016-1021. 
[177] H. Tozaki, T. Fujita, T. Odoriba, A. Terabe, T. Suzuki, C. Tanaka, S. Okabe, S. 
Muranishi, A. Yamamoto, Colon-specific delivery of R68070, a new thromboxane 
synthase inhibitor, using chitosan capsules: Therapeutic effects against 2,4,6-
trinitrobenzene sulfonic acid-induced ulcerative colitis in rats. Life Sciences 64(13) 
(1999) 1155-1162. 
[178] M.L. Lorenzo-Lamosa, C. RemuÃ±Ã¡n-LÃ³pez, J.L. Vila-Jato, M.J. Alonso, 
Design of microencapsulated chitosan microspheres for colonic drug delivery. Journal 
of Controlled Release 52(1-2) (1998) 109-118. 
[179] K. Aiedeh, M.O. Taha, Synthesis of chitosan succinate and chitosan phthalate 
and their evaluation as suggested matrices in orally administered, colon-specific drug 
delivery systems. Archiv der Pharmazie 332(3) (1999) 103-107. 
223 
 
[180] Y.S.R. Krishnaiah, S. Satyanarayana, Y.V. Rama Prasad, S. Narasimha Rao, 
Gamma scintigraphic studies on guar gum matrix tablets for colonic drug delivery in 
healthy human volunteers. Journal of Controlled Release 55(2-3) (1998) 245-252. 
[181] Y.S.R. Krishnaiah, S. Satyanarayana, Y.V. Rama Prasad, Studies of guar gum 
compression-coated 5-aminosalicylic acid tablets for colon-specific drug delivery. 
Drug Development and Industrial Pharmacy 25(5) (1999) 651-657. 
[182] Y.V.R. Prasad, Y.S.R. Krishnaiah, S. Satyanarayana, In vitro evaluation of 
guar gum as a carder for colon-specific drug delivery. Journal of Controlled Release 
51(2-3) (1998) 281-287. 
[183] Y.S.R. Krishnaiah, V. Satyanarayana, B. Dinesh Kumar, R.S. Karthikeyan, In 
vitro drug release studies on guar gum-based colon targeted oral drug delivery 
systems of 5-fluorouracil. European Journal of Pharmaceutical Sciences 16(3) (2002) 
185-192. 
[184] Y.S.R. Krishnaiah, V. Satyanarayana, B.D. Kumar, R.S. Karthikeyan, P. 
Bhaskar, In vivo pharmacokinetics in human volunteers: Oral administered guar gum-
based colon-targeted 5-fluorouracil tablets. European Journal of Pharmaceutical 
Sciences 19(5) (2003) 355-362. 
[185] Y.S.R. Krishnaiah, P. Veer Raju, B. Dinesh Kumar, V. Satyanarayana, R.S. 
Karthikeyan, P. Bhaskar, Pharmacokinetic evaluation of guar gum-based colon-
targeted drug delivery systems of mebendazole in healthy volunteers. Journal of 
Controlled Release 88(1) (2003) 95-103. 
[186] D. Wong, S. Larrabee, K. Clifford, J. Tremblay, D.R. Friend, USP dissolution 
apparatus III (reciprocating cylinder) for screening of guar-based colonic delivery 
formulations. Journal of Controlled Release 47(2) (1997) 173-179. 
[187] S. Milojevic, J.M. Newton, J.H. Cummings, G.R. Gibson, R. Louise Botham, 
S.G. Ring, M. Stockham, M.C. Allwood, Amylose as a coating for drug delivery to 
the colon: Preparation and in vitro evaluation using 5-aminosalicylic acid pellets. 
Journal of Controlled Release 38(1) (1996) 75-84. 
[188] S. Milojevic, J.M. Newton, J.H. Cummings, G.R. Gibson, R.L. Botham, S.G. 
Ring, M. Stockham, M.C. Allwood, Amylose as a coating for drug delivery to the 
colon: Preparation and in vitro evaluation using glucose pellets. Journal of Controlled 
Release 38(1) (1996) 85-94. 
[189] J.H. Cummings, S. Milojevic, M. Harding, W.A. Coward, G.R. Gibson, R.L. 
Botham, S.G. Ring, E.P. Wraight, M.A. Stockham, M.C. Allwood, J.M. Newton, In 
vivo studies of amylose-and ethylcellulose-coated [13C]glucose microspheres as a 
model for drug delivery to the colon. Journal of Controlled Release 40(1-2) (1996) 
123-131. 
[190] L.F. Siew, A.W. Basit, J.M. Newton, The potential of organic-based amylose-
ethylcellulose film coatings as oral colon-specific drug delivery systems. AAPS 
PharmSciTech 1(3) (2000). 
[191] L.F. Siew, A.W. Basit, J.M. Newton, The properties of amylose-ethylcellulose 
films cast from organic-based solvents as potential coatings for colonic drug delivery. 
European Journal of Pharmaceutical Sciences 11(2) (2000) 133-139. 
[192] A. Rubinstein, D. Nakar, A. Sintov, Colonic drug delivery: Enhanced release 
of indomethacin from cross-linked chondroitin matrix in rat cecal content. 
Pharmaceutical Research 9(2) (1992) 276-278. 
[193] S.Y. Lin, J.W. Ayres, Calcium alginate beads as core carriers of 5-
aminosalicylic acid. Pharmaceutical Research 9(9) (1992) 1128-1131. 
224 
 
[194] L. Vervoort, P. Rombaut, G. Van Den Mooter, P. Augustijns, R. Kinget, 
Inulin hydrogels. II. In vitro degradation study. International Journal of Pharmaceutics 
172(1-2) (1998) 137-145. 
[195] H. Brondsted, L. Hovgaard, L. Simonsen, Dextran hydrogels for colon-
specific drug delivery. III. In vitro and in vivo degradation. S.T.P. Pharma Sciences 
5(1) (1995) 60-64. 
[196] L. Simonsen, L. Hovgaard, P.B. Mortensen, H. Brondsted, Dextran hydrogels 
for colon-specific drug delivery. V. Degradation in human intestinal incubation 
models. European Journal of Pharmaceutical Sciences 3(6) (1995) 329-337. 
[197] H.C. Chiu, G.H. Hsiue, Y.P. Lee, L.W. Huang, Synthesis and characterization 
of pH-sensitive dextran hydrogels as a potential colon-specific drug delivery system. 
Journal of Biomaterials Science, Polymer Edition 10(5) (1999) 591-608. 
[198] O. Chambin, G. Dupuis, D. Champion, A. Voilley, Y. Pourcelot, Colon-
specific drug delivery: Influence of solution reticulation properties upon pectin beads 
performance. Int J Pharm 321(1-2) (2006) 86-93. 
[199] I. El-Gibaly, Oral delayed-release system based on Zn-pectinate gel (ZPG) 
microparticles as an alternative carrier to calcium pectinate beads for colonic drug 
delivery. Int J Pharm 232(1-2) (2002) 199-211. 
[200] M. Ashford, J. Fell, D. Attwood, H. Sharma, P. Woodhead, An evaluation of 
pectin as a carrier for drug targeting to the colon. Journal of Controlled Release 26(3) 
(1993) 213-220. 
[201] P. Sriamornsak, J. Nunthanid, Calcium pectinate gel beads for controlled 
release drug delivery: I. Preparation and in vitro release studies. International Journal 
of Pharmaceutics 160(2) (1998) 207-212. 
[202] G.T. Grant, E.R. Morris, D.A. Rees, Biological interactions between 
polysaccharides and divalent cations: The egg box model. FEBS Letters 32(1) (1973) 
195-198. 
[203] L. Miller, J.D. Macmillan, Mode of action of pectic enzymes. II. Further 
purification of exopolygalacturonate lyase and pectinesterase from Clostridium 
multifermentans. Journal of Bacteriology 102(1) (1970) 72-78. 
[204] P. Sriamornsak, J. Nunthanid, Calcium pectinate gel beads for controlled 
release drug delivery: II. Effect of formulation and processing variables on drug 
release. J Microencapsul 16(3) (1999) 303-313. 
[205] P. Sriamornsak, Effect of calcium concentration, hardening agent and drying 
condition on release characteristics of oral proteins from calcium pectinate gel beads. 
Eur J Pharm Sci 8(3) (1999) 221-227. 
[206] F. Maestrelli, N. Zerrouk, M. Cirri, N. Mennini, P. Mura, Microspheres for 
colonic delivery of ketoprofen-hydroxypropyl-beta-cyclodextrin complex. Eur J 
Pharm Sci 34(1) (2008) 1-11. 
[207] F. Maestrelli, M. Cirri, G. Corti, N. Mennini, P. Mura, Development of 
enteric-coated calcium pectinate microspheres intended for colonic drug delivery. Eur 
J Pharm Biopharm 69(2) (2008) 508-518. 
[208] P. Sriamornsak, Investigation of pectin as a carrier for oral delivery of proteins 
using calcium pectinate gel beads. International Journal of Pharmaceutics 169(2) 
(1998) 213-220. 
[209] F. Atyabi, K. Inanloo, R. Dinarvand, Bovine serum albumin-loaded pectinate 
beads as colonic peptide delivery system: preparation and in vitro characterization. 
Drug Deliv 12(6) (2005) 367-375. 
225 
 
[210] O. Munjeri, P. Hodza, E.E. Osim, C.T. Musabayane, An investigation into the 
suitability of amidated pectin hydrogel beads as a delivery matrix for chloroquine. 
Journal of Pharmaceutical Sciences 87(8) (1998) 905-908. 
[211] P. Sriamornsak, S. Puttipipatkhachorn, S. Prakongpan, Calcium pectinate gel 
coated pellets as an alternative carrier to calcium pectinate beads. International 
Journal of Pharmaceutics 156(2) (1997) 189-194. 
[212] S. Bourgeois, M. Gernet, D. Pradeau, A. Andremont, E. Fattal, Evaluation of 
critical formulation parameters influencing the bioactivity of beta-lactamases 
entrapped in pectin beads. Int J Pharm 324(1) (2006) 2-9. 
[213] Z. Aydin, J. Akbuga, Preparation and evaluation of pectin beads. International 
Journal of Pharmaceutics 137(1) (1996) 133-136. 
[214] C.T. Musabayane, O. Munjeri, P. Bwititi, E.E. Osim, Orally administered, 
insulin-loaded amidated pectin hydrogel beads sustain plasma concentrations of 
insulin in streptozotocin-diabetic rats. Journal of Endocrinology 164(1) (2000) 1-6. 
[215] Y. Murata, M. Miyashita, K. Kofuji, E. Miyamoto, S. Kawashima, Drug 
release properties of a gel bead prepared with pectin and hydrolysate. J Control 
Release 95(1) (2004) 61-66. 
[216] I. El-Gibaly, Oral delayed-release system based on Zn-pectinate gel (ZPG) 
microparticles as an alternative carrier to calcium pectinate beads for colonic drug 
delivery. International Journal of Pharmaceutics 232(1-2) (2002) 199-211. 
[217] G. Dupuis, O. Chambin, C. Ge?nelot, D. Champion, Y. Pourcelot, Colonic 
drug delivery: Influence of cross-linking agent on pectin beads properties and role of 
the shell capsule type. Drug Development and Industrial Pharmacy 32(7) (2006) 847-
855. 
[218] K.L.B. Chang, J. Lin, Swelling behavior and the release of protein from 
chitosan-pectin composite particles. Carbohydrate Polymers 43(2) (2000) 163-169. 
[219] S. Bourgeois, A. Laham, M. Besnard, A. Andremont, E. Fattal, In vitro and in 
vivo evaluation of pectin beads for the colon delivery of Î²-lactamases. Journal of 
Drug Targeting 13(5) (2005) 277-284. 
[220] S. Bourgeois, N. Tsapis, H. Honnas, A. Andremont, M. Shakweh, M. Besnard, 
E. Fattal, Colonic delivery of beta-lactamases does not affect amoxicillin 
pharmacokinetics in rats. J Pharm Sci 97(5) (2008) 1853-1863. 
[221] O. Munjeri, J.H. Collett, J.T. Fell, Amidated pectin hydrogel beads for colonic 
drug delivery - An in vitro study. Drug Delivery 4(3) (1997) 207-211. 
[222] P. Sriamornsak, S. Puttipipatkhachorn, Chitosan-pectin composite gel spheres: 
Effect of some formulation variables on drug release. Macromolecular Symposia, Vol. 
216, 2004, pp. 17-21. 
[223] T.H. Kim, Y.H. Park, K.J. Kim, C.S. Cho, Release of albumin from chitosan-
coated pectin beads in vitro. International Journal of Pharmaceutics 250(2) (2003) 
371-383. 
[224] T.W. Wong, S. Nurjaya, Drug release property of chitosan-pectinate beads and 
its changes under the influence of microwave. Eur J Pharm Biopharm 69(1) (2008) 
176-188. 
[225] S. Nurjaya, T.W. Wong, Effects of microwave on drug release properties of 
matrices of pectin. Carbohydrate Polymers 62(3) (2005) 245-257. 
[226] N. Mennini, S. Furlanetto, F. Maestrelli, S. Pinzauti, P. Mura, Response 
surface methodology in the optimization of chitosan-Ca pectinate bead formulations. 
European Journal of Pharmaceutical Sciences 35(4) (2008) 318-325. 
226 
 
[227] Y. Murata, M. Miyashita, M. Kato, K. Kofuji, S. Kawashima, Properties of 
pectin gel bead modified with pectin hydrolysate and chitosan. Advances in Polymer 
Technology 24(1) (2005) 46-50. 
[228] A. Jain, Y. Gupta, S.K. Jain, Potential of calcium pectinate beads for target 
specific drug release to colon. Journal of Drug Targeting 15(4) (2007) 285-294. 
[229] F. Atyabi, S. Majzoob, M. Iman, M. Salehi, F. Dorkoosh, In vitro evaluation 
and modification of pectinate gel beads containing trimethyl chitosan, as a multi-
particulate system for delivery of water-soluble macromolecules to colon. 
Carbohydrate Polymers 61(1) (2005) 39-51. 
[230] V. Pillay, R. Fassihi, In vitro release modulation from crosslinked pellets for 
site-specific drug delivery to the gastrointestinal tract. I. Comparison of pH-
responsive drug release and associated kinetics. J Control Release 59(2) (1999) 229-
242. 
[231] V. Pillay, R. Fassihi, In vitro release modulation from crosslinked pellets for 
site-specific drug delivery to the gastrointestinal tract. II. Physicochemical 
characterization of calcium-alginate, calcium-pectinate and calcium-alginate-pectinate 
pellets. Journal of Controlled Release 59(2) (1999) 243-256. 
[232] L. Liu, M.L. Fishman, K.B. Hicks, M. Kende, G. Ruthel, Pectin/zein beads for 
potential colon-specific drug delivery: Synthesis and in vitro evaluation. Drug 
Delivery 13(6) (2006) 417-423. 
[233] C.M. Lee, D.W. Kim, H.C. Lee, K.Y. Lee, Pectin microspheres for oral colon 
delivery: Preparation using spray drying method and in vitro release of indomethacin. 
Biotechnology and Bioprocess Engineering 9(3) (2004) 191-195. 
[234] M. Chavanpatil, B. Mishra, Studies on pectin as a potential carrier in colonic 
drug delivery. Acta Pharmaceutica Turcica 45(2) (2003) 103-110. 
[235] K. Cheng, L.Y. Lim, Insulin-loaded calcium pectinate nanoparticles: Effects 
of pectin molecular weight and formulation pH. Drug Development and Industrial 
Pharmacy 30(4) (2004) 359-367. 
[236] H. Kim, G. Venkatesh, R. Fassihi, Compactibility characterization of granular 
pectin for tableting operation using a compaction simulator. International Journal of 
Pharmaceutics 161(2) (1998) 149-159. 
[237] P. Mura, F. Maestrelli, M. Cirri, M.L. González Rodríguez, A.M. Rabasco 
Alvarez, Development of enteric-coated pectin-based matrix tablets for colonic 
delivery of theophylline. Journal of Drug Targeting 11(6) (2003) 365-371. 
[238] J. Fell, Studies on pectin formulations for colonic drug delivery. Journal of 
Controlled Release 30(3) (1994) 225-232. 
[239] E.R. Morris, D.A. Powell, M.J. Gidley, D.A. Rees, Conformations and 
interactions of pectins. I. Polymorphism between gel and solid states of calcium 
polygalacturonate. Journal of Molecular Biology 155(4) (1982) 507-516. 
[240] E. Racape, J.F. Thibault, J.C.E. Reitsma, W. Pilnik, Properties of amidated 
pectin II. Polyelectrolyte behavior and calcium binding of amidated pectins and 
amidated pectic acids. Biopolymers 28 (1989) 1435-1448. 
[241] R. Semde, A.J. Moe?s, M.J. Devleeschouwer, K. Amighi, In vitro evaluation 
of epichlorohydrin cross-linked pectins as colon-specific drug delivery carriers. S.T.P. 
Pharma Sciences 12(5) (2002) 293-298. 
[242] R. Semde, A.J. Moe?s, M.J. Devleeschouwer, K. Amighi, Synthesis and 
enzymatic degradation of epichlorohydrin cross-linked pectins. Drug Development 
and Industrial Pharmacy 29(2) (2003) 203-213. 
227 
 
[243] M. Turkoglu, S. Takka, H. Baran, A. Sakr, Pectin-
hydroxyprophylmethylcellulose drug delivery system for colon targeting: Design and 
in vitro evaluation. Pharmazeutische Industrie 61(7) (1999) 662-665. 
[244] S.F. Ahrabi, J. Heina?ma?ki, S.A. Sande, C. Graffner, Influence of neutron 
activation factors on matrix tablets for site specific delivery to the colon. European 
Journal of Pharmaceutical Sciences 10(3) (2000) 225-235. 
[245] P. Sriamornsak, S. Prakongpan, S. Puttipipatkhachorn, R.A. Kennedy, 
Development of sustained release theophylline pellets coated with calcium pectinate. 
Journal of Controlled Release 47(3) (1997) 221-232. 
[246] G.S. MacLeod, J.T. Fell, J.H. Collett, Studies on the physical properties of 
mixed pectin/ethylcellulose films intended for colonic drug delivery. International 
Journal of Pharmaceutics 157(1) (1997) 53-60. 
[247] Z. Wakerly, J.T. Fell, D. Attwood, D. Parkins, Studies on drug release from 
pectin/ethylcellulose film-coated tablets: a potential colonic delivery system. 
International Journal of Pharmaceutics 153(2) (1997) 219-224. 
[248] R. Semde, K. Amighi, M.J. Devleeschouwer, A.J. Moe?s, In vitro evaluation 
of pectin HM/ethylcellulose compression-coated formulations intended for colonic 
drug delivery. S.T.P. Pharma Sciences 9(6) (1999) 561-565. 
[249] H. Kim, R. Fassihi, Application of a binary polymer system in drug release 
rate modulation. 1. Characterization of release mechanism. Journal of Pharmaceutical 
Sciences 86(3) (1997) 316-322. 
[250] H. Kim, R. Fassihi, Application of binary polymer system in drug release rate 
modulation. 2. Influence of formulation variables and hydrodynamic conditions on 
release kinetics. Journal of Pharmaceutical Sciences 86(3) (1997) 323-328. 
[251] M. Turkoglu, T. Ugurlu, In vitro evaluation of pectin-HPMC compression 
coated 5-aminosalicylic acid tablets for colonic delivery. European Journal of 
Pharmaceutics and Biopharmaceutics 53(1) (2002) 65-73. 
[252] K. Ofori-Kwakye, J.T. Fell, Biphasic drug release: The permeability of films 
containing pectin, chitosan and HPMC. International Journal of Pharmaceutics 226(1-
2) (2001) 139-145. 
[253] P. Sriamornsak, J. Nunthanid, S. Wanchana, M. Luangtana-Anan, Composite 
film-coated tablets intended for colon-specific delivery of 5-aminosalicylic acid: 
Using deesterified pectin. Pharmaceutical Development and Technology 8(3) (2003) 
311-318. 
[254] M.M. Meshali, K.E. Gabr, Effect of interpolymer complex formation of 
chitosan with pectin or acacia on the release behavior of chlorpromazine HCl. Int. J. 
Pharm. 89 (1993) 36. 
[255] A. Kramar, S. Turk, F. VrecÌŒer, Statistical optimisation of diclofenac 
sustained release pellets coated with polymethacrylic films. International Journal of 
Pharmaceutics 256(1-2) (2003) 43-52. 
[256] J.G. Hardy, C.G. Wilson, E. Wood, Drug delivery to the proximal colon. 
Journal of Pharmacy and Pharmacology 37(12) (1985) 874-877. 
[257] Y. Zambito, A. Baggiani, V. Carelli, M.F. Serafini, G. Di Colo, Matrices for 
site-specific controlled-delivery of 5-fluorouracil to descending colon. Journal of 
Controlled Release 102(3) (2005) 669-677. 
[258] H. Zhang, I.A. Alsarra, S.H. Neau, An in vitro evaluation of a chitosan-
containing multiparticulate system for macromolecule delivery to the colon. 
International Journal of Pharmaceutics 239(1-2) (2002) 197-205. 
228 
 
[259] V.K. Gupta, T.E. Beckert, J.C. Price, A novel pH- and time-based multi-unit 
potential colonic drug delivery system. I. Development. International Journal of 
Pharmaceutics 213(1-2) (2001) 83-91. 
[260] A. Akhgari, H.A. Garekani, F. Sadeghi, M. Azimaie, Statistical optimization 
of indomethacin pellets coated with pH-dependent methacrylic polymers for possible 
colonic drug delivery. International Journal of Pharmaceutics 305(1-2) (2005) 22-30. 
[261] L.F. Ali Asghar, S. Chandran, Multiparticulate formulation approach to colon 
specific drug delivery: Current perspectives. Journal of Pharmacy and Pharmaceutical 
Sciences 9(3) (2006) 327-338. 
[262] M. Rodriguez, J.L. Vila-Jato, D. Torres, Design of a new multiparticulate 
system for potential site-specific and controlled drug delivery to the colonic region. J 
Control Release 55(1) (1998) 67-77. 
[263] P.J. Watts, L. Barrow, K.P. Steed, C.G. Wilson, R.C. Spiller, C.D. Melia, M.C. 
Davies, The transit rate of different-sized model dosage forms through the human 
colon and the effects of a lactulose-induced catharis. International Journal of 
Pharmaceutics 87(1-3) (1992) 215-221. 
[264] A. Lamprecht, U. SchaÌˆfer, C.M. Lehr, Size-dependent bioadhesion of micro- 
and nanoparticulate carriers to the inflamed colonic mucosa. Pharmaceutical Research 
18(6) (2001) 788-793. 
[265] A. Zhao, C. Bossone, V. PinÌƒeiro-Carrero, T. Shea-Donohue, Biodegradable 
nanoparticles for targeted drug delivery in treatment of inflammatory bowel disease. 
Journal of Pharmacology and Experimental Therapeutics 299(2) (2001) 775-781. 
[266] A. Lamprecht, H. Yamamoto, H. Takeuchi, Y. Kawashima, A pH-sensitive 
microsphere system for the colon delivery of tacrolimus containing nanoparticles. 
Journal of Controlled Release 104(2) (2005) 337-346. 
[267] A. Lamprecht, Multiparticulate systems in the treatment of inflammatory 
bowel disease. Current drug targets. Inflammation and allergy 2(2) (2003) 137-144. 
[268] B. Abrahamsson, M. Alpsten, U.E. Jonsson, P.J. Lundberg, A. Sandberg, M. 
Sundgren, A. Svenheden, J. TÃ¶lli, Gastro-intestinal transit of a multiple-unit 
formulation (metoprolol CR/ZOK) and a non-disintegrating tablet with the emphasis 
on colon. International Journal of Pharmaceutics 140(2) (1996) 229-235. 
[269] V. Pillay, R. Fassihi, Unconventional dissolution methodologies. J Pharm Sci 
88(9) (1999) 843-851. 
[270] M. Siewert, J. Dressman, C.K. Brown, V.P. Shah, FIP/AAPS guidelines to 
dissolution/in vitro release testing of novel/special dosage forms. AAPS 
PharmSciTech 4(1) (2003) E7. 
[271] J.G. Fang, M. Lu, Z.H. Chen, H.H. Zhu, Y. Li, L. Yang, L.M. Wu, Z.L. Liu, 
Antioxidant effects of resveratrol and its analogues against the free-radical-induced 
peroxidation of linoleic acid in micelles. Chemistry 8(18) (2002) 4191-4198. 
[272] J. Li, L. Yang, S.M. Ferguson, T.J. Hudson, S. Watanabe, M. Katsuma, J.A. 
Fix, In vitro evaluation of dissolution behavior for a colon-specific drug delivery 
system (CODES) in multi-pH media using United States Pharmacopeia apparatus II 
and III. AAPS PharmSciTech 3(4) (2002) E33. 
[273] E.L. McConnell, J. Tutas, M.A.M. Mohamed, D. Banning, A.W. Basit, 
Colonic drug delivery using amylose films: The role of aqueous ethylcellulose 
dispersions in controlling drug release. Cellulose 14(1) (2007) 25-34. 
[274] C.W. Leong, J.M. Newton, A.W. Basit, F. Podczeck, J.H. Cummings, S.G. 
Ring, The formation of colonic digestible films of amylose and ethylcellulose from 
aqueous dispersions at temperatures below 37Â°C. European Journal of 
Pharmaceutics and Biopharmaceutics 54(3) (2002) 291-297. 
229 
 
[275] J. Li, L. Yang, S.M. Ferguson, T.J. Hudson, S. Watanabe, M. Katsuma, J.A. 
Fix, In vitro evaluation of dissolution behavior for a colon-specific drug delivery 
system (CODES?) in multi-pH media using United States Pharmacopeia apparatus II 
and III. AAPS PharmSciTech 3(4) (2002). 
[276] L. Yang, S. Watanabe, J. Li, J.S. Chu, M. Katsuma, S. Yokohama, J.A. Fix, 
Effect of colonic lactulose availability on the timing of drug release onset in vivo 
from a unique colon-specific drug delivery system (CODES?). Pharmaceutical 
Research 20(3) (2003) 429-434. 
[277] G. Hawksworth, B.S. Drasar, M.J. Hill, Intestinal bacteria and the hydrolysis 
of glycosidic bonds. J Med Microbiol 4(4) (1971) 451-459. 
[278] C.V. Raghavan, C. Muthulingam, J.A.J.L. Jenita, T.K. Ravi, An in Vitro and 
in Vivo investigation into the suitability of bacterially triggered delivery system for 
colon targeting. Chemical and Pharmaceutical Bulletin 50(7) (2002) 892-895. 
[279] G. Van Den Mooter, C. Samyn, R. Kinget, The relation between swelling 
properties and enzymatic degradation of azo polymers designed for colon-specific 
drug delivery. Pharmaceutical Research 11(12) (1994) 1737-1741. 
[280] L.B. Yang, S. Watanabe, Y. Shi, F. Liu, J.S. Chu, L. J., R. Gu, J.A. Fix, Design and 
in vitro/in vivo evaluation of a novel colon-specific drug delivery system (CODES™). AAPS 
Annual Meeting poster presentation (W4091), Denver, CO., 2001. 
[281] C.J. Seal, J.C. Mathers, Comparative gastrointestinal and plasma cholesterol 
responses of rats fed on cholesterol-free diets supplemented with guar gum and 
sodium alginate. Br J Nutr 85(3) (2001) 317-324. 
[282] Z. Zdunczyk, J. Juskiewicz, M. Wroblewska, B. Krol, Physiological effects of 
lactulose and inulin in the caecum of rats. Arch Anim Nutr 58(1) (2004) 89-98. 
[283] L.F. Siew, S.M. Man, J.M. Newton, A.W. Basit, Amylose formulations for 
drug delivery to the colon: A comparison of two fermentation models to assess 
colonic targeting performance in vitro. International Journal of Pharmaceutics 273(1-2) 
(2004) 129-134. 
[284] P.J. Wilson, A.W. Basit, Exploiting gastrointestinal bacteria to target drugs to 
the colon: An in vitro study using amylose coated tablets. International Journal of 
Pharmaceutics 300(1-2) (2005) 89-94. 
[285] G.R. Gibson, J.H. Cummings, G.T. Macfarlane, Use of a three-stage 
continuous culture system to study the effect of mucin on dissimilatory sulfate 
reduction and methanogenesis by mixed populations of human gut bacteria. Applied 
and Environmental Microbiology 54(11) (1988) 2750-2755. 
[286] G.T. Macfarlane, S. Macfarlane, G.R. Gibson, Validation of a three-stage 
compound continuous culture system for investigating the effect of retention time on 
the ecology and metabolism of bacteria in the human colon. Microbial Ecology 35(2) 
(1998) 180-187. 
[287] K. Molly, M. Vande Woestyne, W. Verstraete, Development of a 5-step multi-
chamber reactor as a simulation of the human intestinal microbial ecosystem. Applied 
Microbiology and Biotechnology 39(2) (1993) 254-258. 
[288] K. Ofori-Kwakye, J.T. Fell, H.L. Sharma, A.M. Smith, Gamma scintigraphic 
evaluation of film-coated tablets intended for colonic or biphasic release. International 
Journal of Pharmaceutics 270(1-2) (2004) 307-313. 
[289] S.S. Davis, J.G. Hardy, S.P. Newman, I.R. Wilding, Gamma scintigraphy in 
the evaluation of pharmaceutical dosage forms. European Journal of Nuclear 
Medicine 19(11) (1992) 971-986. 
[290] J.D.R. Schulze, W.A. Waddington, P.J. Ell, G.E. Parsons, M.D. Coffin, A.W. 
Basit, Concentration-Dependent Effects of Polyethylene Glycol 400 on 
230 
 
Gastrointestinal Transit and Drug Absorption. Pharmaceutical Research 20(12) (2003) 
1984-1988. 
[291] ClinicalTrial.gov, A service of the U.S. National Institutes of 
Health. http://www.clinicaltrial.gov/ct2/results?term=resveratrol. (5297). 
[292] M.E. Davis, M.E. Brewster, Cyclodextrin-based pharmaceutics: past, present 
and future. Nat Rev Drug Discov 3(12) (2004) 1023-1035. 
[293] R.A. Rajewski, V.J. Stella, Pharmaceutical applications of cyclodextrins. 2. In 
vivo drug delivery. J Pharm Sci 85(11) (1996) 1142-1169. 
[294] D. Duchêne, D. Wouessidjewe, G. Ponchel, Cyclodextrins and carrier systems. 
Journal of Controlled Release 62(1-2) (1999) 263-268. 
[295] D.W. Frank, J.E. Gray, R.N. Weaver, Cyclodextrin nephrosis in the rat. Am J 
Pathol 83(2) (1976) 367-382. 
[296] V.J. Stella, R.A. Rajewski, Cyclodextrins: their future in drug formulation and 
delivery. Pharmaceutical research 14(5) (1997) 556-567. 
[297] V. Bertacche, N. Lorenzi, D. Nava, E. Pini, C. Sinico, Host–Guest Interaction 
Study of Resveratrol with Natural and Modified Cyclodextrins. Journal of Inclusion 
Phenomena and Macrocyclic Chemistry 55 (2006) 279–287. 
[298] H.S. Lin, C.S. Chean, Y.Y. Ng, S.Y. Chan, P.C. Ho, 2-hydroxypropyl-beta-
cyclodextrin increases aqueous solubility and photostability of all-trans-retinoic acid. 
J Clin Pharm Ther 25(4) (2000) 265-269. 
[299] T. Higuchi, K.A. Connors, Phase-solubility techniques. Advan Anal Chem 
Instr 4 (1965) 117-212. . 
[300] N. Erden, N. Celebi, A study of the inclusion complex of naproxen with Î²-
cyclodextrin. International journal of pharmaceutics 48(1-3) (1988) 83-89. 
[301] P. Mura, G. Bettinetti, F. Melani, A. Manderioli, Interaction between naproxen 
and chemically modified Î²-cyclodextrins in the liquid and solid state. European 
Journal of Pharmaceutical Sciences 3(6) (1995) 347-355. 
[302] C.F. Hung, Y.K. Lin, Z.R. Huang, J.Y. Fang, Delivery of Resveratrol, a Red 
Wine Polyphenol, from Solutions and Hydrogels via the Skin. Biological & 
pharmaceutical bulletin 31(5) (2008) 955-962. 
[303] K. Uekama, M. Otagiri, Cyclodextrins in drug carrier systems. Critical 
reviews in therapeutic drug carrier systems 3(1) (1987) 1-40. 
[304] M.L. Calabrò, V. Galtieri, P. Cutroneo, S. Tommasini, P. Ficarra, R. Ficarra, 
Study of the extraction procedure by experimental design and validation of a LC 
method for determination of flavonoids in Citrus bergamia juice. Journal of 
Pharmaceutical and Biomedical Analysis 35(2) (2004) 349-363. 
[305] P. Mura, F. Maestrelli, M. Cirri, S. Furlanetto, S. Pinzauti, Differential 
scanning calorimetry as an analytical tool in the study of drug-cyclodextrin 
interactions. Journal of Thermal Analysis and Calorimetry 73(2) (2003) 635-646. 
[306] G. Dollo, P. Le Corre, F. Chevanne, R. Le Verge, Inclusion complexation of 
amide-typed local anaesthetics with [beta]-cyclodextrin and its derivatives. I. 
Physicochemical characterization. International Journal of Pharmaceutics 131(2) 
(1996) 219-228. 
[307] K. Uekama, A. Fujise, F. Hirayama, Improvement of dissolution 
characteristics and chemical stability of prostaglandin E1 by Î³-cyclodextrin 
complexation. Chemical and Pharmaceutical Bulletin 32(1) (1984) 275-279. 
[308] D.M. Goldberg, A. Karumanchiri, E. Ng, J. Yan, E.P. Diamandis, G.J. Soleas, 
Direct Gas Chromatographic-Mass Spectrometric Method To Assay cis-Resveratrol in 
Wines: Preliminary Survey of Its Concentration in Commercial Wines. Journal of 
Agricultural and Food Chemistry 43(5) (1995) 1245-1250. 
231 
 
[309] Q. Chu, M. O'Dwye, M.G. Zeece, Direct Analysis of Resveratrol in Wine by 
Micellar Electrokinetic Capillary Electrophoresis. Journal of Agricultural and Food 
Chemistry 46(2) (1998) 509-513. 
[310] D.M. Goldberg, E. Tsang, A. Karumanchiri, E.P. Diamandis, G. Soleas, E. Ng, 
Method To Assay the Concentrations of Phenolic Constituents of Biological Interest 
in Wines. Analytical Chemistry 68(10) (1996) 1688-1694. 
[311] K.D. McMurtrey, J. Minn, K. Pobanz, T.P. Schultz, Analysis of wines for 
resveratrol using direct injection high-pressure liquid chromatography with 
electrochemical detection. Journal of Agricultural and Food Chemistry 42(10) (1994) 
2077-2080. 
[312] X. Chen, H. He, G. Wang, B. Yang, W. Ren, L. Ma, Q. Yu, Stereospecific 
determination of cis- and trans-resveratrol in rat plasma by HPLC: Application to 
pharmacokinetic studies. Biomedical Chromatography 21(3) (2007) 257-265. 
[313] H. He, X. Chen, G. Wang, J. Wang, A.K. Davey, High-performance liquid 
chromatography spectrometric analysis of trans-resveratrol in rat plasma. Journal of 
Chromatography B: Analytical Technologies in the Biomedical and Life Sciences 
832(2) (2006) 177-180. 
[314] M.E. Juan, R.M. Lamuela-RaventoÌs, M.C. De La Torre-Boronat, J.M. 
Planas, Determination of trans-resveratrol in plasma by HPLC. Analytical Chemistry 
71(3) (1999) 747-750. 
[315] A. Katsagonis, J. Atta-Politou, M.A. Koupparis, HPLC method with UV 
detection for the determination of trans-resveratrol in plasma. Journal of Liquid 
Chromatography and Related Technologies 28(9) (2005) 1393-1405. 
[316] Z. Zhu, G. Klironomos, A. Vachereau, L. Neirinck, D.W. Goodman, 
Determination of trans-resveratrol in human plasma by high-performance liquid 
chromatography. Journal of Chromatography B: Biomedical Sciences and 
Applications 724(2) (1999) 389-392. 
[317] A.A.E. Bertelli, L. Giovannini, R. Stradi, A. Bertelli, J.P. Tillement, Plasma, 
urine and tissue levels of trans- and cis-resveratrol (3,4â€²,5-trihydroxystilbene) after 
short-term or prolonged administration of red wine to rats. International Journal of 
Tissue Reactions 18(2-3) (1996) 67-71. 
[318] A.A.E. Bertelli, L. Giovannini, R. Stradi, S. Urien, J.P. Tillement, A. Bertelli, 
Kinetics of trans- and cis-resveratrol (3, 4â€², 5-trihydroxystilbene) after red wine oral 
administration in rats. International Journal of Clinical Pharmacology Research 16(4-
5) (1996) 77-81. 
[319] D. Blache, I. Rustan, P. Durand, G. Lesgards, N. Loreau, Gas 
chromatographic analysis of resveratrol in plasma, lipoproteins and cells after in vitro 
incubations. Journal of Chromatography B: Biomedical Sciences and Applications 
702(1-2) (1997) 103-110. 
[320] A. Katsagonis, J. Atta-Politou, M.A. Koupparis, HPLC Nethod with UV 
Detection for the Determination of trans-Resveratrol in Plasma. Journal of Liqiud 
Chromatography & Related Technologies 28 (2005) 1393-1405. 
[321] D.J. Boocock, K.R. Patel, G.E.S. Faust, D.P. Normolle, T.H. Marczylo, J.A. 
Crowell, D.E. Brenner, T.D. Booth, A. Gescher, W.P. Steward, Quantitation of trans-
resveratrol and detection of its metabolites in human plasma and urine by high 
performance liquid chromatography. Journal of Chromatography B: Analytical 
Technologies in the Biomedical and Life Sciences 848(2) (2007) 182-187. 
[322] D. Delmas, A. Lancon, D. Colin, B. Jannin, N. Latruffe, Resveratrol as a 
chemopreventive agent: a promising molecule for fighting cancer. Curr Drug Targets 
7(4) (2006) 423-442. 
232 
 
[323] D.J. Boocock, G.E. Faust, K.R. Patel, A.M. Schinas, V.A. Brown, M.P. 
Ducharme, T.D. Booth, J.A. Crowell, M. Perloff, A.J. Gescher, W.P. Steward, D.E. 
Brenner, Phase I dose escalation pharmacokinetic study in healthy volunteers of 
resveratrol, a potential cancer chemopreventive agent. Cancer Epidemiol Biomarkers 
Prev 16(6) (2007) 1246-1252. 
[324] S. Hurst, C.M. Loi, J. Brodfuehrer, A. El-Kattan, Impact of physiological, 
physicochemical and biopharmaceutical factors in absorption and metabolism 
mechanisms on the drug oral bioavailability of rats and humans. Expert opinion on 
drug metabolism & toxicology 3(4) (2007) 469-489. 
[325] O.H. Chan, B.H. Stewart, Physicochemical and drug-delivery considerations 
for oral drug bioavailability. Drug discovery today 1(11) (1996) 461-473. 
[326] A. Maier-Salamon, B. Hagenauer, M. Wirth, F. Gabor, T. Szekeres, W. Jager, 
Increased transport of resveratrol across monolayers of the human intestinal Caco-2 
cells is mediated by inhibition and saturation of metabolites. Pharmaceutical research 
23(9) (2006) 2107-2115. 
[327] H.S. Lin, S.Y. Chan, K.S. Low, M.L. Shoon, P.C. Ho, Kinetic study of a 2-
hydroxypropyl-beta-cyclodextrin-based formulation of all-trans-retinoic acid in 
Sprague-Dawley rats after oral or intravenous administration. J Pharm Sci 89(2) (2000) 
260-267. 
[328] H.S. Lin, W.W. Leong, J.A. Yang, P. Lee, S.Y. Chan, P.C. Ho, 
Biopharmaceutics of 13-cis-retinoic acid (isotretinoin) formulated with modified beta-
cyclodextrins. Int J Pharm (2007). 
[329] H.S. Lin, A.B. Barua, J.A. Olson, K.S. Low, S.Y. Chan, M.L. Shoon, P.C. Ho, 
Pharmacokinetic study of all-trans-retinoyl-beta-D-glucuronide in Sprague-Dawley 
rats after single and multiple intravenous administration(s). Journal of pharmaceutical 
sciences 90(12) (2001) 2023-2031. 
[330] H.S. Lin, W.W. Leong, J.A. Yang, P. Lee, S.Y. Chan, P.C. Ho, 
Biopharmaceutics of 13-cis-retinoic acid (isotretinoin) formulated with modified beta-
cyclodextrins. International journal of pharmaceutics 341(1-2) (2007) 238-245. 
[331] G. Piel, B. Evrard, T. Van Hees, L. Delattre, Comparison of the IV 
pharmacokinetics in sheep of miconazole-cyclodextrin solutions and a micellar 
solution. International journal of pharmaceutics 180(1) (1999) 41-45. 
[332] V.J. Stella, V.M. Rao, E.A. Zannou, V.V. Zia, Mechanisms of drug release 
from cyclodextrin complexes. Adv Drug Deliv Rev 36(1) (1999) 3-16. 
[333] Z. Lu, Y. Zhang, H. Liu, J. Yuan, Z. Zheng, G. Zou, Transport of a cancer 
chemopreventive polyphenol, resveratrol: interaction with serum albumin and 
hemoglobin. Journal of fluorescence 17(5) (2007) 580-587. 
[334] O.H. Chan, B.H. Stewart, Physicochemical and drug delivery considerations 
for oral drug bioavailability. Drug Discovery Today 1(11) (1996) 461-473. 
[335] S. Das, H.S. Lin, P.C. Ho, K.Y. Ng, The impact of aqueous solubility and dose 
on the pharmacokinetic profiles of resveratrol. Pharm Res 25(11) (2008) 2593-2600. 
[336] B.R. Thakur, R.K. Singh, A.K. Handa, Chemistry and Uses of Pectin - A 
Review. Critical Reviews in Food Science and Nutrition 37(1) (1997) 47-73. 
[337] S.M. Cardoso, M.A. Coimbra, J.A. Lopes da Silva, Temperature dependence 
of the formation and melting of pectin-Ca 2+ networks: A rheological study. Food 
Hydrocolloids 17(6) (2003) 801-807. 
[338] P.M. Gilsenan, R.K. Richardson, E.R. Morris, Thermally reversible acid-




[339] D. Lootens, F. Capel, D. Durand, T. Nicolai, P. Boulenguer, V. Langendorff, 
Influence of pH, Ca concentration, temperature and amidation on the gelation of low 
methoxyl pectin. Food Hydrocolloids 17(3) (2003) 237-244. 
[340] P. Sriamornsak, Preliminary investigation of some polysaccharides as a carrier 
for cell entrapment. Eur J Pharm Biopharm 46(2) (1998) 233-236. 
[341] S. Das, K.-Y. Ng, Resveratrol-loaded calcium-pectinate beads: effects of 
formulation parameters on drug release and bead characteristics. Journal of Pharmaceutical 
Sciences (In press). 
[342] S. Bourgeois, A. Laham, M. Besnard, A. Andremont, E. Fattal, In vitro and in 
vivo evaluation of pectin beads for the colon delivery of beta-lactamases. J Drug 
Target 13(5) (2005) 277-284. 
[343] C. Chang, Z.C. Wang, C.Y. Quan, H. Cheng, S.X. Cheng, X.Z. Zhang, R.X. 
Zhuo, Fabrication of a novel pH-sensitive glutaraldehyde cross-linked pectin nanogel 
for drug delivery. J Biomater Sci Polym Ed 18(12) (2007) 1591-1599. 
[344] S.B. Hanauer, D.H. Present, The state of the art in the management of 








OPTIMIZATION OF ZINC-PECTINATE BEAD 
I.I. Formulation design 
Based on results from preliminary experiments, beads were prepared by 
varying: 
a) cross-linking agent (calcium chloride and zinc acetate), while keeping pectin 
concentration (5 % w/v), cross-linking agent concentration (5 % w/v), cross-
linking time (0.5 h), cross-linking solution pH (1.5), pectin to resveratrol ratio 
(3 : 1), and drying condition (RT) constant. 
b) cross-linking solution pH (1.5 and 6.3 (normal pH of 5 % w/v zinc acetate 
solution)), while keeping pectin concentration (5 % w/v), zinc acetate 
concentration (5 % w/v), cross-linking time (0.5 h), pectin to resveratrol ratio 
(3 : 1), and drying condition (RT) constant. 
c) zinc acetate concentration (1, 2.5, 5, and 10 % (w/v)), while keeping pectin 
concentration (5 % w/v), cross-linking time (0.5 h), cross-linking solution pH 
(1.5), pectin to resveratrol ratio (3 : 1), and drying condition (RT) constant. 
d) cross-linking time (0.25, 0.5, 2, and 24 h), while keeping pectin concentration 
(5 % w/v), zinc acetate concentration (5 % w/v), cross-linking solution pH 
(1.5), pectin to resveratrol ratio (3 : 1), and drying condition (RT) constant. 
e) drying condition (FD, RT, 37 ºC, and 50 ºC), while keeping pectin 
concentration (5 % w/v), zinc acetate concentration (5 % w/v), cross-linking 




f) pectin concentration (3, 4, 5, and 6 % (w/v)), while keeping zinc acetate 
concentration (5 % w/v), cross-linking time (0.5 h), cross-linking solution pH 
(1.5), pectin to resveratrol ratio (3 : 1), and drying condition (RT) constant. 
g) pectin to resveratrol ratio (1 : 1, 2 : 1, 3 : 1, and 4 : 1), while keeping pectin 
concentration (5 % w/v), zinc acetate concentration (5 % w/v), cross-linking 
time (0.5 h), cross-linking solution pH (1.5), and drying condition (RT) 
constant. 
 
I.II. Results and Discussion 
I.II.I. Formulation:  As described earlier, bead formation occurs by ionotropic 
gelation method.  When the pectin droplets come in contact with divalent cation (e.g., 
Ca2+, Zn2+), ionic interaction between the negatively charged carboxylic groups of the 
pectin chains and the positively charged divalent calcium or zinc ions leads to 
intermolecular cross-linking and forms gelled spheres.  In addition, this cross-linking 
reduces the solubility and induces non-covalent associations of the carbohydrate 
chains in pectin.  LM pectin leads to formation of a more rigid gel structure due to 
presence of more free carboxylic group for cross-linking than HM pectin [1].  
Furthermore, hydrogen bonding between the amide groups and less hydrophilicity of 
pectin in the presence of the amide groups also leads to increased gel strength [2].  
These interactions in amidated LM pectin allowed the formation of a compact 
pectinate network, in which insoluble resveratrol particles were entrapped.  
Nevertheless, the beads were easily prepared without any sophisticated instruments. 
 
I.II.II. Shape, Size, and weight:  The shape, size, and weight of the wet and dry 
beads are listed in Table I.I.  ER values indicate almost all beads (wet and dry) were 
III 
 
spherical in shape (ER < 1.15).  The wet beads (mean diameter > 2 mm) were much 
bigger than the dry beads (mean diameter = 0.86 - 1.14 mm) except lyophilized beads 
(mean diameter > 2 mm).  However, the results show the influence of formulation 
parameters on the size of the beads.  Similar trends were observed in Ca-pectinate 
beads [3].   
 
I.II.III. Morphology:  Scanning electron micrographs of the beads are presented in 
Figure I.I.  SEM image (X 35) of the resveratrol-free bead shows a smooth surface 
topography (Figure I.IA), while resveratrol-loaded bead shows rough and rugged 
surface at the same magnification (Figure I.IB).  At higher magnification, SEM 
images of the resveratrol-loaded beads’ surface (X 350, Figure I.IC) and cross-section 
(X 500, Figure I.ID) reveal that the drug crystals were embedded in the bead matrix.  
Furthermore, the surface of the Zn-pectinate beads (globular, Figure I.IE) is found to 
be different from Ca-pectinate bead surface (rough and thread like structure, Figure 
I.IF) at the same magnification (X 100).  Similar finding was reported in earlier 






Table I.I:  Size, shape, and weight of the Zn-pectinate beads (Data presented as mean ± SD, N = 50 beads) 
Variables Values Shape (ER ± SD) Size (µm ± SD) Weight of 50 beads (mg ± SD)  
Wet beads Wet beads Wet beads Dry beads Wet beads Dry beads 
Cross-linking 
agent 
Zn 1.06 ± 0.03 1.06 ± 0.03 2160.45 ± 71.25 896.44 ± 7.90 275.53 ± 4.14 23.12 ± 0.03 
Ca 1.07 ± 0.05 1.07 ± 0.05 2211.28 ± 66.23 1077.77 ± 72.97 309.87 ± 3.93 32.62 ± 0.77 
Cross-linking 
pH 
1.5 1.06 ± 0.03 1.06 ± 0.03 2160.45 ± 71.25 896.44 ± 7.90 275.53 ± 4.14 23.12 ± 0.03 




1 1.03 ± 0.01 1.03 ± 0.01 2292.88 ± 35.89 881.09 ± 38.29 321.40 ± 7.89 19.84 ± 0.08 
2.5 1.07 ± 0.02 1.07 ± 0.02 2117.55 ± 50.21 886.96 ± 9.81 311.80 ± 4.62 22.83 ± 0.11 
5 1.06 ± 0.03 1.06 ± 0.03 2160.45 ± 71.25 896.44 ± 7.90 275.53 ± 4.14 23.12 ± 0.03 
10 1.06 ± 0.02 1.06 ± 0.02 2184.85 ± 41.26 1035.16 ± 43.22 268.60 ± 5.72 25.54 ± 0.46 
Cross-linking 
time (h) 
0.25 1.13 ± 0.07 1.13 ± 0.07 2045.66 ± 72.68 894.28 ± 14.38 266.00 ± 2.91 20.38 ± 0.12 
0.5 1.06 ± 0.03 1.06 ± 0.03 2160.45 ± 71.25 896.44 ± 7.90 275.53 ± 4.14 23.12 ± 0.03 
2 1.07 ± 0.07 1.07 ± 0.07 2298.06 ± 72.84 920.48 ± 14.47 326.63 ± 7.71 23.24 ± 0.05 
24 1.10 ± 0.08 1.10 ± 0.08 2299.8 ± 104.84 943.97 ± 15.04 369.73 ± 6.55 24.74 ± 0.24 
Drying RT 1.06 ± 0.03 1.06 ± 0.03 2160.45 ± 71.25 896.44 ± 7.90 275.53 ± 4.14 23.12 ± 0.03 
37 ºC 1.06 ± 0.03 1.06 ± 0.03 2160.45 ± 71.25 895.76 ± 11.13 275.53 ± 4.14 22.03 ± 0.73 
50 ºC 1.06 ± 0.03 1.06 ± 0.03 2160.45 ± 71.25 886.88 ± 7.820 275.53 ± 4.14 20.95 ± 0.51 




3 1.09 ± 0.03 1.09 ± 0.03 2187.33 ± 79.72 892.87 ± 13.27 324.21 ± 6.83 23.38 ± 0.98 
4 1.07 ± 0.03 1.07 ± 0.03 2184.68 ± 115.01 898.47 ± 16.83 317.90 ± 5.38 22.06 ± 0.55 
5 1.06 ± 0.03 1.06 ± 0.03 2160.45 ± 71.25 896.44 ± 7.90 275.53 ± 4.14 23.12 ± 0.03 
6 1.08 ± 0.03 1.08 ± 0.03 2159.57 ± 89.69 907.63 ± 20.25 294.10 ± 5.05 23.81 ± 0.18 
Pectin : 
Resveratrol 
1:1 1.07 ± 0.03 1.07 ± 0.03 2284.74 ± 90.73 1140.67 ± 80.12 364.90 ± 4.91 40.16 ± 0.42 
2:1 1.07 ± 0.04 1.07 ± 0.04 2231.22 ± 94.87 993.01 ± 48.82 311.47 ± 2.92 31.57 ± 0.42 
3:1 1.06 ± 0.03 1.06 ± 0.03 2160.45 ± 71.25 896.44 ± 7.90 275.53 ± 4.14 23.12 ± 0.03 
4:1 1.05 ± 0.03 1.05 ± 0.03 2113.75 ± 68.43 891.37 ± 11.06 273.43 ± 8.05 21.81 ± 0.20 















Figure I.I:  Scanning electron micrographs of blank Zn-pectinate bead surface (X 35) 
(A), surface of resveratrol-loaded Zn-pectinate bead (X 35) (B), surface of resveratrol-
loaded Zn-pectinate bead (X 350) (C), cross-section of resveratrol loaded Zn-pectinate 
bead (X 500) (D),  surface of resveratrol-loaded Zn-pectinate bead (X 100) (E), and 
surface of resveratrol-loaded Ca-pectinate bead (X 100) (F).  Magnifications 
corresponding to each figure are presented in brackets. 
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I.II.IV. FT-IR:  Comparison of the IR spectra of pure resveratrol, resveratrol-free and 
resveratrol-loaded Zn-pectinate beads indicate no chemical interaction of resveratrol with 
beads’ components when formulated into Zn-pectinate beads (Figure I.II).  All 
characteristic peaks of resveratrol (olefinic band at 966 cm-1, C–O stretching at 1383, C–
C olefinic stretching at 1585, and C–C aromatic double-bond stretching at1607 cm-1) are 
present in the resveratrol-loaded bead. 
 
Figure I.II:  FTIR spectra of blank Zn-pectinate bead (A), resveratrol loaded Zn-
pectinate bead (B), and pure resveratrol (C).   
 
I.II.V. Zinc content:  The zinc contents per mg of the beads are depicted in Table I.II.  
The results suggest the potential impact of formulation parameters on the zinc retention 
in the beads.  Zinc content increased with cross-linking solution pH, zinc acetate 
concentration, cross-linking time, and pectin to resveratrol ratio, while content decreased 
with pectin concentration.  Lower amount of zinc is expected to bind with pectin chains 
due to suppression of ionization of the carboxylic group of the pectin chains at low cross-
linking solution pH, which might repress the zinc entrapment.  Augmentation of zinc 
content with increasing zinc acetate concentration and cross-linking time was due to 
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availability of more zinc and more time for the cross-linking, respectively.  One previous 
report described that only small amount of calcium is required for Ca-pectinate network 
formation with the majority of calcium remaining as free calcium chloride in the Ca-
pectinate beads [6].  Similar to Ca-pectinate beads, we anticipated that majority of zinc 
remained as free zinc acetate in Zn-pectinate beads.  At lower pectin to resveratrol ratio, 
less pectin is available for cross-linking which could probably explain lower zinc 
retention.  During bead preparation, when dilute pectin droplets come in contact with zinc 
acetate solution, zinc acetate can easily penetrate into the pectin droplets.  This might be 
the reasons for higher zinc content at lower pectin concentration.  Zinc content was found 
in the order of RT < 37 ºC < 50 ºC < FD.   The higher zinc content per mg of beads is 
rational for lower weighing beads as the weight of the beads decreased with drying 
temperature and was lowest in the case of freeze dried beads.  Similar trends were 
observed in case of calcium retention in Ca-pectinate beads [3].   Zinc is an essential 
micronutrient and 47 weeks oral administration of 25.5 mg.kg-1.day-1 zinc (zinc acetate in 
drinking water) displayed no toxic effect in rats [7].  Thus, observed zinc contents in the 
beads are anticipated to be safe for practical use. 
 
I.II.VI. Effect of formulation parameters:  The WL, MC, EE, and L corresponding to 
each type of formulations are given in Table I.II.  Percent resveratrol retention in the 
beads was plotted against time to represent the drug retention profile (Figure I.IIIA – 
I.IXA), whereas percent SER was plotted against time to depict the swelling-erosion 
behavior of beads in the release media (Figure I.IIIB – I.IXB).  Further, release 
parameters (T75, T50, T25) are cited in Table I.III.   
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Table I.II:  Zn content, WL, MC, EE, and L of the Zn-pectinate beads (Data presented as mean ± SD, N = 3)  
Variables Values Zn content 
(µg.mg-1 ± SD) 
WL (% ± SD) # MC (% ± SD) Direct method # Indirect method 
EE (%) L (%) EE (%) L (%) # 
Cross-linking 
agent 
Zn 54.12 ± 1.92 91.61 ± 0.14 10.09 ± 0.43 k 97.74 ± 0.19 32.58 ± 0.06 97.99 ± 0.10 k 32.66 ± 0.03 
Ca - 90.61 ± 0.19 16.16 ± 1.00 98.34 ± 0.18 32.78 ± 0.06 98.65 ± 0.21 32.88 ± 0.07 
Cross-linking 
pH 
1.5 54.12 ± 1.92 a 91.61 ± 0.14 10.09 ± 0.43 97.74 ± 0.19 32.58 ± 0.06 97.99 ± 0.10 32.66 ± 0.03 




1 33.55 ± 0.87 b 93.82 ± 0.18 6.29 ± 0.95 b 98.16 ± 0.17 32.72 ± 0.06 98.29 ± 0.12 q 32.76 ± 0.04 
2.5 50.44 ± 2.78 92.68 ± 0.1 9.51 ± 0.66 97.81 ± 0.20 32.60 ± 0.07 98.01 ± 0.18 32.67 ± 0.06 
5 54.12 ± 1.92 91.61 ± 0.14 10.09 ± 0.43 97.74 ± 0.19 32.58 ± 0.06 97.99 ± 0.10 32.66 ± 0.03 
10 88.80 ± 0.60 c 90.49 ± 0.09 11.23 ± 0.79 97.16 ± 0.17 32.39 ± 0.06 97.68 ± 0.27 32.56 ± 0.09 
Cross-linking 
time (h) 
0.25 42.35 ± 2.94 d 92.34 ± 0.12 7.78 ± 0.19 l 98.32 ± 0.31 32.77 ± 0.10 98.38 ± 0.04 r 32.79 ± 0.01 
0.5 54.12 ± 1.92 91.61 ± 0.14 10.09 ± 0.43 m 97.74 ± 0.19 32.58 ± 0.06 97.99 ± 0.10 s 32.66 ± 0.03 
2 75.29 ± 0.96 92.88 ± 0.15 12.25 ± 0.79 96.95 ± 0.19 32.32 ± 0.06 97.06 ± 0.85 32.36 ± 0.28 
24 84.00 ± 0.91 93.31 ± 0.18 13.21 ± 0.12 95.96 ± 0.21 31.99 ± 0.07 96.29 ± 0.11 32.09 ± 0.04 
Drying RT 54.12 ± 1.92 e 91.61 ± 0.14 10.09 ± 0.43 e 97.74 ± 0.19 32.58 ± 0.06 97.99 ± 0.10 32.66 ± 0.03 
37 ºC 54.65 ± 0.65 f 92.00 ± 0.18 9.56 ± 0.72 f 97.26 ± 0.23 32.42 ± 0.08 97.99 ± 0.10 32.66 ± 0.03 
50 ºC 85.30 ± 0.42 92.40 ± 0.13 1.45 ± 0.45 97.15 ± 0.27 32.38 ± 0.09 97.99 ± 0.10 32.66 ± 0.03 




3 116.25 ± 1.18 g 92.78 ± 0.45 10.70 ± 1.44 97.28 ± 0.39 32.43 ± 0.13 97.44 ± 0.08 t 32.48 ± 0.03 
4 96.02 ± 0.86 h 93.06 ± 0.21 11.01 ± 0.78 97.09 ± 0.31 32.36 ± 0.10 97.05 ± 0.09 32.35 ± 0.03 
5 54.12 ± 1.92 91.61 ± 0.14 10.09 ± 0.43 97.74 ± 0.19 32.58 ± 0.06 97.99 ± 0.10 32.66 ± 0.03 
6 53.43 ± 2.84 91.90 ± 0.12 10.24 ± 0.72 97.30 ± 0.27 32.43 ± 0.09 97.75 ± 0.05 32.58 ± 0.02 
Pectin : 
Resveratrol 
1:1 45.95 ± 2.05 88.99 ± 0.18 15.07 ± 0.49 n 99.21 ± 0.28 99.21 ± 0.28  99.28 ± 0.10 u 99.28 ± 0.01 
2:1 51.63 ± 2.10 89.86 ± 0.04 12.43 ± 0.24 o 98.66 ± 0.33 49.33 ± 0.16 98.55 ± 0.02 49.27 ± 0.01 
3:1 54.12 ± 1.92 91.61 ± 0.14 10.09 ± 0.43 p 97.74 ± 0.19 32.58 ± 0.06 97.99 ± 0.10 32.66 ± 0.03 
4:1 92.33 ± 0.24 i 92.02 ± 0.16 9.09 ± 0.07 97.27 ± 0.35 24.32 ± 0.09 97.50 ± 0.03 24.37 ± 0.01 
Blank - 111.58 ± 6.60 j 91.73 ± 0.33 8.54 ± 0.17 - - - - 
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a p < 0.05 between cross-linking pH 1.5 and 6.3, b p < 0.05 between zinc acetate concentration 1 % with 2.5, 5, and 10 %, c p < 
0.05 between zinc acetate concentration 10 % with 2.5 and 5 %, d p < 0.05 among cross-linking time 0.25, 0.5, 2, and 24 h, e p 
< 0.05 between drying at RT with 50 °C and FD, f p < 0.05 between drying at 37 °C with 50 °C and FD, g p < 0.05 between 
pectin concentration 3 % with 4, 5, and 6 %, h p < 0.05 between pectin concentration 4 % with 5 and 6 %, i p < 0.05 between 
pectin to resveratrol ratio 4:1 with 1:1, 2:1, and 3:1,  j p < 0.05 between blank beads with pectin to resveratrol ratio 1:1, 2:1, 
3:1, and 4:1, k p < 0.05 between cross-linking agent Ca and Zn, l p < 0.05 between cross-linking time 0.25 h with 0.5, 2, and 24 
h, m p < 0.05 between cross-linking time 0.5 h with  2 and 24 h, n p < 0.05 between pectin to resveratrol ratio 1:1 with 2:1, 3:1, 
4:1, and blank, o p < 0.05 between pectin to resveratrol ratio 2:1 with 3:1, 4:1, and blank, p p < 0.05 between pectin to 
resveratrol ratio 3:1 with 4:1 and blank, q p < 0.05 between zinc acetate concentration 1 and 10 %, r p < 0.05 between cross-
linking time 0.25 h with  2 and 24 h, s p < 0.05 between cross-linking time 0.5 and 24 h, t p < 0.05 among pectin concentration 
3, 4, 5, and 6 %, u p < 0.05 among pectin to resveratrol ratio 1:1, 2:1, 3:1, and 4:1.   




Table I.III:  Release kinetics and parameters of the Zn-pectinate beads 





T 75 (h) T50 (h) T25 (h) 
Cross-linking 
agent 
Zn 0.980 0.997 3.48 ± 0.21 a 6.37 ± 0.20 a 9.26 ± 0.27 a 
Ca 0.972* 0.923 2.18 ± 0.17 4.27 ± 0.15 7.04 ± 0.08 
Cross-linking 
pH 
1.5 0.980 0.997 3.48 ± 0.21 b 6.37 ± 0.20 b 9.26 ± 0.27 b 




1 0.992* 0.982 1.23 ± 0.23 c 3.30 ± 0.24 c 6.38 ± 0.18 c 
2.5 0.986 0.995 2.82 ± 0.36 5.29 ± 0.34 d 7.75 ± 0.31 d 
5 0.980 0.997 3.48 ± 0.21 6.37 ± 0.20 9.26 ± 0.27 
10 0.976 0.998 3.46 ± 0.42 6.31 ± 0.47 9.16 ± 0.52 
Cross-linking 
time (h) 
0.25 0.989 0.990 1.96 ± 0.41 e 4.80 ± 0.27 e 7.64 ± 0.18 e 
0.5 0.980 0.997 3.48 ± 0.21 6.37 ± 0.20 9.26 ± 0.27 
2 0.964 0.995 3.51 ± 0.33 6.52 ± 0.22 9.53 ± 0.36 
24 0.974 0.988 3.41 ± 0.28 6.41 ± 0.23 9.41 ± 0.19 
Drying RT 0.980 0.997 3.48 ± 0.21 6.37 ± 0.20 9.26 ± 0.27 
37 ºC 0.979 0.998 3.47 ± 0.13 6.33 ± 0.03 9.20 ± 0.18 
50 ºC 0.975 0.992 3.53 ± 0.11 6.41 ± 0.19 9.28 ± 0.27 




3 0.988 0.992 2.82 ± 0.42 f 5.70 ± 0.32 8.58 ± 0.22 
4 0.986 0.987 3.00 ± 0.19 5.95 ± 0.35 8.90 ± 0.52 
5 0.980 0.997 3.48 ± 0.21 6.37 ± 0.20 9.26 ± 0.27 
6 0.971 0.998 3.51 ± 0.09 6.39 ± 0.18 9.27 ± 0.35 
Pectin : 
Resveratrol 
1:1 0.994* 0.972 1.95 ± 0.27 g 3.94 ± 0.27 g 6.63 ± 0.21 g 
2:1 0.979 0.996 2.61 ± 0.08 5.33 ± 0.11 8.05 ± 0.16 
3:1 0.980 0.997 3.48 ± 0.21 6.37 ± 0.20 9.26 ± 0.27 
4:1 0.982 0.994 4.10 ± 0.14 7.43 ± 0.21 10.76 ± 0.29 
Enzyme - 0.994* 0.967 2.02 ± 0.23 h 4.20 ± 0.28 h 7.17 ± 0.31 h 
# Data presented as mean ± SD.   
* Release data more appropriately fit with square root of time equation.   
** Release data does not fit with both equations.  
a p < 0.05 between cross-linking agent Zn and Ca, b p < 0.05 between cross-linking pH 
1.5 and 6.3, c p < 0.05 between zinc acetate concentration 1 % with 2.5, 5, and 10 %, d p 
< 0.05 between zinc acetate concentration 2.5 % with 5 and 10 %, e p < 0.05 between 
cross-linking time 0.25 h with 0.5, 2, and 24 h, f p < 0.05 between pectin concentration 3 
% and 6 %, g p < 0.05 among pectin to resveratrol ratio 1:1, 2:1, 3:1, and 4:1, h p < 0.05 




 The effects of different formulation parameters on the size, weight, MC, WL, 
EE, L, resveratrol retention profiles, release parameters, and swelling-erosion behavior of 
the beads in the release media will be discussed in the following sections. 
 
I.II.VI.I. Cross-linking agent   
Zn-pectinate beads (wet and dry) were smaller than Ca-pectinate beads (Table 
I.I).  This was because Zn-pectinate beads are more compact than Ca-pectinate beads.  
Other researchers also noticed similar phenomena [4, 5].  Further, Zn pectinate beads 
were lighter (wet and dry) with less MC and lost more weight during drying than Ca-
pectinate beads (Table I.II).  Instantaneous formation of pectinate network allowed easy 
encapsulation of resveratrol in the pectinate beads.  Indeed, very high percent of 
resveratrol encapsulation (> 95.9 %) was observed in all cases (Table I.II).  Poor aqueous 
solubility of resveratrol was responsible for its high encapsulation in the beads.  
However, Zn-pectinate beads revealed lower resveratrol encapsulation and loading than 
Ca-pectinate beads.  Other researchers also reported lower drug encapsulation in Zn-
pectinate beads than Ca-pectinate beads [4, 5].  This is probably due to formation of 
stronger zinc pectinate network during bead formation, which led to ejection of 
resveratrol towards the outer part of the beads and subsequent drug leakage in the cross-
linking solution.   
Figure I.IIIA (resveratrol retention profile) and Table I.III (T75, T50, and T25) 
demonstrate that Zn-pectinate beads were able to retain higher amount of drug than Ca-
pectinate beads in SIF.  Other researchers also showed similar phenomenon [4, 5, 8, 9].  
Consequently, huge decrease of SER was observed for Zn-pectinate than Ca-pectinate 
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beads (Figure I.IIIB).  Ca-pectinate beads hydrated and swelled fast after contact with 
SIF and subsequently released drug, while Zn-pectinate beads swelled very little.  
Wellner et al. compared different divalent cations for gel forming ability with pectin and 
found zinc was stronger cross-linker than calcium [10].  It was reported that zinc poses 
higher binding ability with a higher affinity than calcium [11], which can form pectinate 
bead with higher gel strength.  As zinc acetate was found to be better cross-linking agent 
than calcium chloride, we decided to use zinc acetate as the cross-linking agent for 
further optimization of the formulation parameters. 
 
I.II.VI.II. Cross-linking solution pH 
Diminution of pH of the cross-linking solution produced beads with smaller size 
(Table I.I).  A probable reason is that at reduced pH, non-ionic interaction occurs along 
with ionic interaction between pectin chains, which led to small and compact beads.  
Weight of beads (wet and dry) slightly increased with increasing cross-linking solution 
pH (Table I.I).  Moreover, MC of the beads was also found to increase with increasing 
pH of cross-linking solution and WL decreased a bit with increasing cross-linking 
solution pH (Table I.II).  Nevertheless, a small increase in encapsulation and loading was 
observed in the present study with decreased cross-linking solution pH (Table I.II).   
Drug retention profile shows that resveratrol retention was significantly higher in 
the case of beads prepared at cross-linking solution pH 1.5 (Figure I.IVA).  Table I.III 
shows that the release parameters (T75, T50, and T25) were significantly lower in the case 
of beads prepared at cross-linking solution with unmodified pH (pH 6.3).  Similar effect 
of cross-linking solution pH on pectinate beads was reported before [4].  Our previous 
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study with Ca-pectinate beads also evidenced similar effect of cross-linking solution pH 
[3].  As shown in Figure I.IVB, SER values were higher in case of beads prepared at pH 
6.3 up to 4 h and then erosion dominated over swelling.  This might be because of the 
formation of a stronger Zn-pectinate network at acidic cross-linking solution [12].  In 
addition to the ionic interaction between carboxylic groups of pectin and zinc cation, 
several non-ionic interactions (e.g., hydrophobic interaction, hydrogen bonding) are 
involve in amidated pectin at pH below 3 (lower than pKa value of pectin), which lead to 
the formation of strong Zn-pectinate network at acidic pH [13-15].  The detail of the non-
ionic interaction was reported in our previous study [3].  Further, like Ca- pectinate 
network, reduction in cross-linking solution pH may lead to conformational transition 
from the two-fold to the more compact three-fold helical conformation of the 
polygalacturonate chains of pectin in the Zn-pectinate network [14].  These observations 
could be applied to explain the consequence of cross-linking solution pH on resveratrol 
retention and SER of Zn-pectinate beads.  Subsequently, we chose cross-linking solution 
pH 1.5 for optimization of the other formulation parameters of resveratrol-loaded Zn-























































Figure I.III:  Effects of cross-linking agents (Zn(CH3COO)2 = zinc acetate, CaCl2 = 
calcium chloride) on retention of resveratrol in the beads (A) and SER of the beads (B).  
















































Figure I.IV:  Effects of cross-linking solution pH on retention of resveratrol in the Zn-
pectinate beads (A) and SER of the Zn-pectinate beads (B).  The beads were incubated in 
SIF.  Data presented as mean ± SD.  * p < 0.05. 
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I.II.VI.III. Zinc acetate concentration   
Because zinc acetate concentration less than 1 % produced irregular-shaped beads 
and above 10 % revealed no improvement of drug retention, concentration was kept 
between 1 to 10 % in the present study (data not shown).  Augmentation of the beads’ 
size and weight was observed with increasing zinc acetate concentration in the cross-
linking medium (Table I.I).  However, some other studies reported an inverse relationship 
between the size and concentration of cross-linking agent [16].  Table I.II demonstrates 
that MC increased with increasing zinc acetate concentration, while WL decreased with 
increasing zinc acetate concentration.  However, a little improvement in EE and L was 
noticed with decreasing zinc acetate concentration (Table I.II).   
Figure I.VA demonstrates that the retention of resveratrol in the beads depends on 
the zinc acetate concentration.  The release of resveratrol was significantly faster at 1 and 
2.5 % zinc acetate than 5 %, while 5 and 10 % zinc acetate showed almost similar drug 
retention pattern.  In addition, the release parameters (T75, T50, and T25) support the above 
phenomena (Table I.III).  Our previous work with Ca-pectinate beads showed increased 
retention of drug with increasing calcium chloride concentration up to a certain value [3].  
Another earlier work also exhibited slower drug release at higher zinc acetate 
concentration [9].  In general, SER decreased with increasing concentration of zinc 
acetate (Figure I.VB).  Very high SERs were detected when beads were prepared at 1 % 
zinc acetate.  It demonstrates an early phase of swelling, followed by rapid erosion of the 
beads.  These differences in drug retention and SER could be explained by difference in 
degree of cross-linking, which could effect the swelling rate and subsequent penetration 
of solvent into the beads.  It was reported that, the calcium cation leads to dimer 
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formation with pectin chain at low calcium concentration, whereas at high calcium 
concentration, enhancement of the number and/or strength of cross-links between pectin 
and calcium ions as well as aggregation of initial dimmers take place [6, 17].  We 
anticipate similar phenomena with Zn-pectinate beads, which led to a higher degree of 
cross-linking with increasing concentration of zinc acetate.  In summary, higher drug 
retention and lower SER were observed due to higher gel strength at higher zinc acetate 
concentrations.  Based on this finding, 5 % zinc acetate was chosen as the optimal 























































Figure I.V:  Effects of zinc acetate concentration on retention of resveratrol in the Zn-
pectinate beads (A) and SER of the Zn-pectinate beads (B).  The beads were incubated in 
SIF.  Data presented as mean ± SD.  * p < 0.05. 
XIX 
 
I.II.VI.IV. Cross-linking time 
The longer cross-linking time resulted larger and heavier (wet and dry) beads 
(Table I.I) with higher MC and lower EE and L (Table I.II).   
The release profiles of resveratrol from the beads prepared with various cross-
linking times are shown in Figure I.VIA.  It is obvious from the figure that the cross-
linking time has great influence on the release of resveratrol from the Zn-pectinate beads.  
Retention of resveratrol was higher when beads were prepared at longer cross-linking 
time (0.5 - 24 h), whereas, retention of resveratrol was the lowest at the shortest cross-
linking time (0.25 h).  However, insignificant differences in drug retention were observed 
among the beads prepared at cross-linking time of 0.5 h, 2 h, and 24 h, although more 
drug retention was noticed in all cases than beads prepared at cross-linking time of 0.25 h 
(Table I.III).  Ei Gibaly et al. have also demonstrated reduced drug release with 
increasing cross-linking time [9].  Lower drug release at higher cross-linking time was 
also evident in the case of Ca-pectinate beads in our previous study [3].  The SER profile 
is depicted in Figure I.VIB.  In our findings and as expected, 0.25 h cross-linking time 
showed the highest SER (swelling of the beads accompanied by erosion and drug 
release).  However, almost similar SER profiles were noticed among 0.5, 2, and 24 h 
cross-linking time.  Promotion of cross-linking between pectin chains and zinc ions with 
respect to time might be the possible explanation for the observed SER and resveratrol 
retention pattern.  Additionally, the aggregation of primary dimmers probably takes place 
at higher cross-linking time, which improves the strength of Zn-pectinate network.  In 
























































Figure I.VI:  Effects of cross-linking time on retention of resveratrol in the Zn-pectinate 
beads (A) and SER of the Zn-pectinate beads (B).  The beads were incubated in SIF.  
Data presented as mean ± SD.  * p < 0.05. 
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I.II.VI.V. Drying condition 
Beads’ size and weight decreased with increasing drying temperature (Table I.I).  
The size of the freeze dried beads was almost similar to the wet beads.  This might be 
because of moisture evaporation from the beads without affecting the bead structure 
during lyophilization.  A clear correlation was found between MC and WL of the beads 
with the drying method (Table I.II).  WL decreased with decreasing drying temperature 
(FD > 50 ºC).  Simultaneously, lower the MC was observed with higher drying 
temperature.  The lyophilized beads and those dried at 50 ºC exhibited minimum MC (FD 
< 50 ºC, MC < 1.5 %).   
The effect of drying condition on retention of resveratrol is illustrated in Figure 
I.VIIA.  Lyophilized beads exhibited lowest drug retention profile among the all drying 
methods.  Further, erosion overshadowed swelling of lyophilized beads (Figure I.VIIB).  
A significant slow release and low SER were observed in the case of beads dried at RT, 
37 ºC, and 50 ºC, although there were almost no differences in drug retention and SER 
profiles among them.  The rapid degradation and higher SER of lyophilized beads can be 
explained by the higher porosity created during drying.  Therefore, lyophilized beads 
were unsuitable for our current purpose.  RT was selected as optimum drying condition 




















































Figure I.VII:  Effects of drying condition on retention of resveratrol in the Zn-pectinate 
beads (A) and SER of the Zn-pectinate beads (B).  The beads were incubated in SIF.  
Data presented as mean ± SD.  * p < 0.05. 
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I.II.VI.VI. Pectin concentration 
 Amidated low methoxy pectin was chosen to prepare resveratrol-loaded beads due 
to its strong Zn-pectinate network formation ability.  Low pectin concentration has low 
consistency that leads to rapid shrinkage of beads during drying and non-spherical shape.  
Our preliminary studies showed irregular shaped bead formation when < 3 % pectin 
concentration was used.  On the other hand, when a > 6% pectin concentration was used, 
beads with a drop like structure were formed due to very high viscosity of high pectin 
concentration (data not shown).  Thus, pectin concentration between 3 to 6 % was chosen 
for optimization.  However, beads’ size, weight, MC, WL, EE, and L were found to be 
independent of the pectin concentration (Table I.I and I.II).   
As shown in Figure I.VIIIA, Table I.III, and Figure I.VIIIB, both drug retention 
capability and SER of the beads slightly increased with increasing pectin concentration (3 
to 5 %).  Higher pectin concentration forms a denser matrix, which probably improves 
drug retention behavior of beads.  However, almost similar resveratrol retention and SER 
was observed between beads prepared with 5 and 6 % pectin.  These observations guided 

















































Figure I.VIII:  Effects of pectin concentration on retention of resveratrol in the Zn-
pectinate beads (A) and SER of the Zn-pectinate beads (B).  The beads were incubated in 
SIF.  Data presented as mean ± SD.  * p < 0.05. 
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I.II.VI.VII. Pectin to resveratrol ratio 
Reduction of pectin to resveratrol ratio produced heavier and bigger beads (Table 
I.I) with higher MC (Table I.II).  This is anticipated because of lower polymer to drug 
ratio.  Further, blank beads were much smaller and lighter with lower MC than 
resveratrol-loaded beads.  WL decreased with decreasing pectin to resveratrol ratio 
(Table I.II).  In general, enhancement of drug concentration results lower EE due to 
reduced polymer to drug ratio [18].  However, the results revealed augmentation of EE 
and L with decreasing pectin to resveratrol ratio (Table I.II).  The reason has been 
described in our earlier study.  Due to poor aqueous solubility of resveratrol, it saturates 
the cross-linking solution after a certain amount at constant temperature.  Thus, addition 
of high amount of resveratrol into the pectin solution led to the high EE and L in the 
beads as only limited amount of resveratrol can diffuse from the beads to the cross-
linking solution. 
Figure I.IXA demonstrated the influence of pectin to resveratrol ratio on retention 
of resveratrol in the beads.  The retention of resveratrol decreased with decreasing pectin 
to resveratrol ratio.  The release parameters (T75, T50 and T25) showed the following 
trend: 1 : 1 < 2 : 1 < 3 : 1 < 4 : 1 (Table I.III).  Our earlier study with Ca-pectinate beads 
showed same trend.  SER decreased with decreasing pectin to resveratrol ratio (Figure 
I.IXB).  Since, only little pectin would be available for drug retention and swelling at low 
pectin to resveratrol ratio, reduction of resveratrol retention and SER are expected in this 





















































Figure I.IX:  Effects of pectin to resveratrol ratio on retention of resveratrol in the Zn-
pectinate beads (A) and SER of the Zn-pectinate beads (B).  The beads were incubated in 
SIF.  Data presented as mean ± SD.  * p < 0.05. 
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I.II.VII. Release media:  After careful and thorough observation of the effects of 
formulation parameters on the beads’ properties, the following parameters were 
employed to prepare resveratrol-loaded pectin beads: zinc acetate as cross-linking agent, 
cross-linking solution pH at 1.5, zinc acetate concentration at 5 %, cross-linking time of 
0.5 h, drying at RT, pectin concentration at 5 %, and pectin to resveratrol ratio of 3 : 1.  
Drug retention and SER profile of the optimized beads in SGF (pH 1.2) and in SIF 
containing 300 PG pectinase (simulating colonic fluid) were noted.  Resveratrol retention 
(Figure I.XA) in the beads was very high (> 94 % after 10 h) and SER (Figure I.XB) was 
very low in SGF.  This indicates the stability of Zn pectinate beads in the gastric 
environment.  Faster release of resveratrol from pectin beads was evident in SIF with 
pectinase than SIF alone.  The release parameters (T75, T50, and T25) were lower in 
presence of pectinase than non-enzymatic degradation (Table I.III).  Similar trend was 
observed with Ca-pectinate beads [3].  Because of enzymatic degradation of the pectinate 













































Figure I.X:  Effects of release media on retention of resveratrol in the Zn-pectinate beads 
(A) and SER of the Zn-pectinate beads (B).  Data presented as mean ± SD.  * p < 0.05. 
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I.II.VIII. Enzymatic degradation:  SEM images of the beads after 3 hr incubation in SIF 
with and without enzyme exhibited many tiny pores throughout the beads (Figure I.XIA 
and I.XIB).  The observation was similar with Ca-pectinate beads.  Much higher number 
of pores was evident with the beads incubated in SIF containing pectinase than SIF alone.  
Enzymatic degradation and subsequent erosion of the pectinate matrix might explain this 
observation.  Resveratrol particles probably fall off through these pores during matrix 





Figure I.XI:  Scanning electron micrographs of surface of resveratrol-loaded Zn-
pectinate bead after 3 h incubation in SIF containing 300 PG pectinase (X 350) (A), and 
surface of resveratrol loaded Zn-pectinate bead after 3 h incubation in SIF (X 350) (B).  
Magnifications corresponding to each figure are presented in brackets. 
 
I.II.IX. Release kinetics:  In the present study, we noticed that the drug release kinetics 
of Ca-pectinate beads as well as Zn-pectinate beads prepared with 1 % zinc acetate, 
cross-linking solution pH of 6.3, and pectin to resveratrol ratio = 1 : 1 together with Zn-
pectinate beads in presence of enzyme showed high correlation with the square root of 
time equation (Table I.III).  Rest of the beads more appropriately fitted with the zero 
order equation (except lyophilized beads which did not fit both equations).  However, 
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these observations do not match with the release kinetics of the Ca-pectinate beads, 
where all release data more appropriately fitted with the square root of time equation [3].  
One example to show the linearity of plots for the cumulative percent resveratrol released 
versus time is presented in Figure I.XII.  Because of the marginal solubility of resveratrol 
in SIF (0.11 ± 0.01 μg.ml−1) [19], most of the resveratrol particles should not dissolve in 
the release media that penetrated into the bead matrix.  Similar to the Ca-pectinate beads, 
the release of resveratrol from the Zn-pectinate beads probably follows the following 
three consecutive phenomena: (i) hydration of the matrix, (ii) swelling and erosion of the 
matrix, and (iii) the release of resveratrol from the matrix as undissolved particles rather 
than diffusion of the soluble resveratrol.  Pores are created in the matrix due to the release 
of undissolved resveratrol particles, which allow more fluid penetration in to the matrix 
and subsequently release of more resveratrol particles occur and ultimately the bead 
matrix erodes.  When the pectinate matrix is strong, the drug release from the beads is 
impeded by less fluid penetration and less erosion of the matrix.   
 
Figure I.XII:  The release of resveratrol from Zn-pectinate beads prepared at different 
cross-linking time, plotted as the cumulative percent resveratrol released versus time.  
Data presented as mean ± SD. 
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I.II.X. Stability:  The stability profile of resveratrol in the optimized beads indicates 
that resveratrol was stable inside the beads at 4 ºC and RT, even after 6 months (Figure 
I.XIII).  Stability was ~ 99.87 % and ~ 98.99 % in the case of storage at 4 ºC and RT, 
respectively, whereas ~ 93 % when stored at accelerated condition (40 ºC).  These results 
indicate desired stability of the formulation at 4 ºC and RT.   
 
Figure I.XIII:  Stability of resveratrol in the optimized resveratrol-loaded Zn-pectinate 
beads.  Data presented as mean ± SD.  # p < 0.05 for the difference between 90 days with 
0,3,7,15, and 30 days, ## p < 0.05 for the difference between 180 days with 0,3,7,15, 30, 
and 90 days, * p < 0.05 for the difference between 40 °C with 4 °C, ** p < 0.05 for the 
difference between 40 °C with 4 °C, and RT.   
 
I.III. Summary  
Because resveratrol has shown preventive as well as therapeutic activity to the 
lower GI diseases (e.g., colorectal cancer, colitis) and it is quickly absorbed and rapidly 
metabolized in the upper GI tract, a delayed release or colon-specific drug delivery 
system is essential to deliver resveratrol in the colonic region.  To fulfill this aim, we 
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have attempted to develop a multi-particulate resveratrol-loaded pectinate bead.  Our 
present study revealed that Zn-pectinate beads are better than Ca-pectinate beads as 
delayed release formulation of resveratrol.  During optimization of the resveratrol-loaded 
Zn-pectinate formulation, formulation parameters appeared to have great influence on 
beads’ properties and drug release characteristics.  The release mechanism of resveratrol 
from most of the Zn-pectinate beads followed zero order equation.  Beads were able to 
encapsulate very high amount of resveratrol and the beads prepared with optimized 
formulation parameters exhibited delayed release of resveratrol.  The beads were also 





CALCIUM-PECTINATE BEAD - PEI 
II.I. Formulation design 
Based on results from our previous experiments, beads were prepared by varying: 
a) PEI concentration (0, 0.05, 0.1, 0.2 and 0.3 % (w/v)); while keeping cross-linking 
time (2 h) and pectin to resveratrol ratio (3 : 1) constant. 
b) cross-linking time (0.08, 0.5, 2, and 24 h); while keeping PEI concentration (0.2 
% (w/v)) and pectin to resveratrol ratio (3 : 1) constant. 
c) pectin to resveratrol ratio (1 : 1 and 3 : 1); while keeping PEI concentration (0.2 
% (w/v)) and cross-linking time (2 h) constant. 
 
II.II. Results 
II.II.I. Morphology:  SEM images of the beads are shown in Figure II.IA – II.IE.  
Rough surface topography was observed (X 75) with resveratrol-loaded beads hardened 
with PEI (Figure II.IA).  Even at higher magnifications (X 1000), resveratrol-free beads 
(Figure II.IB) showed relatively smother surface than resveratrol-loaded beads (X 750, 
Figure II.IC).  Analyses of the SEM photograph of resveratrol-loaded beads hardened 
with PEI reveals that the surface is covered with a rough layer due to the presence of PEI 
(X 750, Figure II.IC), while resveratrol-loaded beads without PEI hardening do not 
exhibit such layer (X 750, Figure II.ID).  The cross-section of the resveratrol-loaded 
beads hardened with PEI also shows a layer at the outer surface of the beads (X 500, 












Figure II.I:  Scanning electron micrographs of the surface of resveratrol-loaded Ca-
pectinate bead treated with PEI (X 75) (A), resveratrol-free Ca-pectinate bead treated 
with PEI (X 1000) (B), resveratrol-loaded Ca-pectinate bead treated with PEI (X 750) 
(C), resveratrol-loaded Ca-pectinate bead without PEI treatement (X 750) (D), and cross-
section of resveratrol-loaded Ca-pectinate bead treated with PEI (X 500) (E).  Beads were 




II.II.II. Size, shape, and weight:  As homogeneous dispersion of resveratrol into 
aqueous solution of pectin was added dropwise to the cross-linking solution, beads were 
formed instantly.  All formulated beads were spherical in shape (ER < 1.15) and more 
than 2 mm in diameter, which upon drying became smaller (about 1 mm in diameter) 
while retaining their spherical shape (Table II.I).  The size of the dry as well as wet beads 
was found to be decreased with increasing PEI concentration, cross-linking time, and 
pectin to resveratrol ratio.  Simultaneously, with increasing PEI concentration, cross-
linking time and pectin to resveratrol ratio, beads (dry) became lighter (Table II.I).   
 
II.II.III. Weight loss during drying:  Table II.II depicts the effect of the formulation 
variables on WL of the beads.  Insignificant but little augmentation of WL was observed 
with increasing PEI concentration, cross-linking time, and pectin to resveratrol ratio.   
 
II.II.IV. Moisture content:  Effect of different formulation variables on MC of the 
beads are listed in Table II.II.  The beads that were hardened with PEI exhibited 
significantly lower MC than the beads without PEI.  Higher PEI concentration and longer 
cross-linking time produced beads with less MC.  Further, higher pectin to resveratrol 




Table II.I:  Size, shape, weight of the Ca-pectinate bead treated with PEI (Beads were prepared at unmodified pH) (Data presented as 
mean ± SD, N = 50 beads) 
Variables Values Size (µm) Shape (ER) Weight of 50 beads (mg) 




0 2271.23 ± 127.27 1148.68 ± 83.85 1.11 ± 0.09 1.14 ± 0.13 326.00 ± 9.41 35.95 ± 0.23 
0.05 2237.28 ± 122.18 1082.35 ± 93.45 1.06 ± 0.04 1.11 ± 0.11 326.95 ± 17.98 34.46 ± 1.96 
0.1 2233.24 ± 127.29 1047.64 ± 62.74 1.04 ± 0.01 1.06 ± 0.05 319.12 ± 5.37 33.62 ± 2.47 
0.2 2183.28 ± 119.27 1002.24 ± 82.91 1.04 ± 0.03 1.08 ± 0.07 312.73 ± 16.55 32.75 ± 3.84 
0.3 2181.25 ± 102.38 994.36 ± 72.53 1.03 ± 0.03 1.05 ± 0.05 313.19 ± 22.72 30.54 ± 1.12 
Cross-linking 
time (h) 
0.08 2218.28 ± 93.27 1058.34 ± 73.24 1.10 ± 0.09 1.14 ± 0.13 319.53 ± 3.65 34.17 ± 4.04 
0.5 2192.38 ± 106.26 1025.27 ± 83.62 1.05 ± 0.05 1.13 ± 0.09 315.24 ± 15.09 33.12 ± 3.81 
2 2183.28 ± 119.27 1002.24 ± 82.91 1.04 ± 0.03 1.08 ± 0.07 312.73 ± 16.55 32.75 ± 3.84 
24 2183.19 ± 112.16 1000.73 ± 94.38 1.03 ± 0.01 1.08 ± 0.07 317.31 ± 18.82 30.12 ± 1.65 
Pectin : 
resveratrol 
1 : 1 2231.27 ± 123.28 1103.73 ± 95.45 1.04 ± 0.02 1.09 ± 0.09 316.54 ± 25.62 35.31 ± 3.73 





Table II.II:  WL, MC, EE, and L of the Ca-pectinate bead treated with PEI (Beads were prepared at unmodified pH) (Data presented as 
mean ± SD, N = 3) 
Variables Values WL (%) MC (%) Direct method # Indirect method 




0 88.97 ± 0.25 18.90 ± 1.22 a 98.18 ± 0.07 32.73 ± 0.02 98.72 ± 0.25 b 32.91 ± 0.08 b 
0.05 89.46 ± 0.09 12.60 ± 0.97 93.75 ± 0.72 31.25 ± 0.24 94.81 ± 0.51 31.60 ± 0.17 
0.1 89.46 ± 0.91 11.45 ± 0.60 79.49 ± 0.56 26.50 ± 0.19 80.19 ± 0.34 26.73 ± 0.11 
0.2 89.49 ± 1.57 10.43 ± 1.64 70.04 ± 0.34 23.35 ± 0.11 70.97 ± 0.47 23.66 ± 0.16 
0.3 90.20 ± 1.04 10.21 ± 1.27 59.53 ± 0.64 19.84 ± 0.21 60.24 ± 0.85 20.08 ± 0.28 
Cross-linking 
time (h) 
0.08 89.31 ± 1.22 12.32 ± 0.29 97.07 ± 1.00 32.36 ± 0.33 98.13 ± 0.51 c 32.71 ± 0.17 c 
0.5 89.45 ± 1.60 11.30 ± 1.86 80.17 ± 0.89 26.72 ± 0.30 81.06 ± 0.73 27.02 ± 0.24 
2 89.49 ± 1.57 10.43 ± 1.64 70.04 ± 0.34 23.35 ± 0.11 70.97 ± 0.47 23.66 ± 0.16 
24 90.47 ± 1.06 10.41 ± 1.02 59.50 ± 0.65 19.83 ± 0.22 60.61 ± 0.85 20.20 ± 0.28 
Pectin : 
resveratrol 
1 : 1 88.84 ± 0.95 10.74 ± 1.54 82.44 ± 1.53 82.44 ± 1.53 83.41 ± 0.85 d 83.41 ± 0.85 d 
3 : 1 89.49 ± 1.57 10.43 ± 1.64 70.04 ± 0.34 23.35 ± 0.11 70.97 ± 0.47 23.66 ± 0.16 
a p < 0.05 between 0 % PEI with 0.05, 0.1, 0.2, and 0.3 % PEI, b p < 0.05 among 0, 0.05, 0.1, 0.2, and 0.3 % PEI, c p < 0.05 among 0.08, 
0.5, 2, and 24 h cross-linking time, d p < 0.05 between 1:1 and 3:1 pectin to resveratrol ratio.  




II.II.V. Encapsulation and loading efficiency:  Formulation variables revealed a 
great influence on the EE and L of the formulated beads (Table II.II).  The data indicate 
the huge reductions of EE and L with increasing PEI concentration.  The EE and L 
significantly reduced when PEI was added to the cross-linking solution in comparison to 
the non hardened beads.  Enhancement of cross-linking time led to immense reduction of 
their EE and L.  Furthermore, increase in pectin to resveratrol ratio led to formation of 
beads with significantly lower EE and L.   
 
II.II.VI. Drug release and swelling-erosion behavior:  Effect of different formulation 
variables on resveratrol retention pattern and SER in the artificial GI environments are 
depicted in Figure II.II to II.IV.  The following sections discuss the effects of different 
formulation parameters on resveratrol retention and swelling-erosion behaviors of the 
beads.  
 
II.II.VI.I. PEI concentration  
This study revealed that PEI concentration plays a crucial role on the stability and 
drug retention capability of the beads during GI transit (Figure II.IIA).  Despite the 
stability of the non-hardened beads in SGF, they were rapidly degraded following their 
subsequent exposure to SIF (< 7.5 % resveratrol retained within the beads at 5 h).  Beads 
prepared with low PEI concentration (0.05 %) also demonstrated quick degradation in 
SIF (< 39 % resveratrol retained within the beads at 5 h), although they were relatively 
more stable than the non-hardened beads.  Contrarily, high PEI concentration (0.3 %) led 
to very strong bead formulation which released a little amount of resveratrol even in SCF 
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(> 80 % resveratrol retained within the beads at 8 h).  Nevertheless, beads formulated 
with 0.2 % PEI gave rise to beads that were stable in SGF and SIF (> 90 % resveratrol 
retained within the beads at 5 h), and slowly released the drug in SCF (> 58 % resveratrol 
retained within the beads at 8 h).  On the other hand, formulation with 0.1 % PEI 
produced beads that were moderately stable in SIF (> 63 % resveratrol retained within the 
beads at 5 h) but very quickly degraded in SCF (~ 12 % resveratrol retained within the 
beads at 8 h).   
Huge swelling was observed for the beads prepared with 0.2 % PEI, whereas 
beads prepared with 0.3 % PEI exhibited very low swelling (Figure II.IIB).  On the other 
hand, beads prepared with 0 to 0.1 % PEI revealed an early phase of swelling followed by 
erosion.  However, SER increased with PEI concentration 0 - 0.2 %.   
 
II.II.VI.II. Cross-linking time 
 Similar to PEI concentration, cross-linking time also had decisive influence on 
beads’ stability in simulated GI fluids (Figure II.III A).  A very short cross-linking time 
(0.08 h) produced beads that were degraded rapidly in SIF (< 13 % resveratrol retained 
within the beads at 5 h), whereas a long cross-linking time (24 h) led to production of 
very strong (stable) beads which remained almost intact even in SCF (> 85 % resveratrol 
retained within the beads at 8 h).  In contrast, intermediate cross-linking time (0.5 and 2 
h), produced beads that showed moderate stability in SIF (~ 68 % resveratrol retained 
within the beads at 5 h) but rapidly degraded in SCF (~ 18 % resveratrol retained within 
the beads at 8 h), and beads that were stable in SIF (> 90 % resveratrol retained within 
the beads at 5 h) but degraded slowly in SCF (> 58 % resveratrol retained within the 
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beads at 8 h), respectively.  However, all formulated beads were stable in SGF (> 96 % 
resveratrol retained within the beads at 2 h). 
SER was very low for beads cross-linked for 24 h, while an early phase of 
swelling followed by rapid erosion was observed in case of beads cross-linked for 0.08 h 
(Figure II.IIIB).  Simultaneously, intermediate cross-linking time (0.5 and 2 h) produced 
beads with high SER.  In general, SER decreased with increasing cross-linking time (0.5 
to 24 h). 
 
II.II.VI.III. Pectin to resveratrol ratio 
 The data indicate that both tested pectin to resveratrol ratio had no influence on 
resveratrol retention within the beads (Figure II.IVA) and swelling-erosion behaviour 
(Figure II.IVB).  Both formulations established their stability in SIF (> 87 % resveratrol 
retained within the beads at 5 h) and slow degradation in SCF (> 52 % resveratrol 
retained within the beads at 8 h).  This study demonstrates that a very high percentage of 
resveratrol can be encapsulated in Ca-pectinate beads without affecting their drug 



















































Figure II.II:  Effects of PEI concentration on retention of resveratrol within the Ca-
pectinate bead treated with PEI (A) and SER of the Ca-pectinate bead treated with PEI 
(B). Beads were prepared at unmodified pH.  The beads were incubated in simulated GI 

















































Figure II.III:  Effects of cross-linking time on retention of resveratrol within the Ca-
pectinate bead treated with PEI (A) and SER of the Ca-pectinate bead treated with PEI 
(B). Beads were prepared at unmodified pH.  The beads were incubated in simulated GI 











P : R = 1 : 1
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Figure II.IV:  Effects of pectin to resveratrol ratio (P : R) on retention of resveratrol 
within the Ca-pectinate bead treated with PEI (A) and SER of the Ca-pectinate bead 
treated with PEI (B). Beads were prepared at unmodified pH.  The beads were incubated 
in simulated GI conditions.  Data presented as mean ± SD.  * p < 0.05.   
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II.II.VII. FTIR:  The FTIR spectra of pure resveratrol, blank and resveratrol-loaded 
bead are depicted in Figure II.V.  All of the major peaks of resveratrol are present in the 
resveratrol-loaded Ca-pectinate bead, indicating that resveratrol was not chemically 
modified when formulated into Ca-pectinate beads. 
 
 
Figure II.V:  FTIR spectra of pure resveratrol (A), resveratrol-loaded Ca-pectinate bead 
treated with PEI (B), and blank Ca-pectinate bead treated with PEI (C).  Beads were 
prepared at unmodified pH.   
 
II.II.VIII. Stability:  The stability profile of the formulated beads at different storage 
conditions is presented in Figure II.VI.  The formulated beads were found to be stable for 
6 months at 4 °C (> 99 %) and RT (> 98.5 %), although stability was low at 40 °C (> 90 





Figure II.VI:  Stability of resveratrol in the optimized resveratrol-loaded Ca-pectinate 
bead treated with PEI.  Beads were prepared at unmodified pH.  Data presented as mean 
± SD.  * p < 0.05 for the difference between 180 days with 0,3,and 7 days, ** p < 0.05 
for the difference between 90 days with 0,3,7, and 15 days, *** p < 0.05 for the 
difference between 180 days with 0,3,7,15, and 30 days, † p < 0.05 for the difference 
between 30 days with 0 and 3 days, †† p < 0.05 for the difference between 90 days with 0, 
3, 7, 15, and 30 days, ††† p < 0.05 for the difference between 180 days with 0, 3, 7, 15, 30, 
and 90 days, # p < 0.05 for the difference between 40 °C with 4 °C and RT. 
 
II.III. Discussion 
 As described in the previous chapter, amidated LM pectins lead to the formation 
of a more compact Ca-pectinate network than non-amidated and/or HM pectins.  
Additionally, in the chapter 1, we have described several advantages of multi-particulate 
systems over single unit dosage forms.  Beads were produced by ionotropic gelation 
method as described in the previous chapter.  Moreover, in the current study, presence of 
PEI in the cross-linking solution further induced cross-linking between pectin chains and 
PEI, which helped in the formation of stronger beads (this will be discussed later in 
detail).   
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The formulated beads were spherical.  The beads were easily prepared without 
any sophisticated instrument.  The morphological examination exhibits rougher surface 
of resveratrol-loaded beads than resveratrol-free beads.  This might be due to presence of 
resveratrol crystals that are embedded in the polymer matrix of resveratrol-loaded beads.  
A clear difference between the surface of the beads hardened with PEI and non-hardened 
beads was observed.  This indicates formation of an additional layer on the surface of the 
beads hardened with PEI.  SEM image of the cross-section also reveals a thin layer on the 
bead surface, which is anticipated due to surface hardening by PEI.  Because of the high 
molecular weight of PEI, most of the PEI was probably unable to penetrate into the core 
of the beads and was therefore localized on the bead surface.   
The size of the particles formed generally depends on the diameter (25G) of the 
needle used to prepare the beads and drying method.  As a 25G needle was used 
throughout the experiment and beads were dried at RT, it is obvious other formulation 
variables were affecting the particle size of the dried beads.  This might be due to more 
compact beads were produced (probably because of pronounced gel bead shrinkage 
caused by syneresis) by increasing PEI concentration in cross-linking solution and 
increasing cross-linking time, which led to smaller and lighter beads with higher WL and 
lower MC.  Moreover, beads with lower pectin to resveratrol ratio led to bigger and 
heavier particles with higher MC and lower WL.  This is anticipated as lesser amount of 
pectin was available in theses beads because of lower polymer to drug ratio.   
 Generally, EE and L of the beads depend on the dissolution of resveratrol into the 
cross-linking solution.  Resveratrol dissolution in the cross-linking solution increases 
with increased PEI concentration and residence time, which ultimately led to decreased 
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EE and L.  Moreover, compact bead formation and pronounced gel bead shrinkage 
(syneresis) at the higher PEI concentration and longer cross-linking time probably 
expelled some resveratrol from the beads, leading to lower EE and L.  In general, 
decrease of polymer to drug ratio leads to lower EE and L [18].  In contrary, EE and L 
increased with decreasing pectin to resveratrol ratio.  The reasons might be similar as 
described in the previous chapter.  After certain amount, resveratrol reaches saturation in 
the solution at constant temperature.  Therefore, when high amount of resveratrol was 
added into the pectin solution, only limited portion (amount required to saturate the cross-
linking solution) of it came out from the beads to the cross-linking solution, which 
consequently led to higher EE and L.   
 Pre-exposure to acidic medium drastically affected the beads’ behavior and 
decreased its resistance in SIF (basically a phosphate buffer, pH 6.8).  In the gastric fluid, 
carboxylic groups of pectin chains at the beads’ surface convert to COOH, as the pH of 
the medium (1.5) is lower than pKa of pectin (3.5).  Simultaneously, displacement of 
calcium ion (Ca2+) with H+ or Na+ occurs at the outer layers of beads.  Thus cross-linked 
Ca-pectinate network is depleted of its cross-linking agent.  But, due to less solubility in 
acidic fluid and lack of repulsion between carboxylic groups, beads retain their relatively 
insoluble and tightly packed spherical structure.  Thus, less swelling-erosion and drug 
release take place in SGF.  However, the COOH groups reconvert to COO- upon 
subsequent exposure to SIF (pH 6.8), which repel each other.  As some Ca2+ already 
depleted from the Ca-pectinate network, a drastic swelling-erosion and subsequent drug 
release occurs [8].  In addition, drug release from Ca-pectinate beads in SIF is further 
accelerated due to solvent penetration into the Ca-pectinate network, followed by ion 
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exchange between Ca2+ and Na+/K+.  These lead to  extended and swelled bead structure 
and partially forming soluble pectin regions, which are more permeable [20].  The whole 
process is called as ‘acid-base attack’.  These observations compelled us to modify the 
beads to obtain the desired profiles. 
The increased resveratrol retention in upper GI conditions in the case of beads 
prepared with increasing concentration of PEI was probably due to the promotion of 
cross-linking between pectin chain and PEI.  A dense surface was formed in presence of 
more than 0.1 % PEI.  Similarly, longer cross-linking time provides more time for cross-
linking of the Ca-pectinate network and hardening of the bead surface, which led to 
formation of stronger beads.  The PEI cross-linking made the Ca-pectinate network more 
stable and prevented the easy dissolution of Ca-pectinate network in the higher pH of the 
intestinal fluid.  In general, cationic polymers have tendency to react with pectin chains 
and form polyelectrolyte complex.  As PEI is a cationic polymer, it cross-links with the 
free carboxylic groups of the Ca-pectinate network.  The mechanism of this cross-linking 
is the covalent interaction between negatively charged carboxylic groups of pectin chains 
and positively charged amine groups of PEI.  Due to the high density of the Ca-pectinate 
network and high molecular weight of PEI (Molecular weight ~ 25,000), may be only 
small amount of PEI penetrated into the core matrix, while most of them remained 
localized on the bead surface and cross-linked with the pectin chains on the beads’ 
surface.  This phenomenon probably led to produce a relatively hard shell on the bead 
surface.  The swelling and drug release of these beads were in a controlled manner unlike 
the beads prepared without PEI.  Low PEI concentration and cross-linking time led to the 
formation of weakly cross-linked beads, which absorbed more water and swelled.   
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Furthermore, 0.2 % PEI in cross-linking solution and cross-linking time of 2 h 
was sufficient to produce strong beads which were able to load very high amount of 
resveratrol (pectin to resveratrol ratio = 1 : 1) and revealed similar resveratrol retention 
pattern (in simulated GI conditions) to the beads prepared with lower amount of 
resveratrol (pectin to resveratrol ratio = 3 : 1).   
However, the release study showed that pectinolytic enzyme was able to degrade 
the beads despite PEI cross-linking, although degradation was slow in the case of the 
beads prepared at high PEI concentration or long cross-linking time.  Consequently, 
stability data indicates that beads were stable when stored at 4 °C and RT.   
To our knowledge, one research group [6, 21] had earlier exploited the role of PEI 
on β-lactamases loaded pectin bead formation.  But, their formulation and evaluation 
procedures were totally different form our study.  They prepared the drug-loaded Ca-
pectinate beads first and then hardened the preformed beads in PEI solution.  Most 
importantly, they did not perform release study in actual simulated GI conditions.  That 
means they missed out the acid-base attack phenomenon which will be obvious in in-vivo 
condition.  In our current study, when PEI was added in the cross-linking solution, cross-
linking of pectin chains with Ca2+ and hardening of the bead surface occurred 
simultaneously with bead formation.  This led to elimination of surface hardening of the 
preformed beads (hence, hardening time), which shortened the production time.  Thus, 
our formulation procedure is unique in the sense that it reduced production cost by 
cutting down extra steps of washing and hardening, and by decreasing production time 
and manpower requirement.  Moreover, sufficiently strong resveratrol-loaded beads were 
produced by this procedure, which could resist acid-base attack of GI tract required for 
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colon-specific delivery.  The researchers [6, 21] also used very high amount of PEI to 
prepare their formations (0.6 – 1 %).  Our data indicates that only a small amount of PEI 
(0.1 – 0.2 %) is needed for the formulation of resveratrol-loaded colon-specific Ca-
pectinate beads.  Since low concentration of PEI was used during bead preparation and 
the excess amount was washed off after cross-linking, very less amount of PEI is likely to 
remain in the beads.  In addition, our formulations can encapsulate very high amount of 
drug (pectin to resveratrol ratio = 3 : 1).   
 
II.IV. Summary  
Because of its rapid absorption and metabolism at the upper GI tract, development 
of a colon-specific delivery system of resveratrol becomes indispensable for the treatment 
of colonic diseases such as colorectal cancer, colonic inflammation etc. (where it is 
potentially active).  Hence, resveratrol-loaded Ca-pectinate beads were developed as 
multi-particulate colon-specific delivery system.  However, Ca-pectinate beads alone 
were not sufficient to exhibit colon-specific release.  Beads prepared with 0.1 % PEI and 
hardened for 2 h or with 0.2 % PEI and hardened for 0.5 h were observed to be the best 
formulations as they could encapsulate more than 80 % of the drug and at the same time 
showed desirable drug release pattern.  However, beads prepared at 0.2 % PEI 
concentration and cross-linked for 2 h also demonstrated a desirable colon-specific drug 
release pattern, although EE was little low.  Very high amount of resveratrol can be 
encapsulated into these beads without altering the resveratrol retention pattern in 
simulated GI conditions.  Because PEI was added in the cross-linking solution, hardening 
of the bead surface occurred simultaneously with bead formation, which eliminated extra 
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formulation steps, and reduced the production time and cost.  Moreover, a small amount 
of PEI is required to prepare the beads with desired release profile.  However, extremely 
slow drug release profile in SCF or moderate stability in SIF of the optimized beads led 




ZINC-PECTINATE BEAD - GLUTARALDEHYDE 
III.I. Formulation design   
Based on results from our previous experiments, beads were prepared by varying: 
a) cross-linking solution pH (1.5 and 6 (normal pH of the solution)); while keeping 
glutaraldehyde concentration (0.5 % (v/v)), cross-linking time (2 h), and pectin to 
resveratrol ratio (3 : 1) constant. 
b) glutaraldehyde concentration (0, 0.1, 0.25, 0.5, and 1 % (v/v)); while keeping 
cross-linking solution pH (1.5), cross-linking time (2 h), and pectin to resveratrol 
ratio (3 : 1) constant. 
c) cross-linking time (0.08, 0.5, 2, and 24 hr); while keeping cross-linking solution 
pH (1.5), glutaraldehyde concentration (0.5 % (v/v)), and pectin to resveratrol 
ratio (3 : 1) constant. 
d) pectin to resveratrol ratio (1 : 1 and 3 : 1); while keeping cross-linking solution 
pH (1.5), glutaraldehyde concentration (0.5 % (v/v)), and cross-linking time (2 h) 
constant. 
e) glutaraldehyde solution pH (1.5 and 4 (normal pH of the solution)); where 
preformed Zn-pectinate beads (prepared at cross-linking solution = 5 % (w/v) zinc 
acetate without glutaraldehyde (pH 1.5), cross-linking time = 2 h, pectin to 
resveratrol ratio = 3 : 1) were suspended in 0.5 % (v/v) glutaraldehyde solution 





III.II. Results   
III.II.I. Morphology:  SEM images of both blank and resveratrol-loaded Ca-pectinate 
beads are shown in Figure III.I.  At X 350 magnification, a smooth surface topography 
was observed for the blank bead (Figure III.IA).  The topology of the resveratrol-loaded 
bead changed to a rough and rugged surface, which was noticed even at lower 
magnification (X 75) (Figure III.IB) as well as at higher magnifications (X 350) (Figure 
III.IC).  This roughness is probably due to resveratrol crystals that were embedded in the 
bead matrix.  Analyses of SEM pictures of cross-section of the drug-loaded beads taken 
at higher magnifications (X 350) revealed a thin layer on the bead surface (Figure III.ID).  
Minor difference between the surface morphology of the beads hardened with 
























Figure III.I:  Scanning electron micrographs of the surface of blank Zn-pectinate bead 
treated with glutaraldehyde (X 350) (A), resveratrol-loaded Zn-pectinate bead treated 
with glutaraldehyde (X 75) (B), resveratrol-loaded Zn-pectinate bead treated with 
glutaraldehyde (X 350) (C), cross-section of resveratrol-loaded Zn-pectinate bead treated 
with glutaraldehyde (X 350) (D), and non-hardened Zn-pectinate beads (X 350) (E).  
Magnifications corresponding to each figure are presented in brackets. 
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III.II.II. Size and shape:  All formulated beads were spherical in shape (ER ≤ 1.10) 
and more than 2 mm in diameter, which upon drying became smaller (about 1 mm in 
diameter) while retained their spherical shape (Table III.I and Figure III.IB).  
Augmentation in size of both wet and dry beads was found with decreasing 
glutaraldehyde concentration, cross-linking time, and pectin to resveratrol ratio, and with 
increasing pH of cross-linking solution and glutaraldehyde solution (in case of 
glutaraldehyde treatment of preformed beads).   
 
III.II.III. Effect of formulation parameters on bead characteristics:  Weights of the 
beads are shown in Table III.I.  Effect of different formulation parameters on WL, MC, 
EE, and L are listed in Table III.II, while their effects on resveratrol retention pattern and 
SER in the artificial GI environment are depicted in Figure III.II – III.VI.  The following 






Table III.I:  Size, shape, and weight of the Zn-pectinate beads treated with glutaraldehyde (Data presented as mean ± SD, N = 
50 beads) 
 
Variables Values Size (µm ± SD) Shape (ER ± SD) Weight of beads (mg ± SD) 
Wet beads Dry beads Wet beads Dry beads Wet beads Dry beads 
Cross-linking 
solution pH 
6.0 2295.27 ± 93.63 947.38 ± 30.28 1.09 ± 0.07 1.07 ± 0.04 344.36 ± 18.03 25.26 ± 0.93 




0 2298.06 ± 72.84 920.48 ± 14.47 1.07 ± 0.07 1.04 ± 0.01 326.66 ± 7.68 23.24 ± 0.05 
0.1 2291.27 ± 99.28 918.47 ± 26.48 1.10 ± 0.08 1.05 ± 0.03 333.35 ± 14.50 23.12 ± 1.46 
0.25 2273.81 ± 92.84 912.93 ± 19.34 1.06 ± 0.05 1.09 ± 0.06 353.76 ± 18.17 22.85 ± 0.84 
0.5 2242.14 ± 83.48 902.03 ± 17.72 1.05 ± 0.03 1.04 ± 0.02 356.25 ± 12.10 22.51 ± 1.10 
1 2240.29 ± 63.82 900.42 ± 37.27 1.09 ± 0.05 1.06 ± 0.05 357.25 ± 18.35 22.14 ± 1.10 
Cross-linking 
time (h) 
0.08 2374.42 ± 72.21 992.62 ± 33.64 1.10 ± 0.09 1.08 ± 0.06 372.74 ± 15.63 28.34 ± 1.02 
0.5 2284.72 ± 82.32 936.76 ± 42.72 1.08 ± 0.04 1.06 ± 0.04 356.57 ± 17.78 24.79 ± 1.56 
2 2242.14 ± 83.48 902.03 ± 17.72 1.05 ± 0.03 1.04 ± 0.02 356.25 ± 12.10 22.51 ± 1.10 
24 2239.63 ± 73.82 898.92 ± 28.64 1.04 ± 0.02 1.07 ± 0.02 360.03 ± 12.57 22.17 ± 0.92 
P : R 1 : 1 2374.42 ± 89.63 1053.62 ± 48.53 1.08 ± 0.05 1.06 ± 0.03 375.22 ± 11.73 31.39 ± 1.47 
3 : 1 2242.14 ± 83.48 902.03 ± 17.72 1.05 ± 0.03 1.04 ± 0.02 356.25 ± 12.10 22.51 ± 1.10 
Post-glu 
solution 
pH 1.5 2273.53 ± 82.55 935.63 ± 28.64 1.04 ± 0.03 1.05 ± 0.03 345.34 ± 15.40 20.21 ± 0.62 




Table III.II:  WL, MC, EE, and L of the Zn-pectinate beads treated with glutaraldehyde (Data presented as mean ± SD, N = 3) 
Variables Values WL (% ± SD) MC (% ± SD) Direct method # Indirect method 
EE (% ± SD) L (% ± SD) EE (% ± SD) L (% ± SD) 
Cross-linking 
solution pH 
6.0 92.66 ± 0.33 a 12.79 ± 1.06 a 95.06 ± 0.32 31.69 ± 0.11 95.66 ± 0.80 31.89 ± 0.27 




0 92.88 ± 0.15 12.25 ± 0.79 e 96.95 ± 0.19 32.32 ± 0.06 97.06 ± 0.85 32.35 ± 0.28 
0.1 93.04 ± 0.72 12.13 ± 1.55 f 96.71 ± 0.89 32.24 ± 0.30 97.03 ± 0.64 32.34 ± 0.21 
0.25 93.53 ± 0.37 10.96 ± 1.17 96.30 ± 0.57 32.10 ±0.19 96.52 ± 0.56 32.17 ± 0.19 
0.5 93.68 ± 0.24 9.05 ± 1.02 96.03 ± 0.41 32.01 ± 0.14 96.11 ± 0.71 32.04 ± 0.24 
1 93.78 ± 0.55 8.95 ± 1.09 94.99 ± 0.31 31.66 ± 0.10 95.86 ± 0.78 31.95 ± 0.26 
Cross-linking 
time (h) 
0.08 92.40 ± 0.17 b 13.87 ± 1.53 b 99.49 ± 0.57 33.16 ± 0.19 99.43 ± 0.40 g 33.14 ± 0.13 g 
0.5 93.05 ± 0.12 c 11.19 ± 1.10 96.68 ± 0.61 32.23 ± 0.20 96.45 ± 0.67 32.15 ± 0.22 
2 93.68 ± 0.24 9.05 ± 1.02 96.03 ± 0.41 32.01 ± 0.14 96.11 ± 0.71 32.04 ± 0.24 
24 93.83 ± 0.46 8.89 ± 1.32 93.85 ± 0.76 31.28 ± 0.25 94.08 ± 0.92 h 31.36 ± 0.31 h 
P : R 1 : 1 91.62 ± 0.59 d 8.64 ± 1.02 98.07 ± 1.09 98.07 ± 1.09 97.95 ± 0.86 d 97.95 ± 0.86 d 
3 : 1 93.68 ± 0.24 9.05 ± 1.02 96.03 ± 0.41 32.01 ± 0.14 96.11 ± 0.71 32.04 ± 0.24 
Post-glu 
solution  
pH 1.5 94.14 ± 0.38 10.35 ± 1.41 95.23 ± 0.46 31.74 ± 0.15 95.73 ± 0.66 31.91 ± 0.22 
pH 4 93.98 ± 0.54 10.92 ± 1.43 94.80 ± 0.90 31.60 ± 0.30 95.26 ± 0.81 31.75 ± 0.27 
a p < 0.05 between pH 6 and pH 1.5, b p < 0.05 between 0.08 h with 2 and 24 h cross-linking time, c p < 0.05 between 0.5 h and 
24 h cross-linking time, d p < 0.05 between pectin to resveratrol ratio 1 : 1 and 3 : 1, e p < 0.05 between 0 % with 0.5 and 1 % 
glutaraldehyde, f p < 0.05 between 0.1 % and 1 % glutaraldehyde, g p < 0.05 between 0.08 h with 0.5, 2, and 24 h cross-linking 
time, b p < 0.05 between 24 h with 0.5 and 2 h cross-linking time. 




III.II.III.I. Effect of cross-linking solution pH 
Reduction of cross-linking solution pH led to produce heavier wet beads and 
lighter dried beads (Table III.I) which contained less moisture after drying and lost 
more weight during drying (Table III.II).  Furthermore, augmentation of EE and L 
was found with decreasing cross-linking solution pH (Table III.II).  When tested in GI 
condition, beads prepared in cross-linking solution pH 1.5 were able to retain most of 
the resveratrol inside the beads (> 93 % of initial resveratrol amount) after incubating 
in SGF for 2 h followed by SIF for 3 h (Figure III.IIA).  But, beads prepared in cross-
linking solution pH 6 (i.e., without modifying the pH) degraded very fast in SIF 
though the beds were stable for first 2 h in SGF.  At the same time, an insight into the 
SER aspect revealed that SER increased with increasing cross-linking solution pH up 
to 4 h (Figure III.IIB).  In contact with simulated GI fluids swelling overpowered 
erosion of the beads prepared in cross-linking solution pH 1.5; whereas, an opposite 
















































Figure III.II:  Effects of cross-linking solution pH on retention of resveratrol within 
the Zn-pectinate bead treated with glutaraldehyde (A) and SER of the Zn-pectinate 
bead treated with glutaraldehyde (B).  The beads were incubated in simulated GI 




III.II.III.II. Effect of glutaraldehyde concentration 
When glutaraldehyde concentration in the cross-linking solution was 
increased, weight of the dry beads decreased, while, weight of the wet beads increased 
(Table III.I).  WL was increased with increasing glutaraldehyde concentration (Table 
III.II).  Simultaneously, moisture content inside the dry beads was decreased 
dramatically with higher glutaraldehyde concentration (Table III.II).  Furthermore, EE 
and L were decreased with increasing glutaraldehyde concentration (Table III.II).  
Beads prepared in 1 % glutaraldehyde exhibited much lower EE than others.  
Although all beads retain most resveratrol into the beads in contact with SGF for 2 h, 
beads prepared in cross-linking solution with 0.1 % or without glutaraldehyde 
degraded very fast in SIF (Figure III.IIIA).  Whereas, beads prepared in cross-linking 
solution with 0.25 % glutaraldehyde degraded slower than previous two but not 
sufficiently slow for colon specificity (~ 59 % of initial resveratrol remained in the 
beads at 5 h).  On the other hand, beads prepared in cross-linking solution with 0.5 
and 1 % glutaraldehyde showed very good stability in upper GI condition and 
degraded very fast in SCF, although there was almost no difference in drug retention 
pattern between them.  More than 93 % of initial resveratrol remained in the beads 
after 5 h in both cases.  When look into SER profile, SERs of beads prepared with 1 
% glutaraldehyde was lower than beads prepared with 0.5 % glutaraldehyde (Figure 
III.IIIB).  Erosion subdued rapid initial swelling of beads after 3 h in case of beads 























































Figure III.III:  Effects of glutaraldehyde concentration on retention of resveratrol 
within the Zn-pectinate bead treated with glutaraldehyde (A) and SER of the Zn-
pectinate bead treated with glutaraldehyde (B).  The beads were incubated in 




III.II.III.III. Effect of cross-linking time 
The beads cross-linked for more time was lighter (Table III.I) and MC was 
noticeably lower (Table III.II).  Increase of WL was found with increasing cross-
linking time (Table III.II).  EE and L drastically decreased with increasing cross-
linking time (Table III.II).  Beads cross-linked for 24 h possessed significantly lower 
EE.  Cross-linking time of 0.08 h produced beads which are unstable in SIF though 
remained almost intact in SGF (Figure III.IVA).  Beads cross-linked for 0.5 h were 
more stable in upper GI fluids (SGF and SIF) and retained more than 72 % of initial 
resveratrol into the beads at 5 h, and degraded very fast in SCF.  On the other hand, 
cross-linking time of 2 and 24 h produced stronger beads which retained about 93 % 
of initial resveratrol after 5 h in GI condition (2 h in SGF followed by 3 h in SIF) and 
immediately released most of the resveratrol in SCF.  In case of beads cross-linked for 
0.08 h, a rapid swelling was observed at 3 h and then rapid erosion took place (Figure 
III.IVB).  Further, for the beads cross-linked for 0.5 h, SER was higher than beads 
cross-linked for 2 and 24 h though swelling was overshadowed by erosion after 3 h.  
Almost similar SER profiles were observed between beads cross-linked for 2 and 24 




















































Figure III.IV:  Effects of cross-linking time on retention of resveratrol within the Zn-
pectinate bead treated with glutaraldehyde (A) and SER of the Zn-pectinate bead 
treated with glutaraldehyde (B).  The beads were incubated in simulated GI 




III.II.III.IV. Effect of pectin to resveratrol ratio 
Weight of beads (both wet and dry) increased with decreasing pectin to 
resveratrol ratio (Table III.I), whereas MC and WL decreased at reduced pectin to 
resveratrol ratio (Table III.II).  Simultaneously, augmentation of EE and L were 
observed when pectin to resveratrol ratio decreased (Table III.II).  Reduction of pectin 
to resveratrol ratio (1 : 1) produced weaker beads which were degraded faster in 
simulated GI condition (~ 63 % resveratrol retained at 5 h) than beads prepared with 
higher pectin to resveratrol ratio (3 : 1) (> 93 % resveratrol retained at 5 h) (Figure 
III.VA).  Greater SER was observed in case of beads prepared with higher pectin to 
resveratrol ratio (Figure III.VB).  Early phase of swelling (first 3 h) followed by 
erosion was noticed for beads prepared with lower pectin to resveratrol ratio. 
 
III.II.III.V. Effect of glutaraldehyde treatment on preformed beads 
When preformed beads were treated with glutaraldehyde solution, weight of 
dried beads (Table III.I) and MC (Table III.II) slightly decreased with reduced 
solution pH, while opposite trends were noticed in case of WL, EE, and L (Table 
III.II).  Preformed beads hardened with glutaraldehyde degraded very fast in SIF 
though degradation was slightly slower in case of glutaraldehyde solution pH 4 
(unmodified pH) (Figure III.VIA).  Resveratrol retentions after 5 h incubation in 
simulated upper GI condition were < 35 % and < 28 % for beads treated with 
glutaraldehyde solution at pH 1.5 and 4, respectively.  On the other hand, beads 
prepared in cross-linking solution containing same percentage of glutaraldehyde at pH 
1.5 produced very strong beads which can retain > 93 % resveratrol after 5 h 
incubation in simulated upper GI condition.  Preformed beads hardened with 
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glutaraldehyde solution at both pH exhibited an early phase swelling (up to 3 h) 
followed by rapid erosion (Figure III.VIB). 
A 











































Figure III.V:  Effect of pectin to resveratrol ratio on retention of resveratrol within 
the Zn-pectinate bead treated with glutaraldehyde (A) and SER of the Zn-pectinate 
bead treated with glutaraldehyde (B).  The beads were incubated in simulated GI 



















































Figure III.VI:  Effect of glutaraldehyde treatment of preformed beads on retention of 
resveratrol within the Zn-pectinate bead treated with glutaraldehyde (A) and SER of 
the Zn-pectinate bead treated with glutaraldehyde (B).  The beads were incubated in 




III.II.IV. FTIR:  The FTIR spectra of pure resveratrol, blank and resveratrol-loaded 
bead are depicted in Figure III.VII.  All of the major peaks of resveratrol are present 
in the resveratrol-loaded Ca-pectinate bead, indicating that resveratrol was not 
chemically modified when formulated into Ca-pectinate beads. 
 
 
Figure III.VII:  FT-IR spectra of pure resveratrol (A), resveratrol-loaded Zn-
pectinate bead treated with glutaraldehyde (B), and blank Zn-pectinate bead treated 
with glutaraldehyde (C). 
 
III.II.V. Stability:  The stability profile of resveratrol in the optimized beads is 
presented in Figure III.VIII.  It can be seen that even after 6 months, stability was > 
99 % in case of storage at 4 ºC and room temperature (RT); whereas, ~ 90 % when 




Figure III.VIII:  Stability of resveratrol in the optimized resveratrol-loaded Zn-
pectinate bead treated with glutaraldehyde.  Data presented as mean ± SD.  * p < 0.05 
for the difference between 180 days and 0 day, ** p < 0.05 for the difference between 
90 days with 0, 3, 7, 15, and 30 days, *** p < 0.05 for the difference between 180 
days with 0, 3, 7, 15, 30, and 90 days, # p < 0.05 for the difference between 40 °C 
with 4 °C and RT.   
 
III.III. Discussion   
 Similar to Ca-pectinate bead formation (described in Chapter 6), ionotropic 
gelation (between the negatively charged carboxylic groups on pectin chains and Zn2+ 
ions) and covalent cross-linking (between hydroxyl groups of pectin chains and 
aldehyde groups of glutaraldehyde) led to the production of gelled spheres.  The 
formulated beads were spherical in shape and easily prepared without any 
sophisticated instruments.  Scanning electron micrographs exhibit that the drug 
crystals are embedded in the polymer matrix, which led to rough surface.  
Micrographs of cross-section revealed a thin layer on the bead surface, which is 
probably due to the extensive cross-linking between pectin chains and glutaraldehyde 
on the bead surface.  This layer formation probably explains different surface 
morphology of the beads prepared with and without glutaraldehyde. 
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 The study revealed that the formulation variables were affecting the particle 
size of the dried beads.  This might be due to more compact beads were produced 
(probably because of pronounced gel bead shrinkage caused by syneresis ) by 
lowering cross-linking solution pH, increasing glutaraldehyde concentration in cross-
linking solution, and increasing cross-linking time, which led to smaller and lighter 
beads with higher WL and lower MC.  Moreover, beads with lower pectin to 
resveratrol ratio led to bigger particles with lower moisture content and weight loss.  
This is anticipated as lesser amount of pectin was available in theses beads because of 
lower polymer to drug ratio.  These observations are similar to Ca-pectinate beads, 
which have been described in the previous section.  
 High resveratrol encapsulations (> 94 %) within the beads were evident due to 
instantaneous gelation of pectin.  Poor aqueous solubility of resveratrol should be 
responsible for such high percentage of drug encapsulation within the beads.  As 
described earlier, EE and L depend on the dissolution of resveratrol into the cross-
linking solution.  Resveratrol dissolution in the cross-linking solution increases with 
increasing cross-linking solution pH, glutaraldehyde concentration, and residence 
time, which led to the reduction of EE and L.  EE and L increased at lower pectin to 
resveratrol ratio.  The probable reason for such observation has been discussed earlier.  
When preformed beads were treated with glutaraldehyde solution, resveratrol leaked 
out both in cross-linking solution and glutaraldehyde solution, which led to lower EE 
and L.  the observations are similar to Ca-pectinate beads.  
 Pre-exposure to acidic medium drastically affects the beads’ behavior and 
decrease its resistance in SIF (basically a phosphate buffer, pH 6.8).  Similar to Ca-
pectinate beads, displacement of zinc ion (Zn2+) with H+ or Na+ might occur at the 
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outer layers of beads in the gastric fluid.  Thus the ‘acid-base attack’ compelled us to 
modify the beads to obtain the desired profiles.   
Drug retention and SER of the formulated beads in the simulated GI condition 
decreased with increased cross-linking solution pH.  We have demonstrated the 
effects of cross-linking solution pH on Zn-pectinate beads in the previous chapter.  
But, those phenomena were not sufficient to resist ‘acid-base attack’ of actual in-vivo 
condition.  Thus, similar effects of glutaraldehyde on Zn-pectinate beads are 
anticipated, which were observed on Ca-pectinate beads.  Two terminal aldehyde 
groups of glutaraldehyde formed acetal linkage with the existing hydroxyl groups of 
pectin chains, which was facilitated under acidic environment [22].  Thus, a more 
compact and strong three dimensional Zn-pectinate network was formed in presence 
of glutaraldehyde at cross-linking solution pH 1.5 than pH 6.  These phenomena were 
responsible for higher resveratrol retention inside the beads formulated at cross-
linking solution pH 1.5 under upper GI conditions.  Simultaneously, rapid swelling by 
water absorption followed by erosion was prominent due to weakly cross-linked bead 
formation at cross-linking solution pH 6.  On the other hand, swelling was 
predominant while erosion was negligible for bead prepared at cross-linking solution 
pH 1.5 due to strong bead formation. 
 The higher amount of glutaraldehyde promoted the formation of cross-links 
between pectin chains (as more glutaraldehyde was available for cross-linking).  
Hence, when the beads were incubated in the simulated upper GI conditions, 
resveratrol retention within the beads increased in case of beads prepared with higher 
glutaraldehyde concentration.  A dense surface was formed in presence of more than 
0.5 % glutaraldehyde.  Similarly, higher cross-linking times provide more time for 
cross-linking of the Zn-pectinate network and hardening of the bead surface, which 
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led to prepare stronger beads.  The glutaraldehyde cross-linking made the Zn-
pectinate network more stable and prevents the easy dissolution of Zn-pectinate 
network in the higher pH ranges of the intestine.  The observations are similar to the 
Ca-pectinate beads.  The swelling and drug release of these beads were in a controlled 
manner unlike the beads prepared without glutaraldehyde.  Erosion of bead surface 
overshadowed swelling in case of beads prepared at low glutaraldehyde concentration 
or cross-linked for shorter time due to formation of weakly cross-linked beads. 
 Increasing resveratrol amount in the beads led to lower drug retention in 
simulated upper GI condition due to reduced pectin amount which is required to form 
cross-linked network.  As the availability of polymer reduced at low pectin to 
resveratrol ratio, water absorption capacity of the beads was also diminished.  In 
addition, erosion of the beads became prevalent due to loose cross-linked pectinate 
network.  This led to lower SER of beads prepared with lower pectin to resveratrol 
ratio.  The release study revealed that pectinolytic enzyme was able to degrade the 
beads despite the presence of glutaraldehyde.  Consequently, stability data indicates 
that beads are stable when stored at 4 °C or RT. 
 As described in the previous section, when beads prepared in cross-linking 
solution containing glutaraldehyde at pH 1.5, cross-linking of pectin chains with 
glutaraldehyde might occur at the inner matrix as well as outer surface of the beads.  
This produced very strong beads which can resist acid-base attack at Upper GI 
condition.  But, if preformed beads were hardened in glutaraldehyde solution even at 
pH 1.5, only beads surface exposed to glutaraldehyde solution and most likely cross-
linking between pectin chains and glutaraldehyde occur exclusively at beads’ surface.  
Thus, strong beads might not be produced in this way.  This may be the probable 
explanation for rapid degradation of these beads in SIF.  Erosion of beads after early 
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swelling should be because of weakly cross-linked bead formation.  These incidences 
reflected the importance of formulation procedure to produce colon-specific pectinate 
beads. 
 
III.IV. Summary   
To our knowledge, till now no researcher has exploited the role of 
glutaraldehyde on Zn-pectinate bead for colon-specific delivery.  We found the 
importance of cross-linking solution pH for the formulation of colon-specific Zn-
pectinate beads hardened with glutaraldehyde.  Our study revealed that beads 
prepared in low cross-linking solution pH can resist acid-base attack, while beads 
prepared in cross-linking solution of unaltered pH cannot.  Moreover, a minimum 
glutaraldehyde concentration and hardening time are essential to produce sufficiently 
strong beads to resist degradation in the upper gastro-intestinal tract.  High resveratrol 
encapsulation within the beads was observed.  The study revealed the importance of 
direct addition of glutaraldehyde in the cross-linking solution.  As described earlier, 
this formulation procedure eliminates some extra formulation steps and consequently 
reduces production cost.  Sufficiently strong resveratrol-loaded beads were produced 
by this procedure, which could resist acid-base attack of GI tract required for colon-
specific delivery.  Our data also indicate that very small amount of glutaraldehyde 
(0.5 %) is needed for formulating resveratrol-loaded colon-specific Zn-pectinate 
beads.  Since low concentration of glutaraldehyde was used during bead preparation 
and the excess was washed off after cross-linking, very less amount of glutaraldehyde 
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